id	sid	tid	token	lemma	pos
ajlm-708	1	1	abstract	abstract	ADJ
ajlm-708	1	2	introduction	introduction	NOUN
ajlm-708	1	3	methods	method	NOUN
ajlm-708	1	4	results	result	VERB
ajlm-708	1	5	discussion	discussion	NOUN
ajlm-708	1	6	acknowledgements	acknowledgement	NOUN
ajlm-708	1	7	references	reference	NOUN
ajlm-708	1	8	about	about	ADP
ajlm-708	1	9	the	the	DET
ajlm-708	1	10	author(s	author(s	NOUN
ajlm-708	1	11	)	)	PUNCT
ajlm-708	1	12	zhiyong	zhiyong	PROPN
ajlm-708	1	13	zhou	zhou	PROPN
ajlm-708	2	1	international	international	PROPN
ajlm-708	2	2	laboratory	laboratory	NOUN
ajlm-708	2	3	branch	branch	NOUN
ajlm-708	2	4	,	,	PUNCT
ajlm-708	2	5	division	division	NOUN
ajlm-708	2	6	of	of	ADP
ajlm-708	2	7	global	global	PROPN
ajlm-708	2	8	hiv	hiv	PROPN
ajlm-708	2	9	&	&	CCONJ
ajlm-708	2	10	tb	tb	PROPN
ajlm-708	2	11	,	,	PUNCT
ajlm-708	2	12	center	center	NOUN
ajlm-708	2	13	for	for	ADP
ajlm-708	2	14	global	global	ADJ
ajlm-708	2	15	health	health	NOUN
ajlm-708	2	16	,	,	PUNCT
ajlm-708	2	17	centers	center	NOUN
ajlm-708	2	18	for	for	ADP
ajlm-708	2	19	disease	disease	NOUN
ajlm-708	2	20	control	control	NOUN
ajlm-708	2	21	and	and	CCONJ
ajlm-708	2	22	prevention	prevention	NOUN
ajlm-708	2	23	,	,	PUNCT
ajlm-708	2	24	atlanta	atlanta	PROPN
ajlm-708	2	25	,	,	PUNCT
ajlm-708	2	26	georgia	georgia	PROPN
ajlm-708	2	27	,	,	PUNCT
ajlm-708	2	28	united	united	PROPN
ajlm-708	2	29	states	states	PROPN
ajlm-708	2	30	kevin	kevin	PROPN
ajlm-708	2	31	tang	tang	PROPN
ajlm-708	2	32	biotechnology	biotechnology	PROPN
ajlm-708	2	33	core	core	PROPN
ajlm-708	2	34	facility	facility	NOUN
ajlm-708	2	35	branch	branch	NOUN
ajlm-708	2	36	,	,	PUNCT
ajlm-708	2	37	division	division	NOUN
ajlm-708	2	38	of	of	ADP
ajlm-708	2	39	scientific	scientific	ADJ
ajlm-708	2	40	resources	resource	NOUN
ajlm-708	2	41	,	,	PUNCT
ajlm-708	2	42	centers	center	NOUN
ajlm-708	2	43	for	for	ADP
ajlm-708	2	44	disease	disease	NOUN
ajlm-708	2	45	control	control	NOUN
ajlm-708	2	46	and	and	CCONJ
ajlm-708	2	47	prevention	prevention	NOUN
ajlm-708	2	48	,	,	PUNCT
ajlm-708	2	49	atlanta	atlanta	PROPN
ajlm-708	2	50	,	,	PUNCT
ajlm-708	2	51	georgia	georgia	PROPN
ajlm-708	2	52	,	,	PUNCT
ajlm-708	2	53	united	united	PROPN
ajlm-708	2	54	states	states	PROPN
ajlm-708	2	55	guoqing	guoqe	VERB
ajlm-708	2	56	zhang	zhang	PROPN
ajlm-708	2	57	international	international	PROPN
ajlm-708	2	58	laboratory	laboratory	NOUN
ajlm-708	2	59	branch	branch	NOUN
ajlm-708	2	60	,	,	PUNCT
ajlm-708	2	61	division	division	NOUN
ajlm-708	2	62	of	of	ADP
ajlm-708	2	63	global	global	PROPN
ajlm-708	2	64	hiv	hiv	PROPN
ajlm-708	2	65	&	&	CCONJ
ajlm-708	2	66	tb	tb	PROPN
ajlm-708	2	67	,	,	PUNCT
ajlm-708	2	68	center	center	NOUN
ajlm-708	2	69	for	for	ADP
ajlm-708	2	70	global	global	ADJ
ajlm-708	2	71	health	health	NOUN
ajlm-708	2	72	,	,	PUNCT
ajlm-708	2	73	centers	center	NOUN
ajlm-708	2	74	for	for	ADP
ajlm-708	2	75	disease	disease	NOUN
ajlm-708	2	76	control	control	NOUN
ajlm-708	2	77	and	and	CCONJ
ajlm-708	2	78	prevention	prevention	NOUN
ajlm-708	2	79	,	,	PUNCT
ajlm-708	2	80	atlanta	atlanta	PROPN
ajlm-708	2	81	,	,	PUNCT
ajlm-708	2	82	georgia	georgia	PROPN
ajlm-708	2	83	,	,	PUNCT
ajlm-708	2	84	united	united	PROPN
ajlm-708	2	85	states	states	PROPN
ajlm-708	2	86	nellie	nellie	PROPN
ajlm-708	2	87	wadonda	wadonda	PROPN
ajlm-708	2	88	-	-	PUNCT
ajlm-708	2	89	kabondo	kabondo	PROPN
ajlm-708	2	90	department	department	NOUN
ajlm-708	2	91	of	of	ADP
ajlm-708	2	92	preventive	preventive	ADJ
ajlm-708	2	93	health	health	NOUN
ajlm-708	2	94	,	,	PUNCT
ajlm-708	2	95	ministry	ministry	PROPN
ajlm-708	2	96	of	of	ADP
ajlm-708	2	97	health	health	PROPN
ajlm-708	2	98	,	,	PUNCT
ajlm-708	2	99	lilongwe	lilongwe	PROPN
ajlm-708	2	100	,	,	PUNCT
ajlm-708	2	101	malawi	malawi	PROPN
ajlm-708	2	102	kundai	kundai	PROPN
ajlm-708	2	103	moyo	moyo	PROPN
ajlm-708	2	104	department	department	PROPN
ajlm-708	2	105	of	of	ADP
ajlm-708	2	106	preventive	preventive	ADJ
ajlm-708	2	107	health	health	NOUN
ajlm-708	2	108	,	,	PUNCT
ajlm-708	2	109	ministry	ministry	PROPN
ajlm-708	2	110	of	of	ADP
ajlm-708	2	111	health	health	PROPN
ajlm-708	2	112	,	,	PUNCT
ajlm-708	2	113	lilongwe	lilongwe	PROPN
ajlm-708	2	114	,	,	PUNCT
ajlm-708	2	115	malawi	malawi	PROPN
ajlm-708	2	116	lori	lori	PROPN
ajlm-708	2	117	a.	a.	PROPN
ajlm-708	2	118	rowe	rowe	PROPN
ajlm-708	2	119	biotechnology	biotechnology	PROPN
ajlm-708	2	120	core	core	PROPN
ajlm-708	2	121	facility	facility	NOUN
ajlm-708	2	122	branch	branch	NOUN
ajlm-708	2	123	,	,	PUNCT
ajlm-708	2	124	division	division	NOUN
ajlm-708	2	125	of	of	ADP
ajlm-708	2	126	scientific	scientific	ADJ
ajlm-708	2	127	resources	resource	NOUN
ajlm-708	2	128	,	,	PUNCT
ajlm-708	2	129	centers	center	NOUN
ajlm-708	2	130	for	for	ADP
ajlm-708	2	131	disease	disease	NOUN
ajlm-708	2	132	control	control	NOUN
ajlm-708	2	133	and	and	CCONJ
ajlm-708	2	134	prevention	prevention	NOUN
ajlm-708	2	135	,	,	PUNCT
ajlm-708	2	136	atlanta	atlanta	PROPN
ajlm-708	2	137	,	,	PUNCT
ajlm-708	2	138	georgia	georgia	PROPN
ajlm-708	2	139	,	,	PUNCT
ajlm-708	3	1	united	united	PROPN
ajlm-708	3	2	states	states	PROPN
ajlm-708	3	3	joshua	joshua	PROPN
ajlm-708	3	4	r.	r.	PROPN
ajlm-708	3	5	devos	devos	PROPN
ajlm-708	3	6	international	international	PROPN
ajlm-708	3	7	laboratory	laboratory	NOUN
ajlm-708	3	8	branch	branch	NOUN
ajlm-708	3	9	,	,	PUNCT
ajlm-708	3	10	division	division	NOUN
ajlm-708	3	11	of	of	ADP
ajlm-708	3	12	global	global	PROPN
ajlm-708	3	13	hiv	hiv	PROPN
ajlm-708	3	14	&	&	CCONJ
ajlm-708	3	15	tb	tb	PROPN
ajlm-708	3	16	,	,	PUNCT
ajlm-708	3	17	center	center	NOUN
ajlm-708	3	18	for	for	ADP
ajlm-708	3	19	global	global	ADJ
ajlm-708	3	20	health	health	NOUN
ajlm-708	3	21	,	,	PUNCT
ajlm-708	3	22	centers	center	NOUN
ajlm-708	3	23	for	for	ADP
ajlm-708	3	24	disease	disease	NOUN
ajlm-708	3	25	control	control	NOUN
ajlm-708	3	26	and	and	CCONJ
ajlm-708	3	27	prevention	prevention	NOUN
ajlm-708	3	28	,	,	PUNCT
ajlm-708	3	29	atlanta	atlanta	PROPN
ajlm-708	3	30	,	,	PUNCT
ajlm-708	3	31	georgia	georgia	PROPN
ajlm-708	3	32	,	,	PUNCT
ajlm-708	3	33	united	united	PROPN
ajlm-708	3	34	states	states	PROPN
ajlm-708	3	35	nick	nick	PROPN
ajlm-708	3	36	wagar	wagar	PROPN
ajlm-708	3	37	international	international	ADJ
ajlm-708	3	38	laboratory	laboratory	NOUN
ajlm-708	3	39	branch	branch	NOUN
ajlm-708	3	40	,	,	PUNCT
ajlm-708	3	41	division	division	NOUN
ajlm-708	3	42	of	of	ADP
ajlm-708	3	43	global	global	PROPN
ajlm-708	3	44	hiv	hiv	PROPN
ajlm-708	3	45	&	&	CCONJ
ajlm-708	3	46	tb	tb	PROPN
ajlm-708	3	47	,	,	PUNCT
ajlm-708	3	48	center	center	NOUN
ajlm-708	3	49	for	for	ADP
ajlm-708	3	50	global	global	ADJ
ajlm-708	3	51	health	health	NOUN
ajlm-708	3	52	,	,	PUNCT
ajlm-708	3	53	centers	center	NOUN
ajlm-708	3	54	for	for	ADP
ajlm-708	3	55	disease	disease	NOUN
ajlm-708	3	56	control	control	NOUN
ajlm-708	3	57	and	and	CCONJ
ajlm-708	3	58	prevention	prevention	NOUN
ajlm-708	3	59	,	,	PUNCT
ajlm-708	3	60	atlanta	atlanta	PROPN
ajlm-708	3	61	,	,	PUNCT
ajlm-708	3	62	georgia	georgia	PROPN
ajlm-708	3	63	,	,	PUNCT
ajlm-708	3	64	united	united	PROPN
ajlm-708	3	65	states	states	PROPN
ajlm-708	3	66	du	du	PROPN
ajlm-708	3	67	-	-	PROPN
ajlm-708	3	68	ping	ping	ADJ
ajlm-708	3	69	zheng	zheng	PROPN
ajlm-708	3	70	international	international	PROPN
ajlm-708	3	71	laboratory	laboratory	NOUN
ajlm-708	3	72	branch	branch	NOUN
ajlm-708	3	73	,	,	PUNCT
ajlm-708	3	74	division	division	NOUN
ajlm-708	3	75	of	of	ADP
ajlm-708	3	76	global	global	PROPN
ajlm-708	3	77	hiv	hiv	PROPN
ajlm-708	3	78	&	&	CCONJ
ajlm-708	3	79	tb	tb	PROPN
ajlm-708	3	80	,	,	PUNCT
ajlm-708	3	81	center	center	NOUN
ajlm-708	3	82	for	for	ADP
ajlm-708	3	83	global	global	ADJ
ajlm-708	3	84	health	health	NOUN
ajlm-708	3	85	,	,	PUNCT
ajlm-708	3	86	centers	center	NOUN
ajlm-708	3	87	for	for	ADP
ajlm-708	3	88	disease	disease	NOUN
ajlm-708	3	89	control	control	NOUN
ajlm-708	3	90	and	and	CCONJ
ajlm-708	3	91	prevention	prevention	NOUN
ajlm-708	3	92	,	,	PUNCT
ajlm-708	3	93	atlanta	atlanta	PROPN
ajlm-708	3	94	,	,	PUNCT
ajlm-708	3	95	georgia	georgia	PROPN
ajlm-708	3	96	,	,	PUNCT
ajlm-708	3	97	united	united	PROPN
ajlm-708	3	98	states	states	PROPN
ajlm-708	3	99	hongxiong	hongxiong	PROPN
ajlm-708	3	100	guo	guo	PROPN
ajlm-708	3	101	international	international	PROPN
ajlm-708	3	102	laboratory	laboratory	NOUN
ajlm-708	3	103	branch	branch	NOUN
ajlm-708	3	104	,	,	PUNCT
ajlm-708	3	105	division	division	NOUN
ajlm-708	3	106	of	of	ADP
ajlm-708	3	107	global	global	PROPN
ajlm-708	3	108	hiv	hiv	PROPN
ajlm-708	3	109	&	&	CCONJ
ajlm-708	3	110	tb	tb	PROPN
ajlm-708	3	111	,	,	PUNCT
ajlm-708	3	112	center	center	NOUN
ajlm-708	3	113	for	for	ADP
ajlm-708	3	114	global	global	ADJ
ajlm-708	3	115	health	health	NOUN
ajlm-708	3	116	,	,	PUNCT
ajlm-708	3	117	centers	center	NOUN
ajlm-708	3	118	for	for	ADP
ajlm-708	3	119	disease	disease	NOUN
ajlm-708	3	120	control	control	NOUN
ajlm-708	3	121	and	and	CCONJ
ajlm-708	3	122	prevention	prevention	NOUN
ajlm-708	3	123	,	,	PUNCT
ajlm-708	3	124	atlanta	atlanta	PROPN
ajlm-708	3	125	,	,	PUNCT
ajlm-708	3	126	georgia	georgia	PROPN
ajlm-708	3	127	,	,	PUNCT
ajlm-708	3	128	united	united	PROPN
ajlm-708	3	129	states	states	PROPN
ajlm-708	3	130	john	john	PROPN
ajlm-708	3	131	nkengasong	nkengasong	PROPN
ajlm-708	3	132	international	international	PROPN
ajlm-708	3	133	laboratory	laboratory	NOUN
ajlm-708	3	134	branch	branch	NOUN
ajlm-708	3	135	,	,	PUNCT
ajlm-708	3	136	division	division	NOUN
ajlm-708	3	137	of	of	ADP
ajlm-708	3	138	global	global	PROPN
ajlm-708	3	139	hiv	hiv	PROPN
ajlm-708	3	140	&	&	CCONJ
ajlm-708	3	141	tb	tb	PROPN
ajlm-708	3	142	,	,	PUNCT
ajlm-708	3	143	center	center	NOUN
ajlm-708	3	144	for	for	ADP
ajlm-708	3	145	global	global	ADJ
ajlm-708	3	146	health	health	NOUN
ajlm-708	3	147	,	,	PUNCT
ajlm-708	3	148	centers	center	NOUN
ajlm-708	3	149	for	for	ADP
ajlm-708	3	150	disease	disease	NOUN
ajlm-708	3	151	control	control	NOUN
ajlm-708	3	152	and	and	CCONJ
ajlm-708	3	153	prevention	prevention	NOUN
ajlm-708	3	154	,	,	PUNCT
ajlm-708	3	155	atlanta	atlanta	PROPN
ajlm-708	3	156	,	,	PUNCT
ajlm-708	3	157	georgia	georgia	PROPN
ajlm-708	3	158	,	,	PUNCT
ajlm-708	3	159	united	united	PROPN
ajlm-708	3	160	states	states	PROPN
ajlm-708	3	161	mike	mike	PROPN
ajlm-708	3	162	frace	frace	PROPN
ajlm-708	3	163	biotechnology	biotechnology	NOUN
ajlm-708	3	164	core	core	NOUN
ajlm-708	3	165	facility	facility	NOUN
ajlm-708	3	166	branch	branch	NOUN
ajlm-708	3	167	,	,	PUNCT
ajlm-708	3	168	division	division	NOUN
ajlm-708	3	169	of	of	ADP
ajlm-708	3	170	scientific	scientific	ADJ
ajlm-708	3	171	resources	resource	NOUN
ajlm-708	3	172	,	,	PUNCT
ajlm-708	3	173	centers	center	NOUN
ajlm-708	3	174	for	for	ADP
ajlm-708	3	175	disease	disease	NOUN
ajlm-708	3	176	control	control	NOUN
ajlm-708	3	177	and	and	CCONJ
ajlm-708	3	178	prevention	prevention	NOUN
ajlm-708	3	179	,	,	PUNCT
ajlm-708	3	180	atlanta	atlanta	PROPN
ajlm-708	3	181	,	,	PUNCT
ajlm-708	3	182	georgia	georgia	PROPN
ajlm-708	3	183	,	,	PUNCT
ajlm-708	3	184	united	united	PROPN
ajlm-708	3	185	states	states	PROPN
ajlm-708	3	186	scott	scott	PROPN
ajlm-708	3	187	sammons	sammons	PROPN
ajlm-708	3	188	biotechnology	biotechnology	PROPN
ajlm-708	3	189	core	core	PROPN
ajlm-708	3	190	facility	facility	NOUN
ajlm-708	3	191	branch	branch	NOUN
ajlm-708	3	192	,	,	PUNCT
ajlm-708	3	193	division	division	NOUN
ajlm-708	3	194	of	of	ADP
ajlm-708	3	195	scientific	scientific	ADJ
ajlm-708	3	196	resources	resource	NOUN
ajlm-708	3	197	,	,	PUNCT
ajlm-708	3	198	centers	center	NOUN
ajlm-708	3	199	for	for	ADP
ajlm-708	3	200	disease	disease	NOUN
ajlm-708	3	201	control	control	NOUN
ajlm-708	3	202	and	and	CCONJ
ajlm-708	3	203	prevention	prevention	NOUN
ajlm-708	3	204	,	,	PUNCT
ajlm-708	3	205	atlanta	atlanta	PROPN
ajlm-708	3	206	,	,	PUNCT
ajlm-708	3	207	georgia	georgia	PROPN
ajlm-708	3	208	,	,	PUNCT
ajlm-708	3	209	united	united	PROPN
ajlm-708	3	210	states	states	PROPN
ajlm-708	3	211	chunfu	chunfu	PROPN
ajlm-708	3	212	yang	yang	PROPN
ajlm-708	3	213	international	international	PROPN
ajlm-708	3	214	laboratory	laboratory	PROPN
ajlm-708	3	215	branch	branch	NOUN
ajlm-708	3	216	,	,	PUNCT
ajlm-708	3	217	division	division	NOUN
ajlm-708	3	218	of	of	ADP
ajlm-708	3	219	global	global	PROPN
ajlm-708	3	220	hiv	hiv	PROPN
ajlm-708	3	221	&	&	CCONJ
ajlm-708	3	222	tb	tb	PROPN
ajlm-708	3	223	,	,	PUNCT
ajlm-708	3	224	center	center	NOUN
ajlm-708	3	225	for	for	ADP
ajlm-708	3	226	global	global	ADJ
ajlm-708	3	227	health	health	NOUN
ajlm-708	3	228	,	,	PUNCT
ajlm-708	3	229	centers	center	NOUN
ajlm-708	3	230	for	for	ADP
ajlm-708	3	231	disease	disease	NOUN
ajlm-708	3	232	control	control	NOUN
ajlm-708	3	233	and	and	CCONJ
ajlm-708	3	234	prevention	prevention	NOUN
ajlm-708	3	235	,	,	PUNCT
ajlm-708	3	236	atlanta	atlanta	PROPN
ajlm-708	3	237	,	,	PUNCT
ajlm-708	3	238	georgia	georgia	PROPN
ajlm-708	3	239	,	,	PUNCT
ajlm-708	3	240	united	united	PROPN
ajlm-708	3	241	states	states	PROPN
ajlm-708	3	242	citation	citation	PROPN
ajlm-708	3	243	zhou	zhou	PROPN
ajlm-708	4	1	z	z	PROPN
ajlm-708	4	2	,	,	PUNCT
ajlm-708	4	3	tang	tang	PROPN
ajlm-708	5	1	k	k	PROPN
ajlm-708	5	2	,	,	PUNCT
ajlm-708	5	3	zhang	zhang	PROPN
ajlm-708	5	4	g	g	PROPN
ajlm-708	5	5	,	,	PUNCT
ajlm-708	5	6	et	et	PROPN
ajlm-708	5	7	al	al	PROPN
ajlm-708	5	8	.	.	PUNCT
ajlm-708	5	9	detection	detection	NOUN
ajlm-708	5	10	of	of	ADP
ajlm-708	5	11	minority	minority	NOUN
ajlm-708	5	12	drug	drug	NOUN
ajlm-708	5	13	resistant	resistant	ADJ
ajlm-708	5	14	mutations	mutation	NOUN
ajlm-708	5	15	in	in	ADP
ajlm-708	5	16	malawian	malawian	ADJ
ajlm-708	5	17	hiv-1	hiv-1	X
ajlm-708	5	18	subtype	subtype	NOUN
ajlm-708	5	19	c	c	NOUN
ajlm-708	5	20	-	-	PUNCT
ajlm-708	5	21	positive	positive	ADJ
ajlm-708	5	22	patients	patient	NOUN
ajlm-708	5	23	initiating	initiate	VERB
ajlm-708	5	24	and	and	CCONJ
ajlm-708	5	25	on	on	ADP
ajlm-708	5	26	first	first	ADJ
ajlm-708	5	27	-	-	PUNCT
ajlm-708	5	28	line	line	NOUN
ajlm-708	5	29	antiretroviral	antiretroviral	ADJ
ajlm-708	5	30	therapy	therapy	NOUN
ajlm-708	5	31	.	.	PUNCT
ajlm-708	6	1	afr	afr	PROPN
ajlm-708	6	2	j	j	PROPN
ajlm-708	6	3	lab	lab	PROPN
ajlm-708	6	4	med	med	PROPN
ajlm-708	6	5	.	.	PUNCT
ajlm-708	6	6	2018;7(1	2018;7(1	NUM
ajlm-708	6	7	)	)	PUNCT
ajlm-708	6	8	,	,	PUNCT
ajlm-708	6	9	a708	a708	PROPN
ajlm-708	6	10	.	.	PUNCT
ajlm-708	6	11	https://doi.org/10.4102/ajlm.v7i1.708	https://doi.org/10.4102/ajlm.v7i1.708	PROPN
ajlm-708	6	12	original	original	ADJ
ajlm-708	6	13	research	research	NOUN
ajlm-708	6	14	detection	detection	NOUN
ajlm-708	6	15	of	of	ADP
ajlm-708	6	16	minority	minority	NOUN
ajlm-708	6	17	drug	drug	NOUN
ajlm-708	6	18	resistant	resistant	ADJ
ajlm-708	6	19	mutations	mutation	NOUN
ajlm-708	6	20	in	in	ADP
ajlm-708	6	21	malawian	malawian	ADJ
ajlm-708	6	22	hiv-1	hiv-1	X
ajlm-708	6	23	subtype	subtype	NOUN
ajlm-708	6	24	c	c	NOUN
ajlm-708	6	25	-	-	PUNCT
ajlm-708	6	26	positive	positive	ADJ
ajlm-708	6	27	patients	patient	NOUN
ajlm-708	6	28	initiating	initiate	VERB
ajlm-708	6	29	and	and	CCONJ
ajlm-708	6	30	on	on	ADP
ajlm-708	6	31	first	first	ADJ
ajlm-708	6	32	-	-	PUNCT
ajlm-708	6	33	line	line	NOUN
ajlm-708	6	34	antiretroviral	antiretroviral	ADJ
ajlm-708	6	35	therapy	therapy	NOUN
ajlm-708	6	36	zhiyong	zhiyong	PROPN
ajlm-708	6	37	zhou	zhou	PROPN
ajlm-708	6	38	,	,	PUNCT
ajlm-708	6	39	kevin	kevin	PROPN
ajlm-708	6	40	tang	tang	PROPN
ajlm-708	6	41	,	,	PUNCT
ajlm-708	6	42	guoqing	guoqe	VERB
ajlm-708	6	43	zhang	zhang	PROPN
ajlm-708	6	44	,	,	PUNCT
ajlm-708	6	45	nellie	nellie	PROPN
ajlm-708	6	46	wadonda	wadonda	PROPN
ajlm-708	6	47	-	-	PUNCT
ajlm-708	6	48	kabondo	kabondo	NOUN
ajlm-708	6	49	,	,	PUNCT
ajlm-708	6	50	kundai	kundai	PROPN
ajlm-708	6	51	moyo	moyo	PROPN
ajlm-708	6	52	,	,	PUNCT
ajlm-708	6	53	lori	lori	PROPN
ajlm-708	6	54	a.	a.	PROPN
ajlm-708	6	55	rowe	rowe	PROPN
ajlm-708	6	56	,	,	PUNCT
ajlm-708	6	57	joshua	joshua	PROPN
ajlm-708	6	58	r.	r.	PROPN
ajlm-708	6	59	devos	devos	PROPN
ajlm-708	6	60	,	,	PUNCT
ajlm-708	6	61	nick	nick	PROPN
ajlm-708	6	62	wagar	wagar	PROPN
ajlm-708	6	63	,	,	PUNCT
ajlm-708	6	64	du	du	ADJ
ajlm-708	6	65	-	-	ADJ
ajlm-708	6	66	ping	ping	ADJ
ajlm-708	6	67	zheng	zheng	PROPN
ajlm-708	6	68	,	,	PUNCT
ajlm-708	6	69	hongxiong	hongxiong	PROPN
ajlm-708	6	70	guo	guo	PROPN
ajlm-708	6	71	,	,	PUNCT
ajlm-708	6	72	john	john	PROPN
ajlm-708	6	73	nkengasong	nkengasong	PROPN
ajlm-708	6	74	,	,	PUNCT
ajlm-708	6	75	mike	mike	PROPN
ajlm-708	6	76	frace	frace	NOUN
ajlm-708	6	77	,	,	PUNCT
ajlm-708	6	78	scott	scott	PROPN
ajlm-708	6	79	sammons	sammons	PROPN
ajlm-708	6	80	,	,	PUNCT
ajlm-708	6	81	chunfu	chunfu	NOUN
ajlm-708	6	82	yang	yang	PROPN
ajlm-708	6	83	received	receive	VERB
ajlm-708	6	84	:	:	PUNCT
ajlm-708	6	85	13	13	NUM
ajlm-708	6	86	oct	oct	PROPN
ajlm-708	6	87	.	.	PROPN
ajlm-708	6	88	2017	2017	NUM
ajlm-708	6	89	;	;	PUNCT
ajlm-708	6	90	accepted	accept	VERB
ajlm-708	6	91	:	:	PUNCT
ajlm-708	6	92	01	01	NUM
ajlm-708	6	93	feb	feb	NOUN
ajlm-708	6	94	.	.	PROPN
ajlm-708	6	95	2018	2018	NUM
ajlm-708	6	96	;	;	PUNCT
ajlm-708	6	97	published	publish	VERB
ajlm-708	6	98	:	:	PUNCT
ajlm-708	6	99	30	30	NUM
ajlm-708	6	100	may	may	PROPN
ajlm-708	6	101	2018	2018	NUM
ajlm-708	6	102	copyright	copyright	NOUN
ajlm-708	6	103	:	:	PUNCT
ajlm-708	6	104	©	©	PROPN
ajlm-708	6	105	2018	2018	NUM
ajlm-708	6	106	.	.	PUNCT
ajlm-708	7	1	the	the	DET
ajlm-708	7	2	author(s	author(s	PROPN
ajlm-708	7	3	)	)	PUNCT
ajlm-708	7	4	.	.	PUNCT
ajlm-708	8	1	licensee	licensee	NOUN
ajlm-708	8	2	:	:	PUNCT
ajlm-708	8	3	aosis	aosis	NOUN
ajlm-708	8	4	.	.	PUNCT
ajlm-708	9	1	this	this	PRON
ajlm-708	9	2	is	be	AUX
ajlm-708	9	3	an	an	DET
ajlm-708	9	4	open	open	ADJ
ajlm-708	9	5	access	access	NOUN
ajlm-708	9	6	article	article	NOUN
ajlm-708	9	7	distributed	distribute	VERB
ajlm-708	9	8	under	under	ADP
ajlm-708	9	9	the	the	DET
ajlm-708	9	10	terms	term	NOUN
ajlm-708	9	11	of	of	ADP
ajlm-708	9	12	the	the	DET
ajlm-708	9	13	creative	creative	ADJ
ajlm-708	9	14	commons	common	NOUN
ajlm-708	9	15	attribution	attribution	NOUN
ajlm-708	9	16	license	license	NOUN
ajlm-708	9	17	,	,	PUNCT
ajlm-708	9	18	which	which	PRON
ajlm-708	9	19	permits	permit	VERB
ajlm-708	9	20	unrestricted	unrestricted	ADJ
ajlm-708	9	21	use	use	NOUN
ajlm-708	9	22	,	,	PUNCT
ajlm-708	9	23	distribution	distribution	NOUN
ajlm-708	9	24	,	,	PUNCT
ajlm-708	9	25	and	and	CCONJ
ajlm-708	9	26	reproduction	reproduction	NOUN
ajlm-708	9	27	in	in	ADP
ajlm-708	9	28	any	any	DET
ajlm-708	9	29	medium	medium	NOUN
ajlm-708	9	30	,	,	PUNCT
ajlm-708	9	31	provided	provide	VERB
ajlm-708	9	32	the	the	DET
ajlm-708	9	33	original	original	ADJ
ajlm-708	9	34	work	work	NOUN
ajlm-708	9	35	is	be	AUX
ajlm-708	9	36	properly	properly	ADV
ajlm-708	9	37	cited	cite	VERB
ajlm-708	9	38	.	.	PUNCT
ajlm-708	10	1	abstract	abstract	ADJ
ajlm-708	10	2	background	background	NOUN
ajlm-708	10	3	:	:	PUNCT
ajlm-708	10	4	minority	minority	NOUN
ajlm-708	10	5	drug	drug	NOUN
ajlm-708	10	6	resistance	resistance	NOUN
ajlm-708	10	7	mutations	mutation	NOUN
ajlm-708	10	8	(	(	PUNCT
ajlm-708	10	9	drms	drm	NOUN
ajlm-708	10	10	)	)	PUNCT
ajlm-708	10	11	that	that	PRON
ajlm-708	10	12	are	be	AUX
ajlm-708	10	13	often	often	ADV
ajlm-708	10	14	missed	miss	VERB
ajlm-708	10	15	by	by	ADP
ajlm-708	10	16	sanger	sanger	PROPN
ajlm-708	10	17	sequencing	sequencing	NOUN
ajlm-708	10	18	are	be	AUX
ajlm-708	10	19	clinically	clinically	ADV
ajlm-708	10	20	significant	significant	ADJ
ajlm-708	10	21	,	,	PUNCT
ajlm-708	10	22	as	as	SCONJ
ajlm-708	10	23	they	they	PRON
ajlm-708	10	24	can	can	AUX
ajlm-708	10	25	cause	cause	VERB
ajlm-708	10	26	virologic	virologic	ADJ
ajlm-708	10	27	failure	failure	NOUN
ajlm-708	10	28	in	in	ADP
ajlm-708	10	29	individuals	individual	NOUN
ajlm-708	10	30	treated	treat	VERB
ajlm-708	10	31	with	with	ADP
ajlm-708	10	32	antiretroviral	antiretroviral	ADJ
ajlm-708	10	33	therapy	therapy	NOUN
ajlm-708	10	34	(	(	PUNCT
ajlm-708	10	35	art	art	NOUN
ajlm-708	10	36	)	)	PUNCT
ajlm-708	10	37	drugs	drug	NOUN
ajlm-708	10	38	.	.	PUNCT
ajlm-708	11	1	objective	objective	NOUN
ajlm-708	11	2	:	:	PUNCT
ajlm-708	11	3	this	this	DET
ajlm-708	11	4	study	study	NOUN
ajlm-708	11	5	aimed	aim	VERB
ajlm-708	11	6	to	to	PART
ajlm-708	11	7	estimate	estimate	VERB
ajlm-708	11	8	the	the	DET
ajlm-708	11	9	prevalence	prevalence	NOUN
ajlm-708	11	10	of	of	ADP
ajlm-708	11	11	minor	minor	ADJ
ajlm-708	11	12	drms	drm	NOUN
ajlm-708	11	13	among	among	ADP
ajlm-708	11	14	patients	patient	NOUN
ajlm-708	11	15	enrolled	enrol	VERB
ajlm-708	11	16	in	in	ADP
ajlm-708	11	17	a	a	DET
ajlm-708	11	18	malawi	malawi	NOUN
ajlm-708	11	19	hiv	hiv	PROPN
ajlm-708	11	20	drug	drug	PROPN
ajlm-708	11	21	resistance	resistance	NOUN
ajlm-708	11	22	monitoring	monitoring	NOUN
ajlm-708	11	23	survey	survey	NOUN
ajlm-708	11	24	at	at	ADP
ajlm-708	11	25	baseline	baseline	NOUN
ajlm-708	11	26	and	and	CCONJ
ajlm-708	11	27	at	at	ADP
ajlm-708	11	28	one	one	NUM
ajlm-708	11	29	year	year	NOUN
ajlm-708	11	30	after	after	ADP
ajlm-708	11	31	initiation	initiation	NOUN
ajlm-708	11	32	of	of	ADP
ajlm-708	11	33	art	art	NOUN
ajlm-708	11	34	.	.	PUNCT
ajlm-708	12	1	methods	method	NOUN
ajlm-708	12	2	:	:	PUNCT
ajlm-708	12	3	forty	forty	NUM
ajlm-708	12	4	-	-	PUNCT
ajlm-708	12	5	one	one	NUM
ajlm-708	12	6	plasma	plasma	NOUN
ajlm-708	12	7	specimens	specimen	NOUN
ajlm-708	12	8	collected	collect	VERB
ajlm-708	12	9	from	from	ADP
ajlm-708	12	10	hiv-1	hiv-1	X
ajlm-708	12	11	subtype	subtype	NOUN
ajlm-708	12	12	c	c	NOUN
ajlm-708	12	13	-	-	PUNCT
ajlm-708	12	14	positive	positive	ADJ
ajlm-708	12	15	patients	patient	NOUN
ajlm-708	12	16	and	and	CCONJ
ajlm-708	12	17	seven	seven	NUM
ajlm-708	12	18	clonal	clonal	ADJ
ajlm-708	12	19	control	control	NOUN
ajlm-708	12	20	samples	sample	NOUN
ajlm-708	12	21	were	be	AUX
ajlm-708	12	22	analysed	analyse	VERB
ajlm-708	12	23	using	use	VERB
ajlm-708	12	24	ultra	ultra	ADJ
ajlm-708	12	25	-	-	ADJ
ajlm-708	12	26	deep	deep	ADJ
ajlm-708	12	27	sequencing	sequencing	NOUN
ajlm-708	12	28	technology	technology	NOUN
ajlm-708	12	29	.	.	PUNCT
ajlm-708	13	1	results	result	NOUN
ajlm-708	13	2	:	:	PUNCT
ajlm-708	13	3	deep	deep	ADJ
ajlm-708	13	4	sequencing	sequencing	NOUN
ajlm-708	13	5	identified	identify	VERB
ajlm-708	13	6	all	all	DET
ajlm-708	13	7	72	72	NUM
ajlm-708	13	8	drms	drm	NOUN
ajlm-708	13	9	detected	detect	VERB
ajlm-708	13	10	by	by	ADP
ajlm-708	13	11	sanger	sanger	PROPN
ajlm-708	13	12	sequencing	sequence	VERB
ajlm-708	13	13	at	at	ADP
ajlm-708	13	14	the	the	DET
ajlm-708	13	15	level	level	NOUN
ajlm-708	13	16	of	of	ADP
ajlm-708	13	17	≥20	≥20	NOUN
ajlm-708	13	18	%	%	NOUN
ajlm-708	13	19	and	and	CCONJ
ajlm-708	13	20	79	79	NUM
ajlm-708	13	21	additional	additional	ADJ
ajlm-708	13	22	minority	minority	NOUN
ajlm-708	13	23	drms	drm	NOUN
ajlm-708	13	24	at	at	ADP
ajlm-708	13	25	the	the	DET
ajlm-708	13	26	level	level	NOUN
ajlm-708	13	27	of	of	ADP
ajlm-708	13	28	<	<	X
ajlm-708	13	29	20	20	NUM
ajlm-708	13	30	%	%	NOUN
ajlm-708	13	31	from	from	ADP
ajlm-708	13	32	the	the	DET
ajlm-708	13	33	41	41	NUM
ajlm-708	13	34	malawian	malawian	ADJ
ajlm-708	13	35	clinical	clinical	ADJ
ajlm-708	13	36	specimens	specimen	NOUN
ajlm-708	13	37	.	.	PUNCT
ajlm-708	14	1	overall	overall	ADJ
ajlm-708	14	2	,	,	PUNCT
ajlm-708	14	3	drms	drm	NOUN
ajlm-708	14	4	were	be	AUX
ajlm-708	14	5	detected	detect	VERB
ajlm-708	14	6	in	in	ADP
ajlm-708	14	7	85	85	NUM
ajlm-708	14	8	%	%	NOUN
ajlm-708	14	9	of	of	ADP
ajlm-708	14	10	pre	pre	NOUN
ajlm-708	14	11	-	-	NOUN
ajlm-708	14	12	art	art	NOUN
ajlm-708	14	13	and	and	CCONJ
ajlm-708	14	14	90.5	90.5	NUM
ajlm-708	14	15	%	%	NOUN
ajlm-708	14	16	of	of	ADP
ajlm-708	14	17	virologic	virologic	ADJ
ajlm-708	14	18	failure	failure	NOUN
ajlm-708	14	19	patients	patient	NOUN
ajlm-708	14	20	by	by	ADP
ajlm-708	14	21	deep	deep	ADJ
ajlm-708	14	22	sequencing	sequencing	NOUN
ajlm-708	14	23	.	.	PUNCT
ajlm-708	15	1	among	among	ADP
ajlm-708	15	2	pre	pre	ADJ
ajlm-708	15	3	-	-	ADJ
ajlm-708	15	4	art	art	ADJ
ajlm-708	15	5	patients	patient	NOUN
ajlm-708	15	6	,	,	PUNCT
ajlm-708	15	7	deep	deep	ADJ
ajlm-708	15	8	sequencing	sequencing	NOUN
ajlm-708	15	9	identified	identify	VERB
ajlm-708	15	10	a	a	DET
ajlm-708	15	11	statistically	statistically	ADV
ajlm-708	15	12	significant	significant	ADJ
ajlm-708	15	13	higher	high	ADJ
ajlm-708	15	14	prevalence	prevalence	NOUN
ajlm-708	15	15	of	of	ADP
ajlm-708	15	16	drms	drm	NOUN
ajlm-708	15	17	to	to	PART
ajlm-708	15	18	nucleoside	nucleoside	VERB
ajlm-708	15	19	reverse	reverse	VERB
ajlm-708	15	20	transcriptase	transcriptase	NOUN
ajlm-708	15	21	inhibitors	inhibitor	NOUN
ajlm-708	15	22	(	(	PUNCT
ajlm-708	15	23	nrtis	nrtis	PROPN
ajlm-708	15	24	)	)	PUNCT
ajlm-708	15	25	compared	compare	VERB
ajlm-708	15	26	with	with	ADP
ajlm-708	15	27	sanger	sanger	PROPN
ajlm-708	15	28	sequencing	sequencing	NOUN
ajlm-708	15	29	.	.	PUNCT
ajlm-708	16	1	the	the	DET
ajlm-708	16	2	difference	difference	NOUN
ajlm-708	16	3	was	be	AUX
ajlm-708	16	4	mainly	mainly	ADV
ajlm-708	16	5	due	due	ADJ
ajlm-708	16	6	to	to	ADP
ajlm-708	16	7	the	the	DET
ajlm-708	16	8	high	high	ADJ
ajlm-708	16	9	prevalence	prevalence	NOUN
ajlm-708	16	10	of	of	ADP
ajlm-708	16	11	minority	minority	NOUN
ajlm-708	16	12	k65r	k65r	PROPN
ajlm-708	16	13	and	and	CCONJ
ajlm-708	16	14	m184i	m184i	PROPN
ajlm-708	16	15	mutations	mutation	NOUN
ajlm-708	16	16	.	.	PUNCT
ajlm-708	17	1	most	most	ADJ
ajlm-708	17	2	virologic	virologic	ADJ
ajlm-708	17	3	failure	failure	NOUN
ajlm-708	17	4	patients	patient	NOUN
ajlm-708	17	5	harboured	harbour	VERB
ajlm-708	17	6	drms	drm	NOUN
ajlm-708	17	7	against	against	ADP
ajlm-708	17	8	both	both	DET
ajlm-708	17	9	nrtis	nrtis	PROPN
ajlm-708	17	10	and	and	CCONJ
ajlm-708	17	11	non	non	ADJ
ajlm-708	17	12	-	-	ADJ
ajlm-708	17	13	nucleoside	nucleoside	ADJ
ajlm-708	17	14	reverse	reverse	ADJ
ajlm-708	17	15	transcriptase	transcriptase	NOUN
ajlm-708	17	16	inhibitors	inhibitor	NOUN
ajlm-708	17	17	(	(	PUNCT
ajlm-708	17	18	nnrtis	nnrtis	ADJ
ajlm-708	17	19	)	)	PUNCT
ajlm-708	17	20	.	.	PUNCT
ajlm-708	18	1	these	these	DET
ajlm-708	18	2	minority	minority	NOUN
ajlm-708	18	3	drms	drm	NOUN
ajlm-708	18	4	contributed	contribute	VERB
ajlm-708	18	5	to	to	ADP
ajlm-708	18	6	the	the	DET
ajlm-708	18	7	increased	increase	VERB
ajlm-708	18	8	or	or	CCONJ
ajlm-708	18	9	enhanced	enhance	VERB
ajlm-708	18	10	virologic	virologic	ADJ
ajlm-708	18	11	failures	failure	NOUN
ajlm-708	18	12	in	in	ADP
ajlm-708	18	13	these	these	DET
ajlm-708	18	14	patients	patient	NOUN
ajlm-708	18	15	.	.	PUNCT
ajlm-708	19	1	conclusion	conclusion	NOUN
ajlm-708	19	2	:	:	PUNCT
ajlm-708	19	3	the	the	DET
ajlm-708	19	4	results	result	NOUN
ajlm-708	19	5	revealed	reveal	VERB
ajlm-708	19	6	the	the	DET
ajlm-708	19	7	presence	presence	NOUN
ajlm-708	19	8	of	of	ADP
ajlm-708	19	9	minority	minority	NOUN
ajlm-708	19	10	drms	drm	NOUN
ajlm-708	19	11	to	to	ADP
ajlm-708	19	12	nrtis	nrtis	PROPN
ajlm-708	19	13	and	and	CCONJ
ajlm-708	19	14	nnrtis	nnrtis	ADJ
ajlm-708	19	15	in	in	ADP
ajlm-708	19	16	specimens	specimen	NOUN
ajlm-708	19	17	collected	collect	VERB
ajlm-708	19	18	at	at	ADP
ajlm-708	19	19	baseline	baseline	ADJ
ajlm-708	19	20	and	and	CCONJ
ajlm-708	19	21	virologic	virologic	ADJ
ajlm-708	19	22	failure	failure	NOUN
ajlm-708	19	23	time	time	NOUN
ajlm-708	19	24	points	point	NOUN
ajlm-708	19	25	.	.	PUNCT
ajlm-708	20	1	these	these	DET
ajlm-708	20	2	minority	minority	NOUN
ajlm-708	20	3	drms	drm	NOUN
ajlm-708	20	4	not	not	PART
ajlm-708	20	5	only	only	ADV
ajlm-708	20	6	increased	increase	VERB
ajlm-708	20	7	resistance	resistance	NOUN
ajlm-708	20	8	levels	level	NOUN
ajlm-708	20	9	to	to	ADP
ajlm-708	20	10	nrtis	nrtis	PROPN
ajlm-708	20	11	and	and	CCONJ
ajlm-708	20	12	nnrtis	nnrtis	ADJ
ajlm-708	20	13	for	for	ADP
ajlm-708	20	14	the	the	DET
ajlm-708	20	15	prescribed	prescribed	ADJ
ajlm-708	20	16	art	art	NOUN
ajlm-708	20	17	,	,	PUNCT
ajlm-708	20	18	but	but	CCONJ
ajlm-708	20	19	also	also	ADV
ajlm-708	20	20	expanded	expand	VERB
ajlm-708	20	21	resistance	resistance	NOUN
ajlm-708	20	22	to	to	ADP
ajlm-708	20	23	additional	additional	ADJ
ajlm-708	20	24	major	major	ADJ
ajlm-708	20	25	first	first	ADJ
ajlm-708	20	26	-	-	PUNCT
ajlm-708	20	27	line	line	NOUN
ajlm-708	20	28	art	art	NOUN
ajlm-708	20	29	drugs	drug	NOUN
ajlm-708	20	30	.	.	PUNCT
ajlm-708	21	1	this	this	DET
ajlm-708	21	2	study	study	NOUN
ajlm-708	21	3	suggested	suggest	VERB
ajlm-708	21	4	that	that	SCONJ
ajlm-708	21	5	drug	drug	NOUN
ajlm-708	21	6	resistance	resistance	NOUN
ajlm-708	21	7	testing	testing	NOUN
ajlm-708	21	8	that	that	PRON
ajlm-708	21	9	uses	use	VERB
ajlm-708	21	10	more	more	ADJ
ajlm-708	21	11	sensitive	sensitive	ADJ
ajlm-708	21	12	technologies	technology	NOUN
ajlm-708	21	13	,	,	PUNCT
ajlm-708	21	14	is	be	AUX
ajlm-708	21	15	needed	need	VERB
ajlm-708	21	16	in	in	ADP
ajlm-708	21	17	this	this	DET
ajlm-708	21	18	setting	setting	NOUN
ajlm-708	21	19	.	.	PUNCT
ajlm-708	22	1	introduction	introduction	NOUN
ajlm-708	22	2	rapid	rapid	ADJ
ajlm-708	22	3	scale	scale	NOUN
ajlm-708	22	4	-	-	PUNCT
ajlm-708	22	5	up	up	NOUN
ajlm-708	22	6	of	of	ADP
ajlm-708	22	7	antiretroviral	antiretroviral	ADJ
ajlm-708	22	8	therapy	therapy	NOUN
ajlm-708	22	9	(	(	PUNCT
ajlm-708	22	10	art	art	NOUN
ajlm-708	22	11	)	)	PUNCT
ajlm-708	22	12	over	over	ADP
ajlm-708	22	13	the	the	DET
ajlm-708	22	14	past	past	ADJ
ajlm-708	22	15	decade	decade	NOUN
ajlm-708	22	16	has	have	AUX
ajlm-708	22	17	remarkably	remarkably	ADV
ajlm-708	22	18	reduced	reduce	VERB
ajlm-708	22	19	the	the	DET
ajlm-708	22	20	mortality	mortality	NOUN
ajlm-708	22	21	and	and	CCONJ
ajlm-708	22	22	morbidity	morbidity	NOUN
ajlm-708	22	23	of	of	ADP
ajlm-708	22	24	hiv	hiv	PROPN
ajlm-708	22	25	-	-	PUNCT
ajlm-708	22	26	positive	positive	ADJ
ajlm-708	22	27	patients	patient	NOUN
ajlm-708	22	28	and	and	CCONJ
ajlm-708	22	29	decreased	decrease	VERB
ajlm-708	22	30	hiv	hiv	PROPN
ajlm-708	22	31	transmission	transmission	NOUN
ajlm-708	22	32	.	.	PUNCT
ajlm-708	23	1	seventeen	seventeen	NUM
ajlm-708	23	2	million	million	NUM
ajlm-708	23	3	hiv-1	hiv-1	X
ajlm-708	23	4	-	-	PUNCT
ajlm-708	23	5	positive	positive	ADJ
ajlm-708	23	6	patients	patient	NOUN
ajlm-708	23	7	around	around	ADP
ajlm-708	23	8	the	the	DET
ajlm-708	23	9	world	world	NOUN
ajlm-708	23	10	were	be	AUX
ajlm-708	23	11	receiving	receive	VERB
ajlm-708	23	12	art	art	NOUN
ajlm-708	23	13	by	by	ADP
ajlm-708	23	14	the	the	DET
ajlm-708	23	15	end	end	NOUN
ajlm-708	23	16	of	of	ADP
ajlm-708	23	17	2015.1	2015.1	NUM
ajlm-708	23	18	however	however	ADV
ajlm-708	23	19	,	,	PUNCT
ajlm-708	23	20	the	the	DET
ajlm-708	23	21	scale	scale	NOUN
ajlm-708	23	22	-	-	PUNCT
ajlm-708	23	23	up	up	NOUN
ajlm-708	23	24	of	of	ADP
ajlm-708	23	25	art	art	NOUN
ajlm-708	23	26	in	in	ADP
ajlm-708	23	27	resource	resource	NOUN
ajlm-708	23	28	-	-	PUNCT
ajlm-708	23	29	limited	limit	VERB
ajlm-708	23	30	settings	setting	NOUN
ajlm-708	23	31	without	without	ADP
ajlm-708	23	32	adequate	adequate	ADJ
ajlm-708	23	33	treatment	treatment	NOUN
ajlm-708	23	34	monitoring	monitoring	NOUN
ajlm-708	23	35	has	have	AUX
ajlm-708	23	36	raised	raise	VERB
ajlm-708	23	37	concern	concern	NOUN
ajlm-708	23	38	about	about	ADP
ajlm-708	23	39	the	the	DET
ajlm-708	23	40	development	development	NOUN
ajlm-708	23	41	of	of	ADP
ajlm-708	23	42	hiv	hiv	PROPN
ajlm-708	23	43	drug	drug	NOUN
ajlm-708	23	44	resistance	resistance	NOUN
ajlm-708	23	45	.	.	PUNCT
ajlm-708	24	1	the	the	DET
ajlm-708	24	2	quasi	quasi	ADJ
ajlm-708	24	3	-	-	ADJ
ajlm-708	24	4	species	species	ADJ
ajlm-708	24	5	nature	nature	NOUN
ajlm-708	24	6	of	of	ADP
ajlm-708	24	7	hiv-1	hiv-1	PUNCT
ajlm-708	24	8	makes	make	VERB
ajlm-708	24	9	the	the	DET
ajlm-708	24	10	detection	detection	NOUN
ajlm-708	24	11	of	of	ADP
ajlm-708	24	12	drug	drug	NOUN
ajlm-708	24	13	resistant	resistant	ADJ
ajlm-708	24	14	mutations	mutation	NOUN
ajlm-708	24	15	(	(	PUNCT
ajlm-708	24	16	drms	drm	NOUN
ajlm-708	24	17	)	)	PUNCT
ajlm-708	24	18	more	more	ADV
ajlm-708	24	19	difficult	difficult	ADJ
ajlm-708	24	20	,	,	PUNCT
ajlm-708	24	21	because	because	SCONJ
ajlm-708	24	22	the	the	DET
ajlm-708	24	23	commonly	commonly	ADV
ajlm-708	24	24	-	-	PUNCT
ajlm-708	24	25	used	use	VERB
ajlm-708	24	26	sanger	sanger	PROPN
ajlm-708	24	27	sequencing	sequence	VERB
ajlm-708	24	28	for	for	ADP
ajlm-708	24	29	drug	drug	NOUN
ajlm-708	24	30	resistance	resistance	NOUN
ajlm-708	24	31	testing	testing	NOUN
ajlm-708	24	32	is	be	AUX
ajlm-708	24	33	incapable	incapable	ADJ
ajlm-708	24	34	of	of	ADP
ajlm-708	24	35	detecting	detect	VERB
ajlm-708	24	36	these	these	DET
ajlm-708	24	37	drug	drug	NOUN
ajlm-708	24	38	resistant	resistant	ADJ
ajlm-708	24	39	hiv	hiv	PROPN
ajlm-708	24	40	variants	variant	NOUN
ajlm-708	24	41	at	at	ADP
ajlm-708	24	42	a	a	DET
ajlm-708	24	43	level	level	NOUN
ajlm-708	24	44	of	of	ADP
ajlm-708	24	45	less	less	ADJ
ajlm-708	24	46	than	than	ADP
ajlm-708	24	47	20	20	NUM
ajlm-708	24	48	%	%	NOUN
ajlm-708	24	49	of	of	ADP
ajlm-708	24	50	the	the	DET
ajlm-708	24	51	viral	viral	ADJ
ajlm-708	24	52	population.2,3,4,5	population.2,3,4,5	NOUN
ajlm-708	24	53	minority	minority	NOUN
ajlm-708	24	54	drug	drug	NOUN
ajlm-708	24	55	resistant	resistant	ADJ
ajlm-708	24	56	variants	variant	NOUN
ajlm-708	24	57	(	(	PUNCT
ajlm-708	24	58	also	also	ADV
ajlm-708	24	59	known	know	VERB
ajlm-708	24	60	as	as	ADP
ajlm-708	24	61	low	low	ADJ
ajlm-708	24	62	-	-	PUNCT
ajlm-708	24	63	frequency	frequency	NOUN
ajlm-708	24	64	mutants	mutant	NOUN
ajlm-708	24	65	)	)	PUNCT
ajlm-708	24	66	that	that	PRON
ajlm-708	24	67	are	be	AUX
ajlm-708	24	68	not	not	PART
ajlm-708	24	69	detected	detect	VERB
ajlm-708	24	70	by	by	ADP
ajlm-708	24	71	sanger	sanger	PROPN
ajlm-708	24	72	sequencing	sequencing	NOUN
ajlm-708	24	73	are	be	AUX
ajlm-708	24	74	clinically	clinically	ADV
ajlm-708	24	75	important	important	ADJ
ajlm-708	24	76	,	,	PUNCT
ajlm-708	24	77	as	as	SCONJ
ajlm-708	24	78	they	they	PRON
ajlm-708	24	79	can	can	AUX
ajlm-708	24	80	cause	cause	VERB
ajlm-708	24	81	virologic	virologic	ADJ
ajlm-708	24	82	failure	failure	NOUN
ajlm-708	24	83	in	in	ADP
ajlm-708	24	84	patients	patient	NOUN
ajlm-708	24	85	treated	treat	VERB
ajlm-708	24	86	with	with	ADP
ajlm-708	24	87	art	art	NOUN
ajlm-708	24	88	for	for	ADP
ajlm-708	24	89	the	the	DET
ajlm-708	24	90	first	first	ADJ
ajlm-708	24	91	time.6,7,8,9	time.6,7,8,9	NOUN
ajlm-708	24	92	recent	recent	ADJ
ajlm-708	24	93	studies	study	NOUN
ajlm-708	24	94	have	have	AUX
ajlm-708	24	95	demonstrated	demonstrate	VERB
ajlm-708	24	96	that	that	SCONJ
ajlm-708	24	97	particular	particular	ADJ
ajlm-708	24	98	drug	drug	NOUN
ajlm-708	24	99	resistant	resistant	ADJ
ajlm-708	24	100	hiv	hiv	PROPN
ajlm-708	24	101	mutant	mutant	NOUN
ajlm-708	24	102	viruses	virus	NOUN
ajlm-708	24	103	are	be	AUX
ajlm-708	24	104	clinically	clinically	ADV
ajlm-708	24	105	significant	significant	ADJ
ajlm-708	24	106	at	at	ADP
ajlm-708	24	107	a	a	DET
ajlm-708	24	108	level	level	NOUN
ajlm-708	24	109	of	of	ADP
ajlm-708	24	110	1	1	NUM
ajlm-708	24	111	%	%	NOUN
ajlm-708	24	112	of	of	ADP
ajlm-708	24	113	the	the	DET
ajlm-708	24	114	viral	viral	ADJ
ajlm-708	24	115	population	population	NOUN
ajlm-708	24	116	,	,	PUNCT
ajlm-708	24	117	as	as	SCONJ
ajlm-708	24	118	the	the	DET
ajlm-708	24	119	minority	minority	NOUN
ajlm-708	24	120	variants	variant	NOUN
ajlm-708	24	121	can	can	AUX
ajlm-708	24	122	replicate	replicate	VERB
ajlm-708	24	123	quickly	quickly	ADV
ajlm-708	24	124	and	and	CCONJ
ajlm-708	24	125	become	become	VERB
ajlm-708	24	126	the	the	DET
ajlm-708	24	127	predominant	predominant	ADJ
ajlm-708	24	128	viral	viral	ADJ
ajlm-708	24	129	population	population	NOUN
ajlm-708	24	130	through	through	ADP
ajlm-708	24	131	the	the	DET
ajlm-708	24	132	selective	selective	ADJ
ajlm-708	24	133	pressure	pressure	NOUN
ajlm-708	24	134	of	of	ADP
ajlm-708	24	135	art	art	NOUN
ajlm-708	24	136	drugs	drug	NOUN
ajlm-708	24	137	,	,	PUNCT
ajlm-708	24	138	leading	lead	VERB
ajlm-708	24	139	to	to	ADP
ajlm-708	24	140	treatment	treatment	NOUN
ajlm-708	24	141	failure.9,10	failure.9,10	NOUN
ajlm-708	24	142	however	however	ADV
ajlm-708	24	143	,	,	PUNCT
ajlm-708	24	144	in	in	ADP
ajlm-708	24	145	the	the	DET
ajlm-708	24	146	absence	absence	NOUN
ajlm-708	24	147	of	of	ADP
ajlm-708	24	148	drug	drug	NOUN
ajlm-708	24	149	pressure	pressure	NOUN
ajlm-708	24	150	in	in	ADP
ajlm-708	24	151	treatment	treatment	NOUN
ajlm-708	24	152	-	-	PUNCT
ajlm-708	24	153	naïve	naïve	ADJ
ajlm-708	24	154	patients	patient	NOUN
ajlm-708	24	155	,	,	PUNCT
ajlm-708	24	156	the	the	DET
ajlm-708	24	157	stability	stability	NOUN
ajlm-708	24	158	of	of	ADP
ajlm-708	24	159	transmitted	transmit	VERB
ajlm-708	24	160	drms	drm	NOUN
ajlm-708	24	161	is	be	AUX
ajlm-708	24	162	different.11	different.11	NOUN
ajlm-708	24	163	for	for	ADP
ajlm-708	24	164	instance	instance	NOUN
ajlm-708	24	165	,	,	PUNCT
ajlm-708	24	166	a	a	DET
ajlm-708	24	167	transmitted	transmit	VERB
ajlm-708	24	168	m184v	m184v	PROPN
ajlm-708	24	169	mutation	mutation	NOUN
ajlm-708	24	170	can	can	AUX
ajlm-708	24	171	quickly	quickly	ADV
ajlm-708	24	172	revert	revert	VERB
ajlm-708	24	173	to	to	ADP
ajlm-708	24	174	wild	wild	ADJ
ajlm-708	24	175	-	-	PUNCT
ajlm-708	24	176	type	type	NOUN
ajlm-708	24	177	due	due	ADJ
ajlm-708	24	178	to	to	ADP
ajlm-708	24	179	diminished	diminish	VERB
ajlm-708	24	180	viral	viral	ADJ
ajlm-708	24	181	fitness.12	fitness.12	NOUN
ajlm-708	24	182	in	in	ADP
ajlm-708	24	183	patients	patient	NOUN
ajlm-708	24	184	on	on	ADP
ajlm-708	24	185	art	art	NOUN
ajlm-708	24	186	,	,	PUNCT
ajlm-708	24	187	minority	minority	NOUN
ajlm-708	24	188	drms	drm	NOUN
ajlm-708	24	189	may	may	AUX
ajlm-708	24	190	persist	persist	VERB
ajlm-708	24	191	for	for	ADP
ajlm-708	24	192	months	month	NOUN
ajlm-708	24	193	or	or	CCONJ
ajlm-708	24	194	years	year	NOUN
ajlm-708	24	195	during	during	ADP
ajlm-708	24	196	and	and	CCONJ
ajlm-708	24	197	post	post	ADJ
ajlm-708	24	198	-	-	ADJ
ajlm-708	24	199	art.13,14,15	art.13,14,15	ADV
ajlm-708	24	200	these	these	DET
ajlm-708	24	201	minority	minority	NOUN
ajlm-708	24	202	drms	drm	NOUN
ajlm-708	24	203	,	,	PUNCT
ajlm-708	24	204	not	not	PART
ajlm-708	24	205	detected	detect	VERB
ajlm-708	24	206	by	by	ADP
ajlm-708	24	207	sanger	sanger	PROPN
ajlm-708	24	208	sequencing	sequencing	PROPN
ajlm-708	24	209	,	,	PUNCT
ajlm-708	24	210	present	present	ADJ
ajlm-708	24	211	a	a	DET
ajlm-708	24	212	need	need	NOUN
ajlm-708	24	213	for	for	ADP
ajlm-708	24	214	more	more	ADV
ajlm-708	24	215	sensitive	sensitive	ADJ
ajlm-708	24	216	methods	method	NOUN
ajlm-708	24	217	to	to	PART
ajlm-708	24	218	detect	detect	VERB
ajlm-708	24	219	the	the	DET
ajlm-708	24	220	minority	minority	NOUN
ajlm-708	24	221	drms	drm	NOUN
ajlm-708	24	222	in	in	ADP
ajlm-708	24	223	a	a	DET
ajlm-708	24	224	clinical	clinical	ADJ
ajlm-708	24	225	sample	sample	NOUN
ajlm-708	24	226	.	.	PUNCT
ajlm-708	25	1	deep	deep	ADJ
ajlm-708	25	2	sequencing	sequencing	NOUN
ajlm-708	25	3	or	or	CCONJ
ajlm-708	25	4	next	next	ADJ
ajlm-708	25	5	-	-	PUNCT
ajlm-708	25	6	generation	generation	NOUN
ajlm-708	25	7	sequencing	sequencing	NOUN
ajlm-708	25	8	technologies	technology	NOUN
ajlm-708	25	9	are	be	AUX
ajlm-708	25	10	extensively	extensively	ADV
ajlm-708	25	11	used	use	VERB
ajlm-708	25	12	to	to	PART
ajlm-708	25	13	examine	examine	VERB
ajlm-708	25	14	hiv	hiv	PROPN
ajlm-708	25	15	viral	viral	ADJ
ajlm-708	25	16	diversity	diversity	NOUN
ajlm-708	25	17	and	and	CCONJ
ajlm-708	25	18	minority	minority	NOUN
ajlm-708	25	19	drug	drug	NOUN
ajlm-708	25	20	resistant	resistant	ADJ
ajlm-708	25	21	variants	variant	NOUN
ajlm-708	25	22	.	.	PUNCT
ajlm-708	26	1	next	next	ADJ
ajlm-708	26	2	-	-	PUNCT
ajlm-708	26	3	generation	generation	NOUN
ajlm-708	26	4	sequencing	sequencing	NOUN
ajlm-708	26	5	is	be	AUX
ajlm-708	26	6	a	a	DET
ajlm-708	26	7	highly	highly	ADV
ajlm-708	26	8	sensitive	sensitive	ADJ
ajlm-708	26	9	and	and	CCONJ
ajlm-708	26	10	high	high	ADJ
ajlm-708	26	11	-	-	PUNCT
ajlm-708	26	12	throughput	throughput	NOUN
ajlm-708	26	13	sequencing	sequence	VERB
ajlm-708	26	14	platform	platform	NOUN
ajlm-708	26	15	.	.	PUNCT
ajlm-708	27	1	it	it	PRON
ajlm-708	27	2	can	can	AUX
ajlm-708	27	3	detect	detect	VERB
ajlm-708	27	4	hiv	hiv	PROPN
ajlm-708	27	5	variants	variant	NOUN
ajlm-708	27	6	that	that	PRON
ajlm-708	27	7	make	make	VERB
ajlm-708	27	8	up	up	ADP
ajlm-708	27	9	0.05	0.05	NUM
ajlm-708	27	10	%	%	NOUN
ajlm-708	27	11	to	to	PART
ajlm-708	27	12	1	1	NUM
ajlm-708	27	13	%	%	NOUN
ajlm-708	27	14	of	of	ADP
ajlm-708	27	15	viral	viral	ADJ
ajlm-708	27	16	populations.16,17,18,19,20,21	populations.16,17,18,19,20,21	NOUN
ajlm-708	27	17	as	as	ADP
ajlm-708	27	18	part	part	NOUN
ajlm-708	27	19	of	of	ADP
ajlm-708	27	20	hiv	hiv	PROPN
ajlm-708	27	21	drug	drug	NOUN
ajlm-708	27	22	resistance	resistance	NOUN
ajlm-708	27	23	surveillance	surveillance	NOUN
ajlm-708	27	24	by	by	ADP
ajlm-708	27	25	the	the	DET
ajlm-708	27	26	malawi	malawi	PROPN
ajlm-708	27	27	ministry	ministry	PROPN
ajlm-708	27	28	of	of	ADP
ajlm-708	27	29	health	health	PROPN
ajlm-708	27	30	,	,	PUNCT
ajlm-708	27	31	a	a	DET
ajlm-708	27	32	prospective	prospective	ADJ
ajlm-708	27	33	cohort	cohort	NOUN
ajlm-708	27	34	study	study	NOUN
ajlm-708	27	35	to	to	PART
ajlm-708	27	36	monitor	monitor	VERB
ajlm-708	27	37	art	art	NOUN
ajlm-708	27	38	outcomes	outcome	NOUN
ajlm-708	27	39	and	and	CCONJ
ajlm-708	27	40	drug	drug	NOUN
ajlm-708	27	41	resistance	resistance	NOUN
ajlm-708	27	42	development	development	NOUN
ajlm-708	27	43	was	be	AUX
ajlm-708	27	44	conducted	conduct	VERB
ajlm-708	27	45	among	among	ADP
ajlm-708	27	46	patients	patient	NOUN
ajlm-708	27	47	from	from	ADP
ajlm-708	27	48	art	art	NOUN
ajlm-708	27	49	initiation	initiation	NOUN
ajlm-708	27	50	to	to	ADP
ajlm-708	27	51	one	one	NUM
ajlm-708	27	52	year	year	NOUN
ajlm-708	27	53	later	later	ADV
ajlm-708	27	54	.	.	PUNCT
ajlm-708	28	1	in	in	ADP
ajlm-708	28	2	this	this	DET
ajlm-708	28	3	2008	2008	NUM
ajlm-708	28	4	art	art	NOUN
ajlm-708	28	5	patient	patient	NOUN
ajlm-708	28	6	monitoring	monitoring	NOUN
ajlm-708	28	7	survey	survey	NOUN
ajlm-708	28	8	,	,	PUNCT
ajlm-708	28	9	6.1	6.1	NUM
ajlm-708	28	10	%	%	NOUN
ajlm-708	28	11	of	of	ADP
ajlm-708	28	12	the	the	DET
ajlm-708	28	13	patients	patient	NOUN
ajlm-708	28	14	on	on	ADP
ajlm-708	28	15	art	art	NOUN
ajlm-708	28	16	for	for	ADP
ajlm-708	28	17	12–15	12–15	NUM
ajlm-708	28	18	months	month	NOUN
ajlm-708	28	19	harboured	harbour	VERB
ajlm-708	28	20	drug	drug	NOUN
ajlm-708	28	21	resistant	resistant	ADJ
ajlm-708	28	22	hiv.22	hiv.22	NOUN
ajlm-708	28	23	the	the	DET
ajlm-708	28	24	most	most	ADV
ajlm-708	28	25	common	common	ADJ
ajlm-708	28	26	non	non	ADJ
ajlm-708	28	27	-	-	ADJ
ajlm-708	28	28	nucleoside	nucleoside	ADJ
ajlm-708	28	29	reverse	reverse	ADJ
ajlm-708	28	30	transcriptase	transcriptase	NOUN
ajlm-708	28	31	inhibitor	inhibitor	NOUN
ajlm-708	28	32	(	(	PUNCT
ajlm-708	28	33	nnrti	nnrti	NOUN
ajlm-708	28	34	)	)	PUNCT
ajlm-708	28	35	mutations	mutation	NOUN
ajlm-708	28	36	were	be	AUX
ajlm-708	28	37	k103n	k103n	PROPN
ajlm-708	28	38	(	(	PUNCT
ajlm-708	28	39	58.1	58.1	NUM
ajlm-708	28	40	%	%	NOUN
ajlm-708	28	41	)	)	PUNCT
ajlm-708	28	42	,	,	PUNCT
ajlm-708	28	43	y181c	y181c	PROPN
ajlm-708	28	44	(	(	PUNCT
ajlm-708	28	45	41.9	41.9	NUM
ajlm-708	28	46	%	%	NOUN
ajlm-708	28	47	)	)	PUNCT
ajlm-708	28	48	and	and	CCONJ
ajlm-708	28	49	g190a	g190a	NOUN
ajlm-708	28	50	(	(	PUNCT
ajlm-708	28	51	6.5	6.5	NUM
ajlm-708	28	52	%	%	NOUN
ajlm-708	28	53	)	)	PUNCT
ajlm-708	28	54	,	,	PUNCT
ajlm-708	28	55	and	and	CCONJ
ajlm-708	28	56	the	the	DET
ajlm-708	28	57	most	most	ADV
ajlm-708	28	58	frequent	frequent	ADJ
ajlm-708	28	59	nucleoside	nucleoside	NOUN
ajlm-708	28	60	reverse	reverse	NOUN
ajlm-708	28	61	transcriptase	transcriptase	NOUN
ajlm-708	28	62	inhibitor	inhibitor	NOUN
ajlm-708	28	63	(	(	PUNCT
ajlm-708	28	64	nrti	nrti	NOUN
ajlm-708	28	65	)	)	PUNCT
ajlm-708	28	66	mutation	mutation	NOUN
ajlm-708	28	67	was	be	AUX
ajlm-708	28	68	m184v	m184v	VERB
ajlm-708	28	69	(	(	PUNCT
ajlm-708	28	70	61.3	61.3	NUM
ajlm-708	28	71	%	%	NOUN
ajlm-708	28	72	)	)	PUNCT
ajlm-708	28	73	.	.	PUNCT
ajlm-708	29	1	the	the	DET
ajlm-708	29	2	drms	drm	NOUN
ajlm-708	29	3	conferring	confer	VERB
ajlm-708	29	4	resistance	resistance	NOUN
ajlm-708	29	5	against	against	ADP
ajlm-708	29	6	nnrti	nnrti	PROPN
ajlm-708	29	7	at	at	ADP
ajlm-708	29	8	baseline	baseline	PROPN
ajlm-708	29	9	were	be	AUX
ajlm-708	29	10	associated	associate	VERB
ajlm-708	29	11	with	with	ADP
ajlm-708	29	12	drms	drm	NOUN
ajlm-708	29	13	detected	detect	VERB
ajlm-708	29	14	at	at	ADP
ajlm-708	29	15	12–15	12–15	NUM
ajlm-708	29	16	months	month	NOUN
ajlm-708	29	17	on	on	ADP
ajlm-708	29	18	art.22	art.22	NOUN
ajlm-708	29	19	the	the	DET
ajlm-708	29	20	present	present	ADJ
ajlm-708	29	21	study	study	NOUN
ajlm-708	29	22	aimed	aim	VERB
ajlm-708	29	23	to	to	PART
ajlm-708	29	24	evaluate	evaluate	VERB
ajlm-708	29	25	parallel	parallel	ADJ
ajlm-708	29	26	tagged	tag	VERB
ajlm-708	29	27	deep	deep	ADJ
ajlm-708	29	28	sequencing	sequence	VERB
ajlm-708	29	29	primers	primer	NOUN
ajlm-708	29	30	on	on	ADP
ajlm-708	29	31	clinical	clinical	ADJ
ajlm-708	29	32	samples	sample	NOUN
ajlm-708	29	33	and	and	CCONJ
ajlm-708	29	34	to	to	PART
ajlm-708	29	35	investigate	investigate	VERB
ajlm-708	29	36	the	the	DET
ajlm-708	29	37	profile	profile	NOUN
ajlm-708	29	38	of	of	ADP
ajlm-708	29	39	minority	minority	NOUN
ajlm-708	29	40	drms	drm	NOUN
ajlm-708	29	41	and	and	CCONJ
ajlm-708	29	42	their	their	PRON
ajlm-708	29	43	association	association	NOUN
ajlm-708	29	44	with	with	ADP
ajlm-708	29	45	virologic	virologic	ADJ
ajlm-708	29	46	failure	failure	NOUN
ajlm-708	29	47	in	in	ADP
ajlm-708	29	48	the	the	DET
ajlm-708	29	49	same	same	ADJ
ajlm-708	29	50	malawi	malawi	PROPN
ajlm-708	29	51	art	art	NOUN
ajlm-708	29	52	monitoring	monitoring	NOUN
ajlm-708	29	53	cohort	cohort	NOUN
ajlm-708	29	54	.	.	PUNCT
ajlm-708	30	1	methods	method	NOUN
ajlm-708	30	2	ethical	ethical	ADJ
ajlm-708	30	3	considerations	consideration	NOUN
ajlm-708	30	4	the	the	DET
ajlm-708	30	5	study	study	NOUN
ajlm-708	30	6	protocol	protocol	NOUN
ajlm-708	30	7	was	be	AUX
ajlm-708	30	8	approved	approve	VERB
ajlm-708	30	9	by	by	ADP
ajlm-708	30	10	the	the	DET
ajlm-708	30	11	national	national	PROPN
ajlm-708	30	12	health	health	PROPN
ajlm-708	30	13	sciences	sciences	PROPN
ajlm-708	30	14	research	research	PROPN
ajlm-708	30	15	committee	committee	PROPN
ajlm-708	30	16	of	of	ADP
ajlm-708	30	17	malawi	malawi	PROPN
ajlm-708	30	18	institutional	institutional	PROPN
ajlm-708	30	19	review	review	PROPN
ajlm-708	30	20	board	board	NOUN
ajlm-708	30	21	(	(	PUNCT
ajlm-708	30	22	#	#	SYM
ajlm-708	30	23	1001	1001	NUM
ajlm-708	30	24	)	)	PUNCT
ajlm-708	30	25	.	.	PUNCT
ajlm-708	31	1	the	the	DET
ajlm-708	31	2	use	use	NOUN
ajlm-708	31	3	of	of	ADP
ajlm-708	31	4	de	de	ADJ
ajlm-708	31	5	-	-	ADJ
ajlm-708	31	6	identified	identify	VERB
ajlm-708	31	7	data	datum	NOUN
ajlm-708	31	8	and	and	CCONJ
ajlm-708	31	9	drug	drug	NOUN
ajlm-708	31	10	resistance	resistance	NOUN
ajlm-708	31	11	testing	testing	NOUN
ajlm-708	31	12	using	use	VERB
ajlm-708	31	13	sanger	sanger	PROPN
ajlm-708	31	14	sequencing	sequencing	NOUN
ajlm-708	31	15	and	and	CCONJ
ajlm-708	31	16	roche	roche	NOUN
ajlm-708	31	17	454	454	NUM
ajlm-708	31	18	deep	deep	ADV
ajlm-708	31	19	sequencing	sequencing	NOUN
ajlm-708	31	20	at	at	ADP
ajlm-708	31	21	the	the	DET
ajlm-708	31	22	centers	center	NOUN
ajlm-708	31	23	for	for	ADP
ajlm-708	31	24	disease	disease	NOUN
ajlm-708	31	25	control	control	NOUN
ajlm-708	31	26	and	and	CCONJ
ajlm-708	31	27	prevention	prevention	NOUN
ajlm-708	31	28	’s	’s	PART
ajlm-708	31	29	(	(	PUNCT
ajlm-708	31	30	cdc	cdc	PROPN
ajlm-708	31	31	)	)	PUNCT
ajlm-708	31	32	global	global	PROPN
ajlm-708	31	33	hiv	hiv	PROPN
ajlm-708	31	34	drug	drug	PROPN
ajlm-708	31	35	resistance	resistance	NOUN
ajlm-708	31	36	laboratory	laboratory	NOUN
ajlm-708	31	37	,	,	PUNCT
ajlm-708	31	38	was	be	AUX
ajlm-708	31	39	determined	determine	VERB
ajlm-708	31	40	to	to	PART
ajlm-708	31	41	be	be	AUX
ajlm-708	31	42	non	non	ADJ
ajlm-708	31	43	-	-	ADJ
ajlm-708	31	44	human	human	ADJ
ajlm-708	31	45	subjects	subject	NOUN
ajlm-708	31	46	research	research	NOUN
ajlm-708	31	47	under	under	ADP
ajlm-708	31	48	cdc	cdc	PROPN
ajlm-708	31	49	protocol	protocol	PROPN
ajlm-708	31	50	#	#	SYM
ajlm-708	31	51	6501	6501	NUM
ajlm-708	31	52	by	by	ADP
ajlm-708	31	53	the	the	DET
ajlm-708	31	54	office	office	NOUN
ajlm-708	31	55	of	of	ADP
ajlm-708	31	56	the	the	DET
ajlm-708	31	57	associate	associate	ADJ
ajlm-708	31	58	director	director	NOUN
ajlm-708	31	59	for	for	ADP
ajlm-708	31	60	science	science	NOUN
ajlm-708	31	61	at	at	ADP
ajlm-708	31	62	the	the	DET
ajlm-708	31	63	center	center	NOUN
ajlm-708	31	64	for	for	ADP
ajlm-708	31	65	global	global	ADJ
ajlm-708	31	66	health	health	NOUN
ajlm-708	31	67	,	,	PUNCT
ajlm-708	31	68	cdc	cdc	PROPN
ajlm-708	31	69	,	,	PUNCT
ajlm-708	31	70	atlanta	atlanta	PROPN
ajlm-708	31	71	,	,	PUNCT
ajlm-708	31	72	georgia	georgia	PROPN
ajlm-708	31	73	,	,	PUNCT
ajlm-708	31	74	united	united	PROPN
ajlm-708	31	75	states	states	PROPN
ajlm-708	31	76	.	.	PUNCT
ajlm-708	32	1	clinical	clinical	ADJ
ajlm-708	32	2	samples	sample	NOUN
ajlm-708	32	3	between	between	ADP
ajlm-708	32	4	february	february	PROPN
ajlm-708	32	5	and	and	CCONJ
ajlm-708	32	6	june	june	PROPN
ajlm-708	32	7	2008	2008	NUM
ajlm-708	32	8	,	,	PUNCT
ajlm-708	32	9	hiv-1	hiv-1	X
ajlm-708	32	10	-	-	ADJ
ajlm-708	32	11	positive	positive	ADJ
ajlm-708	32	12	patients	patient	NOUN
ajlm-708	32	13	aged	age	VERB
ajlm-708	32	14	15	15	NUM
ajlm-708	32	15	years	year	NOUN
ajlm-708	32	16	or	or	CCONJ
ajlm-708	32	17	older	old	ADJ
ajlm-708	32	18	,	,	PUNCT
ajlm-708	32	19	who	who	PRON
ajlm-708	32	20	initiated	initiate	VERB
ajlm-708	32	21	first	first	ADJ
ajlm-708	32	22	-	-	PUNCT
ajlm-708	32	23	line	line	NOUN
ajlm-708	32	24	art	art	NOUN
ajlm-708	32	25	at	at	ADP
ajlm-708	32	26	four	four	NUM
ajlm-708	32	27	art	art	NOUN
ajlm-708	32	28	clinics	clinic	NOUN
ajlm-708	32	29	following	follow	VERB
ajlm-708	32	30	the	the	DET
ajlm-708	32	31	malawi	malawi	PROPN
ajlm-708	32	32	art	art	NOUN
ajlm-708	32	33	guidelines	guideline	NOUN
ajlm-708	32	34	,	,	PUNCT
ajlm-708	32	35	were	be	AUX
ajlm-708	32	36	enrolled	enrol	VERB
ajlm-708	32	37	.	.	PUNCT
ajlm-708	33	1	patients	patient	NOUN
ajlm-708	33	2	were	be	AUX
ajlm-708	33	3	treated	treat	VERB
ajlm-708	33	4	with	with	ADP
ajlm-708	33	5	a	a	DET
ajlm-708	33	6	first	first	ADJ
ajlm-708	33	7	-	-	PUNCT
ajlm-708	33	8	line	line	NOUN
ajlm-708	33	9	regimen	regimen	NOUN
ajlm-708	33	10	combination	combination	NOUN
ajlm-708	33	11	of	of	ADP
ajlm-708	33	12	stavudine	stavudine	NOUN
ajlm-708	33	13	,	,	PUNCT
ajlm-708	33	14	lamivudine	lamivudine	NOUN
ajlm-708	33	15	and	and	CCONJ
ajlm-708	33	16	nevirapine	nevirapine	ADJ
ajlm-708	33	17	,	,	PUNCT
ajlm-708	33	18	or	or	CCONJ
ajlm-708	33	19	an	an	DET
ajlm-708	33	20	alternative	alternative	ADJ
ajlm-708	33	21	first	first	ADJ
ajlm-708	33	22	-	-	PUNCT
ajlm-708	33	23	line	line	NOUN
ajlm-708	33	24	regimen	regiman	NOUN
ajlm-708	33	25	of	of	ADP
ajlm-708	33	26	stavudine	stavudine	NOUN
ajlm-708	33	27	to	to	ADP
ajlm-708	33	28	zidovudine	zidovudine	PROPN
ajlm-708	33	29	substitutions	substitution	NOUN
ajlm-708	33	30	in	in	ADP
ajlm-708	33	31	case	case	NOUN
ajlm-708	33	32	of	of	ADP
ajlm-708	33	33	toxicity	toxicity	NOUN
ajlm-708	33	34	.	.	PUNCT
ajlm-708	34	1	plasma	plasma	NOUN
ajlm-708	34	2	specimens	specimen	NOUN
ajlm-708	34	3	were	be	AUX
ajlm-708	34	4	collected	collect	VERB
ajlm-708	34	5	before	before	ADP
ajlm-708	34	6	art	art	NOUN
ajlm-708	34	7	initiation	initiation	NOUN
ajlm-708	34	8	and	and	CCONJ
ajlm-708	34	9	at	at	ADP
ajlm-708	34	10	12–15	12–15	NUM
ajlm-708	34	11	months	month	NOUN
ajlm-708	34	12	on	on	ADP
ajlm-708	34	13	art	art	NOUN
ajlm-708	34	14	for	for	ADP
ajlm-708	34	15	viral	viral	ADJ
ajlm-708	34	16	load	load	NOUN
ajlm-708	34	17	and	and	CCONJ
ajlm-708	34	18	hiv	hiv	PROPN
ajlm-708	34	19	drug	drug	NOUN
ajlm-708	34	20	resistance	resistance	NOUN
ajlm-708	34	21	testing.22	testing.22	PROPN
ajlm-708	34	22	in	in	ADP
ajlm-708	34	23	the	the	DET
ajlm-708	34	24	present	present	ADJ
ajlm-708	34	25	study	study	NOUN
ajlm-708	34	26	,	,	PUNCT
ajlm-708	34	27	we	we	PRON
ajlm-708	34	28	selected	select	VERB
ajlm-708	34	29	plasma	plasma	NOUN
ajlm-708	34	30	specimens	specimen	NOUN
ajlm-708	34	31	that	that	PRON
ajlm-708	34	32	had	have	VERB
ajlm-708	34	33	enough	enough	ADJ
ajlm-708	34	34	volume	volume	NOUN
ajlm-708	34	35	available	available	ADJ
ajlm-708	34	36	to	to	PART
ajlm-708	34	37	evaluate	evaluate	VERB
ajlm-708	34	38	the	the	DET
ajlm-708	34	39	assay	assay	NOUN
ajlm-708	34	40	.	.	PUNCT
ajlm-708	35	1	these	these	PRON
ajlm-708	35	2	were	be	AUX
ajlm-708	35	3	20	20	NUM
ajlm-708	35	4	samples	sample	NOUN
ajlm-708	35	5	collected	collect	VERB
ajlm-708	35	6	from	from	ADP
ajlm-708	35	7	participants	participant	NOUN
ajlm-708	35	8	before	before	ADP
ajlm-708	35	9	art	art	NOUN
ajlm-708	35	10	initiation	initiation	NOUN
ajlm-708	35	11	with	with	ADP
ajlm-708	35	12	viral	viral	ADJ
ajlm-708	35	13	loads	load	NOUN
ajlm-708	35	14	ranging	range	VERB
ajlm-708	35	15	from	from	ADP
ajlm-708	35	16	10	10	NUM
ajlm-708	35	17	471	471	NUM
ajlm-708	35	18	to	to	PART
ajlm-708	35	19	2	2	NUM
ajlm-708	35	20	041	041	NUM
ajlm-708	35	21	738	738	NUM
ajlm-708	35	22	copies	copy	NOUN
ajlm-708	35	23	/	/	SYM
ajlm-708	35	24	ml	ml	NOUN
ajlm-708	35	25	and	and	CCONJ
ajlm-708	35	26	21	21	NUM
ajlm-708	35	27	samples	sample	NOUN
ajlm-708	35	28	collected	collect	VERB
ajlm-708	35	29	from	from	ADP
ajlm-708	35	30	art	art	NOUN
ajlm-708	35	31	patients	patient	NOUN
ajlm-708	35	32	at	at	ADP
ajlm-708	35	33	virologic	virologic	ADJ
ajlm-708	35	34	failure	failure	NOUN
ajlm-708	35	35	(	(	PUNCT
ajlm-708	35	36	defined	define	VERB
ajlm-708	35	37	as	as	ADP
ajlm-708	35	38	viral	viral	ADJ
ajlm-708	35	39	load	load	NOUN
ajlm-708	35	40	≥1000	≥1000	PUNCT
ajlm-708	35	41	copies	copy	NOUN
ajlm-708	35	42	/	/	SYM
ajlm-708	35	43	ml	ml	NOUN
ajlm-708	35	44	)	)	PUNCT
ajlm-708	35	45	after	after	ADP
ajlm-708	35	46	12–15	12–15	NUM
ajlm-708	35	47	months	month	NOUN
ajlm-708	35	48	on	on	ADP
ajlm-708	35	49	art	art	NOUN
ajlm-708	35	50	(	(	PUNCT
ajlm-708	35	51	viral	viral	ADJ
ajlm-708	35	52	load	load	NOUN
ajlm-708	35	53	ranging	range	VERB
ajlm-708	35	54	from	from	ADP
ajlm-708	35	55	1738	1738	NUM
ajlm-708	35	56	to	to	ADP
ajlm-708	35	57	776	776	NUM
ajlm-708	35	58	247	247	NUM
ajlm-708	35	59	copies	copy	NOUN
ajlm-708	35	60	/	/	SYM
ajlm-708	35	61	ml	ml	NOUN
ajlm-708	35	62	)	)	PUNCT
ajlm-708	35	63	.	.	PUNCT
ajlm-708	36	1	in	in	ADP
ajlm-708	36	2	addition	addition	NOUN
ajlm-708	36	3	,	,	PUNCT
ajlm-708	36	4	six	six	NUM
ajlm-708	36	5	plasmid	plasmid	ADJ
ajlm-708	36	6	clones	clone	NOUN
ajlm-708	36	7	and	and	CCONJ
ajlm-708	36	8	one	one	NUM
ajlm-708	36	9	mixed	mixed	ADJ
ajlm-708	36	10	clone	clone	NOUN
ajlm-708	36	11	containing	contain	VERB
ajlm-708	36	12	1	1	NUM
ajlm-708	36	13	%	%	NOUN
ajlm-708	36	14	mutant	mutant	NOUN
ajlm-708	36	15	(	(	PUNCT
ajlm-708	36	16	2495	2495	NUM
ajlm-708	36	17	copies/µl	copies/µl	NOUN
ajlm-708	36	18	)	)	PUNCT
ajlm-708	36	19	under	under	ADP
ajlm-708	36	20	the	the	DET
ajlm-708	36	21	background	background	NOUN
ajlm-708	36	22	of	of	ADP
ajlm-708	36	23	a	a	DET
ajlm-708	36	24	wild	wild	ADJ
ajlm-708	36	25	-	-	PUNCT
ajlm-708	36	26	type	type	NOUN
ajlm-708	36	27	clone	clone	NOUN
ajlm-708	36	28	were	be	AUX
ajlm-708	36	29	prepared	prepare	VERB
ajlm-708	36	30	and	and	CCONJ
ajlm-708	36	31	used	use	VERB
ajlm-708	36	32	to	to	PART
ajlm-708	36	33	verify	verify	VERB
ajlm-708	36	34	sequence	sequence	NOUN
ajlm-708	36	35	accuracy	accuracy	NOUN
ajlm-708	36	36	in	in	ADP
ajlm-708	36	37	this	this	DET
ajlm-708	36	38	study	study	NOUN
ajlm-708	36	39	.	.	PUNCT
ajlm-708	37	1	all	all	PRON
ajlm-708	37	2	of	of	ADP
ajlm-708	37	3	these	these	DET
ajlm-708	37	4	plasmid	plasmid	ADJ
ajlm-708	37	5	clones	clone	NOUN
ajlm-708	37	6	were	be	AUX
ajlm-708	37	7	derived	derive	VERB
ajlm-708	37	8	from	from	ADP
ajlm-708	37	9	the	the	DET
ajlm-708	37	10	malawian	malawian	ADJ
ajlm-708	37	11	cohort	cohort	NOUN
ajlm-708	37	12	samples	sample	NOUN
ajlm-708	37	13	.	.	PUNCT
ajlm-708	38	1	all	all	DET
ajlm-708	38	2	plasmids	plasmid	NOUN
ajlm-708	38	3	were	be	AUX
ajlm-708	38	4	constructed	construct	VERB
ajlm-708	38	5	using	use	VERB
ajlm-708	38	6	topotm	topotm	NOUN
ajlm-708	38	7	vectors	vector	NOUN
ajlm-708	38	8	in	in	ADP
ajlm-708	38	9	escherichia	escherichia	NOUN
ajlm-708	38	10	coli	coli	NOUN
ajlm-708	38	11	(	(	PUNCT
ajlm-708	38	12	thermo	thermo	NOUN
ajlm-708	38	13	fisher	fisher	PROPN
ajlm-708	38	14	scientific	scientific	PROPN
ajlm-708	38	15	,	,	PUNCT
ajlm-708	38	16	carlsbad	carlsbad	PROPN
ajlm-708	38	17	,	,	PUNCT
ajlm-708	38	18	california	california	PROPN
ajlm-708	38	19	,	,	PUNCT
ajlm-708	38	20	united	united	PROPN
ajlm-708	38	21	states	states	PROPN
ajlm-708	38	22	)	)	PUNCT
ajlm-708	38	23	.	.	PUNCT
ajlm-708	39	1	the	the	DET
ajlm-708	39	2	six	six	NUM
ajlm-708	39	3	wild	wild	ADJ
ajlm-708	39	4	-	-	PUNCT
ajlm-708	39	5	type	type	NOUN
ajlm-708	39	6	plasmid	plasmid	ADJ
ajlm-708	39	7	clones	clone	NOUN
ajlm-708	39	8	contained	contain	VERB
ajlm-708	39	9	the	the	DET
ajlm-708	39	10	hiv-1	hiv-1	X
ajlm-708	39	11	pol	pol	NOUN
ajlm-708	39	12	gene	gene	NOUN
ajlm-708	39	13	without	without	ADP
ajlm-708	39	14	any	any	DET
ajlm-708	39	15	drms	drm	NOUN
ajlm-708	39	16	,	,	PUNCT
ajlm-708	39	17	and	and	CCONJ
ajlm-708	39	18	the	the	DET
ajlm-708	39	19	mutant	mutant	ADJ
ajlm-708	39	20	clone	clone	NOUN
ajlm-708	39	21	contained	contain	VERB
ajlm-708	39	22	drms	drm	NOUN
ajlm-708	39	23	at	at	ADP
ajlm-708	39	24	codons	codon	NOUN
ajlm-708	39	25	103	103	NUM
ajlm-708	39	26	,	,	PUNCT
ajlm-708	39	27	181	181	NUM
ajlm-708	39	28	,	,	PUNCT
ajlm-708	39	29	184	184	NUM
ajlm-708	39	30	and	and	CCONJ
ajlm-708	39	31	190	190	NUM
ajlm-708	39	32	of	of	ADP
ajlm-708	39	33	the	the	DET
ajlm-708	39	34	hiv-1	hiv-1	X
ajlm-708	39	35	pol	pol	NOUN
ajlm-708	39	36	gene	gene	NOUN
ajlm-708	39	37	.	.	PUNCT
ajlm-708	40	1	viral	viral	ADJ
ajlm-708	40	2	ribonucleic	ribonucleic	ADJ
ajlm-708	40	3	acid	acid	NOUN
ajlm-708	40	4	extraction	extraction	NOUN
ajlm-708	40	5	and	and	CCONJ
ajlm-708	40	6	reverse	reverse	ADJ
ajlm-708	40	7	transcriptase	transcriptase	NOUN
ajlm-708	40	8	polymerase	polymerase	NOUN
ajlm-708	40	9	chain	chain	NOUN
ajlm-708	40	10	reaction	reaction	NOUN
ajlm-708	40	11	rna	rna	PROPN
ajlm-708	40	12	was	be	AUX
ajlm-708	40	13	extracted	extract	VERB
ajlm-708	40	14	from	from	ADP
ajlm-708	40	15	plasma	plasma	NOUN
ajlm-708	40	16	specimens	specimen	NOUN
ajlm-708	40	17	using	use	VERB
ajlm-708	40	18	the	the	DET
ajlm-708	40	19	automated	automate	VERB
ajlm-708	40	20	abbott	abbott	PROPN
ajlm-708	40	21	™	™	PROPN
ajlm-708	40	22	sample	sample	NOUN
ajlm-708	40	23	preparation	preparation	NOUN
ajlm-708	40	24	system	system	NOUN
ajlm-708	40	25	(	(	PUNCT
ajlm-708	40	26	m2000sp	m2000sp	NOUN
ajlm-708	40	27	)	)	PUNCT
ajlm-708	40	28	(	(	PUNCT
ajlm-708	40	29	abbott	abbott	PROPN
ajlm-708	40	30	laboratories	laboratories	PROPN
ajlm-708	40	31	.	.	PUNCT
ajlm-708	41	1	abbott	abbott	PROPN
ajlm-708	41	2	park	park	PROPN
ajlm-708	41	3	,	,	PUNCT
ajlm-708	41	4	illinois	illinois	PROPN
ajlm-708	41	5	,	,	PUNCT
ajlm-708	41	6	united	united	PROPN
ajlm-708	41	7	states	states	PROPN
ajlm-708	41	8	)	)	PUNCT
ajlm-708	41	9	.	.	PUNCT
ajlm-708	42	1	the	the	DET
ajlm-708	42	2	copy	copy	NOUN
ajlm-708	42	3	number	number	NOUN
ajlm-708	42	4	of	of	ADP
ajlm-708	42	5	hiv-1	hiv-1	PUNCT
ajlm-708	42	6	rna	rna	NOUN
ajlm-708	42	7	was	be	AUX
ajlm-708	42	8	measured	measure	VERB
ajlm-708	42	9	using	use	VERB
ajlm-708	42	10	rt	rt	NOUN
ajlm-708	42	11	-	-	PUNCT
ajlm-708	42	12	qpcr	qpcr	ADV
ajlm-708	42	13	on	on	ADP
ajlm-708	42	14	the	the	DET
ajlm-708	42	15	m2000rt	m2000rt	NOUN
ajlm-708	42	16	real	real	ADJ
ajlm-708	42	17	time	time	NOUN
ajlm-708	42	18	analyzer	analyzer	NOUN
ajlm-708	42	19	(	(	PUNCT
ajlm-708	42	20	abbott	abbott	PROPN
ajlm-708	42	21	laboratories	laboratories	PROPN
ajlm-708	42	22	.	.	PUNCT
ajlm-708	43	1	abbott	abbott	PROPN
ajlm-708	43	2	park	park	PROPN
ajlm-708	43	3	,	,	PUNCT
ajlm-708	43	4	illinois	illinois	PROPN
ajlm-708	43	5	,	,	PUNCT
ajlm-708	43	6	united	unite	VERB
ajlm-708	43	7	states).22	states).22	PROPN
ajlm-708	43	8	the	the	DET
ajlm-708	43	9	viral	viral	ADJ
ajlm-708	43	10	rna	rna	NOUN
ajlm-708	43	11	was	be	AUX
ajlm-708	43	12	subjected	subject	VERB
ajlm-708	43	13	to	to	ADP
ajlm-708	43	14	one	one	NUM
ajlm-708	43	15	-	-	PUNCT
ajlm-708	43	16	step	step	NOUN
ajlm-708	43	17	rt	rt	ADJ
ajlm-708	43	18	-	-	PUNCT
ajlm-708	43	19	pcr	pcr	ADJ
ajlm-708	43	20	amplification	amplification	NOUN
ajlm-708	43	21	as	as	SCONJ
ajlm-708	43	22	described	describe	VERB
ajlm-708	43	23	previously.11	previously.11	ADJ
ajlm-708	43	24	parallel	parallel	ADJ
ajlm-708	43	25	deep	deep	ADJ
ajlm-708	43	26	sequencing	sequence	VERB
ajlm-708	43	27	degenerate	degenerate	ADJ
ajlm-708	43	28	primers	primer	NOUN
ajlm-708	43	29	,	,	PUNCT
ajlm-708	43	30	capable	capable	ADJ
ajlm-708	43	31	of	of	ADP
ajlm-708	43	32	amplifying	amplify	VERB
ajlm-708	43	33	multiple	multiple	ADJ
ajlm-708	43	34	hiv-1	hiv-1	X
ajlm-708	43	35	group	group	NOUN
ajlm-708	43	36	m	m	PART
ajlm-708	43	37	subtypes	subtype	NOUN
ajlm-708	43	38	,	,	PUNCT
ajlm-708	43	39	were	be	AUX
ajlm-708	43	40	designed	design	VERB
ajlm-708	43	41	based	base	VERB
ajlm-708	43	42	on	on	ADP
ajlm-708	43	43	the	the	DET
ajlm-708	43	44	hiv-1	hiv-1	PUNCT
ajlm-708	43	45	pol	pol	NOUN
ajlm-708	43	46	gene	gene	NOUN
ajlm-708	43	47	sequences	sequence	NOUN
ajlm-708	43	48	(	(	PUNCT
ajlm-708	43	49	www.hiv.lanl.gov	www.hiv.lanl.gov	PROPN
ajlm-708	43	50	)	)	PUNCT
ajlm-708	43	51	(	(	PUNCT
ajlm-708	43	52	table	table	NOUN
ajlm-708	43	53	1	1	NUM
ajlm-708	43	54	)	)	PUNCT
ajlm-708	43	55	.	.	PUNCT
ajlm-708	44	1	six	six	NUM
ajlm-708	44	2	overlapping	overlap	VERB
ajlm-708	44	3	primer	primer	NOUN
ajlm-708	44	4	sets	set	NOUN
ajlm-708	44	5	(	(	PUNCT
ajlm-708	44	6	forward	forward	ADV
ajlm-708	44	7	and	and	CCONJ
ajlm-708	44	8	reverse	reverse	VERB
ajlm-708	44	9	)	)	PUNCT
ajlm-708	44	10	were	be	AUX
ajlm-708	44	11	used	use	VERB
ajlm-708	44	12	for	for	ADP
ajlm-708	44	13	bidirectional	bidirectional	ADJ
ajlm-708	44	14	coverage	coverage	NOUN
ajlm-708	44	15	of	of	ADP
ajlm-708	44	16	protease	protease	NOUN
ajlm-708	44	17	amino	amino	NOUN
ajlm-708	44	18	acids	acid	NOUN
ajlm-708	44	19	6	6	NUM
ajlm-708	44	20	to	to	PART
ajlm-708	44	21	99	99	NUM
ajlm-708	44	22	and	and	CCONJ
ajlm-708	44	23	reverse	reverse	VERB
ajlm-708	44	24	transcriptase	transcriptase	NOUN
ajlm-708	44	25	amino	amino	NOUN
ajlm-708	44	26	acids	acid	NOUN
ajlm-708	44	27	1	1	NUM
ajlm-708	44	28	to	to	ADP
ajlm-708	44	29	251	251	NUM
ajlm-708	44	30	.	.	PUNCT
ajlm-708	45	1	the	the	DET
ajlm-708	45	2	size	size	NOUN
ajlm-708	45	3	of	of	ADP
ajlm-708	45	4	the	the	DET
ajlm-708	45	5	assembled	assemble	VERB
ajlm-708	45	6	gene	gene	NOUN
ajlm-708	45	7	fragment	fragment	NOUN
ajlm-708	45	8	was	be	AUX
ajlm-708	45	9	1035	1035	NUM
ajlm-708	45	10	base	base	NOUN
ajlm-708	45	11	pairs	pair	NOUN
ajlm-708	45	12	.	.	PUNCT
ajlm-708	46	1	these	these	DET
ajlm-708	46	2	six	six	NUM
ajlm-708	46	3	primers	primer	NOUN
ajlm-708	46	4	,	,	PUNCT
ajlm-708	46	5	tailed	tail	VERB
ajlm-708	46	6	with	with	ADP
ajlm-708	46	7	roche	roche	PROPN
ajlm-708	46	8	454	454	NUM
ajlm-708	46	9	adaptor	adaptor	NOUN
ajlm-708	46	10	and	and	CCONJ
ajlm-708	46	11	multiplex	multiplex	PROPN
ajlm-708	46	12	identifier	identifier	NOUN
ajlm-708	46	13	sequences	sequence	NOUN
ajlm-708	46	14	(	(	PUNCT
ajlm-708	46	15	tags	tag	NOUN
ajlm-708	46	16	)	)	PUNCT
ajlm-708	46	17	,	,	PUNCT
ajlm-708	46	18	were	be	AUX
ajlm-708	46	19	synthesised	synthesise	VERB
ajlm-708	46	20	at	at	ADP
ajlm-708	46	21	the	the	DET
ajlm-708	46	22	cdc	cdc	PROPN
ajlm-708	46	23	biotechnology	biotechnology	PROPN
ajlm-708	46	24	core	core	NOUN
ajlm-708	46	25	facility	facility	NOUN
ajlm-708	46	26	.	.	PUNCT
ajlm-708	47	1	for	for	ADP
ajlm-708	47	2	pcr	pcr	ADJ
ajlm-708	47	3	amplification	amplification	NOUN
ajlm-708	47	4	,	,	PUNCT
ajlm-708	47	5	a	a	DET
ajlm-708	47	6	50µl	50µl	ADJ
ajlm-708	47	7	reaction	reaction	NOUN
ajlm-708	47	8	contained	contain	VERB
ajlm-708	47	9	1×	1×	NUM
ajlm-708	47	10	accuprime	accuprime	ADJ
ajlm-708	47	11	pcr	pcr	PROPN
ajlm-708	47	12	buffer	buffer	NOUN
ajlm-708	47	13	ii	ii	NOUN
ajlm-708	47	14	(	(	PUNCT
ajlm-708	47	15	thermo	thermo	NOUN
ajlm-708	47	16	fisher	fisher	PROPN
ajlm-708	47	17	scientific	scientific	PROPN
ajlm-708	47	18	,	,	PUNCT
ajlm-708	47	19	carlsbad	carlsbad	PROPN
ajlm-708	47	20	,	,	PUNCT
ajlm-708	47	21	california	california	PROPN
ajlm-708	47	22	,	,	PUNCT
ajlm-708	47	23	united	united	PROPN
ajlm-708	47	24	states	states	PROPN
ajlm-708	47	25	)	)	PUNCT
ajlm-708	47	26	,	,	PUNCT
ajlm-708	47	27	0.5	0.5	NUM
ajlm-708	47	28	u	u	NOUN
ajlm-708	47	29	accuprime	accuprime	ADJ
ajlm-708	47	30	taq	taq	PROPN
ajlm-708	47	31	high	high	ADJ
ajlm-708	47	32	fidelity	fidelity	PROPN
ajlm-708	47	33	(	(	PUNCT
ajlm-708	47	34	thermo	thermo	NOUN
ajlm-708	47	35	fisher	fisher	PROPN
ajlm-708	47	36	scientific	scientific	PROPN
ajlm-708	47	37	,	,	PUNCT
ajlm-708	47	38	carlsbad	carlsbad	PROPN
ajlm-708	47	39	,	,	PUNCT
ajlm-708	47	40	california	california	PROPN
ajlm-708	47	41	,	,	PUNCT
ajlm-708	47	42	united	united	PROPN
ajlm-708	47	43	states	states	PROPN
ajlm-708	47	44	)	)	PUNCT
ajlm-708	47	45	,	,	PUNCT
ajlm-708	47	46	13.5	13.5	NUM
ajlm-708	47	47	µl	µl	ADP
ajlm-708	47	48	water	water	NOUN
ajlm-708	47	49	,	,	PUNCT
ajlm-708	47	50	0.3	0.3	NUM
ajlm-708	47	51	µm	µm	NOUN
ajlm-708	47	52	,	,	PUNCT
ajlm-708	47	53	each	each	DET
ajlm-708	47	54	forward	forward	ADV
ajlm-708	47	55	and	and	CCONJ
ajlm-708	47	56	reverse	reverse	ADJ
ajlm-708	47	57	primer	primer	NOUN
ajlm-708	47	58	,	,	PUNCT
ajlm-708	47	59	and	and	CCONJ
ajlm-708	47	60	2	2	NUM
ajlm-708	47	61	µl	µl	ADP
ajlm-708	47	62	dna	dna	PROPN
ajlm-708	47	63	.	.	PUNCT
ajlm-708	48	1	all	all	DET
ajlm-708	48	2	reactions	reaction	NOUN
ajlm-708	48	3	were	be	AUX
ajlm-708	48	4	performed	perform	VERB
ajlm-708	48	5	in	in	ADP
ajlm-708	48	6	9700	9700	NUM
ajlm-708	48	7	thermal	thermal	ADJ
ajlm-708	48	8	cyclers	cycler	NOUN
ajlm-708	48	9	(	(	PUNCT
ajlm-708	48	10	applied	apply	VERB
ajlm-708	48	11	biosystems	biosystem	NOUN
ajlm-708	48	12	,	,	PUNCT
ajlm-708	48	13	austin	austin	PROPN
ajlm-708	48	14	,	,	PUNCT
ajlm-708	48	15	texas	texas	PROPN
ajlm-708	48	16	,	,	PUNCT
ajlm-708	48	17	united	united	PROPN
ajlm-708	48	18	states	states	PROPN
ajlm-708	48	19	)	)	PUNCT
ajlm-708	48	20	under	under	ADP
ajlm-708	48	21	the	the	DET
ajlm-708	48	22	following	follow	VERB
ajlm-708	48	23	program	program	NOUN
ajlm-708	48	24	:	:	PUNCT
ajlm-708	48	25	95	95	NUM
ajlm-708	49	1	°	°	NUM
ajlm-708	49	2	c	c	NOUN
ajlm-708	49	3	for	for	ADP
ajlm-708	49	4	10	10	NUM
ajlm-708	49	5	minutes	minute	NOUN
ajlm-708	49	6	(	(	PUNCT
ajlm-708	49	7	min	min	NOUN
ajlm-708	49	8	)	)	PUNCT
ajlm-708	49	9	;	;	PUNCT
ajlm-708	49	10	five	five	NUM
ajlm-708	49	11	cycles	cycle	NOUN
ajlm-708	49	12	of	of	ADP
ajlm-708	49	13	94	94	NUM
ajlm-708	49	14	°	°	ADP
ajlm-708	49	15	c	c	NOUN
ajlm-708	49	16	for	for	ADP
ajlm-708	49	17	20	20	NUM
ajlm-708	49	18	seconds	second	NOUN
ajlm-708	49	19	(	(	PUNCT
ajlm-708	49	20	s	s	NOUN
ajlm-708	49	21	)	)	PUNCT
ajlm-708	49	22	,	,	PUNCT
ajlm-708	49	23	48	48	NUM
ajlm-708	49	24	°	°	NUM
ajlm-708	49	25	c	c	NOUN
ajlm-708	49	26	for	for	ADP
ajlm-708	49	27	20	20	NUM
ajlm-708	49	28	s	s	NOUN
ajlm-708	49	29	,	,	PUNCT
ajlm-708	49	30	and	and	CCONJ
ajlm-708	49	31	72	72	NUM
ajlm-708	49	32	°	°	NOUN
ajlm-708	49	33	c	c	NOUN
ajlm-708	49	34	for	for	ADP
ajlm-708	49	35	1	1	NUM
ajlm-708	49	36	min	min	NOUN
ajlm-708	49	37	for	for	ADP
ajlm-708	49	38	annealing	anneal	VERB
ajlm-708	49	39	the	the	DET
ajlm-708	49	40	primers	primer	NOUN
ajlm-708	49	41	with	with	ADP
ajlm-708	49	42	unique	unique	ADJ
ajlm-708	49	43	molecular	molecular	ADJ
ajlm-708	49	44	tags	tag	NOUN
ajlm-708	49	45	followed	follow	VERB
ajlm-708	49	46	by	by	ADP
ajlm-708	49	47	35	35	NUM
ajlm-708	49	48	cycles	cycle	NOUN
ajlm-708	49	49	of	of	ADP
ajlm-708	49	50	94	94	NUM
ajlm-708	49	51	°	°	ADP
ajlm-708	49	52	c	c	NOUN
ajlm-708	49	53	for	for	ADP
ajlm-708	49	54	30	30	NUM
ajlm-708	49	55	s	s	NOUN
ajlm-708	49	56	,	,	PUNCT
ajlm-708	49	57	60	60	NUM
ajlm-708	49	58	°	°	NUM
ajlm-708	49	59	c	c	NOUN
ajlm-708	49	60	for	for	ADP
ajlm-708	49	61	20	20	NUM
ajlm-708	49	62	s	s	NOUN
ajlm-708	49	63	,	,	PUNCT
ajlm-708	49	64	72	72	NUM
ajlm-708	49	65	°	°	NUM
ajlm-708	49	66	c	c	NOUN
ajlm-708	49	67	for	for	ADP
ajlm-708	49	68	30	30	NUM
ajlm-708	49	69	s	s	NOUN
ajlm-708	49	70	;	;	PUNCT
ajlm-708	49	71	and	and	CCONJ
ajlm-708	49	72	one	one	NUM
ajlm-708	49	73	cycle	cycle	NOUN
ajlm-708	49	74	of	of	ADP
ajlm-708	49	75	72	72	NUM
ajlm-708	49	76	°	°	ADP
ajlm-708	49	77	c	c	NOUN
ajlm-708	49	78	for	for	ADP
ajlm-708	49	79	5	5	NUM
ajlm-708	49	80	min	min	NOUN
ajlm-708	49	81	.	.	PUNCT
ajlm-708	50	1	the	the	DET
ajlm-708	50	2	reaction	reaction	NOUN
ajlm-708	50	3	products	product	NOUN
ajlm-708	50	4	were	be	AUX
ajlm-708	50	5	confirmed	confirm	VERB
ajlm-708	50	6	by	by	ADP
ajlm-708	50	7	1	1	NUM
ajlm-708	50	8	%	%	NOUN
ajlm-708	50	9	agarose	agarose	NOUN
ajlm-708	50	10	gel	gel	NOUN
ajlm-708	50	11	electrophoresis	electrophoresis	NOUN
ajlm-708	50	12	.	.	PUNCT
ajlm-708	51	1	the	the	DET
ajlm-708	51	2	amplicons	amplicon	NOUN
ajlm-708	51	3	were	be	AUX
ajlm-708	51	4	purified	purify	VERB
ajlm-708	51	5	using	use	VERB
ajlm-708	51	6	the	the	DET
ajlm-708	51	7	agencourt	agencourt	NOUN
ajlm-708	51	8	ampure	ampure	NOUN
ajlm-708	51	9	xp	xp	PROPN
ajlm-708	51	10	beads	bead	NOUN
ajlm-708	51	11	(	(	PUNCT
ajlm-708	51	12	beckman	beckman	PROPN
ajlm-708	51	13	coulter	coulter	PROPN
ajlm-708	51	14	,	,	PUNCT
ajlm-708	51	15	beverly	beverly	PROPN
ajlm-708	51	16	,	,	PUNCT
ajlm-708	51	17	massachusetts	massachusetts	PROPN
ajlm-708	51	18	,	,	PUNCT
ajlm-708	51	19	united	united	PROPN
ajlm-708	51	20	states	states	PROPN
ajlm-708	51	21	)	)	PUNCT
ajlm-708	51	22	or	or	CCONJ
ajlm-708	51	23	qiagen	qiagen	NOUN
ajlm-708	51	24	gel	gel	NOUN
ajlm-708	51	25	purification	purification	NOUN
ajlm-708	51	26	kits	kit	NOUN
ajlm-708	51	27	(	(	PUNCT
ajlm-708	51	28	qiagen	qiagen	PROPN
ajlm-708	51	29	,	,	PUNCT
ajlm-708	51	30	germantown	germantown	PROPN
ajlm-708	51	31	,	,	PUNCT
ajlm-708	51	32	maryland	maryland	PROPN
ajlm-708	51	33	,	,	PUNCT
ajlm-708	51	34	united	united	PROPN
ajlm-708	51	35	states	states	PROPN
ajlm-708	51	36	)	)	PUNCT
ajlm-708	51	37	and	and	CCONJ
ajlm-708	51	38	then	then	ADV
ajlm-708	51	39	quantified	quantify	VERB
ajlm-708	51	40	using	use	VERB
ajlm-708	51	41	the	the	DET
ajlm-708	51	42	quant	quant	NOUN
ajlm-708	51	43	-	-	PUNCT
ajlm-708	51	44	it	it	PRON
ajlm-708	51	45	picogreen	picogreen	VERB
ajlm-708	51	46	dsdna	dsdna	NOUN
ajlm-708	51	47	kit	kit	NOUN
ajlm-708	51	48	(	(	PUNCT
ajlm-708	51	49	thermo	thermo	NOUN
ajlm-708	51	50	fisher	fisher	PROPN
ajlm-708	51	51	scientific	scientific	PROPN
ajlm-708	51	52	,	,	PUNCT
ajlm-708	51	53	carlsbad	carlsbad	PROPN
ajlm-708	51	54	,	,	PUNCT
ajlm-708	51	55	california	california	PROPN
ajlm-708	51	56	,	,	PUNCT
ajlm-708	51	57	united	united	PROPN
ajlm-708	51	58	states	states	PROPN
ajlm-708	51	59	)	)	PUNCT
ajlm-708	51	60	.	.	PUNCT
ajlm-708	52	1	each	each	DET
ajlm-708	52	2	sample	sample	NOUN
ajlm-708	52	3	had	have	VERB
ajlm-708	52	4	its	its	PRON
ajlm-708	52	5	own	own	ADJ
ajlm-708	52	6	unique	unique	ADJ
ajlm-708	52	7	tag	tag	NOUN
ajlm-708	52	8	sequences	sequence	NOUN
ajlm-708	52	9	for	for	ADP
ajlm-708	52	10	its	its	PRON
ajlm-708	52	11	six	six	NUM
ajlm-708	52	12	amplicons	amplicon	NOUN
ajlm-708	52	13	.	.	PUNCT
ajlm-708	53	1	six	six	NUM
ajlm-708	53	2	barcoded	barcode	VERB
ajlm-708	53	3	samples	sample	NOUN
ajlm-708	53	4	were	be	AUX
ajlm-708	53	5	pooled	pool	VERB
ajlm-708	53	6	and	and	CCONJ
ajlm-708	53	7	sequenced	sequence	VERB
ajlm-708	53	8	in	in	ADP
ajlm-708	53	9	one	one	NUM
ajlm-708	53	10	region	region	NOUN
ajlm-708	53	11	.	.	PUNCT
ajlm-708	54	1	a	a	DET
ajlm-708	54	2	total	total	NOUN
ajlm-708	54	3	of	of	ADP
ajlm-708	54	4	eight	eight	NUM
ajlm-708	54	5	regions	region	NOUN
ajlm-708	54	6	were	be	AUX
ajlm-708	54	7	used	use	VERB
ajlm-708	54	8	for	for	ADP
ajlm-708	54	9	48	48	NUM
ajlm-708	54	10	samples	sample	NOUN
ajlm-708	54	11	on	on	ADP
ajlm-708	54	12	a	a	DET
ajlm-708	54	13	plate	plate	NOUN
ajlm-708	54	14	.	.	PUNCT
ajlm-708	55	1	pcr	pcr	ADJ
ajlm-708	55	2	amplicons	amplicon	NOUN
ajlm-708	55	3	from	from	ADP
ajlm-708	55	4	six	six	NUM
ajlm-708	55	5	samples	sample	NOUN
ajlm-708	55	6	were	be	AUX
ajlm-708	55	7	pooled	pool	VERB
ajlm-708	55	8	in	in	ADP
ajlm-708	55	9	equal	equal	ADJ
ajlm-708	55	10	amounts	amount	NOUN
ajlm-708	55	11	,	,	PUNCT
ajlm-708	55	12	and	and	CCONJ
ajlm-708	55	13	amplified	amplify	VERB
ajlm-708	55	14	in	in	ADP
ajlm-708	55	15	water	water	NOUN
ajlm-708	55	16	-	-	PUNCT
ajlm-708	55	17	in	in	ADP
ajlm-708	55	18	-	-	PUNCT
ajlm-708	55	19	oil	oil	NOUN
ajlm-708	55	20	emulsion	emulsion	NOUN
ajlm-708	55	21	pcr	pcr	NOUN
ajlm-708	55	22	at	at	ADP
ajlm-708	55	23	the	the	DET
ajlm-708	55	24	cdc	cdc	PROPN
ajlm-708	55	25	biotechnology	biotechnology	PROPN
ajlm-708	55	26	core	core	PROPN
ajlm-708	55	27	facility	facility	NOUN
ajlm-708	55	28	.	.	PUNCT
ajlm-708	56	1	amplicons	amplicon	NOUN
ajlm-708	56	2	of	of	ADP
ajlm-708	56	3	41	41	NUM
ajlm-708	56	4	field	field	NOUN
ajlm-708	56	5	samples	sample	NOUN
ajlm-708	56	6	and	and	CCONJ
ajlm-708	56	7	seven	seven	NUM
ajlm-708	56	8	plasmid	plasmid	ADJ
ajlm-708	56	9	dna	dna	NOUN
ajlm-708	56	10	samples	sample	NOUN
ajlm-708	56	11	were	be	AUX
ajlm-708	56	12	sequenced	sequence	VERB
ajlm-708	56	13	on	on	ADP
ajlm-708	56	14	the	the	DET
ajlm-708	56	15	454	454	NUM
ajlm-708	56	16	platform	platform	NOUN
ajlm-708	56	17	(	(	PUNCT
ajlm-708	56	18	gs	gs	NOUN
ajlm-708	56	19	-	-	PUNCT
ajlm-708	56	20	flx	flx	NOUN
ajlm-708	56	21	,	,	PUNCT
ajlm-708	56	22	roche	roche	PROPN
ajlm-708	56	23	applied	apply	VERB
ajlm-708	56	24	science	science	NOUN
ajlm-708	56	25	,	,	PUNCT
ajlm-708	56	26	indianapolis	indianapolis	PROPN
ajlm-708	56	27	,	,	PUNCT
ajlm-708	56	28	indiana	indiana	PROPN
ajlm-708	56	29	,	,	PUNCT
ajlm-708	56	30	united	united	PROPN
ajlm-708	56	31	states	states	PROPN
ajlm-708	56	32	)	)	PUNCT
ajlm-708	56	33	.	.	PUNCT
ajlm-708	57	1	table	table	NOUN
ajlm-708	57	2	1	1	NUM
ajlm-708	57	3	:	:	PUNCT
ajlm-708	57	4	 	 	SPACE
ajlm-708	57	5	hiv-1	hiv-1	X
ajlm-708	57	6	primers	primer	NOUN
ajlm-708	57	7	designed	design	VERB
ajlm-708	57	8	and	and	CCONJ
ajlm-708	57	9	used	use	VERB
ajlm-708	57	10	for	for	ADP
ajlm-708	57	11	amplifying	amplifying	ADJ
ajlm-708	57	12	pol	pol	NOUN
ajlm-708	57	13	gene	gene	NOUN
ajlm-708	57	14	amplicons	amplicon	NOUN
ajlm-708	57	15	with	with	ADP
ajlm-708	57	16	the	the	DET
ajlm-708	57	17	deep	deep	ADJ
ajlm-708	57	18	sequencing	sequencing	NOUN
ajlm-708	57	19	method	method	NOUN
ajlm-708	57	20	.	.	PUNCT
ajlm-708	58	1	deep	deep	ADJ
ajlm-708	58	2	sequencing	sequence	VERB
ajlm-708	58	3	analysis	analysis	NOUN
ajlm-708	58	4	sequence	sequence	NOUN
ajlm-708	58	5	files	file	NOUN
ajlm-708	58	6	generated	generate	VERB
ajlm-708	58	7	by	by	ADP
ajlm-708	58	8	roche	roche	PROPN
ajlm-708	58	9	454	454	NUM
ajlm-708	58	10	deep	deep	ADJ
ajlm-708	58	11	sequencing	sequencing	NOUN
ajlm-708	58	12	were	be	AUX
ajlm-708	58	13	analysed	analyse	VERB
ajlm-708	58	14	using	use	VERB
ajlm-708	58	15	gs	gs	PROPN
ajlm-708	58	16	amplicon	amplicon	NOUN
ajlm-708	58	17	variant	variant	NOUN
ajlm-708	58	18	analyzer	analyzer	NOUN
ajlm-708	58	19	pipeline	pipeline	NOUN
ajlm-708	58	20	from	from	ADP
ajlm-708	58	21	roche	roche	PROPN
ajlm-708	58	22	applied	apply	VERB
ajlm-708	58	23	science	science	NOUN
ajlm-708	58	24	(	(	PUNCT
ajlm-708	58	25	indianapolis	indianapolis	PROPN
ajlm-708	58	26	,	,	PUNCT
ajlm-708	58	27	indiana	indiana	PROPN
ajlm-708	58	28	,	,	PUNCT
ajlm-708	58	29	united	united	PROPN
ajlm-708	58	30	states	states	PROPN
ajlm-708	58	31	)	)	PUNCT
ajlm-708	58	32	.	.	PUNCT
ajlm-708	59	1	the	the	DET
ajlm-708	59	2	deep	deep	ADJ
ajlm-708	59	3	sequencing	sequencing	NOUN
ajlm-708	59	4	analysis	analysis	NOUN
ajlm-708	59	5	process	process	NOUN
ajlm-708	59	6	in	in	ADP
ajlm-708	59	7	the	the	DET
ajlm-708	59	8	present	present	ADJ
ajlm-708	59	9	study	study	NOUN
ajlm-708	59	10	included	include	VERB
ajlm-708	59	11	quality	quality	NOUN
ajlm-708	59	12	restriction	restriction	NOUN
ajlm-708	59	13	for	for	ADP
ajlm-708	59	14	base	base	NOUN
ajlm-708	59	15	call	call	NOUN
ajlm-708	59	16	setting	set	VERB
ajlm-708	59	17	at	at	ADP
ajlm-708	59	18	60	60	NUM
ajlm-708	59	19	for	for	ADP
ajlm-708	59	20	signal	signal	ADJ
ajlm-708	59	21	intensity	intensity	NOUN
ajlm-708	59	22	.	.	PUNCT
ajlm-708	60	1	all	all	DET
ajlm-708	60	2	amplicon	amplicon	NOUN
ajlm-708	60	3	reads	read	VERB
ajlm-708	60	4	of	of	ADP
ajlm-708	60	5	alignment	alignment	NOUN
ajlm-708	60	6	and	and	CCONJ
ajlm-708	60	7	single	single	ADJ
ajlm-708	60	8	nucleotide	nucleotide	ADJ
ajlm-708	60	9	polymorphism	polymorphism	NOUN
ajlm-708	60	10	(	(	PUNCT
ajlm-708	60	11	snp	snp	PROPN
ajlm-708	60	12	)	)	PUNCT
ajlm-708	60	13	,	,	PUNCT
ajlm-708	60	14	calling	call	VERB
ajlm-708	60	15	against	against	ADP
ajlm-708	60	16	the	the	DET
ajlm-708	60	17	hxb2	hxb2	PROPN
ajlm-708	60	18	reference	reference	NOUN
ajlm-708	60	19	sequence	sequence	NOUN
ajlm-708	60	20	,	,	PUNCT
ajlm-708	60	21	were	be	AUX
ajlm-708	60	22	evaluated	evaluate	VERB
ajlm-708	60	23	with	with	ADP
ajlm-708	60	24	a	a	DET
ajlm-708	60	25	quality	quality	NOUN
ajlm-708	60	26	score	score	NOUN
ajlm-708	60	27	≥	≥	NOUN
ajlm-708	60	28	25	25	NUM
ajlm-708	60	29	and	and	CCONJ
ajlm-708	60	30	read	read	VERB
ajlm-708	60	31	length	length	NOUN
ajlm-708	60	32	≥	≥	NOUN
ajlm-708	60	33	220	220	NUM
ajlm-708	60	34	base	base	NOUN
ajlm-708	60	35	pairs	pair	NOUN
ajlm-708	60	36	.	.	PUNCT
ajlm-708	61	1	sequence	sequence	NOUN
ajlm-708	61	2	accuracy	accuracy	NOUN
ajlm-708	61	3	of	of	ADP
ajlm-708	61	4	roche	roche	PROPN
ajlm-708	61	5	454	454	NUM
ajlm-708	61	6	runs	run	NOUN
ajlm-708	61	7	was	be	AUX
ajlm-708	61	8	evaluated	evaluate	VERB
ajlm-708	61	9	using	use	VERB
ajlm-708	61	10	the	the	DET
ajlm-708	61	11	sequences	sequence	NOUN
ajlm-708	61	12	generated	generate	VERB
ajlm-708	61	13	by	by	ADP
ajlm-708	61	14	sanger	sanger	PROPN
ajlm-708	61	15	sequencing	sequencing	NOUN
ajlm-708	61	16	of	of	ADP
ajlm-708	61	17	the	the	DET
ajlm-708	61	18	seven	seven	NUM
ajlm-708	61	19	plasmid	plasmid	ADJ
ajlm-708	61	20	clones	clone	NOUN
ajlm-708	61	21	.	.	PUNCT
ajlm-708	62	1	the	the	DET
ajlm-708	62	2	minority	minority	NOUN
ajlm-708	62	3	variant	variant	NOUN
ajlm-708	62	4	was	be	AUX
ajlm-708	62	5	defined	define	VERB
ajlm-708	62	6	as	as	ADP
ajlm-708	62	7	a	a	DET
ajlm-708	62	8	snp	snp	NOUN
ajlm-708	62	9	detected	detect	VERB
ajlm-708	62	10	at	at	ADP
ajlm-708	62	11	>	>	X
ajlm-708	62	12	0.68	0.68	NUM
ajlm-708	62	13	%	%	NOUN
ajlm-708	62	14	and	and	CCONJ
ajlm-708	62	15	<	<	X
ajlm-708	62	16	20	20	NUM
ajlm-708	62	17	%	%	NOUN
ajlm-708	62	18	of	of	ADP
ajlm-708	62	19	the	the	DET
ajlm-708	62	20	frequency	frequency	NOUN
ajlm-708	62	21	of	of	ADP
ajlm-708	62	22	mutations	mutation	NOUN
ajlm-708	62	23	.	.	PUNCT
ajlm-708	63	1	for	for	ADP
ajlm-708	63	2	drm	drm	PROPN
ajlm-708	63	3	analysis	analysis	NOUN
ajlm-708	63	4	,	,	PUNCT
ajlm-708	63	5	mutations	mutation	NOUN
ajlm-708	63	6	were	be	AUX
ajlm-708	63	7	called	call	VERB
ajlm-708	63	8	and	and	CCONJ
ajlm-708	63	9	grouped	group	VERB
ajlm-708	63	10	based	base	VERB
ajlm-708	63	11	on	on	ADP
ajlm-708	63	12	international	international	ADJ
ajlm-708	63	13	aids	aids	PROPN
ajlm-708	63	14	society	society	NOUN
ajlm-708	63	15	(	(	PUNCT
ajlm-708	63	16	ias)-usa	ias)-usa	PROPN
ajlm-708	63	17	2011	2011	NUM
ajlm-708	63	18	recommendations.23	recommendations.23	ADJ
ajlm-708	63	19	additional	additional	ADJ
ajlm-708	63	20	mutations	mutation	NOUN
ajlm-708	63	21	for	for	ADP
ajlm-708	63	22	those	those	DET
ajlm-708	63	23	samples	sample	NOUN
ajlm-708	63	24	collected	collect	VERB
ajlm-708	63	25	before	before	SCONJ
ajlm-708	63	26	art	art	NOUN
ajlm-708	63	27	initiation	initiation	NOUN
ajlm-708	63	28	were	be	AUX
ajlm-708	63	29	analysed	analyse	VERB
ajlm-708	63	30	based	base	VERB
ajlm-708	63	31	on	on	ADP
ajlm-708	63	32	the	the	DET
ajlm-708	63	33	2009	2009	NUM
ajlm-708	63	34	world	world	NOUN
ajlm-708	63	35	health	health	NOUN
ajlm-708	63	36	organization	organization	NOUN
ajlm-708	63	37	surveillance	surveillance	NOUN
ajlm-708	63	38	drm	drm	PROPN
ajlm-708	63	39	list.24	list.24	PROPN
ajlm-708	63	40	standard	standard	NOUN
ajlm-708	63	41	sanger	sanger	PROPN
ajlm-708	63	42	sequencing	sequence	VERB
ajlm-708	63	43	the	the	DET
ajlm-708	63	44	standard	standard	ADJ
ajlm-708	63	45	genotyping	genotyping	NOUN
ajlm-708	63	46	of	of	ADP
ajlm-708	63	47	hiv	hiv	PROPN
ajlm-708	63	48	drug	drug	NOUN
ajlm-708	63	49	resistance	resistance	NOUN
ajlm-708	63	50	was	be	AUX
ajlm-708	63	51	performed	perform	VERB
ajlm-708	63	52	on	on	ADP
ajlm-708	63	53	all	all	DET
ajlm-708	63	54	plasma	plasma	NOUN
ajlm-708	63	55	samples	sample	NOUN
ajlm-708	63	56	using	use	VERB
ajlm-708	63	57	an	an	DET
ajlm-708	63	58	in	in	ADP
ajlm-708	63	59	-	-	PUNCT
ajlm-708	63	60	house	house	NOUN
ajlm-708	63	61	population	population	NOUN
ajlm-708	63	62	-	-	PUNCT
ajlm-708	63	63	based	base	VERB
ajlm-708	63	64	sequencing	sequence	VERB
ajlm-708	63	65	assay.11	assay.11	ADJ
ajlm-708	63	66	raw	raw	ADJ
ajlm-708	63	67	sequencing	sequence	VERB
ajlm-708	63	68	data	datum	NOUN
ajlm-708	63	69	were	be	AUX
ajlm-708	63	70	analysed	analyse	VERB
ajlm-708	63	71	using	use	VERB
ajlm-708	63	72	the	the	DET
ajlm-708	63	73	customised	customised	ADJ
ajlm-708	63	74	recall	recall	PROPN
ajlm-708	63	75	software	software	PROPN
ajlm-708	63	76	,	,	PUNCT
ajlm-708	63	77	v.2.24	v.2.24	X
ajlm-708	63	78	(	(	PUNCT
ajlm-708	63	79	provided	provide	VERB
ajlm-708	63	80	by	by	ADP
ajlm-708	63	81	dr	dr	PROPN
ajlm-708	63	82	.	.	PROPN
ajlm-708	63	83	richard	richard	PROPN
ajlm-708	63	84	harrigan	harrigan	PROPN
ajlm-708	63	85	from	from	ADP
ajlm-708	63	86	british	british	PROPN
ajlm-708	63	87	columbia	columbia	PROPN
ajlm-708	63	88	’s	’s	PART
ajlm-708	63	89	center	center	PROPN
ajlm-708	63	90	for	for	ADP
ajlm-708	63	91	excellence	excellence	NOUN
ajlm-708	63	92	in	in	ADP
ajlm-708	63	93	hiv	hiv	PROPN
ajlm-708	63	94	/	/	SYM
ajlm-708	63	95	aids	aids	PROPN
ajlm-708	63	96	research	research	PROPN
ajlm-708	63	97	,	,	PUNCT
ajlm-708	63	98	vancouver	vancouver	PROPN
ajlm-708	63	99	,	,	PUNCT
ajlm-708	63	100	canada).25	canada).25	PROPN
ajlm-708	63	101	the	the	DET
ajlm-708	63	102	mixed	mixed	ADJ
ajlm-708	63	103	mutation	mutation	NOUN
ajlm-708	63	104	calling	call	VERB
ajlm-708	63	105	threshold	threshold	NOUN
ajlm-708	63	106	was	be	AUX
ajlm-708	63	107	set	set	VERB
ajlm-708	63	108	at	at	ADP
ajlm-708	63	109	≥	≥	NOUN
ajlm-708	63	110	20	20	NUM
ajlm-708	63	111	%	%	NOUN
ajlm-708	63	112	of	of	ADP
ajlm-708	63	113	the	the	DET
ajlm-708	63	114	main	main	ADJ
ajlm-708	63	115	peak	peak	NOUN
ajlm-708	63	116	.	.	PUNCT
ajlm-708	64	1	the	the	DET
ajlm-708	64	2	drms	drm	NOUN
ajlm-708	64	3	were	be	AUX
ajlm-708	64	4	analysed	analyse	VERB
ajlm-708	64	5	as	as	SCONJ
ajlm-708	64	6	stated	state	VERB
ajlm-708	64	7	above	above	ADV
ajlm-708	64	8	for	for	ADP
ajlm-708	64	9	parallel	parallel	ADJ
ajlm-708	64	10	deep	deep	ADJ
ajlm-708	64	11	sequencing	sequencing	NOUN
ajlm-708	64	12	results	result	NOUN
ajlm-708	64	13	.	.	PUNCT
ajlm-708	65	1	statistical	statistical	ADJ
ajlm-708	65	2	analysis	analysis	NOUN
ajlm-708	65	3	all	all	DET
ajlm-708	65	4	statistical	statistical	ADJ
ajlm-708	65	5	analysis	analysis	NOUN
ajlm-708	65	6	was	be	AUX
ajlm-708	65	7	performed	perform	VERB
ajlm-708	65	8	using	use	VERB
ajlm-708	65	9	spss	spss	PROPN
ajlm-708	65	10	statistics	statistics	PROPN
ajlm-708	65	11	v19	v19	PROPN
ajlm-708	65	12	(	(	PUNCT
ajlm-708	65	13	spss	spss	PROPN
ajlm-708	65	14	inc	inc	PROPN
ajlm-708	65	15	.	.	PROPN
ajlm-708	65	16	,	,	PUNCT
ajlm-708	65	17	chicago	chicago	PROPN
ajlm-708	65	18	,	,	PUNCT
ajlm-708	65	19	illinois	illinois	PROPN
ajlm-708	65	20	,	,	PUNCT
ajlm-708	65	21	united	united	PROPN
ajlm-708	65	22	states	states	PROPN
ajlm-708	65	23	)	)	PUNCT
ajlm-708	65	24	.	.	PUNCT
ajlm-708	66	1	the	the	DET
ajlm-708	66	2	wilcoxon	wilcoxon	ADJ
ajlm-708	66	3	signed	sign	VERB
ajlm-708	66	4	-	-	PUNCT
ajlm-708	66	5	rank	rank	NOUN
ajlm-708	66	6	test	test	NOUN
ajlm-708	66	7	was	be	AUX
ajlm-708	66	8	used	use	VERB
ajlm-708	66	9	to	to	PART
ajlm-708	66	10	analyse	analyse	VERB
ajlm-708	66	11	the	the	DET
ajlm-708	66	12	statistical	statistical	ADJ
ajlm-708	66	13	differences	difference	NOUN
ajlm-708	66	14	in	in	ADP
ajlm-708	66	15	the	the	DET
ajlm-708	66	16	number	number	NOUN
ajlm-708	66	17	of	of	ADP
ajlm-708	66	18	drms	drm	NOUN
ajlm-708	66	19	detected	detect	VERB
ajlm-708	66	20	between	between	ADP
ajlm-708	66	21	sanger	sanger	PROPN
ajlm-708	66	22	sequencing	sequencing	NOUN
ajlm-708	66	23	and	and	CCONJ
ajlm-708	66	24	deep	deep	ADJ
ajlm-708	66	25	sequencing	sequencing	NOUN
ajlm-708	66	26	.	.	PUNCT
ajlm-708	67	1	fisher	fisher	PROPN
ajlm-708	67	2	’s	’s	PART
ajlm-708	67	3	exact	exact	ADJ
ajlm-708	67	4	test	test	NOUN
ajlm-708	67	5	was	be	AUX
ajlm-708	67	6	used	use	VERB
ajlm-708	67	7	to	to	PART
ajlm-708	67	8	compare	compare	VERB
ajlm-708	67	9	the	the	DET
ajlm-708	67	10	prevalence	prevalence	NOUN
ajlm-708	67	11	of	of	ADP
ajlm-708	67	12	hiv	hiv	PROPN
ajlm-708	67	13	drug	drug	NOUN
ajlm-708	67	14	resistance	resistance	NOUN
ajlm-708	67	15	by	by	ADP
ajlm-708	67	16	these	these	DET
ajlm-708	67	17	two	two	NUM
ajlm-708	67	18	methods	method	NOUN
ajlm-708	67	19	.	.	PUNCT
ajlm-708	68	1	a	a	DET
ajlm-708	68	2	p	p	NOUN
ajlm-708	68	3	-	-	PUNCT
ajlm-708	68	4	value	value	NOUN
ajlm-708	68	5	of	of	ADP
ajlm-708	68	6	<	<	X
ajlm-708	68	7	0.05	0.05	NUM
ajlm-708	68	8	was	be	AUX
ajlm-708	68	9	considered	consider	VERB
ajlm-708	68	10	statistically	statistically	ADV
ajlm-708	68	11	significant	significant	ADJ
ajlm-708	68	12	.	.	PUNCT
ajlm-708	69	1	results	result	NOUN
ajlm-708	69	2	parallel	parallel	VERB
ajlm-708	69	3	deep	deep	ADJ
ajlm-708	69	4	sequencing	sequence	VERB
ajlm-708	69	5	coverage	coverage	NOUN
ajlm-708	69	6	and	and	CCONJ
ajlm-708	69	7	estimate	estimate	NOUN
ajlm-708	69	8	of	of	ADP
ajlm-708	69	9	sequence	sequence	NOUN
ajlm-708	69	10	errors	error	NOUN
ajlm-708	69	11	the	the	DET
ajlm-708	69	12	gs	gs	NOUN
ajlm-708	69	13	-	-	PUNCT
ajlm-708	69	14	flx	flx	NOUN
ajlm-708	69	15	deep	deep	ADJ
ajlm-708	69	16	sequencing	sequencing	NOUN
ajlm-708	69	17	of	of	ADP
ajlm-708	69	18	a	a	DET
ajlm-708	69	19	single	single	ADJ
ajlm-708	69	20	run	run	NOUN
ajlm-708	69	21	yielded	yield	VERB
ajlm-708	69	22	246	246	NUM
ajlm-708	69	23	849	849	NUM
ajlm-708	69	24	raw	raw	ADJ
ajlm-708	69	25	sequence	sequence	NOUN
ajlm-708	69	26	reads	read	NOUN
ajlm-708	69	27	,	,	PUNCT
ajlm-708	70	1	of	of	ADP
ajlm-708	70	2	which	which	PRON
ajlm-708	70	3	242	242	NUM
ajlm-708	70	4	246	246	NUM
ajlm-708	70	5	(	(	PUNCT
ajlm-708	70	6	98.1	98.1	NUM
ajlm-708	70	7	%	%	NOUN
ajlm-708	70	8	)	)	PUNCT
ajlm-708	70	9	reads	read	NOUN
ajlm-708	70	10	passed	pass	VERB
ajlm-708	70	11	the	the	DET
ajlm-708	70	12	quality	quality	NOUN
ajlm-708	70	13	restrictions	restriction	NOUN
ajlm-708	70	14	with	with	ADP
ajlm-708	70	15	a	a	DET
ajlm-708	70	16	mean	mean	ADJ
ajlm-708	70	17	read	read	NOUN
ajlm-708	70	18	length	length	NOUN
ajlm-708	70	19	of	of	ADP
ajlm-708	70	20	270	270	NUM
ajlm-708	70	21	nucleotides	nucleotide	NOUN
ajlm-708	70	22	,	,	PUNCT
ajlm-708	70	23	while	while	SCONJ
ajlm-708	70	24	4603	4603	NUM
ajlm-708	70	25	(	(	PUNCT
ajlm-708	70	26	1.9	1.9	NUM
ajlm-708	70	27	%	%	NOUN
ajlm-708	70	28	)	)	PUNCT
ajlm-708	70	29	low	low	ADJ
ajlm-708	70	30	-	-	PUNCT
ajlm-708	70	31	quality	quality	NOUN
ajlm-708	70	32	sequences	sequence	NOUN
ajlm-708	70	33	were	be	AUX
ajlm-708	70	34	removed	remove	VERB
ajlm-708	70	35	from	from	ADP
ajlm-708	70	36	the	the	DET
ajlm-708	70	37	analysis	analysis	NOUN
ajlm-708	70	38	pipeline	pipeline	NOUN
ajlm-708	70	39	.	.	PUNCT
ajlm-708	71	1	on	on	ADP
ajlm-708	71	2	average	average	ADJ
ajlm-708	71	3	,	,	PUNCT
ajlm-708	71	4	5490	5490	NUM
ajlm-708	71	5	reads	read	NOUN
ajlm-708	71	6	per	per	ADP
ajlm-708	71	7	sample	sample	NOUN
ajlm-708	71	8	were	be	AUX
ajlm-708	71	9	obtained	obtain	VERB
ajlm-708	71	10	(	(	PUNCT
ajlm-708	71	11	range	range	NOUN
ajlm-708	71	12	from	from	ADP
ajlm-708	71	13	420	420	NUM
ajlm-708	71	14	to	to	ADP
ajlm-708	71	15	5673	5673	NUM
ajlm-708	71	16	reads	read	NOUN
ajlm-708	71	17	)	)	PUNCT
ajlm-708	71	18	.	.	PUNCT
ajlm-708	72	1	from	from	ADP
ajlm-708	72	2	the	the	DET
ajlm-708	72	3	1	1	NUM
ajlm-708	72	4	%	%	NOUN
ajlm-708	72	5	mixed	mixed	ADJ
ajlm-708	72	6	clone	clone	NOUN
ajlm-708	72	7	,	,	PUNCT
ajlm-708	72	8	k103n	k103n	PROPN
ajlm-708	72	9	was	be	AUX
ajlm-708	72	10	not	not	PART
ajlm-708	72	11	detected	detect	VERB
ajlm-708	72	12	within	within	ADP
ajlm-708	72	13	the	the	DET
ajlm-708	72	14	520	520	NUM
ajlm-708	72	15	sequence	sequence	NOUN
ajlm-708	72	16	reads	read	NOUN
ajlm-708	72	17	;	;	PUNCT
ajlm-708	72	18	y181c	y181c	PROPN
ajlm-708	72	19	and	and	CCONJ
ajlm-708	72	20	m184v	m184v	PROPN
ajlm-708	72	21	were	be	AUX
ajlm-708	72	22	detected	detect	VERB
ajlm-708	72	23	at	at	ADP
ajlm-708	72	24	the	the	DET
ajlm-708	72	25	level	level	NOUN
ajlm-708	72	26	of	of	ADP
ajlm-708	72	27	1.03	1.03	NUM
ajlm-708	72	28	%	%	NOUN
ajlm-708	72	29	with	with	ADP
ajlm-708	72	30	1335	1335	NUM
ajlm-708	72	31	reads	read	NOUN
ajlm-708	72	32	,	,	PUNCT
ajlm-708	72	33	while	while	SCONJ
ajlm-708	72	34	g190a	g190a	NOUN
ajlm-708	72	35	was	be	AUX
ajlm-708	72	36	detected	detect	VERB
ajlm-708	72	37	at	at	ADP
ajlm-708	72	38	0.97	0.97	NUM
ajlm-708	72	39	%	%	NOUN
ajlm-708	72	40	with	with	ADP
ajlm-708	72	41	785	785	NUM
ajlm-708	72	42	reads	read	NOUN
ajlm-708	72	43	.	.	PUNCT
ajlm-708	73	1	the	the	DET
ajlm-708	73	2	mean	mean	ADJ
ajlm-708	73	3	error	error	NOUN
ajlm-708	73	4	rate	rate	NOUN
ajlm-708	73	5	plus	plus	CCONJ
ajlm-708	73	6	two	two	NUM
ajlm-708	73	7	standard	standard	ADJ
ajlm-708	73	8	deviations	deviation	NOUN
ajlm-708	73	9	was	be	AUX
ajlm-708	73	10	0.43	0.43	NUM
ajlm-708	73	11	from	from	ADP
ajlm-708	73	12	the	the	DET
ajlm-708	73	13	six	six	NUM
ajlm-708	73	14	control	control	NOUN
ajlm-708	73	15	plasmid	plasmid	ADJ
ajlm-708	73	16	clones	clone	NOUN
ajlm-708	73	17	.	.	PUNCT
ajlm-708	74	1	sequence	sequence	NOUN
ajlm-708	74	2	errors	error	NOUN
ajlm-708	74	3	mostly	mostly	ADV
ajlm-708	74	4	occurred	occur	VERB
ajlm-708	74	5	at	at	ADP
ajlm-708	74	6	the	the	DET
ajlm-708	74	7	overlapping	overlap	VERB
ajlm-708	74	8	areas	area	NOUN
ajlm-708	74	9	of	of	ADP
ajlm-708	74	10	amplicons	amplicon	NOUN
ajlm-708	74	11	in	in	ADP
ajlm-708	74	12	the	the	DET
ajlm-708	74	13	rt	rt	PROPN
ajlm-708	74	14	gene	gene	NOUN
ajlm-708	74	15	.	.	PUNCT
ajlm-708	75	1	there	there	PRON
ajlm-708	75	2	was	be	VERB
ajlm-708	75	3	only	only	ADV
ajlm-708	75	4	one	one	NUM
ajlm-708	75	5	snp	snp	NOUN
ajlm-708	75	6	showing	show	VERB
ajlm-708	75	7	an	an	DET
ajlm-708	75	8	error	error	NOUN
ajlm-708	75	9	rate	rate	NOUN
ajlm-708	75	10	of	of	ADP
ajlm-708	75	11	0.68	0.68	NUM
ajlm-708	75	12	%	%	NOUN
ajlm-708	75	13	at	at	ADP
ajlm-708	75	14	codon	codon	NOUN
ajlm-708	75	15	17	17	NUM
ajlm-708	75	16	of	of	ADP
ajlm-708	75	17	the	the	DET
ajlm-708	75	18	pr	pr	NOUN
ajlm-708	75	19	gene	gene	NOUN
ajlm-708	75	20	in	in	ADP
ajlm-708	75	21	a	a	DET
ajlm-708	75	22	polyg	polyg	NOUN
ajlm-708	75	23	region	region	NOUN
ajlm-708	75	24	(	(	PUNCT
ajlm-708	75	25	ggggggca	ggggggca	NOUN
ajlm-708	75	26	,	,	PUNCT
ajlm-708	75	27	nucleotide	nucleotide	NOUN
ajlm-708	75	28	35	35	NUM
ajlm-708	75	29	,	,	PUNCT
ajlm-708	75	30	figure	figure	NOUN
ajlm-708	75	31	1	1	NUM
ajlm-708	75	32	)	)	PUNCT
ajlm-708	75	33	.	.	PUNCT
ajlm-708	76	1	this	this	DET
ajlm-708	76	2	error	error	NOUN
ajlm-708	76	3	at	at	ADP
ajlm-708	76	4	pr	pr	NOUN
ajlm-708	76	5	codon	codon	PROPN
ajlm-708	76	6	17	17	NUM
ajlm-708	76	7	was	be	AUX
ajlm-708	76	8	not	not	PART
ajlm-708	76	9	in	in	ADP
ajlm-708	76	10	the	the	DET
ajlm-708	76	11	drm	drm	PROPN
ajlm-708	76	12	position	position	NOUN
ajlm-708	76	13	according	accord	VERB
ajlm-708	76	14	to	to	ADP
ajlm-708	76	15	ias	ias	PROPN
ajlm-708	76	16	and	and	CCONJ
ajlm-708	76	17	stanford	stanford	PROPN
ajlm-708	76	18	hiv	hiv	PROPN
ajlm-708	76	19	database	database	PROPN
ajlm-708	76	20	definitions	definition	NOUN
ajlm-708	76	21	.	.	PUNCT
ajlm-708	77	1	another	another	DET
ajlm-708	77	2	high	high	ADJ
ajlm-708	77	3	-	-	PUNCT
ajlm-708	77	4	error	error	NOUN
ajlm-708	77	5	site	site	NOUN
ajlm-708	77	6	was	be	AUX
ajlm-708	77	7	codons	codon	NOUN
ajlm-708	77	8	63	63	NUM
ajlm-708	77	9	of	of	ADP
ajlm-708	77	10	the	the	DET
ajlm-708	77	11	rt	rt	PROPN
ajlm-708	77	12	gene	gene	NOUN
ajlm-708	77	13	(	(	PUNCT
ajlm-708	77	14	nucleotides	nucleotide	NOUN
ajlm-708	77	15	470	470	NUM
ajlm-708	77	16	and	and	CCONJ
ajlm-708	77	17	471	471	NUM
ajlm-708	77	18	,	,	PUNCT
ajlm-708	77	19	figure	figure	NOUN
ajlm-708	77	20	1	1	NUM
ajlm-708	77	21	)	)	PUNCT
ajlm-708	77	22	,	,	PUNCT
ajlm-708	77	23	with	with	ADP
ajlm-708	77	24	a	a	DET
ajlm-708	77	25	0.61	0.61	NUM
ajlm-708	77	26	%	%	NOUN
ajlm-708	77	27	error	error	NOUN
ajlm-708	77	28	rate	rate	NOUN
ajlm-708	77	29	.	.	PUNCT
ajlm-708	78	1	based	base	VERB
ajlm-708	78	2	on	on	ADP
ajlm-708	78	3	these	these	DET
ajlm-708	78	4	background	background	NOUN
ajlm-708	78	5	errors	error	NOUN
ajlm-708	78	6	for	for	ADP
ajlm-708	78	7	each	each	DET
ajlm-708	78	8	nucleotide	nucleotide	NOUN
ajlm-708	78	9	position	position	NOUN
ajlm-708	78	10	,	,	PUNCT
ajlm-708	78	11	the	the	DET
ajlm-708	78	12	frequency	frequency	NOUN
ajlm-708	78	13	>	>	X
ajlm-708	78	14	0.68	0.68	NUM
ajlm-708	78	15	%	%	NOUN
ajlm-708	78	16	error	error	NOUN
ajlm-708	78	17	rate	rate	NOUN
ajlm-708	78	18	was	be	AUX
ajlm-708	78	19	used	use	VERB
ajlm-708	78	20	as	as	ADP
ajlm-708	78	21	the	the	DET
ajlm-708	78	22	threshold	threshold	NOUN
ajlm-708	78	23	for	for	ADP
ajlm-708	78	24	true	true	ADJ
ajlm-708	78	25	snps	snps	PROPN
ajlm-708	78	26	when	when	SCONJ
ajlm-708	78	27	evaluating	evaluate	VERB
ajlm-708	78	28	the	the	DET
ajlm-708	78	29	minority	minority	NOUN
ajlm-708	78	30	drms	drm	NOUN
ajlm-708	78	31	in	in	ADP
ajlm-708	78	32	the	the	DET
ajlm-708	78	33	clinical	clinical	ADJ
ajlm-708	78	34	samples	sample	NOUN
ajlm-708	78	35	.	.	PUNCT
ajlm-708	79	1	figure	figure	NOUN
ajlm-708	79	2	1	1	NUM
ajlm-708	79	3	:	:	PUNCT
ajlm-708	79	4	error	error	NOUN
ajlm-708	79	5	frequency	frequency	NOUN
ajlm-708	79	6	of	of	ADP
ajlm-708	79	7	454	454	NUM
ajlm-708	79	8	deep	deep	ADJ
ajlm-708	79	9	sequencing	sequencing	NOUN
ajlm-708	79	10	on	on	ADP
ajlm-708	79	11	the	the	DET
ajlm-708	79	12	six	six	NUM
ajlm-708	79	13	plasmid	plasmid	ADJ
ajlm-708	79	14	control	control	NOUN
ajlm-708	79	15	clones	clone	NOUN
ajlm-708	79	16	at	at	ADP
ajlm-708	79	17	each	each	DET
ajlm-708	79	18	nucleotide	nucleotide	ADJ
ajlm-708	79	19	position	position	NOUN
ajlm-708	79	20	from	from	ADP
ajlm-708	79	21	amplified	amplify	VERB
ajlm-708	79	22	amplicons	amplicon	NOUN
ajlm-708	79	23	.	.	PUNCT
ajlm-708	80	1	the	the	DET
ajlm-708	80	2	x	x	VERB
ajlm-708	80	3	axis	axis	NOUN
ajlm-708	80	4	is	be	AUX
ajlm-708	80	5	the	the	DET
ajlm-708	80	6	nucleotide	nucleotide	ADJ
ajlm-708	80	7	sequence	sequence	NOUN
ajlm-708	80	8	location	location	NOUN
ajlm-708	80	9	in	in	ADP
ajlm-708	80	10	protease	protease	NOUN
ajlm-708	80	11	and	and	CCONJ
ajlm-708	80	12	reverse	reverse	ADJ
ajlm-708	80	13	transcriptase	transcriptase	NOUN
ajlm-708	80	14	genes	gene	NOUN
ajlm-708	80	15	;	;	PUNCT
ajlm-708	80	16	the	the	DET
ajlm-708	80	17	y	y	PROPN
ajlm-708	80	18	axis	axis	NOUN
ajlm-708	80	19	is	be	AUX
ajlm-708	80	20	the	the	DET
ajlm-708	80	21	percentage	percentage	NOUN
ajlm-708	80	22	of	of	ADP
ajlm-708	80	23	single	single	ADJ
ajlm-708	80	24	nucleotide	nucleotide	ADJ
ajlm-708	80	25	polymorphism	polymorphism	NOUN
ajlm-708	80	26	error	error	NOUN
ajlm-708	80	27	.	.	PUNCT
ajlm-708	81	1	comparative	comparative	ADJ
ajlm-708	81	2	analysis	analysis	NOUN
ajlm-708	81	3	of	of	ADP
ajlm-708	81	4	drug	drug	NOUN
ajlm-708	81	5	resistance	resistance	NOUN
ajlm-708	81	6	mutations	mutation	NOUN
ajlm-708	81	7	detected	detect	VERB
ajlm-708	81	8	by	by	ADP
ajlm-708	81	9	parallel	parallel	ADJ
ajlm-708	81	10	deep	deep	ADJ
ajlm-708	81	11	sequencing	sequencing	NOUN
ajlm-708	81	12	and	and	CCONJ
ajlm-708	81	13	sanger	sanger	PROPN
ajlm-708	81	14	sequencing	sequence	VERB
ajlm-708	81	15	barcoded	barcode	VERB
ajlm-708	81	16	deep	deep	ADJ
ajlm-708	81	17	sequencing	sequence	VERB
ajlm-708	81	18	primers	primer	NOUN
ajlm-708	81	19	amplified	amplify	VERB
ajlm-708	81	20	all	all	DET
ajlm-708	81	21	amplicons	amplicon	NOUN
ajlm-708	81	22	from	from	ADP
ajlm-708	81	23	the	the	DET
ajlm-708	81	24	clinical	clinical	ADJ
ajlm-708	81	25	samples	sample	NOUN
ajlm-708	81	26	.	.	PUNCT
ajlm-708	82	1	roche	roche	PROPN
ajlm-708	82	2	gs	gs	PROPN
ajlm-708	82	3	-	-	PUNCT
ajlm-708	82	4	flx	flx	NOUN
ajlm-708	82	5	deep	deep	ADJ
ajlm-708	82	6	sequencing	sequencing	NOUN
ajlm-708	82	7	identified	identify	VERB
ajlm-708	82	8	all	all	DET
ajlm-708	82	9	72	72	NUM
ajlm-708	82	10	of	of	ADP
ajlm-708	82	11	the	the	DET
ajlm-708	82	12	drms	drm	NOUN
ajlm-708	82	13	that	that	PRON
ajlm-708	82	14	had	have	AUX
ajlm-708	82	15	been	be	AUX
ajlm-708	82	16	detected	detect	VERB
ajlm-708	82	17	by	by	ADP
ajlm-708	82	18	sanger	sanger	PROPN
ajlm-708	82	19	sequencing	sequence	VERB
ajlm-708	82	20	at	at	ADP
ajlm-708	82	21	a	a	DET
ajlm-708	82	22	level	level	NOUN
ajlm-708	82	23	of	of	ADP
ajlm-708	82	24	≥	≥	NOUN
ajlm-708	82	25	20	20	NUM
ajlm-708	82	26	%	%	NOUN
ajlm-708	82	27	from	from	ADP
ajlm-708	82	28	the	the	DET
ajlm-708	82	29	41	41	NUM
ajlm-708	82	30	clinical	clinical	ADJ
ajlm-708	82	31	malawian	malawian	ADJ
ajlm-708	82	32	samples	sample	NOUN
ajlm-708	82	33	.	.	PUNCT
ajlm-708	83	1	additionally	additionally	ADV
ajlm-708	83	2	,	,	PUNCT
ajlm-708	83	3	a	a	DET
ajlm-708	83	4	total	total	NOUN
ajlm-708	83	5	of	of	ADP
ajlm-708	83	6	79	79	NUM
ajlm-708	83	7	drms	drm	NOUN
ajlm-708	83	8	were	be	AUX
ajlm-708	83	9	exclusively	exclusively	ADV
ajlm-708	83	10	detected	detect	VERB
ajlm-708	83	11	by	by	ADP
ajlm-708	83	12	deep	deep	ADJ
ajlm-708	83	13	sequencing	sequencing	NOUN
ajlm-708	83	14	.	.	PUNCT
ajlm-708	84	1	thus	thus	ADV
ajlm-708	84	2	,	,	PUNCT
ajlm-708	84	3	sanger	sanger	PROPN
ajlm-708	84	4	sequencing	sequence	VERB
ajlm-708	84	5	missed	miss	VERB
ajlm-708	84	6	52.3	52.3	NUM
ajlm-708	84	7	%	%	NOUN
ajlm-708	84	8	of	of	ADP
ajlm-708	84	9	drms	drm	NOUN
ajlm-708	84	10	at	at	ADP
ajlm-708	84	11	a	a	DET
ajlm-708	84	12	level	level	NOUN
ajlm-708	84	13	of	of	ADP
ajlm-708	84	14	<	<	X
ajlm-708	84	15	20	20	NUM
ajlm-708	84	16	%	%	NOUN
ajlm-708	84	17	in	in	ADP
ajlm-708	84	18	these	these	DET
ajlm-708	84	19	clinical	clinical	ADJ
ajlm-708	84	20	samples	sample	NOUN
ajlm-708	84	21	.	.	PUNCT
ajlm-708	85	1	the	the	DET
ajlm-708	85	2	differences	difference	NOUN
ajlm-708	85	3	in	in	ADP
ajlm-708	85	4	the	the	DET
ajlm-708	85	5	numbers	number	NOUN
ajlm-708	85	6	of	of	ADP
ajlm-708	85	7	drms	drm	NOUN
ajlm-708	85	8	detected	detect	VERB
ajlm-708	85	9	by	by	ADP
ajlm-708	85	10	these	these	DET
ajlm-708	85	11	two	two	NUM
ajlm-708	85	12	sequencing	sequence	VERB
ajlm-708	85	13	approaches	approach	NOUN
ajlm-708	85	14	were	be	AUX
ajlm-708	85	15	significant	significant	ADJ
ajlm-708	85	16	against	against	ADP
ajlm-708	85	17	nrtis	nrtis	PROPN
ajlm-708	85	18	(	(	PUNCT
ajlm-708	85	19	p	p	NOUN
ajlm-708	85	20	=	=	NOUN
ajlm-708	85	21	0.004	0.004	NUM
ajlm-708	85	22	)	)	PUNCT
ajlm-708	85	23	and	and	CCONJ
ajlm-708	85	24	nnrtis	nnrtis	ADJ
ajlm-708	85	25	(	(	PUNCT
ajlm-708	85	26	p	p	NOUN
ajlm-708	85	27	=	=	NOUN
ajlm-708	85	28	0.0001	0.0001	NUM
ajlm-708	85	29	)	)	PUNCT
ajlm-708	85	30	.	.	PUNCT
ajlm-708	86	1	further	far	ADV
ajlm-708	86	2	,	,	PUNCT
ajlm-708	86	3	the	the	DET
ajlm-708	86	4	cohen	cohen	NOUN
ajlm-708	86	5	’s	’s	PART
ajlm-708	86	6	effect	effect	NOUN
ajlm-708	86	7	size	size	NOUN
ajlm-708	86	8	value	value	NOUN
ajlm-708	86	9	(	(	PUNCT
ajlm-708	86	10	d	d	NOUN
ajlm-708	86	11	=	=	SYM
ajlm-708	86	12	0.91	0.91	NUM
ajlm-708	86	13	and	and	CCONJ
ajlm-708	86	14	0.79	0.79	NUM
ajlm-708	86	15	)	)	PUNCT
ajlm-708	86	16	suggests	suggest	VERB
ajlm-708	86	17	a	a	DET
ajlm-708	86	18	moderate	moderate	ADJ
ajlm-708	86	19	to	to	PART
ajlm-708	86	20	high	high	ADJ
ajlm-708	86	21	practical	practical	ADJ
ajlm-708	86	22	significance	significance	NOUN
ajlm-708	86	23	.	.	PUNCT
ajlm-708	87	1	no	no	DET
ajlm-708	87	2	significant	significant	ADJ
ajlm-708	87	3	difference	difference	NOUN
ajlm-708	87	4	was	be	AUX
ajlm-708	87	5	found	find	VERB
ajlm-708	87	6	in	in	ADP
ajlm-708	87	7	detection	detection	NOUN
ajlm-708	87	8	of	of	ADP
ajlm-708	87	9	protease	protease	NOUN
ajlm-708	87	10	inhibitor	inhibitor	NOUN
ajlm-708	87	11	(	(	PUNCT
ajlm-708	87	12	pi	pi	NOUN
ajlm-708	87	13	)	)	PUNCT
ajlm-708	87	14	mutations	mutation	NOUN
ajlm-708	87	15	(	(	PUNCT
ajlm-708	87	16	p	p	NOUN
ajlm-708	87	17	=	=	NOUN
ajlm-708	87	18	0.083	0.083	NUM
ajlm-708	87	19	)	)	PUNCT
ajlm-708	87	20	(	(	PUNCT
ajlm-708	87	21	figure	figure	NOUN
ajlm-708	87	22	2	2	NUM
ajlm-708	87	23	)	)	PUNCT
ajlm-708	87	24	.	.	PUNCT
ajlm-708	88	1	figure	figure	VERB
ajlm-708	88	2	2	2	NUM
ajlm-708	88	3	:	:	PUNCT
ajlm-708	88	4	comparison	comparison	NOUN
ajlm-708	88	5	of	of	ADP
ajlm-708	88	6	mean	mean	ADJ
ajlm-708	88	7	number	number	NOUN
ajlm-708	88	8	of	of	ADP
ajlm-708	88	9	hiv-1	hiv-1	PUNCT
ajlm-708	88	10	drug	drug	NOUN
ajlm-708	88	11	resistant	resistant	ADJ
ajlm-708	88	12	mutations	mutation	NOUN
ajlm-708	88	13	detected	detect	VERB
ajlm-708	88	14	by	by	ADP
ajlm-708	88	15	sanger	sanger	PROPN
ajlm-708	88	16	and	and	CCONJ
ajlm-708	88	17	deep	deep	ADJ
ajlm-708	88	18	sequencing	sequence	VERB
ajlm-708	88	19	methods	method	NOUN
ajlm-708	88	20	.	.	PUNCT
ajlm-708	89	1	the	the	DET
ajlm-708	89	2	vertical	vertical	ADJ
ajlm-708	89	3	bars	bar	NOUN
ajlm-708	89	4	present	present	ADJ
ajlm-708	89	5	mean	mean	ADJ
ajlm-708	89	6	number	number	NOUN
ajlm-708	89	7	of	of	ADP
ajlm-708	89	8	mutations	mutation	NOUN
ajlm-708	89	9	±	±	NOUN
ajlm-708	89	10	standard	standard	PROPN
ajlm-708	89	11	error	error	NOUN
ajlm-708	89	12	;	;	PUNCT
ajlm-708	89	13	p	p	X
ajlm-708	89	14	<	<	X
ajlm-708	89	15	0.05	0.05	NUM
ajlm-708	89	16	was	be	AUX
ajlm-708	89	17	considered	consider	VERB
ajlm-708	89	18	statistically	statistically	ADV
ajlm-708	89	19	significant	significant	ADJ
ajlm-708	89	20	.	.	PUNCT
ajlm-708	90	1	prevalence	prevalence	NOUN
ajlm-708	90	2	of	of	ADP
ajlm-708	90	3	minority	minority	NOUN
ajlm-708	90	4	drug	drug	NOUN
ajlm-708	90	5	resistance	resistance	NOUN
ajlm-708	90	6	mutations	mutation	NOUN
ajlm-708	90	7	in	in	ADP
ajlm-708	90	8	baseline	baseline	ADJ
ajlm-708	90	9	samples	sample	NOUN
ajlm-708	90	10	before	before	ADP
ajlm-708	90	11	antiretroviral	antiretroviral	ADJ
ajlm-708	90	12	therapy	therapy	NOUN
ajlm-708	90	13	initiation	initiation	NOUN
ajlm-708	90	14	overall	overall	ADV
ajlm-708	90	15	,	,	PUNCT
ajlm-708	90	16	the	the	DET
ajlm-708	90	17	frequency	frequency	NOUN
ajlm-708	90	18	of	of	ADP
ajlm-708	90	19	drms	drm	NOUN
ajlm-708	90	20	increased	increase	VERB
ajlm-708	90	21	by	by	ADP
ajlm-708	90	22	deep	deep	ADJ
ajlm-708	90	23	sequencing	sequencing	NOUN
ajlm-708	90	24	with	with	ADP
ajlm-708	90	25	minority	minority	NOUN
ajlm-708	90	26	drms	drm	NOUN
ajlm-708	90	27	being	be	AUX
ajlm-708	90	28	detected	detect	VERB
ajlm-708	90	29	in	in	ADP
ajlm-708	90	30	17	17	NUM
ajlm-708	90	31	(	(	PUNCT
ajlm-708	90	32	85	85	NUM
ajlm-708	90	33	%	%	NOUN
ajlm-708	90	34	)	)	PUNCT
ajlm-708	90	35	of	of	ADP
ajlm-708	90	36	the	the	DET
ajlm-708	90	37	20	20	NUM
ajlm-708	90	38	pre	pre	ADJ
ajlm-708	90	39	-	-	ADJ
ajlm-708	90	40	art	art	ADJ
ajlm-708	90	41	samples	sample	NOUN
ajlm-708	90	42	by	by	ADP
ajlm-708	90	43	deep	deep	ADJ
ajlm-708	90	44	sequencing	sequencing	NOUN
ajlm-708	90	45	.	.	PUNCT
ajlm-708	91	1	minority	minority	NOUN
ajlm-708	91	2	nrti	nrti	PROPN
ajlm-708	91	3	were	be	AUX
ajlm-708	91	4	detected	detect	VERB
ajlm-708	91	5	in	in	ADP
ajlm-708	91	6	10	10	NUM
ajlm-708	91	7	(	(	PUNCT
ajlm-708	91	8	50	50	NUM
ajlm-708	91	9	%	%	NOUN
ajlm-708	91	10	)	)	PUNCT
ajlm-708	91	11	of	of	ADP
ajlm-708	91	12	these	these	DET
ajlm-708	91	13	samples	sample	NOUN
ajlm-708	91	14	and	and	CCONJ
ajlm-708	91	15	nnrti	nnrti	NOUN
ajlm-708	91	16	mutations	mutation	NOUN
ajlm-708	91	17	in	in	ADP
ajlm-708	91	18	14	14	NUM
ajlm-708	91	19	(	(	PUNCT
ajlm-708	91	20	70	70	NUM
ajlm-708	91	21	%	%	NOUN
ajlm-708	91	22	)	)	PUNCT
ajlm-708	91	23	,	,	PUNCT
ajlm-708	91	24	while	while	SCONJ
ajlm-708	91	25	minority	minority	NOUN
ajlm-708	91	26	pi	pi	NOUN
ajlm-708	91	27	mutations	mutation	NOUN
ajlm-708	91	28	were	be	AUX
ajlm-708	91	29	found	find	VERB
ajlm-708	91	30	in	in	ADP
ajlm-708	91	31	three	three	NUM
ajlm-708	91	32	(	(	PUNCT
ajlm-708	91	33	15	15	NUM
ajlm-708	91	34	%	%	NOUN
ajlm-708	91	35	)	)	PUNCT
ajlm-708	91	36	of	of	ADP
ajlm-708	91	37	the	the	DET
ajlm-708	91	38	20	20	NUM
ajlm-708	91	39	samples	sample	NOUN
ajlm-708	91	40	.	.	PUNCT
ajlm-708	92	1	in	in	ADP
ajlm-708	92	2	addition	addition	NOUN
ajlm-708	92	3	,	,	PUNCT
ajlm-708	92	4	the	the	DET
ajlm-708	92	5	number	number	NOUN
ajlm-708	92	6	of	of	ADP
ajlm-708	92	7	drms	drm	NOUN
ajlm-708	92	8	detected	detect	VERB
ajlm-708	92	9	by	by	ADP
ajlm-708	92	10	deep	deep	ADJ
ajlm-708	92	11	sequencing	sequencing	NOUN
ajlm-708	92	12	was	be	AUX
ajlm-708	92	13	higher	high	ADJ
ajlm-708	92	14	than	than	ADP
ajlm-708	92	15	sanger	sanger	PROPN
ajlm-708	92	16	sequencing	sequencing	NOUN
ajlm-708	92	17	.	.	PUNCT
ajlm-708	93	1	this	this	DET
ajlm-708	93	2	increase	increase	NOUN
ajlm-708	93	3	of	of	ADP
ajlm-708	93	4	drm	drm	ADJ
ajlm-708	93	5	numbers	number	NOUN
ajlm-708	93	6	detected	detect	VERB
ajlm-708	93	7	by	by	ADP
ajlm-708	93	8	deep	deep	ADJ
ajlm-708	93	9	sequencing	sequencing	NOUN
ajlm-708	93	10	was	be	AUX
ajlm-708	93	11	statistically	statistically	ADV
ajlm-708	93	12	significant	significant	ADJ
ajlm-708	93	13	for	for	ADP
ajlm-708	93	14	nrti	nrti	NOUN
ajlm-708	93	15	(	(	PUNCT
ajlm-708	93	16	2/20	2/20	NUM
ajlm-708	93	17	vs	vs	ADP
ajlm-708	93	18	13/20	13/20	NUM
ajlm-708	93	19	,	,	PUNCT
ajlm-708	93	20	p	p	X
ajlm-708	93	21	=	=	NOUN
ajlm-708	93	22	0.015	0.015	NUM
ajlm-708	93	23	)	)	PUNCT
ajlm-708	93	24	,	,	PUNCT
ajlm-708	93	25	but	but	CCONJ
ajlm-708	93	26	not	not	PART
ajlm-708	93	27	for	for	ADP
ajlm-708	93	28	nnrti	nnrti	NOUN
ajlm-708	93	29	(	(	PUNCT
ajlm-708	93	30	9/20	9/20	NUM
ajlm-708	93	31	vs	vs	ADP
ajlm-708	93	32	14/20	14/20	NUM
ajlm-708	93	33	,	,	PUNCT
ajlm-708	93	34	p	p	X
ajlm-708	93	35	=	=	NOUN
ajlm-708	93	36	0.13	0.13	NUM
ajlm-708	93	37	)	)	PUNCT
ajlm-708	93	38	or	or	CCONJ
ajlm-708	93	39	pi	pi	NOUN
ajlm-708	93	40	(	(	PUNCT
ajlm-708	93	41	0/20	0/20	NUM
ajlm-708	93	42	vs	vs	ADP
ajlm-708	93	43	3/20	3/20	NUM
ajlm-708	93	44	,	,	PUNCT
ajlm-708	93	45	p	p	NOUN
ajlm-708	93	46	=	=	NOUN
ajlm-708	93	47	0.235	0.235	NUM
ajlm-708	93	48	)	)	PUNCT
ajlm-708	93	49	when	when	SCONJ
ajlm-708	93	50	compared	compare	VERB
ajlm-708	93	51	to	to	ADP
ajlm-708	93	52	sanger	sanger	PROPN
ajlm-708	93	53	sequencing	sequencing	NOUN
ajlm-708	93	54	.	.	PUNCT
ajlm-708	94	1	the	the	DET
ajlm-708	94	2	most	most	ADV
ajlm-708	94	3	common	common	ADJ
ajlm-708	94	4	minority	minority	NOUN
ajlm-708	94	5	nrti	nrti	NOUN
ajlm-708	94	6	mutation	mutation	NOUN
ajlm-708	94	7	was	be	AUX
ajlm-708	94	8	k65r	k65r	NOUN
ajlm-708	94	9	(	(	PUNCT
ajlm-708	94	10	6	6	NUM
ajlm-708	94	11	of	of	ADP
ajlm-708	94	12	20	20	NUM
ajlm-708	94	13	)	)	PUNCT
ajlm-708	94	14	,	,	PUNCT
ajlm-708	94	15	followed	follow	VERB
ajlm-708	94	16	by	by	ADP
ajlm-708	94	17	m184i	m184i	PROPN
ajlm-708	94	18	(	(	PUNCT
ajlm-708	94	19	2	2	NUM
ajlm-708	94	20	of	of	ADP
ajlm-708	94	21	20	20	NUM
ajlm-708	94	22	,	,	PUNCT
ajlm-708	94	23	table	table	NOUN
ajlm-708	94	24	2	2	NUM
ajlm-708	94	25	)	)	PUNCT
ajlm-708	94	26	.	.	PUNCT
ajlm-708	95	1	the	the	DET
ajlm-708	95	2	snp	snp	ADJ
ajlm-708	95	3	frequency	frequency	NOUN
ajlm-708	95	4	for	for	ADP
ajlm-708	95	5	k65r	k65r	NOUN
ajlm-708	95	6	ranged	range	VERB
ajlm-708	95	7	from	from	ADP
ajlm-708	95	8	0.7	0.7	NUM
ajlm-708	95	9	%	%	NOUN
ajlm-708	95	10	to	to	ADP
ajlm-708	95	11	2.5	2.5	NUM
ajlm-708	95	12	%	%	NOUN
ajlm-708	95	13	of	of	ADP
ajlm-708	95	14	the	the	DET
ajlm-708	95	15	sequence	sequence	NOUN
ajlm-708	95	16	reads	read	VERB
ajlm-708	95	17	in	in	ADP
ajlm-708	95	18	these	these	DET
ajlm-708	95	19	six	six	NUM
ajlm-708	95	20	patients	patient	NOUN
ajlm-708	95	21	and	and	CCONJ
ajlm-708	95	22	both	both	DET
ajlm-708	95	23	mutant	mutant	ADJ
ajlm-708	95	24	alleles	allele	NOUN
ajlm-708	95	25	of	of	ADP
ajlm-708	95	26	agg	agg	PROPN
ajlm-708	95	27	and	and	CCONJ
ajlm-708	95	28	aga	aga	PROPN
ajlm-708	95	29	were	be	AUX
ajlm-708	95	30	detected	detect	VERB
ajlm-708	95	31	in	in	ADP
ajlm-708	95	32	these	these	DET
ajlm-708	95	33	hiv-1	hiv-1	X
ajlm-708	95	34	subtype	subtype	NOUN
ajlm-708	95	35	c	c	NOUN
ajlm-708	95	36	-	-	PUNCT
ajlm-708	95	37	positive	positive	ADJ
ajlm-708	95	38	samples	sample	NOUN
ajlm-708	95	39	.	.	PUNCT
ajlm-708	96	1	the	the	DET
ajlm-708	96	2	common	common	ADJ
ajlm-708	96	3	minority	minority	NOUN
ajlm-708	96	4	nnrti	nnrti	NOUN
ajlm-708	96	5	mutations	mutation	NOUN
ajlm-708	96	6	detected	detect	VERB
ajlm-708	96	7	were	be	AUX
ajlm-708	96	8	v106	v106	PROPN
ajlm-708	96	9	m	m	NOUN
ajlm-708	96	10	,	,	PUNCT
ajlm-708	96	11	v179	v179	PROPN
ajlm-708	96	12	t	t	PROPN
ajlm-708	96	13	and	and	CCONJ
ajlm-708	96	14	g190a	g190a	PROPN
ajlm-708	96	15	(	(	PUNCT
ajlm-708	96	16	3/20	3/20	NUM
ajlm-708	96	17	each	each	PRON
ajlm-708	96	18	)	)	PUNCT
ajlm-708	96	19	,	,	PUNCT
ajlm-708	96	20	followed	follow	VERB
ajlm-708	96	21	by	by	ADP
ajlm-708	96	22	e138k	e138k	PROPN
ajlm-708	96	23	and	and	CCONJ
ajlm-708	96	24	y181c	y181c	PROPN
ajlm-708	96	25	(	(	PUNCT
ajlm-708	96	26	2/20	2/20	NUM
ajlm-708	96	27	each	each	DET
ajlm-708	96	28	)	)	PUNCT
ajlm-708	96	29	,	,	PUNCT
ajlm-708	96	30	and	and	CCONJ
ajlm-708	96	31	k101p	k101p	PROPN
ajlm-708	96	32	,	,	PUNCT
ajlm-708	96	33	k103n	k103n	PROPN
ajlm-708	96	34	,	,	PUNCT
ajlm-708	96	35	v108i	v108i	PROPN
ajlm-708	96	36	,	,	PUNCT
ajlm-708	96	37	e138a	e138a	PROPN
ajlm-708	96	38	,	,	PUNCT
ajlm-708	96	39	v179d	v179d	PROPN
ajlm-708	96	40	,	,	PUNCT
ajlm-708	96	41	a190e	a190e	PROPN
ajlm-708	96	42	and	and	CCONJ
ajlm-708	96	43	h221y	h221y	PROPN
ajlm-708	96	44	(	(	PUNCT
ajlm-708	96	45	1/20	1/20	NUM
ajlm-708	96	46	each	each	PRON
ajlm-708	96	47	)	)	PUNCT
ajlm-708	96	48	.	.	PUNCT
ajlm-708	97	1	the	the	DET
ajlm-708	97	2	minority	minority	NOUN
ajlm-708	97	3	pi	pi	NOUN
ajlm-708	97	4	mutations	mutation	NOUN
ajlm-708	97	5	detected	detect	VERB
ajlm-708	97	6	in	in	ADP
ajlm-708	97	7	three	three	NUM
ajlm-708	97	8	of	of	ADP
ajlm-708	97	9	the	the	DET
ajlm-708	97	10	samples	sample	NOUN
ajlm-708	97	11	were	be	AUX
ajlm-708	97	12	m46i	m46i	NOUN
ajlm-708	97	13	(	(	PUNCT
ajlm-708	97	14	2/20	2/20	NUM
ajlm-708	97	15	)	)	PUNCT
ajlm-708	97	16	and	and	CCONJ
ajlm-708	97	17	d30n	d30n	NOUN
ajlm-708	97	18	(	(	PUNCT
ajlm-708	97	19	1/20	1/20	NUM
ajlm-708	97	20	)	)	PUNCT
ajlm-708	97	21	(	(	PUNCT
ajlm-708	97	22	table	table	NOUN
ajlm-708	97	23	2	2	NUM
ajlm-708	97	24	)	)	PUNCT
ajlm-708	97	25	.	.	PUNCT
ajlm-708	98	1	table	table	NOUN
ajlm-708	98	2	2	2	NUM
ajlm-708	98	3	:	:	PUNCT
ajlm-708	98	4	 	 	SPACE
ajlm-708	98	5	number	number	NOUN
ajlm-708	98	6	of	of	ADP
ajlm-708	98	7	drug	drug	NOUN
ajlm-708	98	8	resistance	resistance	NOUN
ajlm-708	98	9	mutations	mutation	NOUN
ajlm-708	98	10	detected	detect	VERB
ajlm-708	98	11	by	by	ADP
ajlm-708	98	12	two	two	NUM
ajlm-708	98	13	sequencing	sequence	VERB
ajlm-708	98	14	methods	method	NOUN
ajlm-708	98	15	against	against	ADP
ajlm-708	98	16	pis	pis	NOUN
ajlm-708	98	17	,	,	PUNCT
ajlm-708	98	18	nrtis	nrtis	PROPN
ajlm-708	98	19	and	and	CCONJ
ajlm-708	98	20	nnrtis	nnrti	VERB
ajlm-708	98	21	from	from	ADP
ajlm-708	98	22	plasma	plasma	NOUN
ajlm-708	98	23	specimens	specimen	NOUN
ajlm-708	98	24	collected	collect	VERB
ajlm-708	98	25	from	from	ADP
ajlm-708	98	26	patients	patient	NOUN
ajlm-708	98	27	before	before	ADP
ajlm-708	98	28	art	art	NOUN
ajlm-708	98	29	initiation	initiation	NOUN
ajlm-708	98	30	and	and	CCONJ
ajlm-708	98	31	at	at	ADP
ajlm-708	98	32	virologic	virologic	ADJ
ajlm-708	98	33	failure†	failure†	ADJ
ajlm-708	98	34	prevalence	prevalence	NOUN
ajlm-708	98	35	of	of	ADP
ajlm-708	98	36	minority	minority	NOUN
ajlm-708	98	37	drug	drug	NOUN
ajlm-708	98	38	resistance	resistance	NOUN
ajlm-708	98	39	mutations	mutation	NOUN
ajlm-708	98	40	in	in	ADP
ajlm-708	98	41	patients	patient	NOUN
ajlm-708	98	42	experiencing	experience	VERB
ajlm-708	98	43	virologic	virologic	ADJ
ajlm-708	98	44	failure	failure	NOUN
ajlm-708	98	45	after	after	ADP
ajlm-708	98	46	antiretroviral	antiretroviral	ADJ
ajlm-708	98	47	therapy	therapy	NOUN
ajlm-708	98	48	overall	overall	ADV
ajlm-708	98	49	,	,	PUNCT
ajlm-708	98	50	minority	minority	NOUN
ajlm-708	98	51	drms	drm	NOUN
ajlm-708	98	52	were	be	AUX
ajlm-708	98	53	detected	detect	VERB
ajlm-708	98	54	by	by	ADP
ajlm-708	98	55	deep	deep	ADJ
ajlm-708	98	56	sequencing	sequencing	NOUN
ajlm-708	98	57	in	in	ADP
ajlm-708	98	58	90.5	90.5	NUM
ajlm-708	98	59	%	%	NOUN
ajlm-708	98	60	(	(	PUNCT
ajlm-708	98	61	19/21	19/21	NUM
ajlm-708	98	62	)	)	PUNCT
ajlm-708	98	63	of	of	ADP
ajlm-708	98	64	the	the	DET
ajlm-708	98	65	patients	patient	NOUN
ajlm-708	98	66	failing	fail	VERB
ajlm-708	98	67	art	art	NOUN
ajlm-708	98	68	.	.	PUNCT
ajlm-708	99	1	of	of	ADP
ajlm-708	99	2	the	the	DET
ajlm-708	99	3	21	21	NUM
ajlm-708	99	4	malawian	malawian	ADJ
ajlm-708	99	5	samples	sample	NOUN
ajlm-708	99	6	,	,	PUNCT
ajlm-708	99	7	minority	minority	NOUN
ajlm-708	99	8	nrti	nrti	NOUN
ajlm-708	99	9	mutations	mutation	NOUN
ajlm-708	99	10	were	be	AUX
ajlm-708	99	11	detected	detect	VERB
ajlm-708	99	12	in	in	ADP
ajlm-708	99	13	8	8	NUM
ajlm-708	99	14	(	(	PUNCT
ajlm-708	99	15	38	38	NUM
ajlm-708	99	16	%	%	NOUN
ajlm-708	99	17	)	)	PUNCT
ajlm-708	99	18	samples	sample	NOUN
ajlm-708	99	19	,	,	PUNCT
ajlm-708	99	20	while	while	SCONJ
ajlm-708	99	21	minority	minority	NOUN
ajlm-708	99	22	nnrti	nnrti	NOUN
ajlm-708	99	23	mutations	mutation	NOUN
ajlm-708	99	24	were	be	AUX
ajlm-708	99	25	detected	detect	VERB
ajlm-708	99	26	in	in	ADP
ajlm-708	99	27	14	14	NUM
ajlm-708	99	28	(	(	PUNCT
ajlm-708	99	29	66.7	66.7	NUM
ajlm-708	99	30	%	%	NOUN
ajlm-708	99	31	)	)	PUNCT
ajlm-708	99	32	samples	sample	NOUN
ajlm-708	99	33	(	(	PUNCT
ajlm-708	99	34	table	table	NOUN
ajlm-708	99	35	2	2	NUM
ajlm-708	99	36	)	)	PUNCT
ajlm-708	99	37	.	.	PUNCT
ajlm-708	100	1	minority	minority	NOUN
ajlm-708	100	2	pi	pi	PROPN
ajlm-708	100	3	mutations	mutation	NOUN
ajlm-708	100	4	were	be	AUX
ajlm-708	100	5	only	only	ADV
ajlm-708	100	6	detected	detect	VERB
ajlm-708	100	7	in	in	ADP
ajlm-708	100	8	3	3	NUM
ajlm-708	100	9	of	of	ADP
ajlm-708	100	10	21	21	NUM
ajlm-708	100	11	(	(	PUNCT
ajlm-708	100	12	14.3	14.3	NUM
ajlm-708	100	13	%	%	NOUN
ajlm-708	100	14	)	)	PUNCT
ajlm-708	100	15	samples	sample	NOUN
ajlm-708	100	16	.	.	PUNCT
ajlm-708	101	1	however	however	ADV
ajlm-708	101	2	,	,	PUNCT
ajlm-708	101	3	the	the	DET
ajlm-708	101	4	increased	increase	VERB
ajlm-708	101	5	number	number	NOUN
ajlm-708	101	6	of	of	ADP
ajlm-708	101	7	minority	minority	NOUN
ajlm-708	101	8	mutations	mutation	NOUN
ajlm-708	101	9	in	in	ADP
ajlm-708	101	10	individual	individual	ADJ
ajlm-708	101	11	patients	patient	NOUN
ajlm-708	101	12	for	for	ADP
ajlm-708	101	13	nrti	nrti	NOUN
ajlm-708	101	14	or	or	CCONJ
ajlm-708	101	15	nnrti	nnrti	NOUN
ajlm-708	101	16	in	in	ADP
ajlm-708	101	17	art	art	NOUN
ajlm-708	101	18	-	-	PUNCT
ajlm-708	101	19	failing	fail	VERB
ajlm-708	101	20	patients	patient	NOUN
ajlm-708	101	21	was	be	AUX
ajlm-708	101	22	not	not	PART
ajlm-708	101	23	statistically	statistically	ADV
ajlm-708	101	24	significant	significant	ADJ
ajlm-708	101	25	(	(	PUNCT
ajlm-708	101	26	nrti	nrti	NOUN
ajlm-708	101	27	:	:	PUNCT
ajlm-708	101	28	12/21	12/21	NUM
ajlm-708	101	29	vs	vs	ADP
ajlm-708	101	30	14/21	14/21	NUM
ajlm-708	101	31	,	,	PUNCT
ajlm-708	101	32	p	p	X
ajlm-708	101	33	>	>	X
ajlm-708	101	34	0.05	0.05	NUM
ajlm-708	101	35	;	;	PUNCT
ajlm-708	101	36	or	or	CCONJ
ajlm-708	101	37	nnrti	nnrti	NOUN
ajlm-708	101	38	:	:	PUNCT
ajlm-708	101	39	18/21	18/21	NUM
ajlm-708	101	40	vs	vs	ADP
ajlm-708	101	41	19/21	19/21	NUM
ajlm-708	101	42	,	,	PUNCT
ajlm-708	101	43	p	p	X
ajlm-708	101	44	>	>	X
ajlm-708	101	45	0.05	0.05	NUM
ajlm-708	101	46	)	)	PUNCT
ajlm-708	101	47	when	when	SCONJ
ajlm-708	101	48	compared	compare	VERB
ajlm-708	101	49	to	to	ADP
ajlm-708	101	50	sanger	sanger	PROPN
ajlm-708	101	51	sequencing	sequencing	NOUN
ajlm-708	101	52	.	.	PUNCT
ajlm-708	102	1	among	among	ADP
ajlm-708	102	2	the	the	DET
ajlm-708	102	3	minority	minority	NOUN
ajlm-708	102	4	nrti	nrti	NOUN
ajlm-708	102	5	mutations	mutation	NOUN
ajlm-708	102	6	,	,	PUNCT
ajlm-708	102	7	m184i	m184i	PROPN
ajlm-708	102	8	was	be	AUX
ajlm-708	102	9	detected	detect	VERB
ajlm-708	102	10	in	in	ADP
ajlm-708	102	11	three	three	NUM
ajlm-708	102	12	samples	sample	NOUN
ajlm-708	102	13	,	,	PUNCT
ajlm-708	102	14	and	and	CCONJ
ajlm-708	102	15	m184v	m184v	PROPN
ajlm-708	102	16	and	and	CCONJ
ajlm-708	102	17	k65r	k65r	NOUN
ajlm-708	102	18	in	in	ADP
ajlm-708	102	19	two	two	NUM
ajlm-708	102	20	samples	sample	NOUN
ajlm-708	102	21	respectively	respectively	ADV
ajlm-708	102	22	.	.	PUNCT
ajlm-708	103	1	other	other	ADJ
ajlm-708	103	2	minority	minority	NOUN
ajlm-708	103	3	mutations	mutation	NOUN
ajlm-708	103	4	including	include	VERB
ajlm-708	103	5	m41l	m41l	NUM
ajlm-708	103	6	,	,	PUNCT
ajlm-708	103	7	a62v	a62v	ADJ
ajlm-708	103	8	,	,	PUNCT
ajlm-708	103	9	d67n	d67n	NOUN
ajlm-708	103	10	,	,	PUNCT
ajlm-708	103	11	t69d	t69d	PROPN
ajlm-708	103	12	,	,	PUNCT
ajlm-708	103	13	v75	v75	PROPN
ajlm-708	103	14	m	m	PROPN
ajlm-708	103	15	,	,	PUNCT
ajlm-708	103	16	t215f	t215f	PROPN
ajlm-708	103	17	and	and	CCONJ
ajlm-708	103	18	k219e	k219e	PROPN
ajlm-708	103	19	were	be	AUX
ajlm-708	103	20	found	find	VERB
ajlm-708	103	21	in	in	ADP
ajlm-708	103	22	one	one	NUM
ajlm-708	103	23	sample	sample	NOUN
ajlm-708	103	24	each	each	PRON
ajlm-708	103	25	.	.	PUNCT
ajlm-708	104	1	among	among	ADP
ajlm-708	104	2	the	the	DET
ajlm-708	104	3	minority	minority	NOUN
ajlm-708	104	4	nnrti	nnrti	NOUN
ajlm-708	104	5	mutations	mutation	NOUN
ajlm-708	104	6	,	,	PUNCT
ajlm-708	104	7	v108i	v108i	PROPN
ajlm-708	104	8	,	,	PUNCT
ajlm-708	104	9	v179	v179	PROPN
ajlm-708	104	10	t	t	NOUN
ajlm-708	104	11	were	be	AUX
ajlm-708	104	12	detected	detect	VERB
ajlm-708	104	13	in	in	ADP
ajlm-708	104	14	four	four	NUM
ajlm-708	104	15	samples	sample	NOUN
ajlm-708	104	16	and	and	CCONJ
ajlm-708	104	17	g190a	g190a	NOUN
ajlm-708	104	18	,	,	PUNCT
ajlm-708	104	19	h221y	h221y	PROPN
ajlm-708	104	20	and	and	CCONJ
ajlm-708	104	21	k101e	k101e	PROPN
ajlm-708	104	22	were	be	AUX
ajlm-708	104	23	detected	detect	VERB
ajlm-708	104	24	in	in	ADP
ajlm-708	104	25	three	three	NUM
ajlm-708	104	26	samples	sample	NOUN
ajlm-708	104	27	.	.	PUNCT
ajlm-708	105	1	other	other	ADJ
ajlm-708	105	2	nnrti	nnrti	NOUN
ajlm-708	105	3	mutations	mutation	NOUN
ajlm-708	105	4	,	,	PUNCT
ajlm-708	105	5	such	such	ADJ
ajlm-708	105	6	as	as	ADP
ajlm-708	105	7	v90i	v90i	PROPN
ajlm-708	105	8	,	,	PUNCT
ajlm-708	105	9	k103n	k103n	PROPN
ajlm-708	105	10	,	,	PUNCT
ajlm-708	105	11	v106a	v106a	PROPN
ajlm-708	105	12	/	/	SYM
ajlm-708	105	13	m	m	PROPN
ajlm-708	105	14	,	,	PUNCT
ajlm-708	105	15	e138a	e138a	PROPN
ajlm-708	105	16	,	,	PUNCT
ajlm-708	105	17	v179e	v179e	PROPN
ajlm-708	105	18	,	,	PUNCT
ajlm-708	105	19	y181c	y181c	PROPN
ajlm-708	105	20	,	,	PUNCT
ajlm-708	105	21	y188c	y188c	PROPN
ajlm-708	105	22	/	/	SYM
ajlm-708	105	23	l	l	PROPN
ajlm-708	105	24	and	and	CCONJ
ajlm-708	105	25	g190e	g190e	PROPN
ajlm-708	105	26	were	be	AUX
ajlm-708	105	27	also	also	ADV
ajlm-708	105	28	found	find	VERB
ajlm-708	105	29	in	in	ADP
ajlm-708	105	30	one	one	NUM
ajlm-708	105	31	or	or	CCONJ
ajlm-708	105	32	two	two	NUM
ajlm-708	105	33	samples	sample	NOUN
ajlm-708	105	34	.	.	PUNCT
ajlm-708	106	1	clinical	clinical	ADJ
ajlm-708	106	2	impact	impact	NOUN
ajlm-708	106	3	of	of	ADP
ajlm-708	106	4	minority	minority	NOUN
ajlm-708	106	5	drug	drug	NOUN
ajlm-708	106	6	resistance	resistance	NOUN
ajlm-708	106	7	mutations	mutation	NOUN
ajlm-708	106	8	detected	detect	VERB
ajlm-708	106	9	by	by	ADP
ajlm-708	106	10	deep	deep	ADJ
ajlm-708	106	11	sequencing	sequencing	NOUN
ajlm-708	106	12	on	on	ADP
ajlm-708	106	13	virologic	virologic	ADJ
ajlm-708	106	14	failure	failure	NOUN
ajlm-708	106	15	to	to	PART
ajlm-708	106	16	study	study	VERB
ajlm-708	106	17	the	the	DET
ajlm-708	106	18	impact	impact	NOUN
ajlm-708	106	19	of	of	ADP
ajlm-708	106	20	minority	minority	NOUN
ajlm-708	106	21	drms	drm	NOUN
ajlm-708	106	22	detected	detect	VERB
ajlm-708	106	23	by	by	ADP
ajlm-708	106	24	deep	deep	ADJ
ajlm-708	106	25	sequencing	sequencing	NOUN
ajlm-708	106	26	on	on	ADP
ajlm-708	106	27	the	the	DET
ajlm-708	106	28	clinical	clinical	ADJ
ajlm-708	106	29	outcome	outcome	NOUN
ajlm-708	106	30	of	of	ADP
ajlm-708	106	31	patients	patient	NOUN
ajlm-708	106	32	on	on	ADP
ajlm-708	106	33	art	art	NOUN
ajlm-708	106	34	,	,	PUNCT
ajlm-708	106	35	we	we	PRON
ajlm-708	106	36	compared	compare	VERB
ajlm-708	106	37	drug	drug	NOUN
ajlm-708	106	38	resistance	resistance	NOUN
ajlm-708	106	39	levels	level	NOUN
ajlm-708	106	40	(	(	PUNCT
ajlm-708	106	41	genotype	genotype	NOUN
ajlm-708	106	42	susceptibility	susceptibility	NOUN
ajlm-708	106	43	score	score	NOUN
ajlm-708	106	44	)	)	PUNCT
ajlm-708	106	45	or	or	CCONJ
ajlm-708	106	46	expansion	expansion	NOUN
ajlm-708	106	47	of	of	ADP
ajlm-708	106	48	drug	drug	NOUN
ajlm-708	106	49	resistance	resistance	NOUN
ajlm-708	106	50	to	to	ADP
ajlm-708	106	51	additional	additional	ADJ
ajlm-708	106	52	drugs	drug	NOUN
ajlm-708	106	53	or	or	CCONJ
ajlm-708	106	54	drug	drug	NOUN
ajlm-708	106	55	classes	class	NOUN
ajlm-708	106	56	from	from	ADP
ajlm-708	106	57	those	those	DET
ajlm-708	106	58	21	21	NUM
ajlm-708	106	59	art	art	NOUN
ajlm-708	106	60	-	-	PUNCT
ajlm-708	106	61	failure	failure	NOUN
ajlm-708	106	62	patients	patient	NOUN
ajlm-708	106	63	against	against	ADP
ajlm-708	106	64	nrtis	nrtis	PROPN
ajlm-708	106	65	and	and	CCONJ
ajlm-708	106	66	nnrtis	nnrtis	ADJ
ajlm-708	106	67	using	use	VERB
ajlm-708	106	68	the	the	DET
ajlm-708	106	69	stanford	stanford	PROPN
ajlm-708	106	70	hiv	hiv	PROPN
ajlm-708	106	71	drug	drug	PROPN
ajlm-708	106	72	resistance	resistance	NOUN
ajlm-708	106	73	database	database	NOUN
ajlm-708	106	74	tool	tool	PROPN
ajlm-708	106	75	.	.	PUNCT
ajlm-708	107	1	among	among	ADP
ajlm-708	107	2	19	19	NUM
ajlm-708	107	3	patients	patient	NOUN
ajlm-708	107	4	with	with	ADP
ajlm-708	107	5	the	the	DET
ajlm-708	107	6	additional	additional	ADJ
ajlm-708	107	7	minority	minority	NOUN
ajlm-708	107	8	drms	drm	NOUN
ajlm-708	107	9	detected	detect	VERB
ajlm-708	107	10	,	,	PUNCT
ajlm-708	107	11	we	we	PRON
ajlm-708	107	12	found	find	VERB
ajlm-708	107	13	that	that	SCONJ
ajlm-708	107	14	seven	seven	NUM
ajlm-708	107	15	(	(	PUNCT
ajlm-708	107	16	36.8	36.8	NUM
ajlm-708	107	17	%	%	NOUN
ajlm-708	107	18	)	)	PUNCT
ajlm-708	107	19	of	of	ADP
ajlm-708	107	20	the	the	DET
ajlm-708	107	21	patients	patient	NOUN
ajlm-708	107	22	had	have	AUX
ajlm-708	107	23	enhanced	enhance	VERB
ajlm-708	107	24	resistance	resistance	NOUN
ajlm-708	107	25	levels	level	NOUN
ajlm-708	107	26	to	to	ADP
ajlm-708	107	27	nrtis	nrtis	PROPN
ajlm-708	107	28	.	.	PUNCT
ajlm-708	108	1	more	more	ADV
ajlm-708	108	2	importantly	importantly	ADV
ajlm-708	108	3	,	,	PUNCT
ajlm-708	108	4	three	three	NUM
ajlm-708	108	5	of	of	ADP
ajlm-708	108	6	the	the	DET
ajlm-708	108	7	seven	seven	NUM
ajlm-708	108	8	patients	patient	NOUN
ajlm-708	108	9	had	have	AUX
ajlm-708	108	10	gained	gain	VERB
ajlm-708	108	11	lowto	lowto	VERB
ajlm-708	108	12	high	high	ADJ
ajlm-708	108	13	-	-	PUNCT
ajlm-708	108	14	level	level	NOUN
ajlm-708	108	15	resistance	resistance	NOUN
ajlm-708	108	16	against	against	ADP
ajlm-708	108	17	tenofovir	tenofovir	NOUN
ajlm-708	108	18	(	(	PUNCT
ajlm-708	108	19	table	table	NOUN
ajlm-708	108	20	3	3	NUM
ajlm-708	108	21	)	)	PUNCT
ajlm-708	108	22	,	,	PUNCT
ajlm-708	108	23	a	a	DET
ajlm-708	108	24	key	key	ADJ
ajlm-708	108	25	component	component	NOUN
ajlm-708	108	26	of	of	ADP
ajlm-708	108	27	the	the	DET
ajlm-708	108	28	current	current	ADJ
ajlm-708	108	29	world	world	PROPN
ajlm-708	108	30	health	health	PROPN
ajlm-708	108	31	organization	organization	NOUN
ajlm-708	108	32	-	-	PUNCT
ajlm-708	108	33	recommended	recommend	VERB
ajlm-708	108	34	firstand	firstand	NOUN
ajlm-708	108	35	second	second	ADJ
ajlm-708	108	36	-	-	PUNCT
ajlm-708	108	37	line	line	NOUN
ajlm-708	108	38	regimens.26	regimens.26	VERB
ajlm-708	108	39	fourteen	fourteen	NUM
ajlm-708	108	40	(	(	PUNCT
ajlm-708	108	41	73.7	73.7	NUM
ajlm-708	108	42	%	%	NOUN
ajlm-708	108	43	)	)	PUNCT
ajlm-708	108	44	out	out	ADP
ajlm-708	108	45	of	of	ADP
ajlm-708	108	46	the	the	DET
ajlm-708	108	47	19	19	NUM
ajlm-708	108	48	patients	patient	NOUN
ajlm-708	108	49	also	also	ADV
ajlm-708	108	50	had	have	VERB
ajlm-708	108	51	an	an	DET
ajlm-708	108	52	enhanced	enhance	VERB
ajlm-708	108	53	resistance	resistance	NOUN
ajlm-708	108	54	level	level	NOUN
ajlm-708	108	55	to	to	ADP
ajlm-708	108	56	nnrtis	nnrtis	ADJ
ajlm-708	108	57	and	and	CCONJ
ajlm-708	108	58	13	13	NUM
ajlm-708	108	59	of	of	ADP
ajlm-708	108	60	these	these	DET
ajlm-708	108	61	14	14	NUM
ajlm-708	108	62	patients	patient	NOUN
ajlm-708	108	63	had	have	AUX
ajlm-708	108	64	intensified	intensify	VERB
ajlm-708	108	65	or	or	CCONJ
ajlm-708	108	66	expanded	expand	VERB
ajlm-708	108	67	resistance	resistance	NOUN
ajlm-708	108	68	profiles	profile	NOUN
ajlm-708	108	69	against	against	ADP
ajlm-708	108	70	the	the	DET
ajlm-708	108	71	second	second	ADJ
ajlm-708	108	72	generation	generation	NOUN
ajlm-708	108	73	of	of	ADP
ajlm-708	108	74	nnrtis	nnrtis	ADJ
ajlm-708	108	75	(	(	PUNCT
ajlm-708	108	76	etravirine	etravirine	NOUN
ajlm-708	108	77	and	and	CCONJ
ajlm-708	108	78	rilpivirine	rilpivirine	VERB
ajlm-708	108	79	)	)	PUNCT
ajlm-708	108	80	(	(	PUNCT
ajlm-708	108	81	table	table	NOUN
ajlm-708	108	82	4	4	NUM
ajlm-708	108	83	)	)	PUNCT
ajlm-708	108	84	.	.	PUNCT
ajlm-708	109	1	furthermore	furthermore	ADV
ajlm-708	109	2	,	,	PUNCT
ajlm-708	109	3	the	the	DET
ajlm-708	109	4	drug	drug	NOUN
ajlm-708	109	5	resistance	resistance	NOUN
ajlm-708	109	6	profile	profile	NOUN
ajlm-708	109	7	analyses	analysis	NOUN
ajlm-708	109	8	revealed	reveal	VERB
ajlm-708	109	9	an	an	DET
ajlm-708	109	10	intermediateor	intermediateor	NOUN
ajlm-708	109	11	high	high	ADJ
ajlm-708	109	12	-	-	PUNCT
ajlm-708	109	13	level	level	NOUN
ajlm-708	109	14	resistance	resistance	NOUN
ajlm-708	109	15	to	to	ADP
ajlm-708	109	16	the	the	DET
ajlm-708	109	17	relevant	relevant	ADJ
ajlm-708	109	18	first	first	ADJ
ajlm-708	109	19	-	-	PUNCT
ajlm-708	109	20	line	line	NOUN
ajlm-708	109	21	regimens	regimen	NOUN
ajlm-708	109	22	(	(	PUNCT
ajlm-708	109	23	stavudine	stavudine	ADJ
ajlm-708	109	24	,	,	PUNCT
ajlm-708	109	25	lamivudine	lamivudine	NOUN
ajlm-708	109	26	and	and	CCONJ
ajlm-708	109	27	nevirapine	nevirapine	PROPN
ajlm-708	109	28	or	or	CCONJ
ajlm-708	109	29	zidovudine	zidovudine	NOUN
ajlm-708	109	30	,	,	PUNCT
ajlm-708	109	31	lamivudine	lamivudine	NOUN
ajlm-708	109	32	and	and	CCONJ
ajlm-708	109	33	nevirapine	nevirapine	ADJ
ajlm-708	109	34	)	)	PUNCT
ajlm-708	109	35	that	that	PRON
ajlm-708	109	36	are	be	AUX
ajlm-708	109	37	prescribed	prescribe	VERB
ajlm-708	109	38	to	to	ADP
ajlm-708	109	39	these	these	DET
ajlm-708	109	40	malawian	malawian	ADJ
ajlm-708	109	41	patients	patient	NOUN
ajlm-708	109	42	and	and	CCONJ
ajlm-708	109	43	which	which	PRON
ajlm-708	109	44	might	might	AUX
ajlm-708	109	45	explain	explain	VERB
ajlm-708	109	46	the	the	DET
ajlm-708	109	47	virologic	virologic	ADJ
ajlm-708	109	48	failures	failure	NOUN
ajlm-708	109	49	these	these	DET
ajlm-708	109	50	patients	patient	NOUN
ajlm-708	109	51	experienced	experience	VERB
ajlm-708	109	52	.	.	PUNCT
ajlm-708	110	1	table	table	NOUN
ajlm-708	110	2	3	3	NUM
ajlm-708	110	3	:	:	PUNCT
ajlm-708	110	4	 	 	SPACE
ajlm-708	110	5	comparison	comparison	NOUN
ajlm-708	110	6	of	of	ADP
ajlm-708	110	7	nrti	nrti	PROPN
ajlm-708	110	8	drug	drug	NOUN
ajlm-708	110	9	resistance	resistance	NOUN
ajlm-708	110	10	mutations	mutation	NOUN
ajlm-708	110	11	detected	detect	VERB
ajlm-708	110	12	from	from	ADP
ajlm-708	110	13	plasma	plasma	NOUN
ajlm-708	110	14	specimens	specimen	NOUN
ajlm-708	110	15	collected	collect	VERB
ajlm-708	110	16	from	from	ADP
ajlm-708	110	17	patients	patient	NOUN
ajlm-708	110	18	with	with	ADP
ajlm-708	110	19	virologic	virologic	ADJ
ajlm-708	110	20	failure	failure	NOUN
ajlm-708	110	21	after	after	ADP
ajlm-708	110	22	12–15	12–15	NUM
ajlm-708	110	23	months	month	NOUN
ajlm-708	110	24	on	on	ADP
ajlm-708	110	25	art	art	NOUN
ajlm-708	110	26	by	by	ADP
ajlm-708	110	27	sanger	sanger	PROPN
ajlm-708	110	28	sequencing	sequencing	NOUN
ajlm-708	110	29	and	and	CCONJ
ajlm-708	110	30	deep	deep	ADJ
ajlm-708	110	31	sequencing	sequencing	NOUN
ajlm-708	110	32	and	and	CCONJ
ajlm-708	110	33	their	their	PRON
ajlm-708	110	34	impacts	impact	NOUN
ajlm-708	110	35	on	on	ADP
ajlm-708	110	36	nrti	nrti	NOUN
ajlm-708	110	37	susceptibility	susceptibility	NOUN
ajlm-708	110	38	.	.	PUNCT
ajlm-708	111	1	discussion	discussion	NOUN
ajlm-708	111	2	the	the	DET
ajlm-708	111	3	present	present	ADJ
ajlm-708	111	4	study	study	NOUN
ajlm-708	111	5	has	have	AUX
ajlm-708	111	6	shown	show	VERB
ajlm-708	111	7	that	that	SCONJ
ajlm-708	111	8	massively	massively	ADV
ajlm-708	111	9	parallel	parallel	ADJ
ajlm-708	111	10	deep	deep	ADJ
ajlm-708	111	11	sequencing	sequencing	NOUN
ajlm-708	111	12	is	be	AUX
ajlm-708	111	13	capable	capable	ADJ
ajlm-708	111	14	of	of	ADP
ajlm-708	111	15	detecting	detect	VERB
ajlm-708	111	16	minority	minority	NOUN
ajlm-708	111	17	hiv-1	hiv-1	X
ajlm-708	111	18	variants	variant	NOUN
ajlm-708	111	19	from	from	ADP
ajlm-708	111	20	hiv-1	hiv-1	X
ajlm-708	111	21	subtype	subtype	NOUN
ajlm-708	111	22	c	c	NOUN
ajlm-708	111	23	clinical	clinical	ADJ
ajlm-708	111	24	samples	sample	NOUN
ajlm-708	111	25	.	.	PUNCT
ajlm-708	112	1	the	the	DET
ajlm-708	112	2	higher	high	ADJ
ajlm-708	112	3	prevalence	prevalence	NOUN
ajlm-708	112	4	of	of	ADP
ajlm-708	112	5	minority	minority	NOUN
ajlm-708	112	6	drms	drm	NOUN
ajlm-708	112	7	in	in	ADP
ajlm-708	112	8	pre	pre	ADJ
ajlm-708	112	9	-	-	ADJ
ajlm-708	112	10	art	art	ADJ
ajlm-708	112	11	malawian	malawian	ADJ
ajlm-708	112	12	patients	patient	NOUN
ajlm-708	112	13	to	to	ADP
ajlm-708	112	14	nrtis	nrtis	VERB
ajlm-708	112	15	by	by	ADP
ajlm-708	112	16	deep	deep	ADJ
ajlm-708	112	17	sequencing	sequencing	NOUN
ajlm-708	112	18	was	be	AUX
ajlm-708	112	19	statistically	statistically	ADV
ajlm-708	112	20	significant	significant	ADJ
ajlm-708	112	21	compared	compare	VERB
ajlm-708	112	22	to	to	ADP
ajlm-708	112	23	sanger	sanger	PROPN
ajlm-708	112	24	sequencing	sequencing	NOUN
ajlm-708	112	25	.	.	PUNCT
ajlm-708	113	1	the	the	DET
ajlm-708	113	2	minority	minority	NOUN
ajlm-708	113	3	mutation	mutation	NOUN
ajlm-708	113	4	profile	profile	NOUN
ajlm-708	113	5	revealed	reveal	VERB
ajlm-708	113	6	that	that	SCONJ
ajlm-708	113	7	the	the	DET
ajlm-708	113	8	increased	increase	VERB
ajlm-708	113	9	minority	minority	NOUN
ajlm-708	113	10	drms	drm	NOUN
ajlm-708	113	11	were	be	AUX
ajlm-708	113	12	associated	associate	VERB
ajlm-708	113	13	with	with	ADP
ajlm-708	113	14	enhanced	enhanced	ADJ
ajlm-708	113	15	dr	dr	PROPN
ajlm-708	113	16	levels	level	NOUN
ajlm-708	113	17	in	in	ADP
ajlm-708	113	18	virologically	virologically	ADV
ajlm-708	113	19	failing	fail	VERB
ajlm-708	113	20	patients	patient	NOUN
ajlm-708	113	21	.	.	PUNCT
ajlm-708	114	1	this	this	DET
ajlm-708	114	2	study	study	NOUN
ajlm-708	114	3	was	be	AUX
ajlm-708	114	4	designed	design	VERB
ajlm-708	114	5	to	to	PART
ajlm-708	114	6	evaluate	evaluate	VERB
ajlm-708	114	7	parallel	parallel	ADJ
ajlm-708	114	8	tagged	tag	VERB
ajlm-708	114	9	deep	deep	ADJ
ajlm-708	114	10	sequencing	sequencing	NOUN
ajlm-708	114	11	in	in	ADP
ajlm-708	114	12	detection	detection	NOUN
ajlm-708	114	13	of	of	ADP
ajlm-708	114	14	minority	minority	NOUN
ajlm-708	114	15	drms	drm	NOUN
ajlm-708	114	16	in	in	ADP
ajlm-708	114	17	samples	sample	NOUN
ajlm-708	114	18	collected	collect	VERB
ajlm-708	114	19	from	from	ADP
ajlm-708	114	20	malawi	malawi	PROPN
ajlm-708	114	21	.	.	PUNCT
ajlm-708	115	1	we	we	PRON
ajlm-708	115	2	successfully	successfully	ADV
ajlm-708	115	3	amplified	amplify	VERB
ajlm-708	115	4	all	all	DET
ajlm-708	115	5	41	41	NUM
ajlm-708	115	6	plasma	plasma	NOUN
ajlm-708	115	7	specimens	specimen	NOUN
ajlm-708	115	8	collected	collect	VERB
ajlm-708	115	9	from	from	ADP
ajlm-708	115	10	the	the	DET
ajlm-708	115	11	patients	patient	NOUN
ajlm-708	115	12	and	and	CCONJ
ajlm-708	115	13	seven	seven	NUM
ajlm-708	115	14	plasmid	plasmid	ADJ
ajlm-708	115	15	dna	dna	NOUN
ajlm-708	115	16	samples	sample	NOUN
ajlm-708	115	17	that	that	PRON
ajlm-708	115	18	generated	generate	VERB
ajlm-708	115	19	242	242	NUM
ajlm-708	115	20	246	246	NUM
ajlm-708	115	21	sequencing	sequence	VERB
ajlm-708	115	22	reads	read	NOUN
ajlm-708	115	23	using	use	VERB
ajlm-708	115	24	the	the	DET
ajlm-708	115	25	degenerate	degenerate	ADJ
ajlm-708	115	26	primers	primer	NOUN
ajlm-708	115	27	designed	design	VERB
ajlm-708	115	28	for	for	ADP
ajlm-708	115	29	hiv-1	hiv-1	X
ajlm-708	115	30	group	group	NOUN
ajlm-708	115	31	m	m	NOUN
ajlm-708	115	32	subtypes	subtype	NOUN
ajlm-708	115	33	and	and	CCONJ
ajlm-708	115	34	circulating	circulate	VERB
ajlm-708	115	35	recombinant	recombinant	ADJ
ajlm-708	115	36	forms	form	NOUN
ajlm-708	115	37	.	.	PUNCT
ajlm-708	116	1	our	our	PRON
ajlm-708	116	2	results	result	NOUN
ajlm-708	116	3	not	not	PART
ajlm-708	116	4	only	only	ADV
ajlm-708	116	5	showed	show	VERB
ajlm-708	116	6	100	100	NUM
ajlm-708	116	7	%	%	NOUN
ajlm-708	116	8	concordance	concordance	NOUN
ajlm-708	116	9	of	of	ADP
ajlm-708	116	10	drms	drm	NOUN
ajlm-708	116	11	detected	detect	VERB
ajlm-708	116	12	by	by	ADP
ajlm-708	116	13	sanger	sanger	PROPN
ajlm-708	116	14	sequencing	sequencing	NOUN
ajlm-708	116	15	and	and	CCONJ
ajlm-708	116	16	deep	deep	ADJ
ajlm-708	116	17	sequencing	sequencing	NOUN
ajlm-708	116	18	,	,	PUNCT
ajlm-708	116	19	but	but	CCONJ
ajlm-708	116	20	deep	deep	ADJ
ajlm-708	116	21	sequencing	sequencing	NOUN
ajlm-708	116	22	also	also	ADV
ajlm-708	116	23	detected	detect	VERB
ajlm-708	116	24	over	over	ADP
ajlm-708	116	25	50	50	NUM
ajlm-708	116	26	%	%	NOUN
ajlm-708	116	27	minority	minority	NOUN
ajlm-708	116	28	drms	drm	NOUN
ajlm-708	116	29	in	in	ADP
ajlm-708	116	30	these	these	DET
ajlm-708	116	31	clinical	clinical	ADJ
ajlm-708	116	32	samples	sample	NOUN
ajlm-708	116	33	.	.	PUNCT
ajlm-708	117	1	at	at	ADP
ajlm-708	117	2	the	the	DET
ajlm-708	117	3	lower	low	ADJ
ajlm-708	117	4	detection	detection	NOUN
ajlm-708	117	5	level	level	NOUN
ajlm-708	117	6	of	of	ADP
ajlm-708	117	7	0.68	0.68	NUM
ajlm-708	117	8	%	%	NOUN
ajlm-708	117	9	,	,	PUNCT
ajlm-708	117	10	set	set	VERB
ajlm-708	117	11	by	by	ADP
ajlm-708	117	12	the	the	DET
ajlm-708	117	13	current	current	ADJ
ajlm-708	117	14	study	study	NOUN
ajlm-708	117	15	,	,	PUNCT
ajlm-708	117	16	minority	minority	NOUN
ajlm-708	117	17	drms	drm	NOUN
ajlm-708	117	18	were	be	AUX
ajlm-708	117	19	detected	detect	VERB
ajlm-708	117	20	in	in	ADP
ajlm-708	117	21	a	a	DET
ajlm-708	117	22	majority	majority	NOUN
ajlm-708	117	23	of	of	ADP
ajlm-708	117	24	samples	sample	NOUN
ajlm-708	117	25	collected	collect	VERB
ajlm-708	117	26	from	from	ADP
ajlm-708	117	27	patients	patient	NOUN
ajlm-708	117	28	before	before	ADP
ajlm-708	117	29	art	art	NOUN
ajlm-708	117	30	initiation	initiation	NOUN
ajlm-708	117	31	and	and	CCONJ
ajlm-708	117	32	at	at	ADP
ajlm-708	117	33	virologic	virologic	ADJ
ajlm-708	117	34	failure	failure	NOUN
ajlm-708	117	35	.	.	PUNCT
ajlm-708	118	1	although	although	SCONJ
ajlm-708	118	2	we	we	PRON
ajlm-708	118	3	only	only	ADV
ajlm-708	118	4	analysed	analyse	VERB
ajlm-708	118	5	hiv-1	hiv-1	X
ajlm-708	118	6	subtype	subtype	NOUN
ajlm-708	118	7	c	c	NOUN
ajlm-708	118	8	-	-	PUNCT
ajlm-708	118	9	positive	positive	ADJ
ajlm-708	118	10	malawian	malawian	ADJ
ajlm-708	118	11	samples	sample	NOUN
ajlm-708	118	12	in	in	ADP
ajlm-708	118	13	this	this	DET
ajlm-708	118	14	study	study	NOUN
ajlm-708	118	15	,	,	PUNCT
ajlm-708	118	16	the	the	DET
ajlm-708	118	17	primers	primer	NOUN
ajlm-708	118	18	were	be	AUX
ajlm-708	118	19	designed	design	VERB
ajlm-708	118	20	for	for	ADP
ajlm-708	118	21	all	all	DET
ajlm-708	118	22	relevant	relevant	ADJ
ajlm-708	118	23	hiv-1	hiv-1	X
ajlm-708	118	24	group	group	NOUN
ajlm-708	118	25	m	m	NOUN
ajlm-708	118	26	subtypes	subtype	NOUN
ajlm-708	118	27	and	and	CCONJ
ajlm-708	118	28	circulating	circulate	VERB
ajlm-708	118	29	recombinant	recombinant	ADJ
ajlm-708	118	30	forms	form	NOUN
ajlm-708	118	31	.	.	PUNCT
ajlm-708	119	1	in	in	ADP
ajlm-708	119	2	fact	fact	NOUN
ajlm-708	119	3	,	,	PUNCT
ajlm-708	119	4	we	we	PRON
ajlm-708	119	5	were	be	AUX
ajlm-708	119	6	able	able	ADJ
ajlm-708	119	7	to	to	PART
ajlm-708	119	8	amplify	amplify	VERB
ajlm-708	119	9	subtype	subtype	NOUN
ajlm-708	119	10	b	b	PROPN
ajlm-708	119	11	,	,	PUNCT
ajlm-708	119	12	b	b	PROPN
ajlm-708	119	13	/	/	SYM
ajlm-708	119	14	c	c	PROPN
ajlm-708	119	15	,	,	PUNCT
ajlm-708	119	16	f	f	PROPN
ajlm-708	119	17	and	and	CCONJ
ajlm-708	119	18	g	g	PROPN
ajlm-708	119	19	samples	sample	NOUN
ajlm-708	119	20	using	use	VERB
ajlm-708	119	21	these	these	DET
ajlm-708	119	22	primers	primer	NOUN
ajlm-708	119	23	which	which	PRON
ajlm-708	119	24	were	be	AUX
ajlm-708	119	25	confirmed	confirm	VERB
ajlm-708	119	26	by	by	ADP
ajlm-708	119	27	gel	gel	NOUN
ajlm-708	119	28	electrophoresis	electrophoresis	NOUN
ajlm-708	119	29	and	and	CCONJ
ajlm-708	119	30	successfully	successfully	ADV
ajlm-708	119	31	detect	detect	VERB
ajlm-708	119	32	5	5	NUM
ajlm-708	119	33	of	of	ADP
ajlm-708	119	34	5	5	NUM
ajlm-708	119	35	subtype	subtype	NOUN
ajlm-708	119	36	b	b	NOUN
ajlm-708	119	37	samples	sample	NOUN
ajlm-708	119	38	using	use	VERB
ajlm-708	119	39	deep	deep	ADJ
ajlm-708	119	40	sequencing	sequence	VERB
ajlm-708	119	41	methods.27	methods.27	ADJ
ajlm-708	119	42	previous	previous	ADJ
ajlm-708	119	43	studies	study	NOUN
ajlm-708	119	44	reported	report	VERB
ajlm-708	119	45	the	the	DET
ajlm-708	119	46	use	use	NOUN
ajlm-708	119	47	of	of	ADP
ajlm-708	119	48	parallel	parallel	ADJ
ajlm-708	119	49	tagged	tag	VERB
ajlm-708	119	50	deep	deep	ADJ
ajlm-708	119	51	sequencing	sequence	VERB
ajlm-708	119	52	methods	method	NOUN
ajlm-708	119	53	in	in	ADP
ajlm-708	119	54	detecting	detect	VERB
ajlm-708	119	55	low	low	ADJ
ajlm-708	119	56	levels	level	NOUN
ajlm-708	119	57	of	of	ADP
ajlm-708	119	58	hiv-1	hiv-1	X
ajlm-708	119	59	subtype	subtype	NOUN
ajlm-708	119	60	b	b	NOUN
ajlm-708	119	61	variants.18,20,21,28,29	variants.18,20,21,28,29	NUM
ajlm-708	119	62	a	a	DET
ajlm-708	119	63	study	study	NOUN
ajlm-708	119	64	by	by	ADP
ajlm-708	119	65	dudley	dudley	PROPN
ajlm-708	119	66	et	et	NOUN
ajlm-708	119	67	al.20	al.20	PROPN
ajlm-708	119	68	evaluated	evaluate	VERB
ajlm-708	119	69	a	a	DET
ajlm-708	119	70	454	454	NUM
ajlm-708	119	71	gs	gs	INTJ
ajlm-708	119	72	junior	junior	ADJ
ajlm-708	119	73	sequencer	sequencer	NOUN
ajlm-708	119	74	by	by	ADP
ajlm-708	119	75	multiplexing	multiplexe	VERB
ajlm-708	119	76	48	48	NUM
ajlm-708	119	77	samples	sample	NOUN
ajlm-708	119	78	collected	collect	VERB
ajlm-708	119	79	from	from	ADP
ajlm-708	119	80	hiv-1	hiv-1	PUNCT
ajlm-708	119	81	subtype	subtype	NOUN
ajlm-708	119	82	b	b	NOUN
ajlm-708	119	83	-	-	PUNCT
ajlm-708	119	84	positive	positive	ADJ
ajlm-708	119	85	individuals	individual	NOUN
ajlm-708	119	86	and	and	CCONJ
ajlm-708	119	87	obtained	obtain	VERB
ajlm-708	119	88	a	a	DET
ajlm-708	119	89	sequencing	sequence	VERB
ajlm-708	119	90	success	success	NOUN
ajlm-708	119	91	rate	rate	NOUN
ajlm-708	119	92	of	of	ADP
ajlm-708	119	93	93	93	NUM
ajlm-708	119	94	%	%	NOUN
ajlm-708	119	95	and	and	CCONJ
ajlm-708	119	96	an	an	DET
ajlm-708	119	97	error	error	NOUN
ajlm-708	119	98	rate	rate	NOUN
ajlm-708	119	99	of	of	ADP
ajlm-708	119	100	0.71	0.71	NUM
ajlm-708	119	101	%	%	NOUN
ajlm-708	119	102	.	.	PUNCT
ajlm-708	120	1	our	our	PRON
ajlm-708	120	2	study	study	NOUN
ajlm-708	120	3	using	use	VERB
ajlm-708	120	4	gs	gs	NOUN
ajlm-708	120	5	-	-	PUNCT
ajlm-708	120	6	flx	flx	NOUN
ajlm-708	120	7	with	with	ADP
ajlm-708	120	8	multiplexing	multiplexing	NOUN
ajlm-708	120	9	on	on	ADP
ajlm-708	120	10	48	48	NUM
ajlm-708	120	11	samples	sample	NOUN
ajlm-708	120	12	collected	collect	VERB
ajlm-708	120	13	from	from	ADP
ajlm-708	120	14	hiv-1	hiv-1	X
ajlm-708	120	15	subtype	subtype	NOUN
ajlm-708	120	16	c	c	NOUN
ajlm-708	120	17	-	-	PUNCT
ajlm-708	120	18	positive	positive	ADJ
ajlm-708	120	19	patients	patient	NOUN
ajlm-708	120	20	showed	show	VERB
ajlm-708	120	21	a	a	DET
ajlm-708	120	22	100	100	NUM
ajlm-708	120	23	%	%	NOUN
ajlm-708	120	24	amplification	amplification	NOUN
ajlm-708	120	25	rate	rate	NOUN
ajlm-708	120	26	and	and	CCONJ
ajlm-708	120	27	0.265	0.265	NUM
ajlm-708	120	28	%	%	NOUN
ajlm-708	120	29	mean	mean	NOUN
ajlm-708	120	30	error	error	NOUN
ajlm-708	120	31	rate	rate	NOUN
ajlm-708	120	32	.	.	PUNCT
ajlm-708	121	1	many	many	ADJ
ajlm-708	121	2	studies	study	NOUN
ajlm-708	121	3	have	have	AUX
ajlm-708	121	4	reported	report	VERB
ajlm-708	121	5	that	that	SCONJ
ajlm-708	121	6	the	the	DET
ajlm-708	121	7	mean	mean	ADJ
ajlm-708	121	8	error	error	NOUN
ajlm-708	121	9	rate	rate	NOUN
ajlm-708	121	10	of	of	ADP
ajlm-708	121	11	pyrosequencing	pyrosequence	VERB
ajlm-708	121	12	techniques	technique	NOUN
ajlm-708	121	13	can	can	AUX
ajlm-708	121	14	be	be	AUX
ajlm-708	121	15	down	down	ADV
ajlm-708	121	16	to	to	ADP
ajlm-708	121	17	0.05	0.05	NUM
ajlm-708	121	18	%	%	NOUN
ajlm-708	121	19	to	to	ADP
ajlm-708	121	20	1%.17,19,21,30	1%.17,19,21,30	NUM
ajlm-708	121	21	the	the	DET
ajlm-708	121	22	error	error	NOUN
ajlm-708	121	23	rates	rate	NOUN
ajlm-708	121	24	for	for	ADP
ajlm-708	121	25	deep	deep	ADJ
ajlm-708	121	26	sequencing	sequencing	NOUN
ajlm-708	121	27	not	not	PART
ajlm-708	121	28	only	only	ADV
ajlm-708	121	29	affect	affect	VERB
ajlm-708	121	30	the	the	DET
ajlm-708	121	31	accuracy	accuracy	NOUN
ajlm-708	121	32	of	of	ADP
ajlm-708	121	33	base	base	NOUN
ajlm-708	121	34	calling	calling	NOUN
ajlm-708	121	35	,	,	PUNCT
ajlm-708	121	36	but	but	CCONJ
ajlm-708	121	37	also	also	ADV
ajlm-708	121	38	impact	impact	VERB
ajlm-708	121	39	the	the	DET
ajlm-708	121	40	sensitivity	sensitivity	NOUN
ajlm-708	121	41	of	of	ADP
ajlm-708	121	42	minority	minority	NOUN
ajlm-708	121	43	variant	variant	NOUN
ajlm-708	121	44	detection	detection	NOUN
ajlm-708	121	45	.	.	PUNCT
ajlm-708	122	1	it	it	PRON
ajlm-708	122	2	has	have	AUX
ajlm-708	122	3	been	be	AUX
ajlm-708	122	4	reported	report	VERB
ajlm-708	122	5	that	that	SCONJ
ajlm-708	122	6	factors	factor	NOUN
ajlm-708	122	7	,	,	PUNCT
ajlm-708	122	8	such	such	ADJ
ajlm-708	122	9	as	as	ADP
ajlm-708	122	10	the	the	DET
ajlm-708	122	11	input	input	NOUN
ajlm-708	122	12	number	number	NOUN
ajlm-708	122	13	of	of	ADP
ajlm-708	122	14	template	template	NOUN
ajlm-708	122	15	molecules	molecule	NOUN
ajlm-708	122	16	,	,	PUNCT
ajlm-708	122	17	sequence	sequence	NOUN
ajlm-708	122	18	primers	primer	NOUN
ajlm-708	122	19	,	,	PUNCT
ajlm-708	122	20	amplicon	amplicon	NOUN
ajlm-708	122	21	length	length	NOUN
ajlm-708	122	22	,	,	PUNCT
ajlm-708	122	23	nucleotide	nucleotide	NOUN
ajlm-708	122	24	sequences	sequence	NOUN
ajlm-708	122	25	,	,	PUNCT
ajlm-708	122	26	pcr	pcr	ADJ
ajlm-708	122	27	errors	error	NOUN
ajlm-708	122	28	and	and	CCONJ
ajlm-708	122	29	operational	operational	ADJ
ajlm-708	122	30	procedures	procedure	NOUN
ajlm-708	122	31	,	,	PUNCT
ajlm-708	122	32	might	might	AUX
ajlm-708	122	33	contribute	contribute	VERB
ajlm-708	122	34	to	to	ADP
ajlm-708	122	35	deep	deep	ADJ
ajlm-708	122	36	sequencing	sequence	VERB
ajlm-708	122	37	assay	assay	NOUN
ajlm-708	122	38	sensitivity	sensitivity	NOUN
ajlm-708	122	39	and	and	CCONJ
ajlm-708	122	40	accuracy.17,31,32,33	accuracy.17,31,32,33	PROPN
ajlm-708	122	41	in	in	ADP
ajlm-708	122	42	addition	addition	NOUN
ajlm-708	122	43	,	,	PUNCT
ajlm-708	122	44	error	error	NOUN
ajlm-708	122	45	rates	rate	NOUN
ajlm-708	122	46	are	be	AUX
ajlm-708	122	47	nucleotide	nucleotide	ADJ
ajlm-708	122	48	position	position	NOUN
ajlm-708	122	49	-	-	PUNCT
ajlm-708	122	50	dependent	dependent	ADJ
ajlm-708	122	51	and	and	CCONJ
ajlm-708	122	52	roche	roche	NOUN
ajlm-708	122	53	454	454	NUM
ajlm-708	122	54	deep	deep	ADJ
ajlm-708	122	55	sequencing	sequence	VERB
ajlm-708	122	56	methods	method	NOUN
ajlm-708	122	57	are	be	AUX
ajlm-708	122	58	prone	prone	ADJ
ajlm-708	122	59	to	to	PART
ajlm-708	122	60	have	have	VERB
ajlm-708	122	61	more	more	ADJ
ajlm-708	122	62	errors	error	NOUN
ajlm-708	122	63	at	at	ADP
ajlm-708	122	64	the	the	DET
ajlm-708	122	65	homopolymeric	homopolymeric	ADJ
ajlm-708	122	66	regions.17,31	regions.17,31	NOUN
ajlm-708	122	67	in	in	ADP
ajlm-708	122	68	the	the	DET
ajlm-708	122	69	present	present	ADJ
ajlm-708	122	70	study	study	NOUN
ajlm-708	122	71	,	,	PUNCT
ajlm-708	122	72	cross	cross	NOUN
ajlm-708	122	73	-	-	ADJ
ajlm-708	122	74	over	over	ADP
ajlm-708	122	75	errors	error	NOUN
ajlm-708	122	76	of	of	ADP
ajlm-708	122	77	major	major	ADJ
ajlm-708	122	78	drms	drm	NOUN
ajlm-708	122	79	between	between	ADP
ajlm-708	122	80	samples	sample	NOUN
ajlm-708	122	81	were	be	AUX
ajlm-708	122	82	not	not	PART
ajlm-708	122	83	found	find	VERB
ajlm-708	122	84	.	.	PUNCT
ajlm-708	123	1	to	to	PART
ajlm-708	123	2	balance	balance	VERB
ajlm-708	123	3	the	the	DET
ajlm-708	123	4	detection	detection	NOUN
ajlm-708	123	5	sensitivity	sensitivity	NOUN
ajlm-708	123	6	with	with	ADP
ajlm-708	123	7	detection	detection	NOUN
ajlm-708	123	8	accuracy	accuracy	NOUN
ajlm-708	123	9	,	,	PUNCT
ajlm-708	123	10	we	we	PRON
ajlm-708	123	11	set	set	VERB
ajlm-708	123	12	up	up	ADP
ajlm-708	123	13	the	the	DET
ajlm-708	123	14	base	base	NOUN
ajlm-708	123	15	calling	call	VERB
ajlm-708	123	16	threshold	threshold	NOUN
ajlm-708	123	17	for	for	ADP
ajlm-708	123	18	low	low	ADJ
ajlm-708	123	19	-	-	PUNCT
ajlm-708	123	20	frequency	frequency	NOUN
ajlm-708	123	21	mutations	mutation	NOUN
ajlm-708	123	22	at	at	ADP
ajlm-708	123	23	>	>	X
ajlm-708	123	24	0.68	0.68	NUM
ajlm-708	123	25	%	%	NOUN
ajlm-708	123	26	(	(	PUNCT
ajlm-708	123	27	mean	mean	VERB
ajlm-708	123	28	error	error	NOUN
ajlm-708	123	29	rate	rate	NOUN
ajlm-708	123	30	+	+	CCONJ
ajlm-708	123	31	2	2	NUM
ajlm-708	123	32	standard	standard	ADJ
ajlm-708	123	33	deviations	deviation	NOUN
ajlm-708	123	34	)	)	PUNCT
ajlm-708	123	35	which	which	PRON
ajlm-708	123	36	was	be	AUX
ajlm-708	123	37	calculated	calculate	VERB
ajlm-708	123	38	based	base	VERB
ajlm-708	123	39	on	on	ADP
ajlm-708	123	40	the	the	DET
ajlm-708	123	41	error	error	NOUN
ajlm-708	123	42	rates	rate	NOUN
ajlm-708	123	43	of	of	ADP
ajlm-708	123	44	individual	individual	ADJ
ajlm-708	123	45	nucleotide	nucleotide	NOUN
ajlm-708	123	46	positions	position	NOUN
ajlm-708	123	47	of	of	ADP
ajlm-708	123	48	six	six	NUM
ajlm-708	123	49	control	control	NOUN
ajlm-708	123	50	plasmid	plasmid	ADJ
ajlm-708	123	51	samples	sample	NOUN
ajlm-708	123	52	.	.	PUNCT
ajlm-708	124	1	in	in	ADP
ajlm-708	124	2	the	the	DET
ajlm-708	124	3	present	present	ADJ
ajlm-708	124	4	study	study	NOUN
ajlm-708	124	5	,	,	PUNCT
ajlm-708	124	6	the	the	DET
ajlm-708	124	7	k103n	k103n	PROPN
ajlm-708	124	8	mutation	mutation	NOUN
ajlm-708	124	9	was	be	AUX
ajlm-708	124	10	not	not	PART
ajlm-708	124	11	detected	detect	VERB
ajlm-708	124	12	from	from	ADP
ajlm-708	124	13	the	the	DET
ajlm-708	124	14	mixed	mixed	ADJ
ajlm-708	124	15	clone	clone	NOUN
ajlm-708	124	16	at	at	ADP
ajlm-708	124	17	1	1	NUM
ajlm-708	124	18	%	%	NOUN
ajlm-708	124	19	of	of	ADP
ajlm-708	124	20	minority	minority	NOUN
ajlm-708	124	21	variant	variant	ADJ
ajlm-708	124	22	level	level	NOUN
ajlm-708	124	23	of	of	ADP
ajlm-708	124	24	control	control	NOUN
ajlm-708	124	25	plasmids	plasmid	NOUN
ajlm-708	124	26	from	from	ADP
ajlm-708	124	27	520	520	NUM
ajlm-708	124	28	reads	read	NOUN
ajlm-708	124	29	.	.	PUNCT
ajlm-708	125	1	this	this	PRON
ajlm-708	125	2	was	be	AUX
ajlm-708	125	3	likely	likely	ADJ
ajlm-708	125	4	due	due	ADJ
ajlm-708	125	5	to	to	ADP
ajlm-708	125	6	not	not	PART
ajlm-708	125	7	having	have	VERB
ajlm-708	125	8	enough	enough	ADJ
ajlm-708	125	9	reads	read	NOUN
ajlm-708	125	10	amplified	amplify	VERB
ajlm-708	125	11	for	for	ADP
ajlm-708	125	12	this	this	DET
ajlm-708	125	13	mixed	mixed	ADJ
ajlm-708	125	14	plasmid	plasmid	NOUN
ajlm-708	125	15	as	as	ADP
ajlm-708	125	16	a	a	DET
ajlm-708	125	17	previous	previous	ADJ
ajlm-708	125	18	study	study	NOUN
ajlm-708	125	19	demonstrated	demonstrate	VERB
ajlm-708	125	20	that	that	SCONJ
ajlm-708	125	21	at	at	ADV
ajlm-708	125	22	least	least	ADJ
ajlm-708	125	23	1950	1950	NUM
ajlm-708	125	24	reads	read	NOUN
ajlm-708	125	25	are	be	AUX
ajlm-708	125	26	required	require	VERB
ajlm-708	125	27	for	for	ADP
ajlm-708	125	28	detecting	detect	VERB
ajlm-708	125	29	a	a	DET
ajlm-708	125	30	minority	minority	NOUN
ajlm-708	125	31	variant	variant	NOUN
ajlm-708	125	32	for	for	ADP
ajlm-708	125	33	k103n	k103n	PROPN
ajlm-708	125	34	mutations	mutation	NOUN
ajlm-708	125	35	at	at	ADP
ajlm-708	125	36	about	about	ADV
ajlm-708	125	37	the	the	DET
ajlm-708	125	38	1	1	NUM
ajlm-708	125	39	%	%	NOUN
ajlm-708	125	40	level.17	level.17	NOUN
ajlm-708	125	41	one	one	NUM
ajlm-708	125	42	limitation	limitation	NOUN
ajlm-708	125	43	of	of	ADP
ajlm-708	125	44	our	our	PRON
ajlm-708	125	45	study	study	NOUN
ajlm-708	125	46	was	be	AUX
ajlm-708	125	47	that	that	SCONJ
ajlm-708	125	48	the	the	DET
ajlm-708	125	49	primer	primer	NOUN
ajlm-708	125	50	pair	pair	NOUN
ajlm-708	125	51	for	for	ADP
ajlm-708	125	52	amplifying	amplifying	ADJ
ajlm-708	125	53	amplicons	amplicon	NOUN
ajlm-708	125	54	containing	contain	VERB
ajlm-708	125	55	codon	codon	PROPN
ajlm-708	125	56	103	103	NUM
ajlm-708	125	57	of	of	ADP
ajlm-708	125	58	rt	rt	PROPN
ajlm-708	125	59	gene	gene	NOUN
ajlm-708	125	60	was	be	AUX
ajlm-708	125	61	not	not	PART
ajlm-708	125	62	optimal	optimal	ADJ
ajlm-708	125	63	for	for	ADP
ajlm-708	125	64	the	the	DET
ajlm-708	125	65	depth	depth	NOUN
ajlm-708	125	66	of	of	ADP
ajlm-708	125	67	coverage	coverage	NOUN
ajlm-708	125	68	.	.	PUNCT
ajlm-708	126	1	some	some	DET
ajlm-708	126	2	minority	minority	NOUN
ajlm-708	126	3	k103n	k103n	PROPN
ajlm-708	126	4	mutations	mutation	NOUN
ajlm-708	126	5	could	could	AUX
ajlm-708	126	6	have	have	AUX
ajlm-708	126	7	been	be	AUX
ajlm-708	126	8	missed	miss	VERB
ajlm-708	126	9	in	in	ADP
ajlm-708	126	10	this	this	DET
ajlm-708	126	11	study	study	NOUN
ajlm-708	126	12	.	.	PUNCT
ajlm-708	127	1	thus	thus	ADV
ajlm-708	127	2	,	,	PUNCT
ajlm-708	127	3	the	the	DET
ajlm-708	127	4	number	number	NOUN
ajlm-708	127	5	of	of	ADP
ajlm-708	127	6	sequence	sequence	NOUN
ajlm-708	127	7	reads	read	NOUN
ajlm-708	127	8	obtained	obtain	VERB
ajlm-708	127	9	for	for	ADP
ajlm-708	127	10	each	each	DET
ajlm-708	127	11	nucleotide	nucleotide	ADJ
ajlm-708	127	12	position	position	NOUN
ajlm-708	127	13	and	and	CCONJ
ajlm-708	127	14	errors	error	NOUN
ajlm-708	127	15	at	at	ADP
ajlm-708	127	16	the	the	DET
ajlm-708	127	17	homopolymeric	homopolymeric	ADJ
ajlm-708	127	18	regions	region	NOUN
ajlm-708	127	19	played	play	VERB
ajlm-708	127	20	an	an	DET
ajlm-708	127	21	important	important	ADJ
ajlm-708	127	22	role	role	NOUN
ajlm-708	127	23	in	in	ADP
ajlm-708	127	24	the	the	DET
ajlm-708	127	25	depth	depth	NOUN
ajlm-708	127	26	of	of	ADP
ajlm-708	127	27	the	the	DET
ajlm-708	127	28	next	next	ADJ
ajlm-708	127	29	-	-	PUNCT
ajlm-708	127	30	generation	generation	NOUN
ajlm-708	127	31	sequencing	sequencing	NOUN
ajlm-708	127	32	.	.	PUNCT
ajlm-708	128	1	our	our	PRON
ajlm-708	128	2	results	result	NOUN
ajlm-708	128	3	from	from	ADP
ajlm-708	128	4	samples	sample	NOUN
ajlm-708	128	5	collected	collect	VERB
ajlm-708	128	6	from	from	ADP
ajlm-708	128	7	patients	patient	NOUN
ajlm-708	128	8	failing	fail	VERB
ajlm-708	128	9	art	art	NOUN
ajlm-708	128	10	and	and	CCONJ
ajlm-708	128	11	initiating	initiate	VERB
ajlm-708	128	12	art	art	NOUN
ajlm-708	128	13	demonstrate	demonstrate	NOUN
ajlm-708	128	14	that	that	SCONJ
ajlm-708	128	15	deep	deep	ADJ
ajlm-708	128	16	sequencing	sequencing	NOUN
ajlm-708	128	17	has	have	VERB
ajlm-708	128	18	the	the	DET
ajlm-708	128	19	added	add	VERB
ajlm-708	128	20	benefit	benefit	NOUN
ajlm-708	128	21	of	of	ADP
ajlm-708	128	22	detecting	detect	VERB
ajlm-708	128	23	low	low	ADJ
ajlm-708	128	24	-	-	PUNCT
ajlm-708	128	25	frequency	frequency	NOUN
ajlm-708	128	26	mutations	mutation	NOUN
ajlm-708	128	27	in	in	ADP
ajlm-708	128	28	this	this	DET
ajlm-708	128	29	malawian	malawian	ADJ
ajlm-708	128	30	cohort	cohort	NOUN
ajlm-708	128	31	.	.	PUNCT
ajlm-708	129	1	overall	overall	ADJ
ajlm-708	129	2	,	,	PUNCT
ajlm-708	129	3	deep	deep	ADJ
ajlm-708	129	4	sequencing	sequencing	NOUN
ajlm-708	129	5	detected	detect	VERB
ajlm-708	129	6	significantly	significantly	ADV
ajlm-708	129	7	more	more	ADJ
ajlm-708	129	8	drms	drm	NOUN
ajlm-708	129	9	than	than	ADP
ajlm-708	129	10	sanger	sanger	PROPN
ajlm-708	129	11	sequencing	sequencing	NOUN
ajlm-708	129	12	.	.	PUNCT
ajlm-708	130	1	of	of	ADP
ajlm-708	130	2	those	those	DET
ajlm-708	130	3	specimens	specimen	NOUN
ajlm-708	130	4	collected	collect	VERB
ajlm-708	130	5	from	from	ADP
ajlm-708	130	6	patients	patient	NOUN
ajlm-708	130	7	initiating	initiate	VERB
ajlm-708	130	8	art	art	NOUN
ajlm-708	130	9	,	,	PUNCT
ajlm-708	130	10	more	more	ADJ
ajlm-708	130	11	drms	drm	NOUN
ajlm-708	130	12	against	against	ADP
ajlm-708	130	13	nrti	nrti	NOUN
ajlm-708	130	14	were	be	AUX
ajlm-708	130	15	detected	detect	VERB
ajlm-708	130	16	by	by	ADP
ajlm-708	130	17	deep	deep	ADJ
ajlm-708	130	18	sequencing	sequencing	NOUN
ajlm-708	130	19	.	.	PUNCT
ajlm-708	131	1	among	among	ADP
ajlm-708	131	2	the	the	DET
ajlm-708	131	3	minority	minority	NOUN
ajlm-708	131	4	drms	drm	NOUN
ajlm-708	131	5	,	,	PUNCT
ajlm-708	131	6	detected	detect	VERB
ajlm-708	131	7	by	by	ADP
ajlm-708	131	8	454	454	NUM
ajlm-708	131	9	deep	deep	ADJ
ajlm-708	131	10	sequencing	sequencing	NOUN
ajlm-708	131	11	,	,	PUNCT
ajlm-708	131	12	k65r	k65r	NOUN
ajlm-708	131	13	and	and	CCONJ
ajlm-708	131	14	m184i	m184i	PROPN
ajlm-708	131	15	were	be	AUX
ajlm-708	131	16	the	the	DET
ajlm-708	131	17	most	most	ADV
ajlm-708	131	18	common	common	ADJ
ajlm-708	131	19	and	and	CCONJ
ajlm-708	131	20	may	may	AUX
ajlm-708	131	21	compromise	compromise	VERB
ajlm-708	131	22	the	the	DET
ajlm-708	131	23	effectiveness	effectiveness	NOUN
ajlm-708	131	24	of	of	ADP
ajlm-708	131	25	both	both	DET
ajlm-708	131	26	firstand	firstand	ADJ
ajlm-708	131	27	second	second	ADJ
ajlm-708	131	28	-	-	PUNCT
ajlm-708	131	29	line	line	NOUN
ajlm-708	131	30	drugs	drug	NOUN
ajlm-708	131	31	used	use	VERB
ajlm-708	131	32	according	accord	VERB
ajlm-708	131	33	to	to	ADP
ajlm-708	131	34	the	the	DET
ajlm-708	131	35	malawi	malawi	PROPN
ajlm-708	131	36	art	art	NOUN
ajlm-708	131	37	guidelines	guideline	NOUN
ajlm-708	131	38	.	.	PUNCT
ajlm-708	132	1	the	the	DET
ajlm-708	132	2	k65r	k65r	PROPN
ajlm-708	132	3	mutation	mutation	NOUN
ajlm-708	132	4	can	can	AUX
ajlm-708	132	5	confer	confer	VERB
ajlm-708	132	6	resistance	resistance	NOUN
ajlm-708	132	7	to	to	AUX
ajlm-708	132	8	stavudine	stavudine	VERB
ajlm-708	132	9	and	and	CCONJ
ajlm-708	132	10	cross	cross	NOUN
ajlm-708	132	11	-	-	NOUN
ajlm-708	132	12	resistance	resistance	NOUN
ajlm-708	132	13	to	to	ADP
ajlm-708	132	14	lamivudine	lamivudine	NOUN
ajlm-708	132	15	,	,	PUNCT
ajlm-708	132	16	abacavir	abacavir	PROPN
ajlm-708	132	17	,	,	PUNCT
ajlm-708	132	18	emtricitabine	emtricitabine	NOUN
ajlm-708	132	19	and	and	CCONJ
ajlm-708	132	20	tenofovir,23,34,35	tenofovir,23,34,35	PROPN
ajlm-708	132	21	and	and	CCONJ
ajlm-708	132	22	is	be	AUX
ajlm-708	132	23	more	more	ADV
ajlm-708	132	24	frequently	frequently	ADV
ajlm-708	132	25	identified	identify	VERB
ajlm-708	132	26	in	in	ADP
ajlm-708	132	27	hiv-1	hiv-1	X
ajlm-708	132	28	subtype	subtype	NOUN
ajlm-708	132	29	c.30,35,36	c.30,35,36	NUM
ajlm-708	132	30	similar	similar	ADJ
ajlm-708	132	31	to	to	ADP
ajlm-708	132	32	previous	previous	ADJ
ajlm-708	132	33	studies	study	NOUN
ajlm-708	132	34	,	,	PUNCT
ajlm-708	132	35	the	the	DET
ajlm-708	132	36	k65r	k65r	PROPN
ajlm-708	132	37	mutation	mutation	NOUN
ajlm-708	132	38	was	be	AUX
ajlm-708	132	39	seen	see	VERB
ajlm-708	132	40	in	in	ADP
ajlm-708	132	41	both	both	DET
ajlm-708	132	42	treatment	treatment	NOUN
ajlm-708	132	43	-	-	PUNCT
ajlm-708	132	44	naïve	naïve	ADJ
ajlm-708	132	45	patients	patient	NOUN
ajlm-708	132	46	and	and	CCONJ
ajlm-708	132	47	patients	patient	NOUN
ajlm-708	132	48	failing	fail	VERB
ajlm-708	132	49	art	art	NOUN
ajlm-708	132	50	in	in	ADP
ajlm-708	132	51	this	this	DET
ajlm-708	132	52	cohort	cohort	NOUN
ajlm-708	132	53	.	.	PUNCT
ajlm-708	133	1	several	several	ADJ
ajlm-708	133	2	studies	study	NOUN
ajlm-708	133	3	have	have	AUX
ajlm-708	133	4	reported	report	VERB
ajlm-708	133	5	that	that	SCONJ
ajlm-708	133	6	increased	increase	VERB
ajlm-708	133	7	presence	presence	NOUN
ajlm-708	133	8	of	of	ADP
ajlm-708	133	9	k65r	k65r	PROPN
ajlm-708	133	10	mutations	mutation	NOUN
ajlm-708	133	11	is	be	AUX
ajlm-708	133	12	caused	cause	VERB
ajlm-708	133	13	by	by	ADP
ajlm-708	133	14	pyrosequencing	pyrosequence	VERB
ajlm-708	133	15	errors	error	NOUN
ajlm-708	133	16	or	or	CCONJ
ajlm-708	133	17	by	by	ADP
ajlm-708	133	18	the	the	DET
ajlm-708	133	19	nucleotide	nucleotide	NOUN
ajlm-708	133	20	template	template	NOUN
ajlm-708	133	21	of	of	ADP
ajlm-708	133	22	subtype	subtype	NOUN
ajlm-708	133	23	c	c	NOUN
ajlm-708	133	24	viruses	virus	NOUN
ajlm-708	133	25	(	(	PUNCT
ajlm-708	133	26	such	such	ADJ
ajlm-708	133	27	as	as	ADP
ajlm-708	133	28	the	the	DET
ajlm-708	133	29	ata	ata	PROPN
ajlm-708	133	30	sequence	sequence	NOUN
ajlm-708	133	31	at	at	ADP
ajlm-708	133	32	codon	codon	PROPN
ajlm-708	133	33	63	63	NUM
ajlm-708	133	34	of	of	ADP
ajlm-708	133	35	the	the	DET
ajlm-708	133	36	rt	rt	PROPN
ajlm-708	133	37	gene).30,32,37	gene).30,32,37	VERB
ajlm-708	133	38	even	even	ADV
ajlm-708	133	39	though	though	SCONJ
ajlm-708	133	40	no	no	DET
ajlm-708	133	41	errors	error	NOUN
ajlm-708	133	42	at	at	ADP
ajlm-708	133	43	codon	codon	PROPN
ajlm-708	133	44	65	65	NUM
ajlm-708	133	45	of	of	ADP
ajlm-708	133	46	the	the	DET
ajlm-708	133	47	rt	rt	PROPN
ajlm-708	133	48	gene	gene	NOUN
ajlm-708	133	49	were	be	AUX
ajlm-708	133	50	found	find	VERB
ajlm-708	133	51	by	by	ADP
ajlm-708	133	52	deep	deep	ADJ
ajlm-708	133	53	sequencing	sequencing	NOUN
ajlm-708	133	54	in	in	ADP
ajlm-708	133	55	the	the	DET
ajlm-708	133	56	current	current	ADJ
ajlm-708	133	57	study	study	NOUN
ajlm-708	133	58	,	,	PUNCT
ajlm-708	133	59	we	we	PRON
ajlm-708	133	60	did	do	AUX
ajlm-708	133	61	find	find	VERB
ajlm-708	133	62	a	a	DET
ajlm-708	133	63	relatively	relatively	ADV
ajlm-708	133	64	higher	high	ADJ
ajlm-708	133	65	error	error	NOUN
ajlm-708	133	66	rate	rate	NOUN
ajlm-708	133	67	at	at	ADP
ajlm-708	133	68	codon	codon	PROPN
ajlm-708	133	69	63	63	NUM
ajlm-708	133	70	of	of	ADP
ajlm-708	133	71	the	the	DET
ajlm-708	133	72	rt	rt	PROPN
ajlm-708	133	73	gene	gene	NOUN
ajlm-708	133	74	in	in	ADP
ajlm-708	133	75	the	the	DET
ajlm-708	133	76	subtype	subtype	NOUN
ajlm-708	133	77	c	c	NOUN
ajlm-708	133	78	plasmid	plasmid	VERB
ajlm-708	133	79	sequences	sequence	NOUN
ajlm-708	133	80	.	.	PUNCT
ajlm-708	134	1	however	however	ADV
ajlm-708	134	2	,	,	PUNCT
ajlm-708	134	3	we	we	PRON
ajlm-708	134	4	did	do	AUX
ajlm-708	134	5	not	not	PART
ajlm-708	134	6	find	find	VERB
ajlm-708	134	7	higher	high	ADJ
ajlm-708	134	8	error	error	NOUN
ajlm-708	134	9	rates	rate	NOUN
ajlm-708	134	10	for	for	ADP
ajlm-708	134	11	k65r	k65r	NOUN
ajlm-708	134	12	compared	compare	VERB
ajlm-708	134	13	with	with	ADP
ajlm-708	134	14	other	other	ADJ
ajlm-708	134	15	drm	drm	PROPN
ajlm-708	134	16	sites	site	NOUN
ajlm-708	134	17	in	in	ADP
ajlm-708	134	18	these	these	DET
ajlm-708	134	19	patients	patient	NOUN
ajlm-708	134	20	.	.	PUNCT
ajlm-708	135	1	the	the	DET
ajlm-708	135	2	m184i	m184i	PROPN
ajlm-708	135	3	mutations	mutation	NOUN
ajlm-708	135	4	were	be	AUX
ajlm-708	135	5	only	only	ADV
ajlm-708	135	6	detected	detect	VERB
ajlm-708	135	7	at	at	ADP
ajlm-708	135	8	low	low	ADJ
ajlm-708	135	9	frequencies	frequency	NOUN
ajlm-708	135	10	by	by	ADP
ajlm-708	135	11	deep	deep	ADJ
ajlm-708	135	12	sequencing	sequencing	NOUN
ajlm-708	135	13	in	in	ADP
ajlm-708	135	14	pre	pre	ADJ
ajlm-708	135	15	-	-	ADJ
ajlm-708	135	16	art	art	ADJ
ajlm-708	135	17	patients	patient	NOUN
ajlm-708	135	18	and	and	CCONJ
ajlm-708	135	19	patients	patient	NOUN
ajlm-708	135	20	with	with	ADP
ajlm-708	135	21	treatment	treatment	NOUN
ajlm-708	135	22	failure	failure	NOUN
ajlm-708	135	23	.	.	PUNCT
ajlm-708	136	1	m184i	m184i	PROPN
ajlm-708	136	2	was	be	AUX
ajlm-708	136	3	considered	consider	VERB
ajlm-708	136	4	to	to	PART
ajlm-708	136	5	be	be	AUX
ajlm-708	136	6	a	a	DET
ajlm-708	136	7	transient	transient	ADJ
ajlm-708	136	8	mutation	mutation	NOUN
ajlm-708	136	9	before	before	SCONJ
ajlm-708	136	10	being	be	AUX
ajlm-708	136	11	replaced	replace	VERB
ajlm-708	136	12	by	by	ADP
ajlm-708	136	13	m184v.19,38,39	m184v.19,38,39	ADV
ajlm-708	136	14	no	no	DET
ajlm-708	136	15	detectable	detectable	ADJ
ajlm-708	136	16	levels	level	NOUN
ajlm-708	136	17	of	of	ADP
ajlm-708	136	18	m184v	m184v	PROPN
ajlm-708	136	19	mutations	mutation	NOUN
ajlm-708	136	20	were	be	AUX
ajlm-708	136	21	found	find	VERB
ajlm-708	136	22	in	in	ADP
ajlm-708	136	23	pre	pre	ADJ
ajlm-708	136	24	-	-	ADJ
ajlm-708	136	25	art	art	ADJ
ajlm-708	136	26	samples	sample	NOUN
ajlm-708	136	27	using	use	VERB
ajlm-708	136	28	deep	deep	ADJ
ajlm-708	136	29	sequencing	sequencing	NOUN
ajlm-708	136	30	,	,	PUNCT
ajlm-708	136	31	but	but	CCONJ
ajlm-708	136	32	m184v	m184v	PROPN
ajlm-708	136	33	mutation	mutation	NOUN
ajlm-708	136	34	was	be	AUX
ajlm-708	136	35	detected	detect	VERB
ajlm-708	136	36	in	in	ADP
ajlm-708	136	37	over	over	ADP
ajlm-708	136	38	three	three	NUM
ajlm-708	136	39	-	-	PUNCT
ajlm-708	136	40	quarters	quarter	NOUN
ajlm-708	136	41	of	of	ADP
ajlm-708	136	42	samples	sample	NOUN
ajlm-708	136	43	from	from	ADP
ajlm-708	136	44	patients	patient	NOUN
ajlm-708	136	45	failing	fail	VERB
ajlm-708	136	46	art	art	NOUN
ajlm-708	136	47	.	.	PUNCT
ajlm-708	137	1	taken	take	VERB
ajlm-708	137	2	together	together	ADV
ajlm-708	137	3	,	,	PUNCT
ajlm-708	137	4	the	the	DET
ajlm-708	137	5	higher	high	ADJ
ajlm-708	137	6	nrti	nrti	PROPN
ajlm-708	137	7	resistance	resistance	NOUN
ajlm-708	137	8	mutations	mutation	NOUN
ajlm-708	137	9	of	of	ADP
ajlm-708	137	10	m184v	m184v	PROPN
ajlm-708	137	11	and	and	CCONJ
ajlm-708	137	12	k65r	k65r	NOUN
ajlm-708	137	13	in	in	ADP
ajlm-708	137	14	patients	patient	NOUN
ajlm-708	137	15	failing	fail	VERB
ajlm-708	137	16	art	art	NOUN
ajlm-708	137	17	were	be	AUX
ajlm-708	137	18	more	more	ADV
ajlm-708	137	19	likely	likely	ADV
ajlm-708	137	20	acquired	acquire	VERB
ajlm-708	137	21	by	by	ADP
ajlm-708	137	22	selective	selective	ADJ
ajlm-708	137	23	drug	drug	NOUN
ajlm-708	137	24	pressure	pressure	NOUN
ajlm-708	137	25	in	in	ADP
ajlm-708	137	26	this	this	DET
ajlm-708	137	27	malawian	malawian	ADJ
ajlm-708	137	28	cohort	cohort	NOUN
ajlm-708	137	29	treated	treat	VERB
ajlm-708	137	30	with	with	ADP
ajlm-708	137	31	a	a	DET
ajlm-708	137	32	regimen	regimen	NOUN
ajlm-708	137	33	containing	contain	VERB
ajlm-708	137	34	stavudine	stavudine	ADJ
ajlm-708	137	35	and	and	CCONJ
ajlm-708	137	36	lamivudine.22	lamivudine.22	NOUN
ajlm-708	137	37	in	in	ADP
ajlm-708	137	38	this	this	DET
ajlm-708	137	39	study	study	NOUN
ajlm-708	137	40	,	,	PUNCT
ajlm-708	137	41	most	most	ADJ
ajlm-708	137	42	samples	sample	NOUN
ajlm-708	137	43	collected	collect	VERB
ajlm-708	137	44	from	from	ADP
ajlm-708	137	45	virologic	virologic	ADJ
ajlm-708	137	46	failure	failure	NOUN
ajlm-708	137	47	patients	patient	NOUN
ajlm-708	137	48	had	have	VERB
ajlm-708	137	49	detectable	detectable	ADJ
ajlm-708	137	50	drms	drm	NOUN
ajlm-708	137	51	to	to	ADP
ajlm-708	137	52	nnrti	nnrti	NOUN
ajlm-708	137	53	by	by	ADP
ajlm-708	137	54	both	both	PRON
ajlm-708	137	55	sanger	sanger	PROPN
ajlm-708	137	56	sequencing	sequencing	NOUN
ajlm-708	137	57	and	and	CCONJ
ajlm-708	137	58	deep	deep	ADJ
ajlm-708	137	59	sequencing	sequencing	NOUN
ajlm-708	137	60	.	.	PUNCT
ajlm-708	138	1	the	the	DET
ajlm-708	138	2	mutations	mutation	NOUN
ajlm-708	138	3	k101e	k101e	PROPN
ajlm-708	138	4	,	,	PUNCT
ajlm-708	138	5	k103n	k103n	PROPN
ajlm-708	138	6	,	,	PUNCT
ajlm-708	138	7	v106a	v106a	PROPN
ajlm-708	138	8	/	/	SYM
ajlm-708	138	9	m	m	PROPN
ajlm-708	138	10	,	,	PUNCT
ajlm-708	138	11	v179d	v179d	PROPN
ajlm-708	138	12	/	/	SYM
ajlm-708	138	13	t	t	PROPN
ajlm-708	138	14	,	,	PUNCT
ajlm-708	138	15	y181c	y181c	PROPN
ajlm-708	138	16	,	,	PUNCT
ajlm-708	138	17	g190a	g190a	PROPN
ajlm-708	138	18	/	/	SYM
ajlm-708	138	19	e	e	PROPN
ajlm-708	138	20	and	and	CCONJ
ajlm-708	138	21	h221y	h221y	PROPN
ajlm-708	138	22	to	to	ADP
ajlm-708	138	23	nnrti	nnrti	PROPN
ajlm-708	138	24	were	be	AUX
ajlm-708	138	25	the	the	DET
ajlm-708	138	26	most	most	ADV
ajlm-708	138	27	common	common	ADJ
ajlm-708	138	28	minority	minority	NOUN
ajlm-708	138	29	mutations	mutation	NOUN
ajlm-708	138	30	detected	detect	VERB
ajlm-708	138	31	in	in	ADP
ajlm-708	138	32	these	these	DET
ajlm-708	138	33	patients	patient	NOUN
ajlm-708	138	34	.	.	PUNCT
ajlm-708	139	1	virus	virus	NOUN
ajlm-708	139	2	with	with	ADP
ajlm-708	139	3	k101e	k101e	PROPN
ajlm-708	139	4	/	/	SYM
ajlm-708	139	5	y181c	y181c	PROPN
ajlm-708	139	6	/	/	SYM
ajlm-708	139	7	g190a	g190a	PROPN
ajlm-708	139	8	and	and	CCONJ
ajlm-708	139	9	other	other	ADJ
ajlm-708	139	10	mutations	mutation	NOUN
ajlm-708	139	11	could	could	AUX
ajlm-708	139	12	increase	increase	VERB
ajlm-708	139	13	levels	level	NOUN
ajlm-708	139	14	of	of	ADP
ajlm-708	139	15	resistance	resistance	NOUN
ajlm-708	139	16	to	to	ADP
ajlm-708	139	17	nevirapine	nevirapine	ADJ
ajlm-708	139	18	893	893	NUM
ajlm-708	139	19	-	-	PUNCT
ajlm-708	139	20	fold.40	fold.40	VERB
ajlm-708	139	21	the	the	DET
ajlm-708	139	22	h221y	h221y	PROPN
ajlm-708	139	23	mutation	mutation	NOUN
ajlm-708	139	24	could	could	AUX
ajlm-708	139	25	also	also	ADV
ajlm-708	139	26	impact	impact	VERB
ajlm-708	139	27	clinical	clinical	ADJ
ajlm-708	139	28	outcomes	outcome	NOUN
ajlm-708	139	29	as	as	ADP
ajlm-708	139	30	y181c	y181c	PROPN
ajlm-708	139	31	/	/	SYM
ajlm-708	139	32	h221y	h221y	NOUN
ajlm-708	139	33	along	along	ADP
ajlm-708	139	34	with	with	ADP
ajlm-708	139	35	the	the	DET
ajlm-708	139	36	k103n	k103n	PROPN
ajlm-708	139	37	or	or	CCONJ
ajlm-708	139	38	k101q	k101q	PROPN
ajlm-708	139	39	mutations	mutation	NOUN
ajlm-708	139	40	could	could	AUX
ajlm-708	139	41	increase	increase	VERB
ajlm-708	139	42	resistance	resistance	NOUN
ajlm-708	139	43	levels	level	NOUN
ajlm-708	139	44	to	to	ADP
ajlm-708	139	45	nevirapine	nevirapine	ADJ
ajlm-708	139	46	over	over	ADP
ajlm-708	139	47	100	100	NUM
ajlm-708	139	48	-	-	NUM
ajlm-708	139	49	fold	fold	ADJ
ajlm-708	139	50	(	(	PUNCT
ajlm-708	139	51	k103n	k103n	PROPN
ajlm-708	139	52	)	)	PUNCT
ajlm-708	139	53	or	or	CCONJ
ajlm-708	139	54	3000	3000	NUM
ajlm-708	139	55	-	-	NUM
ajlm-708	139	56	fold	fold	NOUN
ajlm-708	139	57	(	(	PUNCT
ajlm-708	139	58	k101q).41	k101q).41	VERB
ajlm-708	139	59	the	the	DET
ajlm-708	139	60	drug	drug	NOUN
ajlm-708	139	61	resistance	resistance	NOUN
ajlm-708	139	62	profile	profile	NOUN
ajlm-708	139	63	generated	generate	VERB
ajlm-708	139	64	by	by	ADP
ajlm-708	139	65	deep	deep	ADJ
ajlm-708	139	66	sequencing	sequencing	NOUN
ajlm-708	139	67	revealed	reveal	VERB
ajlm-708	139	68	that	that	SCONJ
ajlm-708	139	69	these	these	DET
ajlm-708	139	70	mutations	mutation	NOUN
ajlm-708	139	71	were	be	AUX
ajlm-708	139	72	associated	associate	VERB
ajlm-708	139	73	with	with	ADP
ajlm-708	139	74	the	the	DET
ajlm-708	139	75	first	first	ADJ
ajlm-708	139	76	-	-	PUNCT
ajlm-708	139	77	line	line	NOUN
ajlm-708	139	78	regimen	regiman	NOUN
ajlm-708	139	79	(	(	PUNCT
ajlm-708	139	80	stavudine	stavudine	PROPN
ajlm-708	139	81	,	,	PUNCT
ajlm-708	139	82	lamivudine	lamivudine	NOUN
ajlm-708	139	83	and	and	CCONJ
ajlm-708	139	84	nevirapine	nevirapine	ADJ
ajlm-708	139	85	)	)	PUNCT
ajlm-708	139	86	.	.	PUNCT
ajlm-708	140	1	the	the	DET
ajlm-708	140	2	drms	drm	NOUN
ajlm-708	140	3	to	to	PART
ajlm-708	140	4	nnrti	nnrti	VERB
ajlm-708	140	5	in	in	ADP
ajlm-708	140	6	pre	pre	ADJ
ajlm-708	140	7	-	-	ADJ
ajlm-708	140	8	art	art	ADJ
ajlm-708	140	9	samples	sample	NOUN
ajlm-708	140	10	were	be	AUX
ajlm-708	140	11	also	also	ADV
ajlm-708	140	12	relatively	relatively	ADV
ajlm-708	140	13	high	high	ADJ
ajlm-708	140	14	in	in	ADP
ajlm-708	140	15	these	these	DET
ajlm-708	140	16	patients	patient	NOUN
ajlm-708	140	17	and	and	CCONJ
ajlm-708	140	18	were	be	AUX
ajlm-708	140	19	likely	likely	ADJ
ajlm-708	140	20	due	due	ADJ
ajlm-708	140	21	to	to	ADP
ajlm-708	140	22	single	single	ADJ
ajlm-708	140	23	-	-	PUNCT
ajlm-708	140	24	dose	dose	NOUN
ajlm-708	140	25	nevirapine	nevirapine	PROPN
ajlm-708	140	26	used	use	VERB
ajlm-708	140	27	in	in	ADP
ajlm-708	140	28	the	the	DET
ajlm-708	140	29	prevention	prevention	NOUN
ajlm-708	140	30	of	of	ADP
ajlm-708	140	31	mother	mother	NOUN
ajlm-708	140	32	-	-	PUNCT
ajlm-708	140	33	to	to	ADP
ajlm-708	140	34	-	-	PUNCT
ajlm-708	140	35	child	child	NOUN
ajlm-708	140	36	transmission	transmission	NOUN
ajlm-708	140	37	program	program	NOUN
ajlm-708	140	38	in	in	ADP
ajlm-708	140	39	malawi.22	malawi.22	NOUN
ajlm-708	140	40	however	however	ADV
ajlm-708	140	41	,	,	PUNCT
ajlm-708	140	42	our	our	PRON
ajlm-708	140	43	results	result	NOUN
ajlm-708	140	44	could	could	AUX
ajlm-708	140	45	not	not	PART
ajlm-708	140	46	rule	rule	VERB
ajlm-708	140	47	out	out	ADP
ajlm-708	140	48	the	the	DET
ajlm-708	140	49	presence	presence	NOUN
ajlm-708	140	50	of	of	ADP
ajlm-708	140	51	transmitted	transmit	VERB
ajlm-708	140	52	drug	drug	NOUN
ajlm-708	140	53	resistance	resistance	NOUN
ajlm-708	140	54	to	to	ADP
ajlm-708	140	55	nnrti	nnrti	NOUN
ajlm-708	140	56	in	in	ADP
ajlm-708	140	57	these	these	DET
ajlm-708	140	58	pre	pre	ADJ
ajlm-708	140	59	-	-	ADJ
ajlm-708	140	60	art	art	ADJ
ajlm-708	140	61	patients	patient	NOUN
ajlm-708	140	62	.	.	PUNCT
ajlm-708	141	1	although	although	SCONJ
ajlm-708	141	2	drms	drm	NOUN
ajlm-708	141	3	against	against	ADP
ajlm-708	141	4	pis	pis	NOUN
ajlm-708	141	5	were	be	AUX
ajlm-708	141	6	not	not	PART
ajlm-708	141	7	detected	detect	VERB
ajlm-708	141	8	using	use	VERB
ajlm-708	141	9	sanger	sanger	PROPN
ajlm-708	141	10	sequencing	sequencing	NOUN
ajlm-708	141	11	,	,	PUNCT
ajlm-708	141	12	they	they	PRON
ajlm-708	141	13	were	be	AUX
ajlm-708	141	14	detected	detect	VERB
ajlm-708	141	15	by	by	ADP
ajlm-708	141	16	deep	deep	ADJ
ajlm-708	141	17	sequencing	sequencing	NOUN
ajlm-708	141	18	in	in	ADP
ajlm-708	141	19	this	this	DET
ajlm-708	141	20	cohort	cohort	NOUN
ajlm-708	141	21	.	.	PUNCT
ajlm-708	142	1	m46i	m46i	NOUN
ajlm-708	142	2	/	/	SYM
ajlm-708	142	3	l	l	NOUN
ajlm-708	142	4	is	be	AUX
ajlm-708	142	5	considered	consider	VERB
ajlm-708	142	6	a	a	DET
ajlm-708	142	7	major	major	ADJ
ajlm-708	142	8	pi	pi	NOUN
ajlm-708	142	9	mutation	mutation	NOUN
ajlm-708	142	10	and	and	CCONJ
ajlm-708	142	11	would	would	AUX
ajlm-708	142	12	increase	increase	VERB
ajlm-708	142	13	drug	drug	NOUN
ajlm-708	142	14	resistance	resistance	NOUN
ajlm-708	142	15	levels	level	NOUN
ajlm-708	142	16	to	to	PART
ajlm-708	142	17	pis	pis	VERB
ajlm-708	142	18	along	along	ADP
ajlm-708	142	19	with	with	ADP
ajlm-708	142	20	other	other	ADJ
ajlm-708	142	21	mutations.34,42	mutations.34,42	NOUN
ajlm-708	142	22	because	because	SCONJ
ajlm-708	142	23	no	no	DET
ajlm-708	142	24	pi	pi	NOUN
ajlm-708	142	25	drugs	drug	NOUN
ajlm-708	142	26	were	be	AUX
ajlm-708	142	27	used	use	VERB
ajlm-708	142	28	in	in	ADP
ajlm-708	142	29	the	the	DET
ajlm-708	142	30	first	first	ADJ
ajlm-708	142	31	-	-	PUNCT
ajlm-708	142	32	line	line	NOUN
ajlm-708	142	33	art	art	NOUN
ajlm-708	142	34	in	in	ADP
ajlm-708	142	35	this	this	DET
ajlm-708	142	36	cohort	cohort	NOUN
ajlm-708	142	37	,	,	PUNCT
ajlm-708	142	38	these	these	DET
ajlm-708	142	39	pi	pi	NOUN
ajlm-708	142	40	mutations	mutation	NOUN
ajlm-708	142	41	were	be	AUX
ajlm-708	142	42	likely	likely	ADJ
ajlm-708	142	43	natural	natural	ADJ
ajlm-708	142	44	polymorphisms	polymorphism	NOUN
ajlm-708	142	45	of	of	ADP
ajlm-708	142	46	hiv-1	hiv-1	X
ajlm-708	142	47	.	.	PUNCT
ajlm-708	143	1	the	the	DET
ajlm-708	143	2	natural	natural	ADJ
ajlm-708	143	3	polymorphism	polymorphism	NOUN
ajlm-708	143	4	of	of	ADP
ajlm-708	143	5	m46i	m46i	PROPN
ajlm-708	143	6	has	have	AUX
ajlm-708	143	7	been	be	AUX
ajlm-708	143	8	reported	report	VERB
ajlm-708	143	9	to	to	PART
ajlm-708	143	10	have	have	VERB
ajlm-708	143	11	a	a	DET
ajlm-708	143	12	replicative	replicative	ADJ
ajlm-708	143	13	advantage	advantage	NOUN
ajlm-708	143	14	for	for	ADP
ajlm-708	143	15	subtype	subtype	NOUN
ajlm-708	143	16	b,43	b,43	VERB
ajlm-708	143	17	while	while	SCONJ
ajlm-708	143	18	the	the	DET
ajlm-708	143	19	impact	impact	NOUN
ajlm-708	143	20	of	of	ADP
ajlm-708	143	21	m46i	m46i	NOUN
ajlm-708	143	22	/	/	SYM
ajlm-708	143	23	l	l	NOUN
ajlm-708	143	24	natural	natural	ADJ
ajlm-708	143	25	polymorphisms	polymorphism	NOUN
ajlm-708	143	26	on	on	ADP
ajlm-708	143	27	the	the	DET
ajlm-708	143	28	development	development	NOUN
ajlm-708	143	29	of	of	ADP
ajlm-708	143	30	drug	drug	NOUN
ajlm-708	143	31	resistance	resistance	NOUN
ajlm-708	143	32	in	in	ADP
ajlm-708	143	33	patients	patient	NOUN
ajlm-708	143	34	is	be	AUX
ajlm-708	143	35	unknown	unknown	ADJ
ajlm-708	143	36	.	.	PUNCT
ajlm-708	144	1	as	as	SCONJ
ajlm-708	144	2	malawi	malawi	PROPN
ajlm-708	144	3	has	have	AUX
ajlm-708	144	4	started	start	VERB
ajlm-708	144	5	to	to	PART
ajlm-708	144	6	use	use	VERB
ajlm-708	144	7	lopinavir	lopinavir	NOUN
ajlm-708	144	8	/	/	SYM
ajlm-708	144	9	ritonavir	ritonavir	PROPN
ajlm-708	144	10	for	for	ADP
ajlm-708	144	11	second	second	ADJ
ajlm-708	144	12	-	-	PUNCT
ajlm-708	144	13	line	line	NOUN
ajlm-708	144	14	regimens,44	regimens,44	NOUN
ajlm-708	144	15	the	the	DET
ajlm-708	144	16	emergence	emergence	NOUN
ajlm-708	144	17	of	of	ADP
ajlm-708	144	18	drms	drm	NOUN
ajlm-708	144	19	to	to	PART
ajlm-708	144	20	pis	pis	VERB
ajlm-708	144	21	should	should	AUX
ajlm-708	144	22	be	be	AUX
ajlm-708	144	23	closely	closely	ADV
ajlm-708	144	24	monitored	monitor	VERB
ajlm-708	144	25	.	.	PUNCT
ajlm-708	145	1	evidence	evidence	NOUN
ajlm-708	145	2	is	be	AUX
ajlm-708	145	3	lacking	lack	VERB
ajlm-708	145	4	in	in	ADP
ajlm-708	145	5	understanding	understand	VERB
ajlm-708	145	6	the	the	DET
ajlm-708	145	7	real	real	ADJ
ajlm-708	145	8	clinical	clinical	ADJ
ajlm-708	145	9	impact	impact	NOUN
ajlm-708	145	10	of	of	ADP
ajlm-708	145	11	minority	minority	NOUN
ajlm-708	145	12	drms	drm	NOUN
ajlm-708	145	13	.	.	PUNCT
ajlm-708	146	1	clinical	clinical	ADJ
ajlm-708	146	2	trials	trial	NOUN
ajlm-708	146	3	are	be	AUX
ajlm-708	146	4	needed	need	VERB
ajlm-708	146	5	to	to	PART
ajlm-708	146	6	accurately	accurately	ADV
ajlm-708	146	7	evaluate	evaluate	VERB
ajlm-708	146	8	the	the	DET
ajlm-708	146	9	clinical	clinical	ADJ
ajlm-708	146	10	consequences	consequence	NOUN
ajlm-708	146	11	of	of	ADP
ajlm-708	146	12	these	these	DET
ajlm-708	146	13	drms	drm	NOUN
ajlm-708	146	14	.	.	PUNCT
ajlm-708	147	1	however	however	ADV
ajlm-708	147	2	,	,	PUNCT
ajlm-708	147	3	our	our	PRON
ajlm-708	147	4	results	result	NOUN
ajlm-708	147	5	indicate	indicate	VERB
ajlm-708	147	6	that	that	SCONJ
ajlm-708	147	7	minority	minority	NOUN
ajlm-708	147	8	mutations	mutation	NOUN
ajlm-708	147	9	detected	detect	VERB
ajlm-708	147	10	by	by	ADP
ajlm-708	147	11	barcoded	barcode	VERB
ajlm-708	147	12	deep	deep	ADJ
ajlm-708	147	13	sequencing	sequencing	NOUN
ajlm-708	147	14	show	show	NOUN
ajlm-708	147	15	an	an	DET
ajlm-708	147	16	increased	increase	VERB
ajlm-708	147	17	or	or	CCONJ
ajlm-708	147	18	expanded	expand	VERB
ajlm-708	147	19	level	level	NOUN
ajlm-708	147	20	of	of	ADP
ajlm-708	147	21	resistance	resistance	NOUN
ajlm-708	147	22	to	to	ADP
ajlm-708	147	23	nrtis	nrtis	PROPN
ajlm-708	147	24	and	and	CCONJ
ajlm-708	147	25	nnrtis	nnrtis	ADJ
ajlm-708	147	26	(	(	PUNCT
ajlm-708	147	27	see	see	VERB
ajlm-708	147	28	mutation	mutation	NOUN
ajlm-708	147	29	scores	score	NOUN
ajlm-708	147	30	in	in	ADP
ajlm-708	147	31	tables	table	NOUN
ajlm-708	147	32	3	3	NUM
ajlm-708	147	33	and	and	CCONJ
ajlm-708	147	34	4	4	NUM
ajlm-708	147	35	)	)	PUNCT
ajlm-708	147	36	.	.	PUNCT
ajlm-708	148	1	for	for	ADP
ajlm-708	148	2	instance	instance	NOUN
ajlm-708	148	3	,	,	PUNCT
ajlm-708	148	4	increased	increase	VERB
ajlm-708	148	5	m184iv	m184iv	NOUN
ajlm-708	148	6	/	/	SYM
ajlm-708	148	7	i	i	PRON
ajlm-708	148	8	mutations	mutation	NOUN
ajlm-708	148	9	would	would	AUX
ajlm-708	148	10	reduce	reduce	VERB
ajlm-708	148	11	susceptibility	susceptibility	NOUN
ajlm-708	148	12	to	to	ADP
ajlm-708	148	13	lamivudine	lamivudine	NOUN
ajlm-708	148	14	and	and	CCONJ
ajlm-708	148	15	emtricitabine	emtricitabine	PROPN
ajlm-708	148	16	(	(	PUNCT
ajlm-708	148	17	scores	score	NOUN
ajlm-708	148	18	from	from	ADP
ajlm-708	148	19	0	0	NUM
ajlm-708	148	20	to	to	ADP
ajlm-708	148	21	60	60	NUM
ajlm-708	148	22	,	,	PUNCT
ajlm-708	148	23	from	from	ADP
ajlm-708	148	24	susceptible	susceptible	ADJ
ajlm-708	148	25	to	to	ADP
ajlm-708	148	26	high	high	ADJ
ajlm-708	148	27	-	-	PUNCT
ajlm-708	148	28	level	level	NOUN
ajlm-708	148	29	of	of	ADP
ajlm-708	148	30	resistance	resistance	NOUN
ajlm-708	148	31	)	)	PUNCT
ajlm-708	148	32	.	.	PUNCT
ajlm-708	149	1	k65r+	k65r+	PROPN
ajlm-708	149	2	m184v	m184v	PROPN
ajlm-708	149	3	/	/	SYM
ajlm-708	149	4	i	i	PRON
ajlm-708	149	5	would	would	AUX
ajlm-708	149	6	reduce	reduce	VERB
ajlm-708	149	7	susceptibility	susceptibility	NOUN
ajlm-708	149	8	to	to	ADP
ajlm-708	149	9	tenofovir	tenofovir	PRON
ajlm-708	149	10	and	and	CCONJ
ajlm-708	149	11	didanosine	didanosine	VERB
ajlm-708	149	12	from	from	ADP
ajlm-708	149	13	low	low	ADJ
ajlm-708	149	14	-	-	PUNCT
ajlm-708	149	15	level	level	NOUN
ajlm-708	149	16	(	(	PUNCT
ajlm-708	149	17	scores	score	NOUN
ajlm-708	149	18	from	from	ADP
ajlm-708	149	19	0	0	NUM
ajlm-708	149	20	to	to	ADP
ajlm-708	149	21	60	60	NUM
ajlm-708	149	22	)	)	PUNCT
ajlm-708	149	23	to	to	ADP
ajlm-708	149	24	high	high	ADJ
ajlm-708	149	25	-	-	PUNCT
ajlm-708	149	26	level	level	NOUN
ajlm-708	149	27	resistance	resistance	NOUN
ajlm-708	149	28	(	(	PUNCT
ajlm-708	149	29	scores	score	NOUN
ajlm-708	149	30	from	from	ADP
ajlm-708	149	31	15	15	NUM
ajlm-708	149	32	to	to	ADP
ajlm-708	149	33	75	75	NUM
ajlm-708	149	34	)	)	PUNCT
ajlm-708	149	35	.	.	PUNCT
ajlm-708	150	1	additionally	additionally	ADV
ajlm-708	150	2	,	,	PUNCT
ajlm-708	150	3	other	other	ADJ
ajlm-708	150	4	individual	individual	ADJ
ajlm-708	150	5	thymidine	thymidine	ADJ
ajlm-708	150	6	-	-	PUNCT
ajlm-708	150	7	analog	analog	NOUN
ajlm-708	150	8	mutations	mutation	NOUN
ajlm-708	150	9	showed	show	VERB
ajlm-708	150	10	an	an	DET
ajlm-708	150	11	intermediate	intermediate	ADJ
ajlm-708	150	12	or	or	CCONJ
ajlm-708	150	13	high	high	ADJ
ajlm-708	150	14	level	level	NOUN
ajlm-708	150	15	of	of	ADP
ajlm-708	150	16	resistance	resistance	NOUN
ajlm-708	150	17	to	to	ADP
ajlm-708	150	18	malawi	malawi	PROPN
ajlm-708	150	19	’s	’s	PART
ajlm-708	150	20	first	first	ADJ
ajlm-708	150	21	-	-	PUNCT
ajlm-708	150	22	line	line	NOUN
ajlm-708	150	23	regimens	regimen	NOUN
ajlm-708	150	24	(	(	PUNCT
ajlm-708	150	25	stavudine	stavudine	ADJ
ajlm-708	150	26	,	,	PUNCT
ajlm-708	150	27	lamivudine	lamivudine	NOUN
ajlm-708	150	28	and	and	CCONJ
ajlm-708	150	29	nevirapine	nevirapine	ADJ
ajlm-708	150	30	)	)	PUNCT
ajlm-708	150	31	.	.	PUNCT
ajlm-708	151	1	these	these	DET
ajlm-708	151	2	low	low	ADJ
ajlm-708	151	3	-	-	PUNCT
ajlm-708	151	4	frequency	frequency	NOUN
ajlm-708	151	5	mutations	mutation	NOUN
ajlm-708	151	6	detected	detect	VERB
ajlm-708	151	7	by	by	ADP
ajlm-708	151	8	the	the	DET
ajlm-708	151	9	barcoded	barcode	VERB
ajlm-708	151	10	parallel	parallel	ADJ
ajlm-708	151	11	sequencing	sequence	VERB
ajlm-708	151	12	added	add	VERB
ajlm-708	151	13	significant	significant	ADJ
ajlm-708	151	14	values	value	NOUN
ajlm-708	151	15	to	to	ADP
ajlm-708	151	16	the	the	DET
ajlm-708	151	17	resistant	resistant	ADJ
ajlm-708	151	18	reservoir	reservoir	NOUN
ajlm-708	151	19	in	in	ADP
ajlm-708	151	20	the	the	DET
ajlm-708	151	21	hiv	hiv	PROPN
ajlm-708	151	22	-	-	PUNCT
ajlm-708	151	23	positive	positive	ADJ
ajlm-708	151	24	population	population	NOUN
ajlm-708	151	25	.	.	PUNCT
ajlm-708	152	1	all	all	DET
ajlm-708	152	2	mutation	mutation	NOUN
ajlm-708	152	3	data	datum	NOUN
ajlm-708	152	4	,	,	PUNCT
ajlm-708	152	5	both	both	DET
ajlm-708	152	6	majority	majority	NOUN
ajlm-708	152	7	and	and	CCONJ
ajlm-708	152	8	minority	minority	NOUN
ajlm-708	152	9	mutations	mutation	NOUN
ajlm-708	152	10	,	,	PUNCT
ajlm-708	152	11	can	can	AUX
ajlm-708	152	12	be	be	AUX
ajlm-708	152	13	used	use	VERB
ajlm-708	152	14	by	by	ADP
ajlm-708	152	15	doctors	doctor	NOUN
ajlm-708	152	16	or	or	CCONJ
ajlm-708	152	17	policy	policy	NOUN
ajlm-708	152	18	makers	maker	NOUN
ajlm-708	152	19	as	as	ADP
ajlm-708	152	20	a	a	DET
ajlm-708	152	21	reference	reference	NOUN
ajlm-708	152	22	when	when	SCONJ
ajlm-708	152	23	changing	change	VERB
ajlm-708	152	24	or	or	CCONJ
ajlm-708	152	25	revising	revise	VERB
ajlm-708	152	26	treatment	treatment	NOUN
ajlm-708	152	27	therapy	therapy	NOUN
ajlm-708	152	28	for	for	ADP
ajlm-708	152	29	patients	patient	NOUN
ajlm-708	152	30	with	with	ADP
ajlm-708	152	31	virologic	virologic	ADJ
ajlm-708	152	32	failure	failure	NOUN
ajlm-708	152	33	or	or	CCONJ
ajlm-708	152	34	country	country	NOUN
ajlm-708	152	35	first	first	ADJ
ajlm-708	152	36	-	-	PUNCT
ajlm-708	152	37	line	line	NOUN
ajlm-708	152	38	regimens	regimen	NOUN
ajlm-708	152	39	in	in	ADP
ajlm-708	152	40	malawi	malawi	PROPN
ajlm-708	152	41	.	.	PUNCT
ajlm-708	153	1	table	table	NOUN
ajlm-708	153	2	4	4	NUM
ajlm-708	153	3	:	:	PUNCT
ajlm-708	153	4	 	 	SPACE
ajlm-708	153	5	comparison	comparison	NOUN
ajlm-708	153	6	of	of	ADP
ajlm-708	153	7	nnrti	nnrti	NOUN
ajlm-708	153	8	drug	drug	PROPN
ajlm-708	153	9	resistance	resistance	NOUN
ajlm-708	153	10	mutations	mutation	NOUN
ajlm-708	153	11	detected	detect	VERB
ajlm-708	153	12	from	from	ADP
ajlm-708	153	13	plasma	plasma	NOUN
ajlm-708	153	14	specimens	specimen	NOUN
ajlm-708	153	15	collected	collect	VERB
ajlm-708	153	16	from	from	ADP
ajlm-708	153	17	patients	patient	NOUN
ajlm-708	153	18	with	with	ADP
ajlm-708	153	19	virologic	virologic	ADJ
ajlm-708	153	20	failure	failure	NOUN
ajlm-708	153	21	after	after	ADP
ajlm-708	153	22	12–15	12–15	NUM
ajlm-708	153	23	months	month	NOUN
ajlm-708	153	24	on	on	ADP
ajlm-708	153	25	art	art	NOUN
ajlm-708	153	26	by	by	ADP
ajlm-708	153	27	sanger	sanger	PROPN
ajlm-708	153	28	sequencing	sequencing	NOUN
ajlm-708	153	29	and	and	CCONJ
ajlm-708	153	30	deep	deep	ADJ
ajlm-708	153	31	sequencing	sequencing	NOUN
ajlm-708	153	32	and	and	CCONJ
ajlm-708	153	33	their	their	PRON
ajlm-708	153	34	impacts	impact	NOUN
ajlm-708	153	35	on	on	ADP
ajlm-708	153	36	nnrti	nnrti	NOUN
ajlm-708	153	37	susceptibility	susceptibility	NOUN
ajlm-708	153	38	.	.	PUNCT
ajlm-708	154	1	limitations	limitation	NOUN
ajlm-708	154	2	this	this	DET
ajlm-708	154	3	study	study	NOUN
ajlm-708	154	4	had	have	VERB
ajlm-708	154	5	its	its	PRON
ajlm-708	154	6	limitations	limitation	NOUN
ajlm-708	154	7	.	.	PUNCT
ajlm-708	155	1	first	first	ADV
ajlm-708	155	2	,	,	PUNCT
ajlm-708	155	3	the	the	DET
ajlm-708	155	4	sample	sample	NOUN
ajlm-708	155	5	size	size	NOUN
ajlm-708	155	6	was	be	AUX
ajlm-708	155	7	small	small	ADJ
ajlm-708	155	8	due	due	ADP
ajlm-708	155	9	to	to	ADP
ajlm-708	155	10	the	the	DET
ajlm-708	155	11	availability	availability	NOUN
ajlm-708	155	12	of	of	ADP
ajlm-708	155	13	remnant	remnant	ADJ
ajlm-708	155	14	samples	sample	NOUN
ajlm-708	155	15	and	and	CCONJ
ajlm-708	155	16	budget	budget	NOUN
ajlm-708	155	17	constraints	constraint	NOUN
ajlm-708	155	18	.	.	PUNCT
ajlm-708	156	1	a	a	DET
ajlm-708	156	2	statistically	statistically	ADV
ajlm-708	156	3	-	-	PUNCT
ajlm-708	156	4	appropriate	appropriate	ADJ
ajlm-708	156	5	sample	sample	NOUN
ajlm-708	156	6	size	size	NOUN
ajlm-708	156	7	should	should	AUX
ajlm-708	156	8	be	be	AUX
ajlm-708	156	9	used	use	VERB
ajlm-708	156	10	for	for	ADP
ajlm-708	156	11	population	population	NOUN
ajlm-708	156	12	-	-	PUNCT
ajlm-708	156	13	level	level	NOUN
ajlm-708	156	14	estimations	estimation	NOUN
ajlm-708	156	15	of	of	ADP
ajlm-708	156	16	drms	drm	NOUN
ajlm-708	156	17	in	in	ADP
ajlm-708	156	18	order	order	NOUN
ajlm-708	156	19	to	to	PART
ajlm-708	156	20	make	make	VERB
ajlm-708	156	21	a	a	DET
ajlm-708	156	22	meaningful	meaningful	ADJ
ajlm-708	156	23	statement	statement	NOUN
ajlm-708	156	24	.	.	PUNCT
ajlm-708	157	1	second	second	ADJ
ajlm-708	157	2	,	,	PUNCT
ajlm-708	157	3	although	although	SCONJ
ajlm-708	157	4	significantly	significantly	ADV
ajlm-708	157	5	increased	increase	VERB
ajlm-708	157	6	minority	minority	NOUN
ajlm-708	157	7	drms	drm	NOUN
ajlm-708	157	8	were	be	AUX
ajlm-708	157	9	observed	observe	VERB
ajlm-708	157	10	in	in	ADP
ajlm-708	157	11	the	the	DET
ajlm-708	157	12	samples	sample	NOUN
ajlm-708	157	13	collected	collect	VERB
ajlm-708	157	14	from	from	ADP
ajlm-708	157	15	pre	pre	ADJ
ajlm-708	157	16	-	-	NOUN
ajlm-708	157	17	art	art	NOUN
ajlm-708	157	18	and	and	CCONJ
ajlm-708	157	19	patients	patient	NOUN
ajlm-708	157	20	with	with	ADP
ajlm-708	157	21	virologic	virologic	ADJ
ajlm-708	157	22	failure	failure	NOUN
ajlm-708	157	23	using	use	VERB
ajlm-708	157	24	roche	roche	PROPN
ajlm-708	157	25	454	454	NUM
ajlm-708	157	26	barcoded	barcode	VERB
ajlm-708	157	27	deep	deep	ADJ
ajlm-708	157	28	sequencing	sequencing	NOUN
ajlm-708	157	29	,	,	PUNCT
ajlm-708	157	30	lack	lack	NOUN
ajlm-708	157	31	of	of	ADP
ajlm-708	157	32	proper	proper	ADJ
ajlm-708	157	33	plasmid	plasmid	ADJ
ajlm-708	157	34	mutant	mutant	ADJ
ajlm-708	157	35	k65r	k65r	PROPN
ajlm-708	157	36	control	control	NOUN
ajlm-708	157	37	in	in	ADP
ajlm-708	157	38	the	the	DET
ajlm-708	157	39	test	test	NOUN
ajlm-708	157	40	might	might	AUX
ajlm-708	157	41	have	have	AUX
ajlm-708	157	42	compromised	compromise	VERB
ajlm-708	157	43	the	the	DET
ajlm-708	157	44	accuracy	accuracy	NOUN
ajlm-708	157	45	of	of	ADP
ajlm-708	157	46	calculating	calculate	VERB
ajlm-708	157	47	the	the	DET
ajlm-708	157	48	k65r	k65r	PROPN
ajlm-708	157	49	mutation	mutation	NOUN
ajlm-708	157	50	rate	rate	NOUN
ajlm-708	157	51	.	.	PUNCT
ajlm-708	158	1	third	third	ADJ
ajlm-708	158	2	,	,	PUNCT
ajlm-708	158	3	some	some	DET
ajlm-708	158	4	methods	method	NOUN
ajlm-708	158	5	in	in	ADP
ajlm-708	158	6	the	the	DET
ajlm-708	158	7	current	current	ADJ
ajlm-708	158	8	study	study	NOUN
ajlm-708	158	9	could	could	AUX
ajlm-708	158	10	not	not	PART
ajlm-708	158	11	be	be	AUX
ajlm-708	158	12	applied	apply	VERB
ajlm-708	158	13	further	far	ADV
ajlm-708	158	14	as	as	ADP
ajlm-708	158	15	a	a	DET
ajlm-708	158	16	result	result	NOUN
ajlm-708	158	17	of	of	ADP
ajlm-708	158	18	the	the	DET
ajlm-708	158	19	454	454	NUM
ajlm-708	158	20	platform	platform	NOUN
ajlm-708	158	21	and	and	CCONJ
ajlm-708	158	22	technologies	technology	NOUN
ajlm-708	158	23	being	be	AUX
ajlm-708	158	24	discontinued	discontinue	VERB
ajlm-708	158	25	due	due	ADJ
ajlm-708	158	26	to	to	ADP
ajlm-708	158	27	high	high	ADJ
ajlm-708	158	28	cost	cost	NOUN
ajlm-708	158	29	and	and	CCONJ
ajlm-708	158	30	errors	error	NOUN
ajlm-708	158	31	at	at	ADP
ajlm-708	158	32	some	some	DET
ajlm-708	158	33	homopolymeric	homopolymeric	ADJ
ajlm-708	158	34	regions	region	NOUN
ajlm-708	158	35	.	.	PUNCT
ajlm-708	159	1	however	however	ADV
ajlm-708	159	2	,	,	PUNCT
ajlm-708	159	3	the	the	DET
ajlm-708	159	4	designed	design	VERB
ajlm-708	159	5	primers	primer	NOUN
ajlm-708	159	6	and	and	CCONJ
ajlm-708	159	7	barcoded	barcode	VERB
ajlm-708	159	8	strategy	strategy	NOUN
ajlm-708	159	9	in	in	ADP
ajlm-708	159	10	the	the	DET
ajlm-708	159	11	current	current	ADJ
ajlm-708	159	12	study	study	NOUN
ajlm-708	159	13	could	could	AUX
ajlm-708	159	14	be	be	AUX
ajlm-708	159	15	applied	apply	VERB
ajlm-708	159	16	to	to	ADP
ajlm-708	159	17	other	other	ADJ
ajlm-708	159	18	deep	deep	ADJ
ajlm-708	159	19	sequencing	sequencing	NOUN
ajlm-708	159	20	platforms	platform	NOUN
ajlm-708	159	21	for	for	ADP
ajlm-708	159	22	hiv	hiv	PROPN
ajlm-708	159	23	drug	drug	NOUN
ajlm-708	159	24	resistance	resistance	NOUN
ajlm-708	159	25	testing	testing	NOUN
ajlm-708	159	26	or	or	CCONJ
ajlm-708	159	27	studies	study	NOUN
ajlm-708	159	28	.	.	PUNCT
ajlm-708	160	1	conclusion	conclusion	NOUN
ajlm-708	160	2	in	in	ADP
ajlm-708	160	3	conclusion	conclusion	NOUN
ajlm-708	160	4	,	,	PUNCT
ajlm-708	160	5	our	our	PRON
ajlm-708	160	6	study	study	NOUN
ajlm-708	160	7	confirmed	confirm	VERB
ajlm-708	160	8	that	that	SCONJ
ajlm-708	160	9	barcoded	barcode	VERB
ajlm-708	160	10	parallel	parallel	ADJ
ajlm-708	160	11	deep	deep	ADJ
ajlm-708	160	12	sequencing	sequencing	NOUN
ajlm-708	160	13	technology	technology	NOUN
ajlm-708	160	14	is	be	AUX
ajlm-708	160	15	capable	capable	ADJ
ajlm-708	160	16	of	of	ADP
ajlm-708	160	17	detecting	detect	VERB
ajlm-708	160	18	minority	minority	NOUN
ajlm-708	160	19	drms	drm	NOUN
ajlm-708	160	20	from	from	ADP
ajlm-708	160	21	clinical	clinical	ADJ
ajlm-708	160	22	patient	patient	NOUN
ajlm-708	160	23	samples	sample	NOUN
ajlm-708	160	24	.	.	PUNCT
ajlm-708	161	1	these	these	DET
ajlm-708	161	2	minority	minority	NOUN
ajlm-708	161	3	drms	drm	NOUN
ajlm-708	161	4	not	not	PART
ajlm-708	161	5	only	only	ADV
ajlm-708	161	6	increased	increase	VERB
ajlm-708	161	7	resistance	resistance	NOUN
ajlm-708	161	8	levels	level	NOUN
ajlm-708	161	9	to	to	ADP
ajlm-708	161	10	the	the	DET
ajlm-708	161	11	antiretroviral	antiretroviral	ADJ
ajlm-708	161	12	drugs	drug	NOUN
ajlm-708	161	13	that	that	PRON
ajlm-708	161	14	are	be	AUX
ajlm-708	161	15	being	be	AUX
ajlm-708	161	16	prescribed	prescribe	VERB
ajlm-708	161	17	,	,	PUNCT
ajlm-708	161	18	but	but	CCONJ
ajlm-708	161	19	they	they	PRON
ajlm-708	161	20	also	also	ADV
ajlm-708	161	21	expanded	expand	VERB
ajlm-708	161	22	resistance	resistance	NOUN
ajlm-708	161	23	to	to	ADP
ajlm-708	161	24	additional	additional	ADJ
ajlm-708	161	25	major	major	ADJ
ajlm-708	161	26	first	first	ADJ
ajlm-708	161	27	-	-	PUNCT
ajlm-708	161	28	line	line	NOUN
ajlm-708	161	29	antiretroviral	antiretroviral	ADJ
ajlm-708	161	30	drugs	drug	NOUN
ajlm-708	161	31	such	such	ADJ
ajlm-708	161	32	as	as	ADP
ajlm-708	161	33	tenofovir	tenofovir	NOUN
ajlm-708	161	34	.	.	PUNCT
ajlm-708	162	1	the	the	DET
ajlm-708	162	2	minority	minority	NOUN
ajlm-708	162	3	drms	drm	NOUN
ajlm-708	162	4	detected	detect	VERB
ajlm-708	162	5	by	by	ADP
ajlm-708	162	6	deep	deep	ADJ
ajlm-708	162	7	sequencing	sequencing	NOUN
ajlm-708	162	8	may	may	AUX
ajlm-708	162	9	be	be	AUX
ajlm-708	162	10	helpful	helpful	ADJ
ajlm-708	162	11	for	for	ADP
ajlm-708	162	12	selecting	select	VERB
ajlm-708	162	13	the	the	DET
ajlm-708	162	14	optimal	optimal	ADJ
ajlm-708	162	15	regimens	regimen	NOUN
ajlm-708	162	16	for	for	ADP
ajlm-708	162	17	patients	patient	NOUN
ajlm-708	162	18	initiating	initiate	VERB
ajlm-708	162	19	art	art	NOUN
ajlm-708	162	20	and	and	CCONJ
ajlm-708	162	21	for	for	ADP
ajlm-708	162	22	patients	patient	NOUN
ajlm-708	162	23	who	who	PRON
ajlm-708	162	24	fail	fail	VERB
ajlm-708	162	25	first	first	ADJ
ajlm-708	162	26	-	-	PUNCT
ajlm-708	162	27	line	line	NOUN
ajlm-708	162	28	regimens	regimen	NOUN
ajlm-708	162	29	.	.	PUNCT
ajlm-708	163	1	acknowledgements	acknowledgement	NOUN
ajlm-708	163	2	this	this	DET
ajlm-708	163	3	work	work	NOUN
ajlm-708	163	4	was	be	AUX
ajlm-708	163	5	supported	support	VERB
ajlm-708	163	6	by	by	ADP
ajlm-708	163	7	the	the	DET
ajlm-708	163	8	president	president	NOUN
ajlm-708	163	9	’s	’s	PART
ajlm-708	163	10	emergency	emergency	NOUN
ajlm-708	163	11	plan	plan	NOUN
ajlm-708	163	12	for	for	ADP
ajlm-708	163	13	aids	aids	NOUN
ajlm-708	163	14	relief	relief	NOUN
ajlm-708	163	15	(	(	PUNCT
ajlm-708	163	16	pepfar	pepfar	NOUN
ajlm-708	163	17	)	)	PUNCT
ajlm-708	163	18	through	through	ADP
ajlm-708	163	19	the	the	DET
ajlm-708	163	20	united	united	PROPN
ajlm-708	163	21	states	states	PROPN
ajlm-708	163	22	centers	center	NOUN
ajlm-708	163	23	for	for	ADP
ajlm-708	163	24	disease	disease	NOUN
ajlm-708	163	25	control	control	NOUN
ajlm-708	163	26	and	and	CCONJ
ajlm-708	163	27	prevention	prevention	NOUN
ajlm-708	163	28	.	.	PUNCT
ajlm-708	164	1	the	the	DET
ajlm-708	164	2	findings	finding	NOUN
ajlm-708	164	3	and	and	CCONJ
ajlm-708	164	4	conclusions	conclusion	NOUN
ajlm-708	164	5	in	in	ADP
ajlm-708	164	6	this	this	DET
ajlm-708	164	7	paper	paper	NOUN
ajlm-708	164	8	are	be	AUX
ajlm-708	164	9	those	those	PRON
ajlm-708	164	10	of	of	ADP
ajlm-708	164	11	the	the	DET
ajlm-708	164	12	authors	author	NOUN
ajlm-708	164	13	and	and	CCONJ
ajlm-708	164	14	do	do	AUX
ajlm-708	164	15	not	not	PART
ajlm-708	164	16	necessarily	necessarily	ADV
ajlm-708	164	17	represent	represent	VERB
ajlm-708	164	18	the	the	DET
ajlm-708	164	19	official	official	ADJ
ajlm-708	164	20	position	position	NOUN
ajlm-708	164	21	of	of	ADP
ajlm-708	164	22	the	the	DET
ajlm-708	164	23	centers	center	NOUN
ajlm-708	164	24	for	for	ADP
ajlm-708	164	25	disease	disease	NOUN
ajlm-708	164	26	control	control	NOUN
ajlm-708	164	27	and	and	CCONJ
ajlm-708	164	28	prevention	prevention	NOUN
ajlm-708	164	29	.	.	PUNCT
ajlm-708	165	1	all	all	DET
ajlm-708	165	2	authors	author	NOUN
ajlm-708	165	3	read	read	VERB
ajlm-708	165	4	and	and	CCONJ
ajlm-708	165	5	approved	approve	VERB
ajlm-708	165	6	the	the	DET
ajlm-708	165	7	final	final	ADJ
ajlm-708	165	8	manuscript	manuscript	NOUN
ajlm-708	165	9	.	.	PUNCT
ajlm-708	166	1	competing	compete	VERB
ajlm-708	166	2	interests	interest	NOUN
ajlm-708	166	3	the	the	DET
ajlm-708	166	4	authors	author	NOUN
ajlm-708	166	5	declare	declare	VERB
ajlm-708	166	6	that	that	SCONJ
ajlm-708	166	7	they	they	PRON
ajlm-708	166	8	have	have	VERB
ajlm-708	166	9	no	no	DET
ajlm-708	166	10	financial	financial	ADJ
ajlm-708	166	11	or	or	CCONJ
ajlm-708	166	12	personal	personal	ADJ
ajlm-708	166	13	relationships	relationship	NOUN
ajlm-708	166	14	which	which	PRON
ajlm-708	166	15	may	may	AUX
ajlm-708	166	16	have	have	AUX
ajlm-708	166	17	inappropriately	inappropriately	ADV
ajlm-708	166	18	influenced	influence	VERB
ajlm-708	166	19	them	they	PRON
ajlm-708	166	20	in	in	ADP
ajlm-708	166	21	writing	write	VERB
ajlm-708	166	22	this	this	DET
ajlm-708	166	23	article	article	NOUN
ajlm-708	166	24	.	.	PUNCT
ajlm-708	167	1	sources	source	NOUN
ajlm-708	167	2	of	of	ADP
ajlm-708	167	3	support	support	NOUN
ajlm-708	167	4	none	none	NOUN
ajlm-708	167	5	.	.	PUNCT
ajlm-708	168	1	authors	author	NOUN
ajlm-708	168	2	’	'	PUNCT
ajlm-708	168	3	contributions	contribution	NOUN
ajlm-708	168	4	c.y	c.y	PROPN
ajlm-708	168	5	.	.	PROPN
ajlm-708	168	6	and	and	CCONJ
ajlm-708	168	7	z.z	z.z	PROPN
ajlm-708	168	8	.	.	PROPN
ajlm-708	168	9	conceived	conceive	VERB
ajlm-708	168	10	and	and	CCONJ
ajlm-708	168	11	designed	design	VERB
ajlm-708	168	12	the	the	DET
ajlm-708	168	13	current	current	ADJ
ajlm-708	168	14	study	study	NOUN
ajlm-708	168	15	.	.	PUNCT
ajlm-708	169	1	l.a.r	l.a.r	PROPN
ajlm-708	169	2	.	.	PUNCT
ajlm-708	170	1	and	and	CCONJ
ajlm-708	170	2	z.z	z.z	PROPN
ajlm-708	170	3	.	.	PROPN
ajlm-708	170	4	performed	perform	VERB
ajlm-708	170	5	the	the	DET
ajlm-708	170	6	deep	deep	ADJ
ajlm-708	170	7	sequencing	sequence	VERB
ajlm-708	170	8	experiments	experiment	NOUN
ajlm-708	170	9	.	.	PUNCT
ajlm-708	171	1	k.t	k.t	PROPN
ajlm-708	171	2	.	.	PROPN
ajlm-708	171	3	and	and	CCONJ
ajlm-708	171	4	g.z	g.z	PROPN
ajlm-708	171	5	.	.	PROPN
ajlm-708	171	6	performed	perform	VERB
ajlm-708	171	7	deep	deep	ADJ
ajlm-708	171	8	sequencing	sequence	VERB
ajlm-708	171	9	analysis	analysis	NOUN
ajlm-708	171	10	and	and	CCONJ
ajlm-708	171	11	statistical	statistical	ADJ
ajlm-708	171	12	analysis	analysis	NOUN
ajlm-708	171	13	.	.	PUNCT
ajlm-708	172	1	n.w.-k	n.w.-k	PROPN
ajlm-708	172	2	.	.	PUNCT
ajlm-708	172	3	and	and	CCONJ
ajlm-708	172	4	k.m	k.m	PROPN
ajlm-708	172	5	.	.	PROPN
ajlm-708	172	6	participated	participate	VERB
ajlm-708	172	7	in	in	ADP
ajlm-708	172	8	a	a	DET
ajlm-708	172	9	prospective	prospective	ADJ
ajlm-708	172	10	cohort	cohort	NOUN
ajlm-708	172	11	study	study	NOUN
ajlm-708	172	12	to	to	PART
ajlm-708	172	13	monitor	monitor	VERB
ajlm-708	172	14	art	art	NOUN
ajlm-708	172	15	outcomes	outcome	NOUN
ajlm-708	172	16	and	and	CCONJ
ajlm-708	172	17	drug	drug	NOUN
ajlm-708	172	18	resistance	resistance	NOUN
ajlm-708	172	19	development	development	NOUN
ajlm-708	172	20	in	in	ADP
ajlm-708	172	21	malawi	malawi	PROPN
ajlm-708	172	22	,	,	PUNCT
ajlm-708	172	23	including	include	VERB
ajlm-708	172	24	sample	sample	NOUN
ajlm-708	172	25	collection	collection	NOUN
ajlm-708	172	26	,	,	PUNCT
ajlm-708	172	27	data	data	NOUN
ajlm-708	172	28	collection	collection	NOUN
ajlm-708	172	29	and	and	CCONJ
ajlm-708	172	30	management	management	NOUN
ajlm-708	172	31	.	.	PUNCT
ajlm-708	173	1	j.r.d	j.r.d	PROPN
ajlm-708	173	2	.	.	PROPN
ajlm-708	173	3	,	,	PUNCT
ajlm-708	173	4	n.w	n.w	PROPN
ajlm-708	173	5	.	.	PROPN
ajlm-708	173	6	and	and	CCONJ
ajlm-708	173	7	h.g	h.g	PROPN
ajlm-708	173	8	.	.	PROPN
ajlm-708	173	9	performed	perform	VERB
ajlm-708	173	10	sanger	sanger	PROPN
ajlm-708	173	11	sequencing	sequencing	NOUN
ajlm-708	173	12	;	;	PUNCT
ajlm-708	174	1	d.-p.z	d.-p.z	PROPN
ajlm-708	174	2	.	.	PROPN
ajlm-708	174	3	,	,	PUNCT
ajlm-708	174	4	m.f	m.f	PROPN
ajlm-708	174	5	.	.	PROPN
ajlm-708	174	6	and	and	CCONJ
ajlm-708	174	7	s.s	s.s	PROPN
ajlm-708	174	8	.	.	PROPN
ajlm-708	174	9	participated	participate	VERB
ajlm-708	174	10	in	in	ADP
ajlm-708	174	11	sequencing	sequence	VERB
ajlm-708	174	12	data	data	NOUN
ajlm-708	174	13	collection	collection	NOUN
ajlm-708	174	14	and	and	CCONJ
ajlm-708	174	15	management	management	NOUN
ajlm-708	174	16	;	;	PUNCT
ajlm-708	174	17	and	and	CCONJ
ajlm-708	174	18	j.n	j.n	PROPN
ajlm-708	174	19	.	.	PROPN
ajlm-708	174	20	supervised	supervise	VERB
ajlm-708	174	21	and	and	CCONJ
ajlm-708	174	22	supported	support	VERB
ajlm-708	174	23	the	the	DET
ajlm-708	174	24	study	study	NOUN
ajlm-708	174	25	.	.	PUNCT
ajlm-708	175	1	z.z	z.z	X
ajlm-708	175	2	.	.	PROPN
ajlm-708	176	1	and	and	CCONJ
ajlm-708	176	2	c.y	c.y	PROPN
ajlm-708	176	3	.	.	PROPN
ajlm-708	176	4	wrote	write	VERB
ajlm-708	176	5	the	the	DET
ajlm-708	176	6	manuscript	manuscript	NOUN
ajlm-708	176	7	.	.	PUNCT
ajlm-708	177	1	references	reference	NOUN
ajlm-708	177	2	usaid	usaid	PROPN
ajlm-708	177	3	.	.	PUNCT
ajlm-708	178	1	17	17	NUM
ajlm-708	178	2	million	million	NUM
ajlm-708	178	3	people	people	NOUN
ajlm-708	178	4	with	with	ADP
ajlm-708	178	5	access	access	NOUN
ajlm-708	178	6	to	to	ADP
ajlm-708	178	7	antiretroviral	antiretroviral	ADJ
ajlm-708	178	8	therapy	therapy	NOUN
ajlm-708	178	9	[	[	X
ajlm-708	178	10	page	page	NOUN
ajlm-708	178	11	on	on	ADP
ajlm-708	178	12	the	the	DET
ajlm-708	178	13	internet	internet	NOUN
ajlm-708	178	14	]	]	PUNCT
ajlm-708	178	15	.	.	PUNCT
ajlm-708	179	1	c2016	c2016	PROPN
ajlm-708	180	1	[	[	X
ajlm-708	180	2	cited	cite	VERB
ajlm-708	180	3	2016	2016	NUM
ajlm-708	180	4	jun	jun	PROPN
ajlm-708	180	5	22	22	NUM
ajlm-708	180	6	]	]	PUNCT
ajlm-708	180	7	.	.	PUNCT
ajlm-708	181	1	available	available	ADJ
ajlm-708	181	2	from	from	ADP
ajlm-708	181	3	:	:	PUNCT
ajlm-708	181	4	http://www.who.int/hiv/mediacentre/news/global-aids-update-2016-news/en/	http://www.who.int/hiv/mediacentre/news/global-aids-update-2016-news/en/	NOUN
ajlm-708	181	5	gunthard	gunthard	PROPN
ajlm-708	181	6	hf	hf	PROPN
ajlm-708	181	7	,	,	PUNCT
ajlm-708	181	8	wong	wong	PROPN
ajlm-708	181	9	jk	jk	PROPN
ajlm-708	181	10	,	,	PUNCT
ajlm-708	181	11	ignacio	ignacio	PROPN
ajlm-708	181	12	cc	cc	PROPN
ajlm-708	181	13	,	,	PUNCT
ajlm-708	181	14	et	et	PROPN
ajlm-708	181	15	al	al	PROPN
ajlm-708	181	16	.	.	PROPN
ajlm-708	182	1	comparative	comparative	ADJ
ajlm-708	182	2	performance	performance	NOUN
ajlm-708	182	3	of	of	ADP
ajlm-708	182	4	high	high	ADJ
ajlm-708	182	5	-	-	PUNCT
ajlm-708	182	6	density	density	NOUN
ajlm-708	182	7	oligonucleotide	oligonucleotide	NOUN
ajlm-708	182	8	sequencing	sequencing	NOUN
ajlm-708	182	9	and	and	CCONJ
ajlm-708	182	10	dideoxynucleotide	dideoxynucleotide	NOUN
ajlm-708	182	11	sequencing	sequencing	NOUN
ajlm-708	182	12	of	of	ADP
ajlm-708	182	13	hiv	hiv	PROPN
ajlm-708	182	14	type	type	NOUN
ajlm-708	182	15	1	1	NUM
ajlm-708	182	16	pol	pol	NOUN
ajlm-708	182	17	from	from	ADP
ajlm-708	182	18	clinical	clinical	ADJ
ajlm-708	182	19	samples	sample	NOUN
ajlm-708	182	20	.	.	PUNCT
ajlm-708	183	1	aids	aids	PROPN
ajlm-708	183	2	res	re	NOUN
ajlm-708	183	3	hum	hum	ADJ
ajlm-708	183	4	retroviruses	retrovirus	NOUN
ajlm-708	183	5	.	.	PUNCT
ajlm-708	184	1	1998;14(10):869–876	1998;14(10):869–876	NUM
ajlm-708	184	2	.	.	PUNCT
ajlm-708	184	3	https://doi.org/10.1089/aid.1998.14.869	https://doi.org/10.1089/aid.1998.14.869	PROPN
ajlm-708	184	4	schuurman	schuurman	PROPN
ajlm-708	184	5	r	r	PROPN
ajlm-708	184	6	,	,	PUNCT
ajlm-708	184	7	brambilla	brambilla	NOUN
ajlm-708	184	8	d	d	PROPN
ajlm-708	184	9	,	,	PUNCT
ajlm-708	184	10	de	de	PROPN
ajlm-708	184	11	groot	groot	PROPN
ajlm-708	184	12	t	t	PROPN
ajlm-708	184	13	,	,	PUNCT
ajlm-708	184	14	et	et	PROPN
ajlm-708	184	15	al	al	PROPN
ajlm-708	184	16	.	.	PROPN
ajlm-708	184	17	underestimation	underestimation	NOUN
ajlm-708	184	18	of	of	ADP
ajlm-708	184	19	hiv	hiv	PROPN
ajlm-708	184	20	type	type	NOUN
ajlm-708	184	21	1	1	NUM
ajlm-708	184	22	drug	drug	NOUN
ajlm-708	184	23	resistance	resistance	NOUN
ajlm-708	184	24	mutations	mutation	NOUN
ajlm-708	184	25	:	:	PUNCT
ajlm-708	184	26	results	result	VERB
ajlm-708	184	27	from	from	ADP
ajlm-708	184	28	the	the	DET
ajlm-708	184	29	enva-2	enva-2	NUM
ajlm-708	184	30	genotyping	genotype	VERB
ajlm-708	184	31	proficiency	proficiency	NOUN
ajlm-708	184	32	program	program	NOUN
ajlm-708	184	33	.	.	PUNCT
ajlm-708	185	1	aids	aids	PROPN
ajlm-708	185	2	res	re	NOUN
ajlm-708	185	3	hum	hum	ADJ
ajlm-708	185	4	retroviruses	retrovirus	NOUN
ajlm-708	185	5	.	.	PUNCT
ajlm-708	186	1	2002;18(4):243–248	2002;18(4):243–248	NUM
ajlm-708	186	2	.	.	PUNCT
ajlm-708	187	1	https://doi.org/10.1089/088922202753472801	https://doi.org/10.1089/088922202753472801	PROPN
ajlm-708	188	1	palmer	palmer	PROPN
ajlm-708	188	2	s	s	PROPN
ajlm-708	188	3	,	,	PUNCT
ajlm-708	188	4	kearney	kearney	PROPN
ajlm-708	188	5	m	m	PROPN
ajlm-708	188	6	,	,	PUNCT
ajlm-708	188	7	maldarelli	maldarelli	PROPN
ajlm-708	188	8	f	f	AUX
ajlm-708	188	9	,	,	PUNCT
ajlm-708	188	10	et	et	PROPN
ajlm-708	188	11	al	al	PROPN
ajlm-708	188	12	.	.	PROPN
ajlm-708	188	13	multiple	multiple	PROPN
ajlm-708	188	14	,	,	PUNCT
ajlm-708	188	15	linked	link	VERB
ajlm-708	188	16	human	human	ADJ
ajlm-708	188	17	immunodeficiency	immunodeficiency	NOUN
ajlm-708	188	18	virus	virus	NOUN
ajlm-708	188	19	type	type	NOUN
ajlm-708	188	20	1	1	NUM
ajlm-708	188	21	drug	drug	NOUN
ajlm-708	188	22	resistance	resistance	NOUN
ajlm-708	188	23	mutations	mutation	NOUN
ajlm-708	188	24	in	in	ADP
ajlm-708	188	25	treatment	treatment	NOUN
ajlm-708	188	26	-	-	PUNCT
ajlm-708	188	27	experienced	experience	VERB
ajlm-708	188	28	patients	patient	NOUN
ajlm-708	188	29	are	be	AUX
ajlm-708	188	30	missed	miss	VERB
ajlm-708	188	31	by	by	ADP
ajlm-708	188	32	standard	standard	ADJ
ajlm-708	188	33	genotype	genotype	NOUN
ajlm-708	188	34	analysis	analysis	NOUN
ajlm-708	188	35	.	.	PUNCT
ajlm-708	189	1	j	j	PROPN
ajlm-708	189	2	clin	clin	PROPN
ajlm-708	189	3	microbiol	microbiol	PROPN
ajlm-708	189	4	.	.	PUNCT
ajlm-708	190	1	2005;43(1):406–413	2005;43(1):406–413	X
ajlm-708	190	2	.	.	PUNCT
ajlm-708	191	1	https://doi.org/10.1128/jcm.43.1.406-413.2005	https://doi.org/10.1128/jcm.43.1.406-413.2005	PROPN
ajlm-708	191	2	kozal	kozal	PROPN
ajlm-708	191	3	mj	mj	PROPN
ajlm-708	191	4	.	.	PROPN
ajlm-708	191	5	drug	drug	NOUN
ajlm-708	191	6	-	-	PUNCT
ajlm-708	191	7	resistant	resistant	ADJ
ajlm-708	191	8	human	human	ADJ
ajlm-708	191	9	immunodefiency	immunodefiency	NOUN
ajlm-708	191	10	virus	virus	NOUN
ajlm-708	191	11	.	.	PUNCT
ajlm-708	192	1	clin	clin	PROPN
ajlm-708	192	2	microbiol	microbiol	PROPN
ajlm-708	192	3	infect	infect	VERB
ajlm-708	192	4	.	.	PUNCT
ajlm-708	193	1	2009;15(suppl	2009;15(suppl	NOUN
ajlm-708	193	2	1):69–73	1):69–73	NUM
ajlm-708	193	3	.	.	PUNCT
ajlm-708	193	4	https://doi.org/10.1111/j.1469-0691.2008.02687.x	https://doi.org/10.1111/j.1469-0691.2008.02687.x	PROPN
ajlm-708	193	5	jourdain	jourdain	PROPN
ajlm-708	193	6	g	g	PROPN
ajlm-708	193	7	,	,	PUNCT
ajlm-708	193	8	ngo	ngo	PROPN
ajlm-708	193	9	-	-	PUNCT
ajlm-708	193	10	giang	giang	PROPN
ajlm-708	193	11	-	-	PUNCT
ajlm-708	193	12	huong	huong	PROPN
ajlm-708	193	13	n	n	CCONJ
ajlm-708	193	14	,	,	PUNCT
ajlm-708	193	15	le	le	X
ajlm-708	193	16	coeur	coeur	X
ajlm-708	193	17	s	s	PROPN
ajlm-708	193	18	,	,	PUNCT
ajlm-708	193	19	et	et	PROPN
ajlm-708	193	20	al	al	PROPN
ajlm-708	193	21	.	.	PROPN
ajlm-708	193	22	intrapartum	intrapartum	PROPN
ajlm-708	193	23	exposure	exposure	NOUN
ajlm-708	193	24	to	to	ADP
ajlm-708	193	25	nevirapine	nevirapine	ADJ
ajlm-708	193	26	and	and	CCONJ
ajlm-708	193	27	subsequent	subsequent	ADJ
ajlm-708	193	28	maternal	maternal	ADJ
ajlm-708	193	29	responses	response	NOUN
ajlm-708	193	30	to	to	ADP
ajlm-708	193	31	nevirapine	nevirapine	ADJ
ajlm-708	193	32	-	-	PUNCT
ajlm-708	193	33	based	base	VERB
ajlm-708	193	34	antiretroviral	antiretroviral	ADJ
ajlm-708	193	35	therapy	therapy	NOUN
ajlm-708	193	36	.	.	PUNCT
ajlm-708	194	1	n	n	PROPN
ajlm-708	194	2	engl	engl	PROPN
ajlm-708	194	3	j	j	PROPN
ajlm-708	194	4	med	med	PROPN
ajlm-708	194	5	.	.	PUNCT
ajlm-708	195	1	2004;351(3):229–240	2004;351(3):229–240	PROPN
ajlm-708	195	2	.	.	PUNCT
ajlm-708	195	3	https://doi.org/10.1056/nejmoa041305	https://doi.org/10.1056/nejmoa041305	PROPN
ajlm-708	195	4	kapoor	kapoor	PROPN
ajlm-708	195	5	a	a	PROPN
ajlm-708	195	6	,	,	PUNCT
ajlm-708	195	7	kapoor	kapoor	PROPN
ajlm-708	195	8	a	a	PROPN
ajlm-708	195	9	,	,	PUNCT
ajlm-708	195	10	vani	vani	PROPN
ajlm-708	195	11	sn	sn	PROPN
ajlm-708	195	12	.	.	PUNCT
ajlm-708	195	13	prevention	prevention	PROPN
ajlm-708	195	14	of	of	ADP
ajlm-708	195	15	mother	mother	NOUN
ajlm-708	195	16	to	to	ADP
ajlm-708	195	17	child	child	NOUN
ajlm-708	195	18	transmission	transmission	NOUN
ajlm-708	195	19	of	of	ADP
ajlm-708	195	20	hiv	hiv	PROPN
ajlm-708	195	21	.	.	PUNCT
ajlm-708	196	1	indian	indian	PROPN
ajlm-708	196	2	j	j	PROPN
ajlm-708	196	3	pediatr	pediatr	PROPN
ajlm-708	196	4	.	.	PUNCT
ajlm-708	197	1	2004;71(3):247–251	2004;71(3):247–251	X
ajlm-708	197	2	.	.	PUNCT
ajlm-708	198	1	https://doi.org/10.1007/bf02724278	https://doi.org/10.1007/bf02724278	PROPN
ajlm-708	198	2	lecossier	lecossier	ADJ
ajlm-708	198	3	d	d	PROPN
ajlm-708	198	4	,	,	PUNCT
ajlm-708	198	5	shulman	shulman	PROPN
ajlm-708	198	6	ns	ns	NOUN
ajlm-708	198	7	,	,	PUNCT
ajlm-708	198	8	morand	morand	NOUN
ajlm-708	198	9	-	-	PUNCT
ajlm-708	198	10	joubert	joubert	PROPN
ajlm-708	198	11	l	l	PROPN
ajlm-708	198	12	,	,	PUNCT
ajlm-708	198	13	et	et	PROPN
ajlm-708	198	14	al	al	PROPN
ajlm-708	198	15	.	.	PUNCT
ajlm-708	198	16	detection	detection	NOUN
ajlm-708	198	17	of	of	ADP
ajlm-708	198	18	minority	minority	NOUN
ajlm-708	198	19	populations	population	NOUN
ajlm-708	198	20	of	of	ADP
ajlm-708	198	21	hiv-1	hiv-1	VERB
ajlm-708	198	22	expressing	express	VERB
ajlm-708	198	23	the	the	DET
ajlm-708	198	24	k103n	k103n	PROPN
ajlm-708	198	25	resistance	resistance	NOUN
ajlm-708	198	26	mutation	mutation	NOUN
ajlm-708	198	27	in	in	ADP
ajlm-708	198	28	patients	patient	NOUN
ajlm-708	198	29	failing	fail	VERB
ajlm-708	198	30	nevirapine	nevirapine	ADJ
ajlm-708	198	31	.	.	PUNCT
ajlm-708	199	1	j	j	PROPN
ajlm-708	199	2	acquir	acquir	PROPN
ajlm-708	199	3	immune	immune	VERB
ajlm-708	199	4	defic	defic	ADJ
ajlm-708	199	5	syndr	syndr	NOUN
ajlm-708	199	6	.	.	PUNCT
ajlm-708	200	1	2005;38(1):37–42	2005;38(1):37–42	NUM
ajlm-708	200	2	.	.	PUNCT
ajlm-708	201	1	https://doi.org/10.1097/00126334-200501010-00007	https://doi.org/10.1097/00126334-200501010-00007	PROPN
ajlm-708	201	2	johnson	johnson	PROPN
ajlm-708	201	3	ja	ja	PROPN
ajlm-708	201	4	,	,	PUNCT
ajlm-708	201	5	li	li	PROPN
ajlm-708	201	6	jf	jf	PROPN
ajlm-708	201	7	,	,	PUNCT
ajlm-708	201	8	wei	wei	PROPN
ajlm-708	201	9	x	x	PROPN
ajlm-708	201	10	,	,	PUNCT
ajlm-708	201	11	et	et	PROPN
ajlm-708	201	12	al	al	PROPN
ajlm-708	201	13	.	.	PUNCT
ajlm-708	201	14	minority	minority	NOUN
ajlm-708	201	15	hiv-1	hiv-1	X
ajlm-708	201	16	drug	drug	NOUN
ajlm-708	201	17	resistance	resistance	NOUN
ajlm-708	201	18	mutations	mutation	NOUN
ajlm-708	201	19	are	be	AUX
ajlm-708	201	20	present	present	ADJ
ajlm-708	201	21	in	in	ADP
ajlm-708	201	22	antiretroviral	antiretroviral	ADJ
ajlm-708	201	23	treatment	treatment	NOUN
ajlm-708	201	24	-	-	PUNCT
ajlm-708	201	25	naive	naive	ADJ
ajlm-708	201	26	populations	population	NOUN
ajlm-708	201	27	and	and	CCONJ
ajlm-708	201	28	associate	associate	VERB
ajlm-708	201	29	with	with	ADP
ajlm-708	201	30	reduced	reduced	ADJ
ajlm-708	201	31	treatment	treatment	NOUN
ajlm-708	201	32	efficacy	efficacy	NOUN
ajlm-708	201	33	.	.	PUNCT
ajlm-708	202	1	plos	plos	PROPN
ajlm-708	202	2	med	med	PROPN
ajlm-708	202	3	.	.	PROPN
ajlm-708	202	4	2008;5(7):e158	2008;5(7):e158	NOUN
ajlm-708	202	5	.	.	PUNCT
ajlm-708	203	1	https://doi.org/10.1371/journal.pmed.0050158	https://doi.org/10.1371/journal.pmed.0050158	NOUN
ajlm-708	203	2	simen	simen	PROPN
ajlm-708	203	3	bb	bb	PROPN
ajlm-708	203	4	,	,	PUNCT
ajlm-708	203	5	simons	simons	PROPN
ajlm-708	203	6	jf	jf	PROPN
ajlm-708	203	7	,	,	PUNCT
ajlm-708	203	8	hullsiek	hullsiek	PROPN
ajlm-708	203	9	kh	kh	PROPN
ajlm-708	203	10	,	,	PUNCT
ajlm-708	203	11	et	et	PROPN
ajlm-708	203	12	al	al	PROPN
ajlm-708	203	13	.	.	PROPN
ajlm-708	204	1	terry	terry	PROPN
ajlm-708	204	2	beirn	beirn	ADJ
ajlm-708	204	3	low	low	ADJ
ajlm-708	204	4	-	-	PUNCT
ajlm-708	204	5	abundance	abundance	NOUN
ajlm-708	204	6	drug	drug	NOUN
ajlm-708	204	7	-	-	PUNCT
ajlm-708	204	8	resistant	resistant	ADJ
ajlm-708	204	9	viral	viral	ADJ
ajlm-708	204	10	variants	variant	NOUN
ajlm-708	204	11	in	in	ADP
ajlm-708	204	12	chronically	chronically	ADV
ajlm-708	204	13	hiv	hiv	NOUN
ajlm-708	204	14	-	-	PUNCT
ajlm-708	204	15	infected	infect	VERB
ajlm-708	204	16	,	,	PUNCT
ajlm-708	204	17	antiretroviral	antiretroviral	ADJ
ajlm-708	204	18	treatment	treatment	NOUN
ajlm-708	204	19	-	-	PUNCT
ajlm-708	204	20	naive	naive	ADJ
ajlm-708	204	21	patients	patient	NOUN
ajlm-708	204	22	significantly	significantly	ADV
ajlm-708	204	23	impact	impact	VERB
ajlm-708	204	24	treatment	treatment	NOUN
ajlm-708	204	25	outcomes	outcome	NOUN
ajlm-708	204	26	.	.	PUNCT
ajlm-708	205	1	j	j	PROPN
ajlm-708	205	2	infect	infect	VERB
ajlm-708	205	3	dis	dis	PROPN
ajlm-708	205	4	.	.	PUNCT
ajlm-708	206	1	2009;199(5):693–701	2009;199(5):693–701	NUM
ajlm-708	206	2	.	.	PUNCT
ajlm-708	207	1	https://doi.org/10.1086/596736	https://doi.org/10.1086/596736	NOUN
ajlm-708	208	1	zhou	zhou	PROPN
ajlm-708	209	1	z	z	X
ajlm-708	209	2	,	,	PUNCT
ajlm-708	209	3	wagar	wagar	X
ajlm-708	209	4	n	n	CCONJ
ajlm-708	209	5	,	,	PUNCT
ajlm-708	209	6	devos	devos	PROPN
ajlm-708	209	7	jr	jr	PROPN
ajlm-708	209	8	,	,	PUNCT
ajlm-708	209	9	et	et	PROPN
ajlm-708	209	10	al	al	PROPN
ajlm-708	209	11	.	.	PUNCT
ajlm-708	209	12	optimization	optimization	NOUN
ajlm-708	209	13	of	of	ADP
ajlm-708	209	14	a	a	DET
ajlm-708	209	15	low	low	ADJ
ajlm-708	209	16	cost	cost	NOUN
ajlm-708	209	17	and	and	CCONJ
ajlm-708	209	18	broadly	broadly	ADV
ajlm-708	209	19	sensitive	sensitive	ADJ
ajlm-708	209	20	genotyping	genotyping	NOUN
ajlm-708	209	21	assay	assay	ADV
ajlm-708	209	22	for	for	ADP
ajlm-708	209	23	hiv-1	hiv-1	VERB
ajlm-708	209	24	drug	drug	NOUN
ajlm-708	209	25	resistance	resistance	NOUN
ajlm-708	209	26	surveillance	surveillance	NOUN
ajlm-708	209	27	and	and	CCONJ
ajlm-708	209	28	monitoring	monitor	VERB
ajlm-708	209	29	in	in	ADP
ajlm-708	209	30	resource	resource	NOUN
ajlm-708	209	31	-	-	PUNCT
ajlm-708	209	32	limited	limit	VERB
ajlm-708	209	33	settings	setting	NOUN
ajlm-708	209	34	.	.	PUNCT
ajlm-708	210	1	plos	plos	PROPN
ajlm-708	210	2	one	one	NUM
ajlm-708	210	3	.	.	PUNCT
ajlm-708	211	1	2011;6(11):e28184	2011;6(11):e28184	X
ajlm-708	211	2	.	.	PUNCT
ajlm-708	212	1	https://doi.org/10.1371/journal.pone.0028184	https://doi.org/10.1371/journal.pone.0028184	NOUN
ajlm-708	212	2	brenner	brenner	NOUN
ajlm-708	212	3	b	b	PROPN
ajlm-708	212	4	,	,	PUNCT
ajlm-708	212	5	routy	routy	PROPN
ajlm-708	212	6	jp	jp	PROPN
ajlm-708	212	7	,	,	PUNCT
ajlm-708	212	8	quan	quan	PROPN
ajlm-708	212	9	y	y	PROPN
ajlm-708	212	10	,	,	PUNCT
ajlm-708	212	11	et	et	PROPN
ajlm-708	212	12	al	al	PROPN
ajlm-708	212	13	.	.	PROPN
ajlm-708	212	14	persistence	persistence	NOUN
ajlm-708	212	15	of	of	ADP
ajlm-708	212	16	multidrug	multidrug	NOUN
ajlm-708	212	17	-	-	PUNCT
ajlm-708	212	18	resistant	resistant	ADJ
ajlm-708	212	19	hiv-1	hiv-1	PUNCT
ajlm-708	212	20	in	in	ADP
ajlm-708	212	21	primary	primary	ADJ
ajlm-708	212	22	infection	infection	NOUN
ajlm-708	212	23	leading	lead	VERB
ajlm-708	212	24	to	to	ADP
ajlm-708	212	25	superinfection	superinfection	NOUN
ajlm-708	212	26	.	.	PUNCT
ajlm-708	213	1	aids	aids	PROPN
ajlm-708	213	2	.	.	PUNCT
ajlm-708	214	1	2004;18(12):1653–1660	2004;18(12):1653–1660	NOUN
ajlm-708	214	2	.	.	PUNCT
ajlm-708	215	1	https://doi.org/10.1097/01.aids.0000131377.28694.04	https://doi.org/10.1097/01.aids.0000131377.28694.04	PROPN
ajlm-708	215	2	metzner	metzner	PROPN
ajlm-708	215	3	kj	kj	PROPN
ajlm-708	215	4	,	,	PUNCT
ajlm-708	215	5	bonhoeffer	bonhoeffer	PROPN
ajlm-708	215	6	s	s	PROPN
ajlm-708	215	7	,	,	PUNCT
ajlm-708	215	8	fischer	fischer	PROPN
ajlm-708	215	9	m	m	PROPN
ajlm-708	215	10	,	,	PUNCT
ajlm-708	215	11	et	et	PROPN
ajlm-708	215	12	al	al	PROPN
ajlm-708	215	13	.	.	PROPN
ajlm-708	215	14	emergence	emergence	NOUN
ajlm-708	215	15	of	of	ADP
ajlm-708	215	16	minor	minor	ADJ
ajlm-708	215	17	populations	population	NOUN
ajlm-708	215	18	of	of	ADP
ajlm-708	215	19	human	human	ADJ
ajlm-708	215	20	immunodeficiency	immunodeficiency	NOUN
ajlm-708	215	21	virus	virus	NOUN
ajlm-708	215	22	type	type	NOUN
ajlm-708	215	23	1	1	NUM
ajlm-708	215	24	carrying	carry	VERB
ajlm-708	215	25	the	the	DET
ajlm-708	215	26	m184v	m184v	PROPN
ajlm-708	215	27	and	and	CCONJ
ajlm-708	215	28	l90	l90	PROPN
ajlm-708	215	29	m	m	PROPN
ajlm-708	215	30	mutations	mutation	NOUN
ajlm-708	215	31	in	in	ADP
ajlm-708	215	32	subjects	subject	NOUN
ajlm-708	215	33	undergoing	undergo	VERB
ajlm-708	215	34	structured	structured	ADJ
ajlm-708	215	35	treatment	treatment	NOUN
ajlm-708	215	36	interruptions	interruption	NOUN
ajlm-708	215	37	.	.	PUNCT
ajlm-708	216	1	j	j	PROPN
ajlm-708	216	2	infect	infect	VERB
ajlm-708	216	3	dis	dis	PROPN
ajlm-708	216	4	.	.	PUNCT
ajlm-708	217	1	2003;188(10):1433–1443	2003;188(10):1433–1443	X
ajlm-708	217	2	.	.	PUNCT
ajlm-708	218	1	https://doi.org/10.1086/379215	https://doi.org/10.1086/379215	VERB
ajlm-708	218	2	hare	hare	PROPN
ajlm-708	218	3	cb	cb	PROPN
ajlm-708	218	4	,	,	PUNCT
ajlm-708	218	5	mellors	mellors	PROPN
ajlm-708	218	6	j	j	PROPN
ajlm-708	218	7	,	,	PUNCT
ajlm-708	219	1	krambrink	krambrink	PROPN
ajlm-708	219	2	a	a	X
ajlm-708	219	3	,	,	PUNCT
ajlm-708	219	4	et	et	PROPN
ajlm-708	219	5	al	al	PROPN
ajlm-708	219	6	.	.	PUNCT
ajlm-708	219	7	detection	detection	NOUN
ajlm-708	219	8	of	of	ADP
ajlm-708	219	9	nonnucleoside	nonnucleoside	ADJ
ajlm-708	219	10	reverse	reverse	NOUN
ajlm-708	219	11	-	-	PUNCT
ajlm-708	219	12	transcriptase	transcriptase	NOUN
ajlm-708	219	13	inhibitor	inhibitor	NOUN
ajlm-708	219	14	-	-	PUNCT
ajlm-708	219	15	resistant	resistant	ADJ
ajlm-708	219	16	hiv-1	hiv-1	PUNCT
ajlm-708	219	17	after	after	ADP
ajlm-708	219	18	discontinuation	discontinuation	NOUN
ajlm-708	219	19	of	of	ADP
ajlm-708	219	20	virologically	virologically	ADV
ajlm-708	219	21	suppressive	suppressive	ADJ
ajlm-708	219	22	antiretroviral	antiretroviral	ADJ
ajlm-708	219	23	therapy	therapy	NOUN
ajlm-708	219	24	.	.	PUNCT
ajlm-708	220	1	clin	clin	PROPN
ajlm-708	220	2	infect	infect	PROPN
ajlm-708	220	3	dis	dis	PROPN
ajlm-708	220	4	.	.	PUNCT
ajlm-708	221	1	2008;47(3):421–424	2008;47(3):421–424	X
ajlm-708	221	2	.	.	PUNCT
ajlm-708	222	1	https://doi.org/10.1086/589867	https://doi.org/10.1086/589867	PRON
ajlm-708	222	2	martinez	martinez	PROPN
ajlm-708	222	3	-	-	PUNCT
ajlm-708	222	4	picado	picado	PROPN
ajlm-708	222	5	j	j	PROPN
ajlm-708	222	6	,	,	PUNCT
ajlm-708	222	7	morales	morales	PROPN
ajlm-708	222	8	-	-	PUNCT
ajlm-708	222	9	lopetegi	lopetegi	PROPN
ajlm-708	222	10	k	k	PROPN
ajlm-708	222	11	,	,	PUNCT
ajlm-708	222	12	wrin	wrin	NOUN
ajlm-708	222	13	t	t	PROPN
ajlm-708	222	14	,	,	PUNCT
ajlm-708	222	15	et	et	PROPN
ajlm-708	222	16	al	al	PROPN
ajlm-708	222	17	.	.	PROPN
ajlm-708	222	18	selection	selection	NOUN
ajlm-708	222	19	of	of	ADP
ajlm-708	222	20	drug	drug	NOUN
ajlm-708	222	21	-	-	PUNCT
ajlm-708	222	22	resistant	resistant	ADJ
ajlm-708	222	23	hiv-1	hiv-1	PUNCT
ajlm-708	222	24	mutants	mutant	NOUN
ajlm-708	222	25	in	in	ADP
ajlm-708	222	26	response	response	NOUN
ajlm-708	222	27	to	to	ADP
ajlm-708	222	28	repeated	repeat	VERB
ajlm-708	222	29	structured	structured	ADJ
ajlm-708	222	30	treatment	treatment	NOUN
ajlm-708	222	31	interruptions	interruption	NOUN
ajlm-708	222	32	.	.	PUNCT
ajlm-708	223	1	aids	aids	PROPN
ajlm-708	223	2	.	.	PUNCT
ajlm-708	224	1	2002;16(6):895–899	2002;16(6):895–899	NUM
ajlm-708	224	2	.	.	PUNCT
ajlm-708	225	1	https://doi.org/10.1097/00002030-200204120-00009	https://doi.org/10.1097/00002030-200204120-00009	PROPN
ajlm-708	225	2	le	le	PROPN
ajlm-708	225	3	t	t	PROPN
ajlm-708	225	4	,	,	PUNCT
ajlm-708	225	5	chiarella	chiarella	PROPN
ajlm-708	225	6	j	j	PROPN
ajlm-708	225	7	,	,	PUNCT
ajlm-708	225	8	simen	simen	PROPN
ajlm-708	225	9	bb	bb	PROPN
ajlm-708	225	10	,	,	PUNCT
ajlm-708	225	11	et	et	PROPN
ajlm-708	225	12	al	al	PROPN
ajlm-708	225	13	.	.	PUNCT
ajlm-708	225	14	low	low	ADJ
ajlm-708	225	15	-	-	PUNCT
ajlm-708	225	16	abundance	abundance	NOUN
ajlm-708	225	17	hiv	hiv	PROPN
ajlm-708	225	18	drug	drug	NOUN
ajlm-708	225	19	-	-	PUNCT
ajlm-708	225	20	resistant	resistant	ADJ
ajlm-708	225	21	viral	viral	ADJ
ajlm-708	225	22	variants	variant	NOUN
ajlm-708	225	23	in	in	ADP
ajlm-708	225	24	treatment	treatment	NOUN
ajlm-708	225	25	-	-	PUNCT
ajlm-708	225	26	experienced	experience	VERB
ajlm-708	225	27	persons	person	NOUN
ajlm-708	225	28	correlate	correlate	VERB
ajlm-708	225	29	with	with	ADP
ajlm-708	225	30	historical	historical	ADJ
ajlm-708	225	31	antiretroviral	antiretroviral	ADJ
ajlm-708	225	32	use	use	NOUN
ajlm-708	225	33	.	.	PUNCT
ajlm-708	226	1	plos	plos	PROPN
ajlm-708	226	2	one	one	NUM
ajlm-708	226	3	.	.	PUNCT
ajlm-708	227	1	2009;4(6):e6079	2009;4(6):e6079	NUM
ajlm-708	227	2	.	.	PUNCT
ajlm-708	228	1	https://doi.org/10.1371/journal.pone.0006079	https://doi.org/10.1371/journal.pone.0006079	PROPN
ajlm-708	228	2	wang	wang	PROPN
ajlm-708	228	3	c	c	PROPN
ajlm-708	228	4	,	,	PUNCT
ajlm-708	228	5	mitsuya	mitsuya	PROPN
ajlm-708	228	6	y	y	PROPN
ajlm-708	228	7	,	,	PUNCT
ajlm-708	228	8	gharizadeh	gharizadeh	VERB
ajlm-708	228	9	b	b	X
ajlm-708	228	10	,	,	PUNCT
ajlm-708	228	11	et	et	PROPN
ajlm-708	228	12	al	al	PROPN
ajlm-708	228	13	.	.	PUNCT
ajlm-708	228	14	characterization	characterization	NOUN
ajlm-708	228	15	of	of	ADP
ajlm-708	228	16	mutation	mutation	NOUN
ajlm-708	228	17	spectra	spectra	NOUN
ajlm-708	228	18	with	with	ADP
ajlm-708	228	19	ultra	ultra	ADJ
ajlm-708	228	20	-	-	ADJ
ajlm-708	228	21	deep	deep	ADJ
ajlm-708	228	22	pyrosequencing	pyrosequencing	NOUN
ajlm-708	228	23	:	:	PUNCT
ajlm-708	228	24	application	application	NOUN
ajlm-708	228	25	to	to	ADP
ajlm-708	228	26	hiv-1	hiv-1	PUNCT
ajlm-708	228	27	drug	drug	NOUN
ajlm-708	228	28	resistance	resistance	NOUN
ajlm-708	228	29	.	.	PUNCT
ajlm-708	229	1	genome	genome	NOUN
ajlm-708	229	2	res	re	NOUN
ajlm-708	229	3	.	.	PUNCT
ajlm-708	230	1	2007;17(8):1195–1201	2007;17(8):1195–1201	NUM
ajlm-708	230	2	.	.	PUNCT
ajlm-708	231	1	https://doi.org/10.1101/gr.6468307	https://doi.org/10.1101/gr.6468307	DET
ajlm-708	231	2	hoffmann	hoffmann	PROPN
ajlm-708	231	3	c	c	PROPN
ajlm-708	231	4	,	,	PUNCT
ajlm-708	231	5	minkah	minkah	PROPN
ajlm-708	231	6	n	n	CCONJ
ajlm-708	231	7	,	,	PUNCT
ajlm-708	231	8	leipzig	leipzig	PROPN
ajlm-708	231	9	j	j	PROPN
ajlm-708	231	10	,	,	PUNCT
ajlm-708	231	11	et	et	PROPN
ajlm-708	231	12	al	al	PROPN
ajlm-708	231	13	.	.	PROPN
ajlm-708	231	14	dna	dna	PROPN
ajlm-708	231	15	bar	bar	NOUN
ajlm-708	231	16	coding	coding	NOUN
ajlm-708	231	17	and	and	CCONJ
ajlm-708	231	18	pyrosequencing	pyrosequence	VERB
ajlm-708	231	19	to	to	PART
ajlm-708	231	20	identify	identify	VERB
ajlm-708	231	21	rare	rare	ADJ
ajlm-708	231	22	hiv	hiv	PROPN
ajlm-708	231	23	drug	drug	NOUN
ajlm-708	231	24	resistance	resistance	NOUN
ajlm-708	231	25	mutations	mutation	NOUN
ajlm-708	231	26	.	.	PUNCT
ajlm-708	232	1	nucleic	nucleic	ADJ
ajlm-708	232	2	acids	acid	NOUN
ajlm-708	232	3	res	re	NOUN
ajlm-708	232	4	.	.	PUNCT
ajlm-708	233	1	2007;35(13):e91	2007;35(13):e91	NUM
ajlm-708	233	2	.	.	PUNCT
ajlm-708	234	1	https://doi.org/10.1093/nar/gkm435	https://doi.org/10.1093/nar/gkm435	PROPN
ajlm-708	234	2	hedskog	hedskog	VERB
ajlm-708	234	3	c	c	NOUN
ajlm-708	234	4	,	,	PUNCT
ajlm-708	234	5	mild	mild	ADJ
ajlm-708	234	6	m	m	NOUN
ajlm-708	234	7	,	,	PUNCT
ajlm-708	234	8	jernberg	jernberg	PROPN
ajlm-708	234	9	j	j	PROPN
ajlm-708	234	10	,	,	PUNCT
ajlm-708	234	11	et	et	PROPN
ajlm-708	234	12	al	al	PROPN
ajlm-708	234	13	.	.	PUNCT
ajlm-708	235	1	dynamics	dynamic	NOUN
ajlm-708	235	2	of	of	ADP
ajlm-708	235	3	hiv-1	hiv-1	X
ajlm-708	235	4	quasispecies	quasispecie	NOUN
ajlm-708	235	5	during	during	ADP
ajlm-708	235	6	antiviral	antiviral	ADJ
ajlm-708	235	7	treatment	treatment	NOUN
ajlm-708	235	8	dissected	dissect	VERB
ajlm-708	235	9	using	use	VERB
ajlm-708	235	10	ultra	ultra	ADJ
ajlm-708	235	11	-	-	ADJ
ajlm-708	235	12	deep	deep	ADJ
ajlm-708	235	13	pyrosequencing	pyrosequencing	NOUN
ajlm-708	235	14	.	.	PUNCT
ajlm-708	236	1	plos	plos	PROPN
ajlm-708	236	2	one	one	NUM
ajlm-708	236	3	.	.	PUNCT
ajlm-708	237	1	2010;5(7):e11345	2010;5(7):e11345	NUM
ajlm-708	237	2	.	.	PUNCT
ajlm-708	237	3	https://doi.org/10.1371/journal.pone.0011345	https://doi.org/10.1371/journal.pone.0011345	PROPN
ajlm-708	237	4	dudley	dudley	PROPN
ajlm-708	238	1	dm	dm	PROPN
ajlm-708	238	2	,	,	PUNCT
ajlm-708	238	3	chin	chin	PROPN
ajlm-708	238	4	en	en	PROPN
ajlm-708	238	5	,	,	PUNCT
ajlm-708	238	6	bimber	bimber	PROPN
ajlm-708	238	7	bn	bn	PROPN
ajlm-708	238	8	,	,	PUNCT
ajlm-708	238	9	et	et	PROPN
ajlm-708	238	10	al	al	PROPN
ajlm-708	238	11	.	.	PUNCT
ajlm-708	238	12	low	low	ADJ
ajlm-708	238	13	-	-	PUNCT
ajlm-708	238	14	cost	cost	NOUN
ajlm-708	238	15	ultra	ultra	ADJ
ajlm-708	238	16	-	-	ADJ
ajlm-708	238	17	wide	wide	ADJ
ajlm-708	238	18	genotyping	genotyping	NOUN
ajlm-708	238	19	using	use	VERB
ajlm-708	238	20	roche/454	roche/454	NOUN
ajlm-708	238	21	pyrosequencing	pyrosequence	VERB
ajlm-708	238	22	for	for	ADP
ajlm-708	238	23	surveillance	surveillance	NOUN
ajlm-708	238	24	of	of	ADP
ajlm-708	238	25	hiv	hiv	PROPN
ajlm-708	238	26	drug	drug	NOUN
ajlm-708	238	27	resistance	resistance	NOUN
ajlm-708	238	28	.	.	PUNCT
ajlm-708	239	1	plos	plos	PROPN
ajlm-708	239	2	one	one	NUM
ajlm-708	239	3	.	.	PUNCT
ajlm-708	240	1	2012;7(5):e36494	2012;7(5):e36494	NOUN
ajlm-708	240	2	.	.	PUNCT
ajlm-708	241	1	https://doi.org/10.1371/journal.pone.0036494	https://doi.org/10.1371/journal.pone.0036494	NOUN
ajlm-708	241	2	zagordi	zagordi	NOUN
ajlm-708	241	3	o	o	NOUN
ajlm-708	241	4	,	,	PUNCT
ajlm-708	241	5	klein	klein	PROPN
ajlm-708	241	6	r	r	PROPN
ajlm-708	241	7	,	,	PUNCT
ajlm-708	241	8	daumer	daumer	NOUN
ajlm-708	241	9	m	m	PROPN
ajlm-708	241	10	,	,	PUNCT
ajlm-708	241	11	et	et	PROPN
ajlm-708	241	12	al	al	PROPN
ajlm-708	241	13	.	.	PROPN
ajlm-708	241	14	error	error	NOUN
ajlm-708	241	15	correction	correction	NOUN
ajlm-708	241	16	of	of	ADP
ajlm-708	241	17	next	next	ADJ
ajlm-708	241	18	-	-	PUNCT
ajlm-708	241	19	generation	generation	NOUN
ajlm-708	241	20	sequencing	sequence	VERB
ajlm-708	241	21	data	datum	NOUN
ajlm-708	241	22	and	and	CCONJ
ajlm-708	241	23	reliable	reliable	ADJ
ajlm-708	241	24	estimation	estimation	NOUN
ajlm-708	241	25	of	of	ADP
ajlm-708	241	26	hiv	hiv	PROPN
ajlm-708	241	27	quasispecies	quasispecie	NOUN
ajlm-708	241	28	.	.	PUNCT
ajlm-708	242	1	nucleic	nucleic	ADJ
ajlm-708	242	2	acids	acid	NOUN
ajlm-708	242	3	res	re	NOUN
ajlm-708	242	4	.	.	PUNCT
ajlm-708	242	5	2010;38(21):7400–7409	2010;38(21):7400–7409	NUM
ajlm-708	242	6	.	.	PUNCT
ajlm-708	243	1	https://doi.org/10.1093/nar/gkq655	https://doi.org/10.1093/nar/gkq655	PROPN
ajlm-708	243	2	wadonda	wadonda	PROPN
ajlm-708	243	3	-	-	PUNCT
ajlm-708	243	4	kabondo	kabondo	NOUN
ajlm-708	243	5	n	n	CCONJ
ajlm-708	243	6	,	,	PUNCT
ajlm-708	243	7	bennett	bennett	PROPN
ajlm-708	243	8	d	d	PROPN
ajlm-708	243	9	,	,	PUNCT
ajlm-708	243	10	van	van	PROPN
ajlm-708	243	11	oosterhout	oosterhout	PROPN
ajlm-708	243	12	jj	jj	PROPN
ajlm-708	243	13	,	,	PUNCT
ajlm-708	243	14	et	et	PROPN
ajlm-708	243	15	al	al	PROPN
ajlm-708	243	16	.	.	PUNCT
ajlm-708	244	1	prevalence	prevalence	NOUN
ajlm-708	244	2	of	of	ADP
ajlm-708	244	3	hiv	hiv	PROPN
ajlm-708	244	4	drug	drug	NOUN
ajlm-708	244	5	resistance	resistance	NOUN
ajlm-708	244	6	before	before	ADP
ajlm-708	244	7	and	and	CCONJ
ajlm-708	244	8	1	1	NUM
ajlm-708	244	9	year	year	NOUN
ajlm-708	244	10	after	after	ADP
ajlm-708	244	11	treatment	treatment	NOUN
ajlm-708	244	12	initiation	initiation	NOUN
ajlm-708	244	13	in	in	ADP
ajlm-708	244	14	4	4	NUM
ajlm-708	244	15	sites	site	NOUN
ajlm-708	244	16	in	in	ADP
ajlm-708	244	17	the	the	DET
ajlm-708	244	18	malawi	malawi	PROPN
ajlm-708	244	19	antiretroviral	antiretroviral	ADJ
ajlm-708	244	20	treatment	treatment	NOUN
ajlm-708	244	21	program	program	NOUN
ajlm-708	244	22	.	.	PUNCT
ajlm-708	245	1	clin	clin	PROPN
ajlm-708	245	2	infect	infect	PROPN
ajlm-708	245	3	dis	dis	PROPN
ajlm-708	245	4	.	.	PUNCT
ajlm-708	246	1	2012;54(suppl	2012;54(suppl	PROPN
ajlm-708	246	2	4):s362	4):s362	NUM
ajlm-708	246	3	–	–	PUNCT
ajlm-708	246	4	s368	s368	PROPN
ajlm-708	246	5	.	.	PUNCT
ajlm-708	247	1	https://doi.org/10.1093/cid/cir987	https://doi.org/10.1093/cid/cir987	PROPN
ajlm-708	247	2	johnson	johnson	PROPN
ajlm-708	247	3	va	va	PROPN
ajlm-708	247	4	,	,	PUNCT
ajlm-708	247	5	calvez	calvez	NOUN
ajlm-708	247	6	v	v	NOUN
ajlm-708	247	7	,	,	PUNCT
ajlm-708	247	8	gunthard	gunthard	NOUN
ajlm-708	247	9	hf	hf	NOUN
ajlm-708	247	10	,	,	PUNCT
ajlm-708	247	11	et	et	PROPN
ajlm-708	247	12	al	al	PROPN
ajlm-708	247	13	.	.	PROPN
ajlm-708	247	14	2011	2011	NUM
ajlm-708	247	15	update	update	NOUN
ajlm-708	247	16	of	of	ADP
ajlm-708	247	17	the	the	DET
ajlm-708	247	18	drug	drug	NOUN
ajlm-708	247	19	resistance	resistance	NOUN
ajlm-708	247	20	mutations	mutation	NOUN
ajlm-708	247	21	in	in	ADP
ajlm-708	247	22	hiv-1	hiv-1	ADJ
ajlm-708	247	23	.	.	PUNCT
ajlm-708	248	1	top	top	ADJ
ajlm-708	248	2	antivir	antivir	PROPN
ajlm-708	248	3	med	med	PROPN
ajlm-708	248	4	.	.	PUNCT
ajlm-708	249	1	2011;19(4):156–164	2011;19(4):156–164	NOUN
ajlm-708	249	2	.	.	PUNCT
ajlm-708	250	1	bennett	bennett	PROPN
ajlm-708	250	2	de	de	PROPN
ajlm-708	250	3	,	,	PUNCT
ajlm-708	250	4	camacho	camacho	PROPN
ajlm-708	250	5	rj	rj	PROPN
ajlm-708	250	6	,	,	PUNCT
ajlm-708	250	7	otelea	otelea	PROPN
ajlm-708	250	8	d	d	PROPN
ajlm-708	250	9	,	,	PUNCT
ajlm-708	250	10	et	et	PROPN
ajlm-708	250	11	al	al	PROPN
ajlm-708	250	12	.	.	PROPN
ajlm-708	250	13	drug	drug	PROPN
ajlm-708	250	14	resistance	resistance	NOUN
ajlm-708	250	15	mutations	mutation	NOUN
ajlm-708	250	16	for	for	ADP
ajlm-708	250	17	surveillance	surveillance	NOUN
ajlm-708	250	18	of	of	ADP
ajlm-708	250	19	transmitted	transmit	VERB
ajlm-708	250	20	hiv-1	hiv-1	X
ajlm-708	250	21	drug	drug	NOUN
ajlm-708	250	22	-	-	PUNCT
ajlm-708	250	23	resistance	resistance	NOUN
ajlm-708	250	24	:	:	PUNCT
ajlm-708	250	25	2009	2009	NUM
ajlm-708	250	26	update	update	NOUN
ajlm-708	250	27	.	.	PUNCT
ajlm-708	251	1	plos	plos	PROPN
ajlm-708	251	2	one	one	NUM
ajlm-708	251	3	.	.	PUNCT
ajlm-708	252	1	2009;4(3):e4724	2009;4(3):e4724	NOUN
ajlm-708	252	2	.	.	PUNCT
ajlm-708	253	1	https://doi.org/10.1371/journal.pone.0004724	https://doi.org/10.1371/journal.pone.0004724	PROPN
ajlm-708	253	2	harrigan	harrigan	PROPN
ajlm-708	253	3	pr	pr	PROPN
ajlm-708	253	4	,	,	PUNCT
ajlm-708	253	5	dong	dong	PROPN
ajlm-708	253	6	w	w	PROPN
ajlm-708	253	7	,	,	PUNCT
ajlm-708	253	8	wynhoven	wynhoven	PROPN
ajlm-708	253	9	b	b	NOUN
ajlm-708	253	10	,	,	PUNCT
ajlm-708	253	11	et	et	PROPN
ajlm-708	253	12	al	al	PROPN
ajlm-708	253	13	.	.	PUNCT
ajlm-708	254	1	performance	performance	NOUN
ajlm-708	254	2	of	of	ADP
ajlm-708	254	3	recall	recall	NOUN
ajlm-708	254	4	basecalling	basecalle	VERB
ajlm-708	254	5	software	software	NOUN
ajlm-708	254	6	for	for	ADP
ajlm-708	254	7	high	high	ADJ
ajlm-708	254	8	-	-	PUNCT
ajlm-708	254	9	throughput	throughput	NOUN
ajlm-708	254	10	hiv	hiv	PROPN
ajlm-708	254	11	drug	drug	NOUN
ajlm-708	254	12	resistance	resistance	NOUN
ajlm-708	254	13	basecalling	basecalle	VERB
ajlm-708	254	14	using	use	VERB
ajlm-708	254	15	“	"	PUNCT
ajlm-708	254	16	in	in	ADP
ajlm-708	254	17	-	-	PUNCT
ajlm-708	254	18	house	house	NOUN
ajlm-708	254	19	”	"	PUNCT
ajlm-708	254	20	methods	method	NOUN
ajlm-708	254	21	.	.	PUNCT
ajlm-708	255	1	the	the	DET
ajlm-708	255	2	xiv	xiv	PROPN
ajlm-708	255	3	international	international	PROPN
ajlm-708	255	4	aids	aids	PROPN
ajlm-708	255	5	conference	conference	NOUN
ajlm-708	255	6	;	;	PUNCT
ajlm-708	255	7	2002	2002	NUM
ajlm-708	255	8	jul	jul	PROPN
ajlm-708	255	9	7–12	7–12	PROPN
ajlm-708	255	10	;	;	PUNCT
ajlm-708	255	11	barcelona	barcelona	PROPN
ajlm-708	255	12	,	,	PUNCT
ajlm-708	255	13	spain	spain	PROPN
ajlm-708	255	14	.	.	PUNCT
ajlm-708	256	1	abstract	abstract	ADJ
ajlm-708	256	2	#	#	SYM
ajlm-708	256	3	tupeb4598	tupeb4598	NOUN
ajlm-708	256	4	.	.	PUNCT
ajlm-708	257	1	who	who	PRON
ajlm-708	257	2	.	.	PUNCT
ajlm-708	258	1	consolidated	consolidated	ADJ
ajlm-708	258	2	guidelines	guideline	NOUN
ajlm-708	258	3	on	on	ADP
ajlm-708	258	4	the	the	DET
ajlm-708	258	5	use	use	NOUN
ajlm-708	258	6	of	of	ADP
ajlm-708	258	7	antiretroviral	antiretroviral	ADJ
ajlm-708	258	8	drugs	drug	NOUN
ajlm-708	258	9	for	for	ADP
ajlm-708	258	10	treating	treat	VERB
ajlm-708	258	11	and	and	CCONJ
ajlm-708	258	12	preventing	prevent	VERB
ajlm-708	258	13	hiv	hiv	PROPN
ajlm-708	258	14	infection	infection	NOUN
ajlm-708	258	15	:	:	PUNCT
ajlm-708	258	16	recommendations	recommendation	NOUN
ajlm-708	258	17	for	for	ADP
ajlm-708	258	18	a	a	DET
ajlm-708	258	19	public	public	ADJ
ajlm-708	258	20	health	health	NOUN
ajlm-708	258	21	approach	approach	NOUN
ajlm-708	258	22	;	;	PUNCT
ajlm-708	258	23	2013	2013	NUM
ajlm-708	258	24	;	;	PUNCT
ajlm-708	258	25	p.	p.	PROPN
ajlm-708	258	26	1–272	1–272	PROPN
ajlm-708	258	27	.	.	PUNCT
ajlm-708	259	1	geneva	geneva	PROPN
ajlm-708	259	2	,	,	PUNCT
ajlm-708	259	3	switzerland	switzerland	PROPN
ajlm-708	259	4	:	:	PUNCT
ajlm-708	259	5	world	world	PROPN
ajlm-708	259	6	health	health	PROPN
ajlm-708	259	7	organization	organization	PROPN
ajlm-708	259	8	.	.	PUNCT
ajlm-708	260	1	zhang	zhang	PROPN
ajlm-708	260	2	g	g	PROPN
ajlm-708	260	3	,	,	PUNCT
ajlm-708	260	4	cai	cai	PROPN
ajlm-708	260	5	f	f	X
ajlm-708	260	6	,	,	PUNCT
ajlm-708	260	7	de	de	PROPN
ajlm-708	260	8	rivera	rivera	PROPN
ajlm-708	260	9	il	il	PROPN
ajlm-708	260	10	,	,	PUNCT
ajlm-708	260	11	et	et	PROPN
ajlm-708	260	12	al	al	PROPN
ajlm-708	260	13	.	.	PUNCT
ajlm-708	261	1	simultaneous	simultaneous	ADJ
ajlm-708	261	2	detection	detection	NOUN
ajlm-708	261	3	of	of	ADP
ajlm-708	261	4	major	major	ADJ
ajlm-708	261	5	drug	drug	NOUN
ajlm-708	261	6	resistance	resistance	NOUN
ajlm-708	261	7	mutations	mutation	NOUN
ajlm-708	261	8	of	of	ADP
ajlm-708	261	9	hiv-1	hiv-1	X
ajlm-708	261	10	subtype	subtype	NOUN
ajlm-708	261	11	b	b	NOUN
ajlm-708	261	12	viruses	virus	NOUN
ajlm-708	261	13	from	from	ADP
ajlm-708	261	14	dried	dry	VERB
ajlm-708	261	15	blood	blood	NOUN
ajlm-708	261	16	spot	spot	NOUN
ajlm-708	261	17	specimens	specimen	NOUN
ajlm-708	261	18	by	by	ADP
ajlm-708	261	19	multiplex	multiplex	PROPN
ajlm-708	261	20	allele	allele	PROPN
ajlm-708	261	21	-	-	PUNCT
ajlm-708	261	22	specific	specific	NOUN
ajlm-708	261	23	assay	assay	NOUN
ajlm-708	261	24	.	.	PUNCT
ajlm-708	262	1	j	j	PROPN
ajlm-708	262	2	clin	clin	PROPN
ajlm-708	262	3	microbiol	microbiol	PROPN
ajlm-708	262	4	.	.	PUNCT
ajlm-708	263	1	2016;54(1):220–222	2016;54(1):220–222	PROPN
ajlm-708	263	2	.	.	PUNCT
ajlm-708	264	1	https://doi.org/10.1128/jcm.02833-15	https://doi.org/10.1128/jcm.02833-15	PROPN
ajlm-708	264	2	avidor	avidor	PROPN
ajlm-708	264	3	b	b	PROPN
ajlm-708	264	4	,	,	PUNCT
ajlm-708	264	5	girshengorn	girshengorn	PROPN
ajlm-708	264	6	s	s	PROPN
ajlm-708	264	7	,	,	PUNCT
ajlm-708	264	8	matus	matus	PROPN
ajlm-708	264	9	n	n	CCONJ
ajlm-708	264	10	,	,	PUNCT
ajlm-708	264	11	et	et	PROPN
ajlm-708	264	12	al	al	PROPN
ajlm-708	264	13	.	.	PUNCT
ajlm-708	264	14	evaluation	evaluation	NOUN
ajlm-708	264	15	of	of	ADP
ajlm-708	264	16	a	a	DET
ajlm-708	264	17	benchtop	benchtop	NOUN
ajlm-708	264	18	hiv	hiv	PROPN
ajlm-708	264	19	ultradeep	ultradeep	ADJ
ajlm-708	264	20	pyrosequencing	pyrosequence	VERB
ajlm-708	264	21	drug	drug	NOUN
ajlm-708	264	22	resistance	resistance	NOUN
ajlm-708	264	23	assay	assay	VERB
ajlm-708	264	24	in	in	ADP
ajlm-708	264	25	the	the	DET
ajlm-708	264	26	clinical	clinical	ADJ
ajlm-708	264	27	laboratory	laboratory	NOUN
ajlm-708	264	28	.	.	PUNCT
ajlm-708	265	1	j	j	PROPN
ajlm-708	265	2	clin	clin	PROPN
ajlm-708	265	3	microbiol	microbiol	PROPN
ajlm-708	265	4	.	.	PUNCT
ajlm-708	266	1	2013;51(3):880–886	2013;51(3):880–886	NUM
ajlm-708	266	2	.	.	PUNCT
ajlm-708	267	1	https://doi.org/10.1128/jcm.02652-12	https://doi.org/10.1128/jcm.02652-12	NOUN
ajlm-708	267	2	mitsuya	mitsuya	PROPN
ajlm-708	267	3	y	y	PROPN
ajlm-708	267	4	,	,	PUNCT
ajlm-708	267	5	varghese	varghese	PROPN
ajlm-708	267	6	v	v	PROPN
ajlm-708	267	7	,	,	PUNCT
ajlm-708	267	8	wang	wang	PROPN
ajlm-708	267	9	c	c	PROPN
ajlm-708	267	10	,	,	PUNCT
ajlm-708	267	11	et	et	PROPN
ajlm-708	267	12	al	al	PROPN
ajlm-708	267	13	.	.	PROPN
ajlm-708	268	1	minority	minority	PROPN
ajlm-708	268	2	human	human	ADJ
ajlm-708	268	3	immunodeficiency	immunodeficiency	NOUN
ajlm-708	268	4	virus	virus	NOUN
ajlm-708	268	5	type	type	VERB
ajlm-708	268	6	1	1	NUM
ajlm-708	268	7	variants	variant	NOUN
ajlm-708	268	8	in	in	ADP
ajlm-708	268	9	antiretroviral	antiretroviral	ADJ
ajlm-708	268	10	-	-	PUNCT
ajlm-708	268	11	naive	naive	ADJ
ajlm-708	268	12	persons	person	NOUN
ajlm-708	268	13	with	with	ADP
ajlm-708	268	14	reverse	reverse	ADJ
ajlm-708	268	15	transcriptase	transcriptase	NOUN
ajlm-708	268	16	codon	codon	NOUN
ajlm-708	268	17	215	215	NUM
ajlm-708	268	18	revertant	revertant	ADJ
ajlm-708	268	19	mutations	mutation	NOUN
ajlm-708	268	20	.	.	PUNCT
ajlm-708	269	1	j	j	PROPN
ajlm-708	269	2	virol	virol	PROPN
ajlm-708	269	3	.	.	PUNCT
ajlm-708	270	1	2008;82(21):10747–10755	2008;82(21):10747–10755	NUM
ajlm-708	270	2	.	.	PUNCT
ajlm-708	271	1	https://doi.org/10.1128/jvi.01827-07	https://doi.org/10.1128/jvi.01827-07	PROPN
ajlm-708	271	2	varghese	varghese	PROPN
ajlm-708	271	3	v	v	PROPN
ajlm-708	271	4	,	,	PUNCT
ajlm-708	271	5	wang	wang	PROPN
ajlm-708	271	6	e	e	PROPN
ajlm-708	271	7	,	,	PUNCT
ajlm-708	271	8	babrzadeh	babrzadeh	PROPN
ajlm-708	271	9	f	f	X
ajlm-708	271	10	,	,	PUNCT
ajlm-708	271	11	et	et	PROPN
ajlm-708	271	12	al	al	PROPN
ajlm-708	271	13	.	.	PROPN
ajlm-708	271	14	nucleic	nucleic	ADJ
ajlm-708	271	15	acid	acid	NOUN
ajlm-708	271	16	template	template	NOUN
ajlm-708	271	17	and	and	CCONJ
ajlm-708	271	18	the	the	DET
ajlm-708	271	19	risk	risk	NOUN
ajlm-708	271	20	of	of	ADP
ajlm-708	271	21	a	a	DET
ajlm-708	271	22	pcr	pcr	NOUN
ajlm-708	271	23	-	-	PUNCT
ajlm-708	271	24	induced	induce	VERB
ajlm-708	271	25	hiv-1	hiv-1	X
ajlm-708	271	26	drug	drug	NOUN
ajlm-708	271	27	resistance	resistance	NOUN
ajlm-708	271	28	mutation	mutation	NOUN
ajlm-708	271	29	.	.	PUNCT
ajlm-708	272	1	plos	plos	PROPN
ajlm-708	272	2	one	one	NUM
ajlm-708	272	3	.	.	PUNCT
ajlm-708	273	1	2010;5(6):e10992	2010;5(6):e10992	NUM
ajlm-708	273	2	.	.	PUNCT
ajlm-708	273	3	https://doi.org/10.1371/journal.pone.0010992	https://doi.org/10.1371/journal.pone.0010992	PROPN
ajlm-708	273	4	larsen	larsen	PROPN
ajlm-708	273	5	bb	bb	PROPN
ajlm-708	273	6	,	,	PUNCT
ajlm-708	273	7	deng	deng	PROPN
ajlm-708	273	8	w	w	PROPN
ajlm-708	273	9	,	,	PUNCT
ajlm-708	273	10	maust	maust	PROPN
ajlm-708	273	11	b	b	NOUN
ajlm-708	273	12	,	,	PUNCT
ajlm-708	273	13	et	et	PROPN
ajlm-708	273	14	al	al	PROPN
ajlm-708	273	15	.	.	PUNCT
ajlm-708	274	1	the	the	DET
ajlm-708	274	2	sensitivity	sensitivity	NOUN
ajlm-708	274	3	of	of	ADP
ajlm-708	274	4	hiv	hiv	PROPN
ajlm-708	274	5	deep	deep	ADJ
ajlm-708	274	6	sequencing	sequencing	NOUN
ajlm-708	274	7	.	.	PUNCT
ajlm-708	275	1	19th	19th	ADJ
ajlm-708	275	2	conference	conference	NOUN
ajlm-708	275	3	on	on	ADP
ajlm-708	275	4	retroviruses	retrovirus	NOUN
ajlm-708	275	5	and	and	CCONJ
ajlm-708	275	6	opportunistic	opportunistic	ADJ
ajlm-708	275	7	infections	infection	NOUN
ajlm-708	275	8	;	;	PUNCT
ajlm-708	275	9	seattle	seattle	PROPN
ajlm-708	275	10	,	,	PUNCT
ajlm-708	275	11	wa	wa	PROPN
ajlm-708	275	12	;	;	PUNCT
ajlm-708	275	13	march	march	PROPN
ajlm-708	275	14	5–8	5–8	NUM
ajlm-708	275	15	,	,	PUNCT
ajlm-708	275	16	2012	2012	NUM
ajlm-708	275	17	.	.	PUNCT
ajlm-708	276	1	paper	paper	NOUN
ajlm-708	276	2	#	#	SYM
ajlm-708	276	3	544	544	NUM
ajlm-708	276	4	.	.	PUNCT
ajlm-708	277	1	shafer	shafer	PROPN
ajlm-708	277	2	rw	rw	PROPN
ajlm-708	277	3	.	.	PUNCT
ajlm-708	277	4	low	low	ADJ
ajlm-708	277	5	-	-	PUNCT
ajlm-708	277	6	abundance	abundance	NOUN
ajlm-708	277	7	drug	drug	NOUN
ajlm-708	277	8	-	-	PUNCT
ajlm-708	277	9	resistant	resistant	ADJ
ajlm-708	277	10	hiv-1	hiv-1	PUNCT
ajlm-708	277	11	variants	variant	NOUN
ajlm-708	277	12	:	:	PUNCT
ajlm-708	277	13	finding	find	VERB
ajlm-708	277	14	significance	significance	NOUN
ajlm-708	277	15	in	in	ADP
ajlm-708	277	16	an	an	DET
ajlm-708	277	17	era	era	NOUN
ajlm-708	277	18	of	of	ADP
ajlm-708	277	19	abundant	abundant	ADJ
ajlm-708	277	20	diagnostic	diagnostic	ADJ
ajlm-708	277	21	and	and	CCONJ
ajlm-708	277	22	therapeutic	therapeutic	ADJ
ajlm-708	277	23	options	option	NOUN
ajlm-708	277	24	.	.	PUNCT
ajlm-708	278	1	j	j	PROPN
ajlm-708	278	2	infect	infect	VERB
ajlm-708	278	3	dis	dis	PROPN
ajlm-708	278	4	.	.	PUNCT
ajlm-708	279	1	2009;199(5):610–612	2009;199(5):610–612	NUM
ajlm-708	279	2	.	.	PUNCT
ajlm-708	279	3	https://doi.org/10.1086/596737	https://doi.org/10.1086/596737	NUM
ajlm-708	279	4	gianella	gianella	PROPN
ajlm-708	279	5	s	s	PART
ajlm-708	279	6	,	,	PUNCT
ajlm-708	279	7	delport	delport	PROPN
ajlm-708	279	8	w	w	PROPN
ajlm-708	279	9	,	,	PUNCT
ajlm-708	279	10	pacold	pacold	VERB
ajlm-708	279	11	me	i	PRON
ajlm-708	279	12	,	,	PUNCT
ajlm-708	279	13	et	et	PROPN
ajlm-708	279	14	al	al	PROPN
ajlm-708	279	15	.	.	PUNCT
ajlm-708	279	16	detection	detection	NOUN
ajlm-708	279	17	of	of	ADP
ajlm-708	279	18	minority	minority	NOUN
ajlm-708	279	19	resistance	resistance	NOUN
ajlm-708	279	20	during	during	ADP
ajlm-708	279	21	early	early	ADJ
ajlm-708	279	22	hiv-1	hiv-1	ADJ
ajlm-708	279	23	infection	infection	NOUN
ajlm-708	279	24	:	:	PUNCT
ajlm-708	279	25	natural	natural	ADJ
ajlm-708	279	26	variation	variation	NOUN
ajlm-708	279	27	and	and	CCONJ
ajlm-708	279	28	spurious	spurious	ADJ
ajlm-708	279	29	detection	detection	NOUN
ajlm-708	279	30	rather	rather	ADV
ajlm-708	279	31	than	than	ADP
ajlm-708	279	32	transmission	transmission	NOUN
ajlm-708	279	33	and	and	CCONJ
ajlm-708	279	34	evolution	evolution	NOUN
ajlm-708	279	35	of	of	ADP
ajlm-708	279	36	multiple	multiple	ADJ
ajlm-708	279	37	viral	viral	ADJ
ajlm-708	279	38	variants	variant	NOUN
ajlm-708	279	39	.	.	PUNCT
ajlm-708	280	1	j	j	PROPN
ajlm-708	280	2	virol	virol	NOUN
ajlm-708	280	3	.	.	PUNCT
ajlm-708	281	1	2011;85(16):8359–8367	2011;85(16):8359–8367	X
ajlm-708	281	2	.	.	PUNCT
ajlm-708	282	1	https://doi.org/10.1128/jvi.02582-10	https://doi.org/10.1128/jvi.02582-10	PROPN
ajlm-708	282	2	johnson	johnson	PROPN
ajlm-708	282	3	va	va	PROPN
ajlm-708	282	4	,	,	PUNCT
ajlm-708	282	5	brun	brun	NOUN
ajlm-708	282	6	-	-	PUNCT
ajlm-708	282	7	vezinet	vezinet	ADJ
ajlm-708	282	8	f	f	NOUN
ajlm-708	282	9	,	,	PUNCT
ajlm-708	282	10	clotet	clotet	PROPN
ajlm-708	282	11	b	b	PROPN
ajlm-708	282	12	,	,	PUNCT
ajlm-708	282	13	et	et	PROPN
ajlm-708	282	14	al	al	PROPN
ajlm-708	282	15	.	.	PUNCT
ajlm-708	282	16	update	update	NOUN
ajlm-708	282	17	of	of	ADP
ajlm-708	282	18	the	the	DET
ajlm-708	282	19	drug	drug	NOUN
ajlm-708	282	20	resistance	resistance	NOUN
ajlm-708	282	21	mutations	mutation	NOUN
ajlm-708	282	22	in	in	ADP
ajlm-708	282	23	hiv-1	hiv-1	ADV
ajlm-708	282	24	:	:	PUNCT
ajlm-708	282	25	spring	spring	NOUN
ajlm-708	282	26	2008	2008	NUM
ajlm-708	282	27	.	.	PUNCT
ajlm-708	283	1	top	top	ADJ
ajlm-708	283	2	hiv	hiv	PROPN
ajlm-708	283	3	med	me	VERB
ajlm-708	283	4	.	.	PUNCT
ajlm-708	284	1	2008;16(1):62–68	2008;16(1):62–68	X
ajlm-708	284	2	.	.	PUNCT
ajlm-708	284	3	kozal	kozal	PROPN
ajlm-708	284	4	mj	mj	PROPN
ajlm-708	284	5	,	,	PUNCT
ajlm-708	284	6	chiarella	chiarella	PROPN
ajlm-708	284	7	j	j	PROPN
ajlm-708	284	8	,	,	PUNCT
ajlm-708	284	9	st	st	PROPN
ajlm-708	284	10	john	john	PROPN
ajlm-708	284	11	ep	ep	PROPN
ajlm-708	284	12	,	,	PUNCT
ajlm-708	284	13	et	et	PROPN
ajlm-708	284	14	al	al	PROPN
ajlm-708	284	15	.	.	PUNCT
ajlm-708	285	1	prevalence	prevalence	NOUN
ajlm-708	285	2	of	of	ADP
ajlm-708	285	3	low	low	ADJ
ajlm-708	285	4	-	-	PUNCT
ajlm-708	285	5	level	level	NOUN
ajlm-708	285	6	hiv-1	hiv-1	X
ajlm-708	285	7	variants	variant	NOUN
ajlm-708	285	8	with	with	ADP
ajlm-708	285	9	reverse	reverse	ADJ
ajlm-708	285	10	transcriptase	transcriptase	NOUN
ajlm-708	285	11	mutation	mutation	NOUN
ajlm-708	285	12	k65r	k65r	NOUN
ajlm-708	285	13	and	and	CCONJ
ajlm-708	285	14	the	the	DET
ajlm-708	285	15	effect	effect	NOUN
ajlm-708	285	16	of	of	ADP
ajlm-708	285	17	antiretroviral	antiretroviral	ADJ
ajlm-708	285	18	drug	drug	NOUN
ajlm-708	285	19	exposure	exposure	NOUN
ajlm-708	285	20	on	on	ADP
ajlm-708	285	21	variant	variant	ADJ
ajlm-708	285	22	levels	level	NOUN
ajlm-708	285	23	.	.	PUNCT
ajlm-708	286	1	antivir	antivir	PROPN
ajlm-708	286	2	ther	ther	ADV
ajlm-708	286	3	.	.	PUNCT
ajlm-708	287	1	2011;16(6):925–929	2011;16(6):925–929	NOUN
ajlm-708	287	2	.	.	PUNCT
ajlm-708	288	1	https://doi.org/10.3851/imp1851	https://doi.org/10.3851/imp1851	NOUN
ajlm-708	288	2	bansode	bansode	VERB
ajlm-708	288	3	v	v	PROPN
ajlm-708	288	4	,	,	PUNCT
ajlm-708	288	5	mccormack	mccormack	PROPN
ajlm-708	288	6	gp	gp	NOUN
ajlm-708	288	7	,	,	PUNCT
ajlm-708	288	8	crampin	crampin	NOUN
ajlm-708	288	9	ac	ac	PROPN
ajlm-708	288	10	,	,	PUNCT
ajlm-708	288	11	et	et	PROPN
ajlm-708	288	12	al	al	PROPN
ajlm-708	288	13	.	.	PUNCT
ajlm-708	289	1	characterizing	characterize	VERB
ajlm-708	289	2	the	the	DET
ajlm-708	289	3	emergence	emergence	NOUN
ajlm-708	289	4	and	and	CCONJ
ajlm-708	289	5	persistence	persistence	NOUN
ajlm-708	289	6	of	of	ADP
ajlm-708	289	7	drug	drug	NOUN
ajlm-708	289	8	resistant	resistant	ADJ
ajlm-708	289	9	mutations	mutation	NOUN
ajlm-708	289	10	in	in	ADP
ajlm-708	289	11	hiv-1	hiv-1	X
ajlm-708	289	12	subtype	subtype	NOUN
ajlm-708	289	13	c	c	NOUN
ajlm-708	289	14	infections	infection	NOUN
ajlm-708	289	15	using	use	VERB
ajlm-708	289	16	454	454	NUM
ajlm-708	289	17	ultra	ultra	ADJ
ajlm-708	289	18	deep	deep	ADJ
ajlm-708	289	19	pyrosequencing	pyrosequencing	NOUN
ajlm-708	289	20	.	.	PUNCT
ajlm-708	290	1	bmc	bmc	PROPN
ajlm-708	290	2	infect	infect	PROPN
ajlm-708	290	3	dis	dis	PROPN
ajlm-708	290	4	.	.	PUNCT
ajlm-708	291	1	2013;13:52	2013;13:52	NUM
ajlm-708	291	2	.	.	PUNCT
ajlm-708	292	1	https://doi.org/10.1186/1471-2334-13-52	https://doi.org/10.1186/1471-2334-13-52	PROPN
ajlm-708	292	2	coutsinos	coutsinos	PROPN
ajlm-708	292	3	d	d	NOUN
ajlm-708	292	4	,	,	PUNCT
ajlm-708	292	5	invernizzi	invernizzi	ADJ
ajlm-708	292	6	cf	cf	NOUN
ajlm-708	292	7	,	,	PUNCT
ajlm-708	292	8	xu	xu	PROPN
ajlm-708	293	1	h	h	PROPN
ajlm-708	293	2	,	,	PUNCT
ajlm-708	293	3	et	et	PROPN
ajlm-708	293	4	al	al	PROPN
ajlm-708	293	5	.	.	PROPN
ajlm-708	293	6	template	template	NOUN
ajlm-708	293	7	usage	usage	NOUN
ajlm-708	293	8	is	be	AUX
ajlm-708	293	9	responsible	responsible	ADJ
ajlm-708	293	10	for	for	ADP
ajlm-708	293	11	the	the	DET
ajlm-708	293	12	preferential	preferential	ADJ
ajlm-708	293	13	acquisition	acquisition	NOUN
ajlm-708	293	14	of	of	ADP
ajlm-708	293	15	the	the	DET
ajlm-708	293	16	k65r	k65r	NOUN
ajlm-708	293	17	reverse	reverse	ADJ
ajlm-708	293	18	transcriptase	transcriptase	NOUN
ajlm-708	293	19	mutation	mutation	NOUN
ajlm-708	293	20	in	in	ADP
ajlm-708	293	21	subtype	subtype	NOUN
ajlm-708	293	22	c	c	NOUN
ajlm-708	293	23	variants	variant	NOUN
ajlm-708	293	24	of	of	ADP
ajlm-708	293	25	human	human	ADJ
ajlm-708	293	26	immunodeficiency	immunodeficiency	NOUN
ajlm-708	293	27	virus	virus	NOUN
ajlm-708	293	28	type	type	NOUN
ajlm-708	293	29	1	1	NUM
ajlm-708	293	30	.	.	PUNCT
ajlm-708	294	1	j	j	PROPN
ajlm-708	294	2	virol	virol	NOUN
ajlm-708	294	3	.	.	PUNCT
ajlm-708	295	1	2009;83(4):2029–2033	2009;83(4):2029–2033	NUM
ajlm-708	295	2	.	.	PUNCT
ajlm-708	296	1	https://doi.org/10.1128/jvi.01349-08	https://doi.org/10.1128/jvi.01349-08	NOUN
ajlm-708	296	2	keulen	keulen	VERB
ajlm-708	296	3	w	w	PROPN
ajlm-708	296	4	,	,	PUNCT
ajlm-708	296	5	nijhuis	nijhuis	PROPN
ajlm-708	296	6	m	m	PROPN
ajlm-708	296	7	,	,	PUNCT
ajlm-708	296	8	schuurman	schuurman	ADJ
ajlm-708	296	9	r	r	PROPN
ajlm-708	296	10	,	,	PUNCT
ajlm-708	296	11	et	et	PROPN
ajlm-708	296	12	al	al	PROPN
ajlm-708	296	13	.	.	PROPN
ajlm-708	297	1	reverse	reverse	PROPN
ajlm-708	297	2	transcriptase	transcriptase	NOUN
ajlm-708	297	3	fidelity	fidelity	NOUN
ajlm-708	297	4	and	and	CCONJ
ajlm-708	297	5	hiv-1	hiv-1	NOUN
ajlm-708	297	6	variation	variation	NOUN
ajlm-708	297	7	.	.	PUNCT
ajlm-708	298	1	science	science	NOUN
ajlm-708	298	2	.	.	PUNCT
ajlm-708	298	3	1997;275(5297):229	1997;275(5297):229	NUM
ajlm-708	298	4	;	;	PUNCT
ajlm-708	298	5	author	author	NOUN
ajlm-708	298	6	reply	reply	VERB
ajlm-708	298	7	230–221	230–221	NUM
ajlm-708	298	8	.	.	PUNCT
ajlm-708	299	1	https://doi.org/10.1128/jvi.74.14.6262-6268.2000	https://doi.org/10.1128/jvi.74.14.6262-6268.2000	PROPN
ajlm-708	299	2	frost	frost	PROPN
ajlm-708	299	3	sdw	sdw	PROPN
ajlm-708	299	4	,	,	PUNCT
ajlm-708	299	5	nijhuis	nijhuis	PROPN
ajlm-708	299	6	m	m	PROPN
ajlm-708	299	7	,	,	PUNCT
ajlm-708	299	8	schuurman	schuurman	ADJ
ajlm-708	299	9	r	r	PROPN
ajlm-708	299	10	,	,	PUNCT
ajlm-708	299	11	et	et	PROPN
ajlm-708	299	12	al	al	PROPN
ajlm-708	299	13	.	.	PROPN
ajlm-708	299	14	evolution	evolution	NOUN
ajlm-708	299	15	of	of	ADP
ajlm-708	299	16	lamivudine	lamivudine	NOUN
ajlm-708	299	17	resistance	resistance	NOUN
ajlm-708	299	18	in	in	ADP
ajlm-708	299	19	human	human	ADJ
ajlm-708	299	20	immunodeficiency	immunodeficiency	NOUN
ajlm-708	299	21	virus	virus	NOUN
ajlm-708	299	22	type	type	VERB
ajlm-708	299	23	1	1	NUM
ajlm-708	299	24	-	-	PUNCT
ajlm-708	299	25	infected	infect	VERB
ajlm-708	299	26	individuals	individual	NOUN
ajlm-708	299	27	:	:	PUNCT
ajlm-708	299	28	the	the	DET
ajlm-708	299	29	relative	relative	ADJ
ajlm-708	299	30	roles	role	NOUN
ajlm-708	299	31	of	of	ADP
ajlm-708	299	32	drift	drift	NOUN
ajlm-708	299	33	and	and	CCONJ
ajlm-708	299	34	selection	selection	NOUN
ajlm-708	299	35	.	.	PUNCT
ajlm-708	300	1	j	j	PROPN
ajlm-708	300	2	virol	virol	NOUN
ajlm-708	300	3	.	.	PUNCT
ajlm-708	301	1	2000;74(14):6262–6268	2000;74(14):6262–6268	NUM
ajlm-708	301	2	.	.	PUNCT
ajlm-708	301	3	qari	qari	PROPN
ajlm-708	301	4	sh	sh	PROPN
ajlm-708	301	5	,	,	PUNCT
ajlm-708	301	6	winters	winters	PROPN
ajlm-708	301	7	m	m	PRON
ajlm-708	301	8	,	,	PUNCT
ajlm-708	301	9	vandamme	vandamme	PROPN
ajlm-708	301	10	am	be	AUX
ajlm-708	301	11	,	,	PUNCT
ajlm-708	301	12	et	et	PROPN
ajlm-708	301	13	al	al	PROPN
ajlm-708	301	14	.	.	PUNCT
ajlm-708	302	1	a	a	DET
ajlm-708	302	2	rapid	rapid	ADJ
ajlm-708	302	3	phenotypic	phenotypic	NOUN
ajlm-708	302	4	assay	assay	NOUN
ajlm-708	302	5	for	for	ADP
ajlm-708	302	6	detecting	detect	VERB
ajlm-708	302	7	multiple	multiple	ADJ
ajlm-708	302	8	nucleoside	nucleoside	NOUN
ajlm-708	302	9	analogue	analogue	NOUN
ajlm-708	302	10	reverse	reverse	NOUN
ajlm-708	302	11	transcriptase	transcriptase	NOUN
ajlm-708	302	12	inhibitor	inhibitor	NOUN
ajlm-708	302	13	-	-	PUNCT
ajlm-708	302	14	resistant	resistant	ADJ
ajlm-708	302	15	hiv-1	hiv-1	PUNCT
ajlm-708	302	16	in	in	ADP
ajlm-708	302	17	plasma	plasma	NOUN
ajlm-708	302	18	.	.	PUNCT
ajlm-708	303	1	antivir	antivir	PROPN
ajlm-708	303	2	ther	ther	ADV
ajlm-708	303	3	.	.	PUNCT
ajlm-708	304	1	2002;7(2):131–139	2002;7(2):131–139	X
ajlm-708	304	2	.	.	PUNCT
ajlm-708	305	1	https://doi.org/10.1155/2012/637263	https://doi.org/10.1155/2012/637263	PROPN
ajlm-708	305	2	jiao	jiao	PROPN
ajlm-708	305	3	l	l	PROPN
ajlm-708	305	4	,	,	PUNCT
ajlm-708	305	5	li	li	PROPN
ajlm-708	305	6	h	h	PROPN
ajlm-708	305	7	,	,	PUNCT
ajlm-708	305	8	li	li	PROPN
ajlm-708	305	9	l	l	PROPN
ajlm-708	305	10	,	,	PUNCT
ajlm-708	305	11	et	et	PROPN
ajlm-708	305	12	al	al	PROPN
ajlm-708	305	13	.	.	PROPN
ajlm-708	305	14	impact	impact	NOUN
ajlm-708	305	15	of	of	ADP
ajlm-708	305	16	novel	novel	ADJ
ajlm-708	305	17	resistance	resistance	NOUN
ajlm-708	305	18	profiles	profile	NOUN
ajlm-708	305	19	in	in	ADP
ajlm-708	305	20	hiv-1	hiv-1	PUNCT
ajlm-708	305	21	reverse	reverse	ADJ
ajlm-708	305	22	transcriptase	transcriptase	NOUN
ajlm-708	305	23	on	on	ADP
ajlm-708	305	24	phenotypic	phenotypic	ADJ
ajlm-708	305	25	resistance	resistance	NOUN
ajlm-708	305	26	to	to	ADP
ajlm-708	305	27	nvp	nvp	PROPN
ajlm-708	305	28	.	.	PUNCT
ajlm-708	306	1	aids	aids	PROPN
ajlm-708	306	2	res	re	NOUN
ajlm-708	306	3	treat	treat	NOUN
ajlm-708	306	4	.	.	PUNCT
ajlm-708	307	1	2012;2012:637263	2012;2012:637263	NUM
ajlm-708	307	2	.	.	PUNCT
ajlm-708	307	3	nwobegahay	nwobegahay	PROPN
ajlm-708	307	4	jm	jm	PROPN
ajlm-708	307	5	,	,	PUNCT
ajlm-708	307	6	bessong	bessong	PROPN
ajlm-708	307	7	po	po	PROPN
ajlm-708	307	8	,	,	PUNCT
ajlm-708	307	9	masebe	masebe	PROPN
ajlm-708	307	10	tm	tm	PROPN
ajlm-708	307	11	,	,	PUNCT
ajlm-708	307	12	et	et	PROPN
ajlm-708	307	13	al	al	PROPN
ajlm-708	307	14	.	.	PUNCT
ajlm-708	308	1	prevalence	prevalence	NOUN
ajlm-708	308	2	of	of	ADP
ajlm-708	308	3	antiretroviral	antiretroviral	ADJ
ajlm-708	308	4	drug	drug	NOUN
ajlm-708	308	5	resistance	resistance	NOUN
ajlm-708	308	6	mutations	mutation	NOUN
ajlm-708	308	7	and	and	CCONJ
ajlm-708	308	8	hiv	hiv	PROPN
ajlm-708	308	9	-	-	PUNCT
ajlm-708	308	10	i	i	PRON
ajlm-708	308	11	subtypes	subtype	NOUN
ajlm-708	308	12	among	among	ADP
ajlm-708	308	13	newly	newly	ADV
ajlm-708	308	14	-	-	PUNCT
ajlm-708	308	15	diagnosed	diagnose	VERB
ajlm-708	308	16	drug	drug	NOUN
ajlm-708	308	17	-	-	PUNCT
ajlm-708	308	18	naive	naive	ADJ
ajlm-708	308	19	persons	person	NOUN
ajlm-708	308	20	visiting	visit	VERB
ajlm-708	308	21	a	a	DET
ajlm-708	308	22	voluntary	voluntary	ADJ
ajlm-708	308	23	testing	testing	NOUN
ajlm-708	308	24	and	and	CCONJ
ajlm-708	308	25	counselling	counselling	NOUN
ajlm-708	308	26	centre	centre	NOUN
ajlm-708	308	27	in	in	ADP
ajlm-708	308	28	northeastern	northeastern	PROPN
ajlm-708	308	29	south	south	PROPN
ajlm-708	308	30	africa	africa	PROPN
ajlm-708	308	31	.	.	PUNCT
ajlm-708	309	1	j	j	PROPN
ajlm-708	309	2	health	health	PROPN
ajlm-708	309	3	popul	popul	PROPN
ajlm-708	309	4	nutr	nutr	PROPN
ajlm-708	309	5	.	.	PUNCT
ajlm-708	310	1	2011;29(4):303–309	2011;29(4):303–309	PROPN
ajlm-708	310	2	.	.	PUNCT
ajlm-708	310	3	https://doi.org/10.3329/jhpn.v29i4.8444	https://doi.org/10.3329/jhpn.v29i4.8444	X
ajlm-708	310	4	manosuthi	manosuthi	VERB
ajlm-708	310	5	w	w	NOUN
ajlm-708	310	6	,	,	PUNCT
ajlm-708	310	7	thongyen	thongyen	NOUN
ajlm-708	310	8	s	s	PROPN
ajlm-708	310	9	,	,	PUNCT
ajlm-708	310	10	nilkamhang	nilkamhang	PROPN
ajlm-708	310	11	s	s	PROPN
ajlm-708	310	12	,	,	PUNCT
ajlm-708	310	13	et	et	PROPN
ajlm-708	310	14	al	al	PROPN
ajlm-708	310	15	.	.	PROPN
ajlm-708	310	16	hiv-1	hiv-1	X
ajlm-708	310	17	drug	drug	NOUN
ajlm-708	310	18	resistance	resistance	NOUN
ajlm-708	310	19	-	-	PUNCT
ajlm-708	310	20	associated	associate	VERB
ajlm-708	310	21	mutations	mutation	NOUN
ajlm-708	310	22	among	among	ADP
ajlm-708	310	23	antiretroviral	antiretroviral	ADJ
ajlm-708	310	24	-	-	PUNCT
ajlm-708	310	25	naive	naive	ADJ
ajlm-708	310	26	thai	thai	ADJ
ajlm-708	310	27	patients	patient	NOUN
ajlm-708	310	28	with	with	ADP
ajlm-708	310	29	chronic	chronic	ADJ
ajlm-708	310	30	hiv-1	hiv-1	PUNCT
ajlm-708	310	31	infection	infection	NOUN
ajlm-708	310	32	.	.	PUNCT
ajlm-708	311	1	j	j	PROPN
ajlm-708	311	2	med	med	PROPN
ajlm-708	311	3	virol	virol	NOUN
ajlm-708	311	4	.	.	PUNCT
ajlm-708	312	1	2013;85(2):194–199	2013;85(2):194–199	X
ajlm-708	312	2	.	.	PUNCT
ajlm-708	312	3	https://doi.org/10.1002/jmv.23452	https://doi.org/10.1002/jmv.23452	PROPN
ajlm-708	312	4	hosseinipour	hosseinipour	PROPN
ajlm-708	312	5	mc	mc	PROPN
ajlm-708	312	6	,	,	PUNCT
ajlm-708	312	7	van	van	PROPN
ajlm-708	312	8	oosterhout	oosterhout	PROPN
ajlm-708	312	9	jj	jj	PROPN
ajlm-708	312	10	,	,	PUNCT
ajlm-708	312	11	weigel	weigel	NOUN
ajlm-708	312	12	r	r	NOUN
ajlm-708	312	13	,	,	PUNCT
ajlm-708	312	14	et	et	PROPN
ajlm-708	312	15	al	al	PROPN
ajlm-708	312	16	.	.	PUNCT
ajlm-708	313	1	the	the	DET
ajlm-708	313	2	public	public	ADJ
ajlm-708	313	3	health	health	NOUN
ajlm-708	313	4	approach	approach	NOUN
ajlm-708	313	5	to	to	PART
ajlm-708	313	6	identify	identify	VERB
ajlm-708	313	7	antiretroviral	antiretroviral	ADJ
ajlm-708	313	8	therapy	therapy	NOUN
ajlm-708	313	9	failure	failure	NOUN
ajlm-708	313	10	:	:	PUNCT
ajlm-708	313	11	high	high	ADJ
ajlm-708	313	12	-	-	PUNCT
ajlm-708	313	13	level	level	NOUN
ajlm-708	313	14	nucleoside	nucleoside	NOUN
ajlm-708	313	15	reverse	reverse	NOUN
ajlm-708	313	16	transcriptase	transcriptase	NOUN
ajlm-708	313	17	inhibitor	inhibitor	NOUN
ajlm-708	313	18	resistance	resistance	NOUN
ajlm-708	313	19	among	among	ADP
ajlm-708	313	20	malawians	malawian	NOUN
ajlm-708	313	21	failing	fail	VERB
ajlm-708	313	22	first	first	ADJ
ajlm-708	313	23	-	-	PUNCT
ajlm-708	313	24	line	line	NOUN
ajlm-708	313	25	antiretroviral	antiretroviral	ADJ
ajlm-708	313	26	therapy	therapy	NOUN
ajlm-708	313	27	.	.	PUNCT
ajlm-708	314	1	aids	aids	PROPN
ajlm-708	314	2	.	.	PUNCT
ajlm-708	315	1	2009;23(9):1127–1134	2009;23(9):1127–1134	PROPN
ajlm-708	315	2	.	.	PUNCT
ajlm-708	316	1	https://doi.org/10.1097/qad.0b013e32832ac34e	https://doi.org/10.1097/qad.0b013e32832ac34e	NOUN